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InTRODUCTIOn
Cardiovascular disease
As one of the leading causes of death in the Western world, cardiovascular disease 
belongs to the biggest health problems in today’s society.1 Moreover, because of 
our dietary habits, sedentary lifestyle, and the aging of the population, the health 
hazards of cardiovascular disease only continue to increase. By 2030, the annual 
national health expenditures towards cardiovascular disease are predicted to have 
doubled.2, 3 Cardiovascular disease can be classified into diseases affecting the 
heart and those affecting the vascular system. Vascular disease may involve the 
arteries, veins, or lymphatic vessels. Arterial disease constitutes the far major-
ity of life-threatening vascular disease, as the arterial circulation provides the 
vital organs with oxygen and nutrients, for which deprivation can be fatal within 
minutes.4
Aortic disease
The aorta is the largest artery in the human body, transporting an average of 200 
million liters of oxygenated blood from the left ventricle of the heart to the body 
during a lifetime. Separating from the heart by the aortic valve, the aorta arches 
over the left main bronchus, after which it extents downwards into the abdominal 
cavity, where it eventually bifurcates into the two iliac arteries. Histologically, 
the aortic wall comprises of three layers: the tunica intima, which is lined by the 
endothelium; a thick tunica media characterized by concentric sheets of elastin 
and collagen; and the outer tunica adventitia containing mainly collagen, vasa 
vasorum, and lymphatics.
The aorta may be affected by various pathologies. First, the connective tissue 
in the tunica media may degenerate with age. This weakening causes the aorta 
to lose its ability to withstand the arterial pressure, resulting in the aorta to 
gradually dilate. When the diameter of the aorta exceeds the estimated original 
diameter by more than 50%, it is considered a pathological enlargement, and 
called an aneurysm. The prevalence of aortic aneurysmal disease is approximately 
2% to 4% in the elderly population, and important risk factors include male 
gender, advanced age, and smoking.5-12 Aneurysms are usually asymptomatic, 
and can therefore remain undetected for many years. However, as aneurysms 
grow, the wall strength decreases, which increases the risk of an aortic rupture 
to occur. This is a catastrophic complication with mortality exceeding 80%.13, 14 
Once detected, aneurysms are therefore prophylactically treated when the risk 
of rupture exceeds the operative risk.15
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Second, a pathologic build-up of white blood cells filled with cholesterol and 
other lipids called foam cells may accumulate within the aortic wall. This process, 
known as atherosclerosis, is a slow yet progressive disease that may begin as 
early as childhood. Due to its systemic nature, not only the aorta, but any artery 
in the human body may become affected. Over time, the deposits of fats and 
cellular products harden and narrow the vessel. This limits the flow of oxygen-
rich blood to organs distal to the lesion, and eventually causes organ dysfunc-
tion. Risk factors for atherosclerosis are well known, and include male gender, 
high blood pressure, diet high in saturated fat, smoking, insulin resistance, and 
chronic inflammation.
Less common are aortic dissections, which occur when the layers of the aortic 
wall become separated resulting from severe long lasting hypertension and/or 
loss of vessel integrity due to high age or connective tissue disorders.16, 17 As 
blood flow separates the layers of the aorta, perfusion to vital organs may become 
obstructed, and weakening of the aortic wall may result in aortic rupture.16, 17 In 
addition to endogenous wall stress, the aorta may also be injured by external 
high-energetic trauma, most importantly a sudden deceleration.18 These blunt 
traumatic aortic injuries are the second leading cause of death after automobile 
and motorcycle crashes, and have relatively young population.19-21 The severity 
of these injuries may vary from a small intimal tear, to pseudoaneurysms, and 
even full aortic ruptures.
non-aortic disease
The various pathologies affecting the aorta may occur in all other arteries in the 
human body as well. However, these vessels –such as the arterial supply to the 
brain, heart, and limbs– are mostly affected by atherosclerotic disease.22 When 
the vessels supplying oxygenated blood to the heart become obstructed, it is 
known as coronary artery disease. Occlusive vascular disease in all other arterial 
systems is referred to as peripheral artery disease (PAD), and most commonly 
involves the arteries in the legs. With 10 to 20% of the population over 65 years 
affected, atherosclerotic disease in the arteries of the lower extremities is very 
common.23, 24 Classic symptoms include leg pain induced by walking, which resolves 
after rest (intermittent claudication). In more advanced stages, perfusion beyond 
the obstruction has severely diminished, causing patients to suffer rest pain and 
even tissue necrosis (critical limb ischemia). Atherosclerotic disease in the arteries 
to the brain is called cerebrovascular disease. Because the brain receives blood 
from four separate arteries, narrowing of these vessels is often asymptomatic. 
However, when an atherosclerotic plaque ruptures, atherothrombic debris causes 
an obstruction of bloodflow downstream. The consequent oxygen deprivation may 
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be temporary, resulting in a transient ischemic attack, or cause permanent dam-
age, which is referred to as an ischemic stroke.
The long-term prognosis after vascular surgery for peripheral occlusive disease 
is generally poor, with 10-year survival rates as low as 25% after 10 years.25 
Cardiovascular causes account for the majority of early and late mortality follow-
ing vascular surgery, surpassing 60%.26 This thesis aims to provide new insights 
in the long-term postoperative prognosis of vascular surgery patients, focusing 
on the role of conventional, as well as unconventional risk factors for the predic-
tion of long-term outcomes.
Aortic surgery
Traditionally, aortic disease was surgically treated through open repair, which 
required a large incision through which the aorta was exposed and the affected 
segmented was replaced by an interposition graft. As an alternative to open repair, 
endovascular repair for the treatment of the diseased aorta was first introduced 
in the early nineties.27, 28 With endovascular repair, exclusion of the diseased aorta 
can be achieved with a small incision in the femoral artery in the groin, through 
which a self-expanding stent graft can be brought up and deployed over the le-
sion. Owing to the less invasive nature of the procedure, endovascular repair 
has been associated with lower perioperative mortality, as well as lower rates of 
complications, need for transfusions, and length of stay compared to open repair 
for abdominal and thoracic aortic pathologies.29-36 Because of these benefits, the 
utilization of endovascular treatment for elective aortic repair has rapidly increased 
since its introduction.14, 29, 37-41
Over the years, numerous studies have clarified many crucial aspects of open 
and endovascular repair, and the relative performance of these two techniques. 
However, knowledge gaps in the current literature remain. For acute aortic sur-
gery, for example, the paradigm shift from open towards endovascular repair 
has not fully caught on yet, most importantly because of a scarcity of evidence 
supporting a benefit of endovascular treatment over open repair. For elective 
repair, little is known about the safety of performing concomitant procedures 
during abdominal aortic aneurysm repair, and whether endovascular repair is 
also preferable for anatomically complex aneurysms.42-44 Additionally, is has 
become apparent that endovascular treatment is associated with more early and 
late graft-related complications compared to open repair, and that endovascular 
patients more commonly undergo reinterventions.45-47 How these complications 
affect long-term outcome, and whether these reinterventions can be performed 
safely, remains largely unclear.
12
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By satisfying some of these knowledge gaps in the current literature, this 
thesis is dedicated to contribute to a better understanding of the prognosis of 
aortic and peripheral artery disease, and thereby improve patient care.
13
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THEsIs OVERVIEW
Part I is dedicated to determine the current role of endovascular repair for the 
treatment of acute aortic pathologies, and assess the potential benefit of endo-
vascular repair in the emergent setting. In Chapter 1, the rate of adoption and 
relative effectiveness of endovascular repair for traumatic thoracic aortic injury 
are assessed in a United States (US) national registry. Chapter 2 is a US na-
tional review of treatment of ruptured thoracic aortic aneurysms, focusing on the 
age-related utilization and outcome of endovascular repair, open repair, and non-
operative treatment. Chapter 3 is a systematic review attempting to clarify the 
role of endovascular repair for the treatment of abdominal aortic aneurysms. In 
Chapter 4, an institutional series of ruptured abdominal aortic aneurysm (AAA) 
repairs is described, attempting to establish risk factors for early mortality follow-
ing ruptured AAA repair, as well as the impact of treatment approach on outcome. 
Chapter 5 focuses on the treatment of symptomatic AAAs, and assesses the 
applicability endovascular repair in this setting.
In Part II, the aim is to clarify, and assess risks associated with operative and 
postoperative aspects of AAA repair. In Chapter 6 and Chapter 7, the authors 
aim to identify the perioperative risks associated with performing concomitant 
procedures during endovascular and open AAA repair, respectively. Chapter 8 
is dedicated to assess the perioperative outcome following endovascular repair 
for anatomically complex abdominal aneurysms, focusing on differences with 
complex open repair, the alternative treatment option, and standard infrarenal 
endovascular repair. The purpose of Chapter 9 is to identify anatomical differ-
ences between patients currently selected for transperitoneal versus retroperi-
toneal AAA repair, and to establish differences in intra-operative characteristics, 
as well as perioperative outcome. In Chapter 10, the authors describe how 
the introduction of endovascular repair has changed the specialty of surgeons 
performing AAA repair. Chapter 11 aims to determine whether differences exist 
in long-term survival and causes of death between patients undergoing endovas-
cular and open repair for AAA. Additionally, the authors sought out to establish 
the influence of presentation on the long-term postoperative prognosis.
In Part III, various complications encountered after AAA repair were scrutinized 
to determine their incidence, significance, and risk factors for their occurrence. 
The purpose of Chapter 12 is to assess the incidence of postoperative bowel 
ischemia following AAA repair in the endovascular era, and identify overall and 
procedure-specific risk factors for its occurrence. Chapter 13 demonstrates the 
impact of renal complications following endovascular repair, and provides an 
analysis of patient-, stent graft-, and procedure-related risk factor for impair-
17
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ment of the postoperative renal function. In Chapter 14 the incidence and 
outcome of conversion surgery from endovascular to open repair are described, 
as well as factors associated with its occurrence.
In Part IV, the authors aim to shed unconventional light on long-term prog-
nosis after (vascular) surgery. Chapter 15 is dedicated to determine the role 
of socioeconomic status as a predictor for survival following surgical treatment 
for peripheral artery disease, abdominal aortic aneurysm and carotid artery 
stenosis, irrespective of healthcare disparities. Chapter 16 is an attempt to 
extrapolate the hypothesis on the importance of socioeconomic deprivation for 
the postoperative prognosis beyond vascular surgery. Chapter 17 clarifies on 
the impact of ischemic heart disease and coronary revascularization in vascular 
surgery patients, focusing on the influence on overall and cause-specific mortal-
ity. Chapter 18 is a comparison between the prognosis of patients with aneu-
rysmal and occlusive disease in order to determine whether these two entities of 
vascular disease are prognostically different.
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ABsTRACT
Objective
Endovascular repair of traumatic thoracic aortic injuries (TTAI) is an alternative to 
conventional open surgical repair. Single institution studies have shown a survival 
benefit with TEVAR, but it is not clear if this is being realized nationally. The pur-
pose of our study was to document trends in the increase in utilization of TEVAR 
and its impact on outcomes of TTAI nationally.
Methods
Patients admitted with a traumatic thoracic aortic injury between 2005 and 2011 
were identified in the National Inpatient Sample (NIS). Patients were grouped by 
treatment into TEVAR, open repair, or nonoperative management groups. Primary 
outcomes were relative utilization over time and in-hospital mortality. Secondary 
outcomes included postoperative complications and length of stay. Multivariable 
logistic regression was performed to identify independent predictors of mortality.
Results
A total of 8384 patients were included, with 2492 (29.7%) undergoing TEVAR, 
848 (10.1%) open repair, and 5044 (60.2%) managed nonoperatively. TEVAR has 
become the dominant treatment option for TTAI over the study period, starting at 
6.5% of interventions in 2005 and accounting for 86.5% of interventions in 2011 
(P<.001). Nonoperative management declined concurrently with the widespread of 
adoption TEVAR (79.8% to 53.7%, P<.001). In-hospital mortality following TEVAR 
decreased over the study period (33.3% in 2005 to 4.9% in 2011, P<.001), while 
an increase in mortality was observed for open repair (13.9% to 19.2%, P<.001). 
Procedural mortality (either TEVAR or open repair) decreased from 14.9% to 6.7% 
(P<.001), and mortality following any TTAI admission declined from 24.5% to 
13.3% over the study period (P<.001). In addition to lower mortality, TEVAR was 
followed by fewer cardiac complications (4.1% vs. 8.5%), P<.001), respiratory 
complications (47.5% vs. 54.8%, P<.001), and shorter length of stay (18.4 vs. 
20.2 days, P=.012) compared to open repair. In adjusted mortality analyses, open 
repair proved to be associated with twice the mortality risk compared to TEVAR 
(OR: 2.1, 95% CI: 1.6 – 2.7), while nonoperative management was associated 
with more than a four-fold increase in mortality (OR: 4.5, 95% CI: 3.8 – 5.3).
Conclusions
TEVAR is now the dominant surgical approach in TTAI with substantial periopera-
tive morbidity and mortality benefits over open aortic repair. Overall mortality 
23
TEVAR for traumatic thoracic aortic injuries
1following admission for TTAI has declined, which is most likely the result of both 
the replacement of open repair by TEVAR, as well as the broadened eligibility for 
operative repair.
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InTRODUCTIOn
Traumatic thoracic aortic injuries (TTAI) remain associated with high morbidity and 
mortality.1 Though highly lethal, TTAI has a relatively low incidence within the gen-
eral population and as such, prior studies were largely limited to single-institution 
retrospective series. Various studies have suggested an in-hospital mortality of 
15% to 30%, beginning with Parmley’s 1958 study.2, 3 Early studies assessing 
perioperative outcome following open repair showed poor results, with both high 
surgical mortality and morbidity, of which a high paraplegia rate was most notable.4
In 1997, Kato et al. were the first to report on endovascular stent grafting for 
TTAI.5 Studies conducted in the following years, which were mostly institutional-
based, suggested a substantial reduction in morbidity and mortality associated 
with TEVAR, compared to open repair and nonoperative treatment.6-11 The Soci-
ety for Vascular Surgery determined that endovascular repair of TTAI remained 
a key area requiring clinical guidelines to aid surgeons, referring physicians, 
and patients in the process of decision-making. In an effort to provide guidance 
for clinical practice, a selected panel of experts was tasked with conducting 
a systematic review and meta-analysis of the existing literature.12 Although 
various recommendations were provided, the panel concluded that the avail-
able evidence was of very low quality and that further evaluation of operative 
management of TTAI was warranted.
Hong et al. were the first to utilize a national database to characterize trends in 
treatment of TTAI and could not confirm the perioperative mortality benefit as-
sociated with TEVAR on a national level.13 Their 2001-2007 Nationwide Inpatient 
Sample (NIS) data are biased, yielding only 14 TEVAR ICD-9 codes prior to 2006 
which underreport its use, as ICD-9 coding did not differentiate a TEVAR from an 
open repair until October 2005.
Since it remains unclear whether these favorable outcomes demonstrated in 
institutional series are being realized nationally and the use of endovascular 
treatment modalities continues to increase, the purpose of our study was to 
provide a contemporaneous update to the study by Hong et al. using specific 
TEVAR coding and further assess the relative effectiveness and trends in the 
use of endovascular repair for traumatic thoracic aortic injury, as well as overall 
outcome following TTAI admission.
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METHODs
Database
For this study, we utilized the NIS. The NIS is the largest US all-payer inpatient 
database, with over 8 million documented annual hospitalizations. The NIS is 
maintained by the Agency for Health Care Research and Quality (AHRQ) as part 
of the Healthcare Cost and Utilization Project.14 The NIS represents 20% of all 
annual U.S. hospitalizations. Through the use of hospital sampling weights, actual 
annual U.S. hospitalization volumes are approximated. These weighted estimates 
are utilized throughout this analysis, as recommended by the AHRQ. The data-
base contains de-identified data only without any protected health information. 
Therefore, Institutional Review Board approval and patient consent were waived.
Patients
Patients were identified using International Classification of Diseases, Ninth 
Revision (ICD-9). All patients with a diagnosis code for traumatic aortic injury 
(901.0) between 2005 and 2011 were included. Identified TTAI patients were 
subsequently grouped by treatment received (TEVAR, open repair, or nonopera-
tive management). Corresponding ICD-9 procedural codes and descriptions were: 
endovascular graft implantation to the thoracic aorta (39.73), open thoracic 
vessel replacement (38.45), or nonoperative management when neither of the 
procedure codes was mentioned.
Documented patient characteristics included demographics (age, sex, race), 
comorbid conditions (coronary artery disease, diabetes, hypertension, heart fail-
ure, chronic obstructive pulmonary disease (COPD), chronic kidney disease, and 
cerebrovascular disease) and concomitant injuries (brain, hemothorax, cardiac, 
pulmonary, liver, spleen, kidney, pelvic organs, gastro-intestinal, skull fracture, 
vertebral fracture, and major orthopedic fracture). Brain injury was defined as 
loss of consciousness lasting longer than 24 hours, brain laceration or contusion, 
or intracerebral hemorrhage. Cardiac and pulmonary injury included both contu-
sion and laceration. A major orthopedic fracture was defined as a fracture of the 
spine, pelvis, or femur. Interventions to treat concurrent injuries were grouped 
into intracranial, thoracic, and abdominal procedures. These interventions did 
not include diagnostic procedures, and were only considered for patients with 
a reported traumatic injury in the corresponding organ. Hospital characteris-
tics included hospital setting (rural, urban non-teaching, urban teaching) and 
hospital bedsize (small medium large). A hospital’s bedsize category is nested 
within location and teaching status. Small hospital bedsize is defined as 1-49, 
50-99 and 1-299 beds, respectively for rural, urban non-teaching and urban 
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teaching hospitals, medium bedsize as 50-99, 100-199, 300-499, respectively, 
and 100+, 200+, and 500+ beds is considered a large bedsize hospital, respec-
tively. Adverse in-hospital outcomes included death, cardiac or respiratory com-
plications, paraplegia, stroke, acute renal failure, wound dehiscence, infection, 
discharge to home, and length of stay. Cardiac complications include postop-
erative myocardial infarction, cardiac arrest, cardiogenic shock, and ventricular 
fibrillation (Supplemental Table 1). A respiratory complication was defined as 
a postoperative pneumonia, pulmonary insufficiency after trauma or surgery, 
transfusion-related acute lung injury, or acute respiratory failure. For paraplegia 
as a postoperative adverse outcome, patients admitted with vertebral fractures 
with spinal cord injury were not included. National cause-specific age-adjusted 
death rates due to traumatic aortic injuries (ICD-10 code: S25.0) were also 
obtained from Wide-ranging Online Data for Epidemiologic Research (WONDER), 
an epidemiological internet based database maintained by Centers for Disease 
Control and Prevention (CDC).15 More information on WONDER can be found on 
http://wonder.cdc.gov/.
statistical analysis
Categorical variables are presented as counts and percentages and continuous 
variables as mean ± standard deviation. Trends over time were assessed using 
the Cochran-Armitage test for trend. Differences were determined using χ2 and 
Fisher’s exact testing for categorical variables, and Student’s t-test and Kruskal-
Wallis test for continuous variables, where appropriate. These analyses included 
an overall test of the three treatment groups, as well as a separate analysis 
comparing TEVAR and open repair patients only. In order to identify risk factors 
for mortality, all variables were first univariately tested using logistic regression 
analysis. Predictors with a p-value ≤ .1 were subsequently entered into a mul-
tivariable model to identify independent risk factors for mortality. Due to the 
limited number of diagnoses that can be provided per patient in this dataset, less 
life-threatening comorbid conditions and concomitant injuries are underreported 
in more complex cases. Since these conditions act as confounders for less severe 
cases, we chose not to include comorbidities and injuries with protective risk 
estimates. All tests were two-sided and significance was considered when p-value 
<0.05. Statistical analysis was performed using the SPSS Statistics 21 (IBM Inc., 
Chicago, IL).
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REsULTs
A total of 8384 patients were included, with 2492 (30%) undergoing TEVAR, 
848 (10%) open repair, and 5044 (60%) undergoing no operative treatment for 
TTAI. Over the study period, the utilization of TEVAR increased from 6.5% of the 
operative volume in 2005 to 87% in 2011 (P<.001, Figure 1). Concurrently, the 
proportion of interventions performed with open repair decreased from 94% to 
14% (P<.001), while the number of patients managed nonoperatively declined 
from 80% to 54% (P<.001).
Baseline and hospital characteristics
Baseline characteristics are detailed in Table 1. TEVAR patients were generally older 
than those undergoing open repair (42.2 vs. 38.4 years, respectively, P<.001). 
Additionally, the TEVAR group included more non-white patients (33% vs. 28%, 
P=.030). TEVAR patients more commonly had coronary artery disease (3.0% vs. 
1.3%, P=.007), diabetes (4.9% vs. 0.6% P<.001), hypertension (20% vs. 16%, 
P=.004), and cerebrovascular disease (P=5.3% vs. 2.9%, P=.005) compared 
to those undergoing open repair. Regarding hospital characteristics, TEVAR was 
more likely to be performed in urban teaching hospitals (91% vs. 85%, P<.001), 
while open repair was more likely performed in large bedsize centers (79% vs. 
91%, P<.001). As TEVAR became more widely utilized, the proportion of patients 
undergoing TEVAR in small or medium bedsize hospitals increased (0% in 2005 to 
28% in 2011, P<.001). For open repair, however, no changes in hospital bedsize 
were observed over time (7% to 8%, P=.635). No difference existed in the pro-
portion of patients transferred from other hospitals between patients undergoing 
Figure 1. Annual proportions of the various treatment strategies for the treatment of TTAI
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TEVAR and open repair (18% vs. 19%, P=.456). However, TEVAR was less often 
performed on the day of admission (57% vs. 66%, P<.001).
Concomitant injuries and interventions
Concomitant injuries were more pronounced in TEVAR patients as compared to 
open repair patients (Table 2). Brain injuries were diagnosed concomitantly in 26% 
of TEVAR patients vs. 17% of open repair patients (P<.001). Similarly, the TEVAR 
group more commonly had cardiac injuries (3.9% vs. 1.1%, P<.001), pulmonary 
Table 1. Baseline and hospital characteristics
Procedure
TEVAR
(N=2492)
Open
Repair
(N=848)
nonoperative
(N=5044)
P-value
Overall TEVAR
vs. OR
Demographics
Age – years (SD) 42.2 (18.3) 38.4 (18.2) 44.6 (20.7) <.001 <.001
Male gender – % 75.2% 72.5% 71.2% .001 .117
Non-white race – % 32.8% 28.1% 32.4% .080 .030
Comorbidities
Coronary disease – % 3.0% 1.3% 6.5% <.001 .007
Diabetes – % 4.9% 0.6% 5.3% <.001 <.001
Hypertension – % 20.2% 15.8% 19.5% .016 .004
Heart Failure – % 1.0% 1.1% 4.2% <.001 .803
COPD – % 3.0% 3.4% 3.3% .726 .553
Chronic kidney disease – % 1.2% 1.1% 1.3% .765 .809
Cerebrovasc disease – % 5.3% 2.9% 2.2% <.001 .005
Hospital Characteristics
Hospital Setting – % <.001 <.001
Rural 2.4% 1.2% 2.8%
Urban non-teaching 6.2% 13.9% 14.2%
Urban teaching 91.4% 85.0% 83.0%
Hospital Bedsize – % <.001 <.001
Small 2.6% 0.5% 2.3%
Medium 18.1% 8.2% 19.6%
Large 79.3% 91.4% 78.1%
Transf. from other hospital 17.5% 18.6% 12.3% <.001 .456
Emergency admission 91.8% 91.1% 93.5% .004 .550
Surgery on day of admissionα – % 57.0% 65.6% - - <.001
COPD: chronic obstructive pulmonary disease
α among emergent admissions only (10% missing cases)
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injuries (32% vs. 22%, P<.001), and spleen juries (25% vs. 21%, P=.007). Also, 
patients undergoing TEVAR more frequently suffered a skull fracture (19% vs. 
15%, P=.017), and vertebral fractures without spinal cord injury (35% vs. 29%, 
P=.002). Regarding the treatment of concurrent injuries, TEVAR patients more 
often underwent intracranial interventions (4.8% vs. 2.5%, P<.001), while no 
difference was observed in the frequency of thoracic (16.9% vs. 18.9%, P=.405), 
and abdominal interventions (13.7% vs. 13.5%, P=.991).
Perioperative outcomes
With an average of 7.8% over the study period, death following TEVAR was con-
siderably lower compared to open repair (13%, P<.001, Table 3), and nonopera-
tive management (24% P<.001). This mortality difference held when comparing 
Table 2. Concomitant injuries and interventions
Procedure
TEVAR
(N=2492)
Open
Repair
(N=848)
nonoperative
(N=5044)
P-value
Overall TEVAR
vs. OR
Number of injuries – median (IQR) 3 (1-4) 2 (1-4) 2 (1-3) <.001 <.001
Brain – % 26.2% 17.2% 24.4% <.001 <.001
Thoracic
Hemothorax – % 11.2% 11.8% 10.4% .341 .659
Cardiac – % 3.9% 1.1% 3.8% <.001 <.001
Pulmonary – % 31.6% 22.4% 24.6% <.001 <.001
Abdominal
Liver – % 24.1% 21.3% 21.4% .028 .104
Spleen – % 25.4% 20.9% 22.3% .003 .007
Kidney – % 13.5% 12.0% 9.6% <.001 .278
Pelvic organs – % 3.1% 2.2% 2.6% .284 .201
GI-tract – % 9.7% 9.5% 8.9% .482 .912
Fractures
Skull fracture – % 18.7% 15.1% 14.2% <.001 .017
Vertebral fracture – % 37.4% 32.1% 31.2% <.001 .005
Spinal involv – % 3.7% 3.4% 4.9% .023 .671
No spinal involv – % 34.7% 28.7% 27.6% <.001 .002
Major orthopedic – % 57.9% 56.8% 48.0% <.001 .587
Interventions
Intracranial – % 4.8% 2.5% 2.6% <.001 .003
Thoracic – % 16.9% 18.9% 17.2% .405 .190
Abdominal – % 13.7% 13.5% 13.7% .991 .954
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TEVAR versus open repair for procedures performed on day of admission (8.5% 
vs. 13%, P=.003). Over time, in-hospital mortality after TEVAR decreased from 
33% in 2005 to 4.9% in 2011 (P<.001, Figure 2). Death among patients who 
underwent open repair remained stable at first, but as the proportion of patients 
undergoing open repair further declined, mortality increased (14% to 19%, 
P<.001). Concurrently with the widespread adoption of TEVAR, death following 
any intervention (i.e. either TEVAR or open repair) decreased from 15% to 6.7% 
(P<.001). Nonoperative management remained associated with the highest mor-
tality with a general trend towards lower mortality, although there was random 
variation over time (27% to 19%, P<.001). Overall mortality following admission 
for TTAI decreased from 25% to 13% (P<.001). A similar decrease in death due 
to TTAI was seen in national CDC data, with mortality declining from 5 to 3 per 
10,000 (40%) between 2000 and 2011 with a continuing downward trend in more 
recent years.15 In addition to lower mortality, TEVAR was associated with fewer 
cardiac complications (4.1% vs. 8.5%, P<.001), and respiratory complications 
(48% vs. 55%, P<.001) compared to open repair. Furthermore, TEVAR was associ-
ated with a shorter length of stay (18.4 vs. 20.2 days, P=.012). Hospital charges, 
however, were significantly higher for TEVAR compared to open repair ($238,392 
vs. $182,403, P<.001). No differences were found in rates of paraplegia, stroke, 
acute renal failure, postoperative infection, and wound dehiscence (Table 3).
Table 3. Postoperative outcomes
Procedure
TEVAR
(N=2492)
Open
Repair
(N=848)
nonoperative
(N=5044)
P-value
Overall TEVAR
vs. OR
Death – % 7.8% 12.7% 24.2% <.001 <.001
Death surgery on day 1 – % 8.5% 13.4% - - .003
Cardiac complication – % 4.1% 8.5% 13.0% <.001 <.001
Paraplegia α – % 0.8% 0.5% 0.6% .428 .480
Stroke complication – % 0.6% 0.6% 0.5% .711 .867
Acute renal failure – % 9.7% 10.0% 10.5% .584 .791
Respiratory – % 47.5% 54.8% 38.3% <.001 <.001
Wound Dehiscence – % 1.2% 1.2% 0.9% .357 .974
Postoperative infection – % 1.8% 2.8% 1.8% .117 .070
Length of stay – days (SD) 18.4 (18.6) 20.2 (18.1) 14.8 (18.8) <.001 .012
Discharge to home – % 64.0% 65.8% 68.5% <.001 .336
Total hospital charges – $ 279,828 238,392 182,403 <.001 <.001
α excluding patients admitted with spinal involved vertebral fractures
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Independent predictors of mortality
Predictors of mortality are listed in Table 4 In adjusted analyses, open repair 
had twice the mortality risk compared to TEVAR (OR: 2.1, 95% CI: 1.6 – 2.7), 
while nonoperative management was associated with a four fold higher mortality 
(OR: 4.5, 95% CI: 3.8 – 5.3). Other risk factors for mortality included age (OR: 
1.1 per 10 years of age, 95% CI: 1.1 – 1.2), male gender (OR: 1.3, 95% CI: 
1.1 – 1.5), and cerebrovascular disease (OR: 2.4, 95% CI: 1.8 – 3.2). Surgery on 
day of admission was also associated with higher mortality risks (OR: 1.6, 95% 
CI: 1.2 – 2.2). Concomitant injuries predictive of mortality included brain injury 
(OR: 1.4, 95% CI: 1.2 – 1.6), hemothorax (OR: 1.6, 95% CI: 1.3 – 1.9), cardiac 
injury (OR: 1.5, 95% CI: 1.1 – 2.0), and major orthopedic injury (OR: 1.3, 95% 
CI: 1.1 – 1.5). In addition, intracranial (OR: 3.0, 95% CI: 2.2 – 4.0), thoracic 
(OR: 1.9, 95% CI: 1.6 – 2.2), and abdominal interventions (OR: 2.1, 95% CI: 
1.8 – 2.5) were established as risk factors for mortality.
We were unable to differentiate between emergent admissions and relatively 
stable patients (e.g., transferred and readmitted patients). However, sensitivity 
analyses were performed among all patients coded as non-elective (93% of 
the total cohort), and no notable differences were observed compared to the 
multivariable model for the cohort as a whole.
DIsCUssIOn
This study demonstrates that TEVAR is now the dominant treatment modality 
for TTAI, with open repair only rarely being performed in recent years. Since 
the proportion of patients managed nonoperatively decreased by 26% (80% to 
Figure 2. Changes in in-hospital mortality over time according to treatment received
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54%), our study indicates that TEVAR may have broadened patient eligibility for 
surgical repair, which has been suggested previously.13 This is also supported by 
the observation that TEVAR patients had more pre-operative comorbidities and 
concomitant injuries compared to patients undergoing open repair. Despite their 
worse condition at admission, this study demonstrates that in-hospital mortality 
and postoperative morbidity of patients selected for TEVAR are substantially lower 
compared to open repair. Due to the shift from open repair towards TEVAR, overall 
procedural mortality has declined, which was confirmed with national CDC data. 
In addition, as TEVAR became more widely used and the proportion of patients 
managed nonoperatively decreased, total mortality following admission for TTAI 
declined as well.
The first comprehensive study on TTAI was carried out in 1958, which defined 
the pathological mechanisms, histopathology, and epidemiologic characteristics 
of the untreated TTAI and was the first to propose management strategies for this 
highly lethal injury.2 Subsequently, open repair became the standard of care. In 
1997, a large prospective multicenter trial conducted by the American Associa-
tion for the Surgery of Trauma (AAST) reported that the operative mortality after 
Table 4. Multivariable predictors of mortality after thoracic aortic injury
Management OR 95% CI P-value
TEVAR Reference - -
Open Repair 2.1 1.6 – 2.7 <.001
Nonoperative 4.5 3.8 – 5.3 <.001
Baseline Characteristics OR 95% CI P-value
Age (per 10 years) 1.1 1.1 – 1.2 <.001
Male gender 1.3 1.1 – 1.5 .001
Congestive heart failure 1.2 0.9 – 1.6 .299
Cerebrovascular disease 2.4 1.8 – 3.2 <.001
Concomitant injuries OR 95% CI P-value
Brain injury 1.4 1.2 – 1.6 <.001
Hemothorax 1.6 1.3 – 1.9 <.001
Cardiac injury 1.5 1.1 – 2.0 .006
Major orthopedic injury 1.3 1.1 – 1.5 <.001
Other interventions OR 95% CI P-value
Intracranial intervention 3.0 2.2 – 4.0 <.001
Thoracic intervention 1.9 1.6 – 2.2 <.001
Abdominal intervention 2.1 1.8 – 2.5 <.001
Timing OR 95% CI P-value
Surgery on day of admission 1.6 1.2 – 2.2 .002
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3 These rates 
are substantially higher than those for open repair in the present study where 
mortality was 12.7% and paraplegia was 0.8%. In that same year, endovascular 
stent-graft placement for TTAI was first described.5 The comparative literature of 
open repair vs. TEVAR has largely been at the institutional level. These studies 
consistently determined that TEVAR was associated with substantial decreases 
in perioperative morbidity and mortality compared to open repair.7-9, 11, 16-19 A 
second AAST analysis was published in 2008, in which 65% of patients were 
treated using endovascular repair.20 With an operative mortality of 7.2% and an 
incidence of paraplegia lower than 1%, perioperative outcomes following TEVAR 
were comparable to our study. In line with the institutional series, this AAST 
follow-up study found favorable perioperative results for TEVAR.20 Yet, Hong et 
al. could not confirm the perioperative mortality benefits associated with TEVAR 
on a national level utilizing the NIS for the years 2001 to 2007.13 The conflicting 
results between these data and the present study may be explained by lower 
patient numbers in the Hong et al. study, as well as confounding resulting from 
the inclusion of data from 2001-2005, prior to the introduction of a specific 
ICD-9 procedure code for TEVAR. In addition, mortality trend analysis showed 
a dramatic decrease in perioperative mortality for TEVAR in the later years of 
our analysis, during which more TEVARs were performed as a proportion of 
total interventions. This could represent a learning curve for both surgeons and 
hospitals,21-23 and may also explain why the earlier NIS study did not find such 
a difference between TEVAR and open repair. Similar to the present study, de 
Mestral et al. showed a rapid increase in the utilization of endovascular repair for 
TTAI using the Canadian National Trauma Registry.24 Interestingly, they reported 
a concurrent increase in nonoperative treatment that was associated with a de-
cline in mortality. As a result, de Mestral et al. recommended that nonoperative 
treatment for TTAI should be a major focus in the endovascular era. In our study, 
however, the proportion of patients treated nonoperatively decreased, and the 
associated mortality remained substantially higher compared to TEVAR over 
the entire length of the study. Further data are needed comparing outcomes of 
patients undergoing TEVAR and those treated nonoperatively stratified by grade 
of the aortic injury.
An unadjusted comparison of adverse postoperative events between TEVAR 
and open repair is complicated by the high diversity and prevalence of con-
comitant injuries. However, as length of stay was shorter, and the incidence 
of postoperative complications such as cardiac and respiratory complications 
was lower among TEVAR patients despite comorbidities and concomitant injuries 
being more pronounced, this further supports the benefits of TEVAR over open 
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repair in the perioperative period. Earlier series showed high rates of paraplegia 
following open repair.3 Our results demonstrated similar low occurrence rates for 
paraplegia, as well as acute renal failure, for open repair and TEVAR, which is in 
line with more recent studies.16, 20 Shorter length of stay after TEVAR has also 
been reported previously.8, 18
In regards to the clinical practice guideline from the SVS selected expert com-
mittee, our results confirm the recommendation that TEVAR should be prefer-
entially performed over open surgical repair and nonoperative management.12 
The use of TEVAR is further supported by recent studies demonstrating good 
long-term results of endovascular repair for TTAI.25-27 The expert panel addition-
ally advised that aortic repair should be performed within 24 hours after admis-
sion barring other serious concomitant nonaortic injuries. However, our results 
showed that surgery on the day of admission was an independent risk factor 
for in-hospital mortality. Since this increased risk may very well be driven by 
patients with relatively severe aortic injuries requiring more urgent treatment, 
we believe that these data should not be used for deriving recommendations in 
regards to the timing of surgery.
TEVAR was more commonly performed in urban teaching hospitals. This was 
anticipated, as novel techniques and technologies such as TEVAR are typically 
introduced first to high volume academic centers. Also, the majority of these 
patients were likely transferred or brought directly to Level 1 trauma centers, 
which are predominantly urban and teaching. Prior literature evaluating differ-
ences in hospital costs between TEVAR and open repair is conflicting. While a 
study from Canada found comparable procedural costs between TEVAR and open 
repair,28 a recent study conducted in Houston found higher hospital charges for 
patients who underwent TEVAR.16 Although procedural costs are not documented 
in the database that was used, the NIS does provide total hospital charges for 
the hospitalization. In line with the more recent study, we found that TEVAR was 
associated with higher total charges. However, treatment of concomitant inju-
ries, which were more pronounced among TEVAR patients, may have contributed 
to this cost difference.
This study has several limitations that should be considered. First, as with 
every ICD-9 based database, the NIS lacks clinically relevant data such as the 
grade of the aortic injury, and hemodynamic status at admission. This lack of 
specificity should be kept in mind when comparing outcome differences between 
treatment strategies, as confounding by indication may influence results. The 
lack of these data may have resulted in heterogeneity particularly in the non-
operative treatment group, as we were unable to differentiate between patients 
who were turned down for surgery due to the severity of the aortic injury or 
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the nonoperative treatment group may have included patients that did not 
undergo aortic repair because the low grade of the aortic injury did not war-
rant repair or because concomitant injuries required more immediate medical 
attention. In addition, previous studies have indicated that results on surgical 
complications from administrative databases should be interpreted with cau-
tion, since these data resources have problems in regards to documentation of 
non-fatal perioperative outcomes.29-31 Furthermore, due to the limited number 
of diagnoses that can be reported per case, common comorbidities and less 
threatening concomitant injuries are underreported in more complex patients. 
As a result, these conditions act as confounders for less severe cases, resulting 
in protective risk estimates in regression analyses. As these estimates did not 
accurately reflect the association with mortality, we decided to exclude these 
variables from further analyses. Also, we were unable to differentiate between 
emergent admissions, and those (re)admitted for their procedure. However, 
sensitivity analyses among all patients coded as non-elective showed no notable 
differences in the multivariable model. Finally, we could not distinguish between 
blunt and penetrating thoracic aortic injuries using ICD-9 coding. However, since 
the majority of chest traumas are of blunt nature,32 we presume our cohort to 
predominantly consist of blunt TTAI patients. Also, the observed high prevalence 
of orthopedic injuries is often observed in blunt trauma patients, and is in line 
with prior studies reporting on blunt TTAI.3
In conclusion, traumatic thoracic aortic injury continues to be a highly lethal 
injury. TEVAR is now the dominant surgical approach in TTAI with substantial 
perioperative morbidity and mortality benefits over open aortic repair. Overall 
mortality following admission for TTAI has declined, which is most likely the re-
sult of both the replacement of open repair by TEVAR, as well as the broadened 
eligibility for operative repair.
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supplemental Table 1. ICD-9 definitions for comorbid conditions, concomitant injuries, 
other interventions, and adverse outcomes
Baseline characteristics ICD-9 codes
Hypertension 401.0-405.11
Coronary artery disease 412-414
Diabetes 250.x
Heart failure 428.x
COPD 492.x, 496.x
Chronic kidney disease 585.x
Cerebrovascular disease 433-438
Concomitant injuries ICD-9 codes
Brain injury 850.3-850.5, 850.9, 851-854.x
Hemothorax 860.2-860.5
Cardiac injury 861.00-861.13
Pulmonary injury 861.20-861.32
Liver injury 864.x
Spleen injury 865.x
Kidney injury 866.x
Pelvic injury 867.x
GI-tract injury 863.x
Skull fracture 800.x-804.x
Vertebral fracture without SCI 805.x
Vertebral fracture with SCI 806.x
Major orthopedic injury 805.x-806.x, 808.x, 820.x, 821.x
Other interventions ICD-9 codes
Intracranial 01.x-02.x (excl.: 01.1)
Thoracic
Cardiac 32.x-34.x (excl.: 33.2, 34.2)
Lung 35.x-37.x (excl.: 37.2)
Abdominal
Liver 50.x (excl.: 50.1)
Spleen 41.1-41.2, 41.4-41.5
Kidney 55.0x (excl.: 55.2)
Pelvic organs 56.x-57.x, 65.x-71.x (excl.: 56.3, 57.3, 65.1, 66.1, 67.1, 68.1, 
70.2, 71.1)
GI-tract 42.x-54.x (excl.: 42.2, 44.1, 45.1, 48.2, 49.2, 50.1, 51.1, 52.2, 
54.2)
Complications ICD-9 codes
Cardiac complication 997.1, 785.51, 427.41, 427.5, 410
Paraplegia 344.1
Stroke complication 997.02
Acute renal failure 584.5-584.9
Respiratory 481, 482, 518.5x, 518.7 518.81, 997.3x,
Wound dehiscence 998.30, 998.31, 998.32
Postoperative infection 998.51, 998.59
12
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4
5
6
7
8
9
10
11
12
13
14
15
16
17
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ABsTRACT
Objective
Endovascular repair (TEVAR) has become an alternative to open repair for the 
treatment of ruptured thoracic aortic aneurysms (rTAA). The aim of this study was 
to assess national trends in the utilization of TEVAR for the treatment of rTAA and 
determine its impact on perioperative outcomes.
Methods
Patients admitted with a ruptured thoracic aortic aneurysm between 1993 and 2012 
were identified from the Nationwide Inpatient Sample (NIS). Patients were grouped 
in accordance with their treatment: TEVAR, open repair, or nonoperative treatment. 
The primary outcomes were treatment trends over time and in-hospital death. 
Secondary outcomes included perioperative complications and length of stay. Trend 
analyses were performed using the Cochran-Armitage test for trend, and adjusted 
mortality risks were established using multivariable logistic regression analysis.
Results
A total of 12,399 patients were included, with 1622 (13%) undergoing TEVAR, 2808 
(23%) undergoing open repair, and 7969 (64%) not undergoing surgical treatment. 
TEVAR has been increasingly utilized from 2% in 2003-2004 of total admissions 
to 43% in 2011-2012 (P<.001). Concurrently, there was a decline in the propor-
tion of patients undergoing open repair (29% to 12%, P<.001) and nonoperative 
treatment (69% to 45%, P<.001). The proportion of patients undergoing surgical 
repair has increased for all age groups since 1993-1994 (P<.001 for all), but was 
most pronounced among those aged 80 years with a 7.5 fold increase. After TEVAR 
was introduced, procedural mortality decreased from 36% to 27% (P<.001), while 
mortality among those undergoing nonoperative remained stable between 63% and 
60% (P=.167). Overall mortality following rTAA admission decreased from 55% to 
42% (P<.001). Since 2005, mortality for open repair was 33% and 22% for TEVAR 
(P<.001). In adjusted analysis, open repair was associated with a two-fold higher 
mortality than TEVAR (OR: 2.0, 95% CI: 1.7 – 2.5).
Conclusion
TEVAR has replaced open repair as primary surgical treatment for rTAA. The introduc-
tion of endovascular treatment appears to have broadened patient eligibility for surgi-
cal treatment, particularly among the elderly. Mortality following rTAA admission has 
declined since the introduction of TEVAR, which is the result of improved operative 
mortality, as well as the increased proportion of patients undergoing surgical repair.
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InTRODUCTIOn
A ruptured descending thoracic aortic aneurysm (rTAA) is a life-threatening di-
agnosis, with an estimated mortality exceeding 90%.1 The majority of patients 
die before making it to the emergency department. For those hemodynamically 
stable enough to reach the hospital and undergo surgery,1 traditional open repair 
requires an emergency thoracotomy to replace the diseased aorta with an inter-
position graft. Despite the fact that hospitalized patients are presumed to have a 
better prognosis, mortality following surgery is as high as 45%,2, 3 with surviving 
patients often suffering disabling complications such as paraplegia and stroke.2, 4-6
As a minimally invasive alternative, endovascular repair (TEVAR) for rTAA was 
first introduced and described by Semba et al in 1997.7, 8 In subsequent years, 
single institution studies were performed to evaluate its feasibility, and perfor-
mance compared to conventional open repair.4, 9-14 Although some of these stud-
ies showed encouraging perioperative results favoring TEVAR, they were often 
limited by small numbers, and the inclusion of other acute aortic pathologies. 
Moreover, an absolute perioperative survival benefit of TEVAR over open repair 
could not be confirmed. 4, 14 Reports on outcome of rTAA using early national 
data from the Nationwide Inpatient Sample (NIS) yielded conflicting results, 
despite an identical TEVAR cohort. While Kilic et al. demonstrated that TEVAR for 
rTAA was associated with significantly lower perioperative in-hospital mortality 
compared to open repair,15 Gopaldas et al. concluded equivalent mortality and 
complication rates for the two treatment approaches.16 Age-stratified trends in 
treatment utilization were not explored in these studies.
Previous studies have demonstrated that for patients presenting with a trau-
matic thoracic aortic injury, the introduction of TEVAR has reduced the propor-
tion of patients managed nonoperatively.17, 18 For rTAA patients, however, it is 
unknown whether the introduction TEVAR has broadened their treatment eligibil-
ity.17 The purpose of this study was to assess national trends in the treatment 
of rTAA, focusing on the relative utilization and outcome of TEVAR, open repair, 
and nonoperative treatment.
METHODs
For this study, we used the Nationwide Inpatient Sample (NIS). The NIS is the 
largest US all-payer inpatient database, and is maintained by the Agency for 
Health Care Research and Quality (AHRQ) as part of the Healthcare Cost and Utili-
zation Project (HCUP). The NIS represents 20% of all annual U.S. hospitalizations. 
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Actual annual hospitalization volumes are approximated using hospital sampling 
weights. The weighted estimates are utilized for all analyses in this study, as rec-
ommended by the AHRQ. The Institutional Review Board of Beth Israel Deaconess 
Medical Center approved this study and patient consent was waived, due to the 
de-identified nature of the data.
Patients were identified using International Classification of Diseases, Ninth Re-
vision (ICD-9). All patients admitted with a ruptured thoracic aortic aneurysm 
(411.1) were identified. Patients were subsequently divided in the open repair 
group (38.35) and the TEVAR group (39.73). Those with a primary diagnosis of a 
ruptured aneurysm without mention of any procedure were considered nonopera-
tively treated. In an effort to capture TEVAR cases before TEVAR procedure coding 
was introduced in 2005, patients with a primary diagnosis of a ruptured thoracic 
aortic aneurysm in combination with mentioning of EVAR (39.71) or insertion of 
non-drug eluting peripheral (non-coronary) vessel stent (39.90) were also consid-
ered to have undergone endovascular repair. Patients with both a procedure code 
for open repair and TEVAR were excluded. In addition, those with a concomitant 
diagnosis for thoracoabdominal aneurysm (diagnosis codes: 441.3-441.9 or pro-
cedure codes: 38.44, 39.71), aortic dissection (diagnosis codes: 441.00-441.03), 
or connective tissue disorder (diagnosis codes: 446.0-446.7, 758.6, 759.82) were 
excluded from this study. To separate ascending from descending aneurysms, 
patients with procedure codes for cardioplegia (39.63), valve surgery (35.00-
35.99), and procedures on the vessels of the heart (36.00-36.99, 37.0, 37.2, 
37.31-37.90, 37.93, 37.99) were also excluded, as they are more likely to repre-
sent aneurysms of the ascending aorta.
Patients were compared on demographics (age, gender, race), and comorbid 
conditions (coronary artery disease, diabetes, hypertension, heart failure, chronic 
obstructive pulmonary disease [COPD], chronic kidney disease, and cerebrovas-
cular disease). We additionally assessed differences in hospital characteristics, 
including hospital bedsize (small, medium, large), setting and teaching status 
(rural, urban non-teaching, urban teaching). Hospital bedsize category varies 
according to location and teaching status. Small hospital bedsize is defined as 
1-49, 50-99 and 1-299 beds, respectively for rural, urban non-teaching and 
urban teaching hospitals, medium bedsize as 50-99, 100-199, 300-499, respec-
tively, and 100+, 200+, and 500+ beds is considered a large bedsize hospital, 
respectively. Adverse in-hospital outcomes included death, cardiac or respira-
tory complications, paraplegia, stroke, acute renal failure, wound dehiscence, 
infection, discharge to home, and length of stay. Cardiac complications include 
postoperative myocardial infarction, cardiac arrest, cardiogenic shock, and 
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ventricular fibrillation (Supplemental Table 1). A respiratory complication was 
defined as a postoperative pneumonia, pulmonary insufficiency after trauma or 
surgery, transfusion-related acute lung injury, or acute respiratory failure.
For this study we also utilized the Wide-ranging Online Data for Epidemiologic 
Research (WONDER), an epidemiological internet based database maintained by 
Centers for Disease Control and Prevention (CDC)19, to assess national cause-
specific age-adjusted death rates due to thoracic aortic aneurysms (ICD-10 code: 
S25.0). More information on WONDER can be found on http://wonder.cdc.gov/.
statistical methods
Baseline characteristics were described as counts and percentages (dichotomous 
variables), or means and standard deviations (continuous variables). Differences 
at baseline were assessed using Pearson’s chi-Square or Fisher’s exact testing, 
and Student’s t-test, where appropriate. Trend analyses were performed using the 
Cochran-Armitage test for trend. In order to assess the independent risk associated 
with treatment option for rTAA, we subsequently performed multivariable logistic 
regression analysis. Predictors with a P <.1 were entered into the multivariable 
model, after which the final model was obtained using stepwise backward elimina-
tion (exit P > .05). As a result of underreporting of less life-threatening conditions 
in more acute patients, less life-threatening comorbid conditions act as confound-
ers for less severe cases. Therefore, we chose not to include comorbidities with 
protective risk estimates on univariate screening. All tests were two-sided and 
significance was considered when P<.05. Statistical analysis was performed using 
SPSS Statistics 21 (IBM Inc., Chicago, IL).
REsULTs
A total of 12,399 patients were included, with 1622 (13%) undergoing TEVAR, 
2808 (23%) undergoing open repair, and 7969 (64%) not undergoing surgical 
treatment.
Epidemiological trends
TEVAR has been increasingly utilized from 2% of total admissions in 2003-2004 
to 43% in 2012 (P<.001, Figure 1). Concurrently, the proportion of patients un-
dergoing open repair declined from 29% to 12% (P<.001). Despite a decrease 
in open repair utilization, the overall proportion of patients undergoing surgical 
repair dramatically increased once TEVAR received FDA approval in 2005 (31% to 
55%, P<.001).
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Although an increase in surgical repair was observed in all age groups, it was 
not uniform. The utilization of surgical treatment for patients under 70 increased 
207% from 1993-1994 to 2011-2012 (P<.001, Figure 2a). For those aged 70-80 
years, this was 177% (P<.001). With a 750% increase over the study period, 
the shift towards operative management was most pronounced among those 
aged 80 and above. Figure 2b illustrates that the adoption to TEVAR started 
relatively early among the eldest patients, as 18% of patients aged 80 and over 
were undergoing TEVAR prior to its FDA approval (<70 years: 3%; 70-80 years: 
9%, P=.004). In 2011-2012, only 14% of patients aged 80+ underwent open 
repair, which was significantly lower compared to the <70 group (24%) and 
70-80 group (25%, P=.008)).
When population-adjusted trends were evaluated, an overall decrease in rTAA 
admissions was observed from 1993 to 2004 (4.7 to 3.6 per million, Figure 
3), a rate that stabilized thereafter. The number of patients surgically treated 
increased since 2003-2004 from 1.4 to 1.9 per million. This was observed among 
patients under 70 years (0.8 to 1.1 per million), but more strongly among pa-
tients aged 80 and above (3.5 to 9.9 per million).
Baseline characteristics
Baseline characteristics are detailed in Table 1. When comparing TEVAR patients 
to those undergoing open repair, we found that TEVAR patients were substantially 
older (72 years vs. 66 years, P<.001). In terms of comorbidities, TEVAR patients 
more often had diabetes (14% vs. 11%, P=.031), and hypertension (75.4% vs. 
60.4%, P<.001). Additionally, coronary artery disease (27% vs. 18%, P<.001), 
Figure 1. Annual proportions of the treatment strategies for the treatment of rTAA
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Figure I. Annual proportions of the treatment strategies for the treatment of rTAA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure IIA. Changes in rates of surgical repair by age (index volume: 1993-1994) 
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and chronic kidney disease (21% vs. 11%, P<.001) were more common among 
those undergoing TEVAR compared to open repair. TEVAR was more often per-
formed in academic centers (85% vs. 75%, P<.001), and larger bedsize hospitals 
(82% vs. 79%, P<.001) compared to open repair.
Figure 2a. Changes in rates of surgical repair by age (index volume: 1993-1994)
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Figure 2b. The proportion of TEVAR vs. open repair per age group
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Figure IIB. The proportion of TEVAR vs. open repair per age group 
 
 
 
Figure III. Population-adjusted trends in rTAA death rates, admission rates, and surgical 
repair utilization (per million) 
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Table 1. Baseline characteristics of patients admitted with for rTAA
Procedure
TEVAR
(N=2492)
Open
Repair
(N=848)
nonoperative
(N=5043)
P-value
Overall
OR vs
TEVAR
Demographics
Age – years (SD) 72.2 (13.2) 66.0 (14.2) 78.2 (12.7) <.001 <.001
Age category – % <.001 <.001
<70 years 36.0% 55.0% 16.3%
70-80 years 30.0% 27.6% 26.3%
80+ years 34.1% 17.4% 57.5%
Female gender – % 49.6% 51.0% 58.4% <.001 .526
Non-white race – % 27.3% 27.1% 23.3% .016 .922
Comorbidities TEVAR
Open
Repair nonoperative Overall
OR vs
TEVAR
Coronary artery disease – % 27.0% 17.8% 23.9% <.001 <.001
Old myocardial infarction – % 7.5% 1.3% 4.5% <.001 <.001
Diabetes – % 14.2% 11.0% 13.4% .096 .031
Hypertension – % 75.4% 60.4% 73.1% <.001 <.001
Heart Failure – % 14.5% 13.3% 14.0% .762 .462
COPD – % 18.7% 17.0% 18.0% .619 .328
Chronic kidney disease – % 20.8% 11.0% 15.2% <.001 <.001
Cerebrovasc disease –% 12.3% 14.0% 6.6% <.001 .263
Socioeconomic status TEVAR
Open
Repair nonoperative Overall
OR vs
TEVAR
Income quartile .538 .207
First 27.1% 25.9% 27.1%
Second 26.6% 27.3% 26.9%
Third 25.6% 22.8% 23.9%
Fourth 20.7% 24.0% 22.2%
Hospital Characteristics TEVAR
Open
Repair nonoperative Overall
OR vs
TEVAR
Hospital Setting – % <.001 <.001
Rural 1.5% 0.7% 11.9%
Urban non-teaching 13.2% 24.2% 31.5%
Urban teaching 85.3% 75.2% 56.5%
Hospital Bedsize – % <.001 <.001
Small 6.3% 3.9% 13.5%
Medium 12.2% 17.4% 17.7%
Large 81.5% 78.7% 68.8%
COPD: chronic obstructive pulmonary disease
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Perioperative mortality
In-hospital mortality was significantly lower for patients undergoing TEVAR com-
pared to open repair (22% vs. 33%, P<.001, Table 2). Following nonoperative 
treatment in-hospital mortality was 60%. In adjusted analysis, open repair was 
associated with a two-fold higher mortality compared to TEVAR (OR: 2.0, 95% 
CI: 1.7 – 2.5), while nonoperative management was associated with a five-fold 
increase in mortality (OR: 5.0, 95% CI: 4.3 – 5.9). From 2005 onward, mortality 
after TEVAR increased non-significantly from 21% to 26% (P=.219, Figure 4), 
while mortality following open repair decreased significantly between 2003-2004 
and 2011-2012 (36% to 29%, P=.005). Overall procedural mortality decreased 
from 36% to 27% (P<.001), while mortality among those undergoing nonopera-
tive remained stable between 63% and 60% (P=0.167). As TEVAR became more 
widely adopted –and the proportion of patients undergoing nonoperative treat-
ment decreased– overall mortality following rTAA admission decreased from 55% 
to 42% (P<.001).
Despite an increase in rTAA admissions among those under age 70 after the 
introduction of TEVAR, in-hospital deaths declined after 2003-2004 (0.6 to 0.4 
per million, Figure 3). Similarly, for those over 80, death following rTAA ad-
mission declined (16.7 to 13.3 per million), even though the rTAA admission 
incidence increased. The population-adjusted incidence of death following rTAA 
in patients 70-80 years of age also decreased considerably (7.1 to 3.0 per mil-
lion), although this was concurrent with a strong decline in admission for rTAA. 
Similar declining trends were seen in the national WONDER data from the CDC, 
Figure 3. Population-adjusted trends in rTAA death rates, admission rates, and surgical 
repair utilization (per million)
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with rTAA mortality among patients less than 70 years declining from 1.0 to 0.8 
per million between 2003-2004 and 2011-2012, and 42 to 22 per million among 
those aged 80 and above.
Table 2 Perioperative outcome of patients admitted for rTAA in accordance with treatment 
strategy.
Procedure
TEVAR
(N=2492)
Open
Repair
(N=848)
nonoperative
(N=5043)
P-value
Overall OR vs
TEVAR
Deathα – % 21.6% 33.2% 59.9% <.001 <.001
Cardiac complication – % 16.6% 31.2% 17.0% <.001 <.001
Paraplegia α – % 3.7% 5.6% 0.6% <.001 .031
Stroke complication – % 3.7% 5.0% 0.8% <.001 .165
Acute renal failure – % 21.8% 25.1% 9.6% <.001 .072
Respiratory – % 33.4% 43.0% 10.6% <.001 <.001
Wound Dehiscence – % 0.9% 3.7% 0.2% <.001 <.001
Postoperative infection – % 0.6% 3.8% 0.2% <.001 <.001
Bleeding complication 14.3% 18.2% 1.2% <.001 .015
Length of stay – days (SD)β 13.7 (12.7) 17.2 (15.0) 5.2 (7.3) <.001 <.001
Discharge to home – % 27.2% 21.1% 9.3% <.001 .002
α Odds ratio open repair vs. TEVAR: 2.0 (95% CI: 1.7 – 2.5); Odds ratio Nonoperative 
treatment vs. TEVAR: 5.0 (95% CI: 4.3 – 5.9) (adjusted for: age, gender, old myocardial 
infarction, congestive heart failure, obstructive pulmonary disease, ZIP household income 
quartile)
β Length of stay among those who did not die during hospitalization
Figure 4. Trends in in-hospital mortality following rTAA admission
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Perioperative complications
In addition to favorable mortality, TEVAR was associated with a lower incidence of 
cardiac complications (17% vs. 31%, P<.001), paraplegia (4% vs. 6%, P=.031), 
respiratory complications (33% vs. 43%, P<.001), wound dehiscence (0.9% vs. 
4%, P<.001), postoperative infection (0.6% vs. 4%, P<.001), and bleeding com-
plications (14% vs. 18%, P=.015) compared to open repair. Additionally, those 
undergoing TEVAR had a significantly shorter hospital stay (14 days vs. 17 days, 
P<.001), and were more likely to be discharged to home (27% vs. 21%, P=.002).
DIsCUssIOn
This study demonstrates that since its introduction, the utilization of endovascular 
repair has rapidly increased for the treatment of rTAA, and is currently the primary 
mode of treatment. Aside from replacing open repair, the use of TEVAR has led to 
an increase in the proportion of rTAA patients being treated surgically, particularly 
among patients older than 80. As a result, the majority of patients admitted for 
rTAA now undergo surgical repair. TEVAR was associated with favorable outcomes 
compared to open repair, despite TEVAR patients being older and having more 
comorbidities. Due to the shift from open repair to TEVAR, and the shift from non-
operative treatment to TEVAR, overall mortality following rTAA admission declined 
over the study period.
The feasibility of endovascular repair in an acute setting for rTAA was first 
described in 1997.7 In 2004, Scheinert et al. reported a 30-day mortality of 
9.7% among a cohort of 31 rTAA patients.10 Other series reported similar en-
couraging results, with mortality ranging between 3.1% and 24.6%. Comparing 
these outcomes to historic results for open repair with mortality of up to 45%,2, 6 
Mitchell et al. concluded that TEVAR has become the treatment of choice for 
acute thoracic aortic surgical emergencies.13 However, comparative studies were 
unable to establish an absolute survival benefit of TEVAR over open repair.4, 11, 14 
Jonker et al. evaluated morbidity and mortality after both operative approaches, 
and demonstrated that TEVAR was associated with a lower rate of periopera-
tive adverse events in a multi-institutional study. Mortality, however, was not 
significantly reduced in TEVAR patients.4 These findings were supported by Patel 
et al. who also demonstrated a lower incidence of adverse events in a composite 
outcome measure.14
When Gopaldas et al. utilized the NIS in an effort to assess national rTAA 
outcomes on a national level for the years both treatments were available 
(2006-2008), neither mortality nor complications rates differed between TEVAR 
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and open repair.16. Conversely, a recent study also utilizing NIS data up until 
2008 found that TEVAR was associated with a reduction in perioperative mortal-
ity compared to open repair.15 In this study, however, open repairs as far back 
as 1998 were compared to TEVAR patients treated in 2008, which resulted in 
substantially higher in-hospital mortality after open repair (53% vs. 29% in 
the Gopaldas study). In the present study using more recent data, we limited 
comparative analysis to data after the introduction of TEVAR. With mortality 
rates similar to the Gopaldas study, we found that perioperative morbidity and 
mortality following TEVAR was significantly lower compared to open repair. This 
in line with a retrospective analysis of Medicare beneficiaries in which Goodney et 
al. found significantly lower perioperative mortality in TEVAR patients compared 
to those undergoing open repair.20
Our study, similar to previous studies utilizing the NIS, is unable to assess 
long-term follow-up. However, previous reports have shown equivalent survival 
at 1- and 5-years, despite a substantially lower perioperative mortality after TE-
VAR.20-22 Patel et al. had similar 5-year findings in a cohort of 69 RTAA patients, 
although no significant differences in survival were observed in the perioperative 
period either.14
While increases in the proportion of patients undergoing surgery were ob-
served in all age groups, patients aged 80 and over benefitted most significantly 
from the introduction of TEVAR, as surgical treatment more than tripled since its 
introduction. This is similar to the increase in operative treatment among elderly 
abdominal aortic aneurysm (AAA) patients observed after the introduction of 
endovascular repair for AAA.23 These trends were also apparent after population-
adjustment, with substantial increases in the number of surgical interventions 
per million, and a concurrent decline in in-hospital death. Aside from elderly 
patients, TEVAR also appeared to be preferred for patients with increased co-
morbidities, as evidenced by increased rates of coronary artery disease, chronic 
kidney disease and hypertension among TEVAR patients compared to those 
undergoing open repair. This phenomenon has been demonstrated for elective 
abdominal and thoracic aortic surgery, and may explain the improved mortality 
trend for open repair due to patients with severe comorbidities now offered the 
endovascular alternative instead of invasive open repair.24, 25
This study has several limitations that should be addressed. First, since the 
NIS is an ICD-9 based database, it does not provide detailed operative or clinical 
data, including hemodynamic status at admission. Consequently, we are unable 
to assess the role of hemodynamics on operative selection. Anatomic data are 
also lacking which may impact the choice of open repair vs. TEVAR and may also 
impact outcome. Additionally, previous studies have indicated that evaluation 
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of surgical complications from administrative databases should be interpreted 
with caution, since documentation of non-fatal perioperative outcomes may be 
incomplete.26-28 Furthermore, only a limited number of diagnoses can be re-
ported per patient. As a result, common comorbidities may be underreported in 
the sickest patients, leading to confounding for less severe cases. Since these 
protective risk estimates do not accurately reflect the association with mortality, 
we decided to exclude these variables from further analyses.
In conclusion, this study shows that TEVAR has been increasingly utilized since 
its introduction, and is associated with significantly lower perioperative morbid-
ity and mortality than traditional open surgical repair. In addition to replacing 
open repair as the dominant surgical approach for rTAA nationally, TEVAR has 
broadened treatment eligibility, with the majority of patients presenting with 
rTAA now undergoing operative intervention. As a result of the shift from open 
repair and nonoperative treatment to TEVAR, overall mortality following RTAA 
admission has decreased in recent years.
Chapter 2
52
REFEREnCEs
1. Johansson G, Markstrom U, Swedenborg J. Ruptured thoracic aortic aneurysms: a 
study of incidence and mortality rates. J Vasc Surg. 1995; 21(6): 985-8.
2. Schermerhorn ML, Giles KA, Hamdan AD, Dalhberg SE, Hagberg R, Pomposelli F. 
Population-based outcomes of open descending thoracic aortic aneurysm repair. J Vasc 
Surg. 2008; 48(4): 821-7.
3. Crawford ES, Hess KR, Cohen ES, Coselli JS, Safi HJ. Ruptured aneurysm of the 
descending thoracic and thoracoabdominal aorta. Analysis according to size and treat-
ment. Ann Surg. 1991; 213(5): 417-25; discussion 25-6.
4. Jonker FH, Verhagen HJ, Lin PH, Heijmen RH, Trimarchi S, Lee WA, et al. Open surgery 
versus endovascular repair of ruptured thoracic aortic aneurysms. J Vasc Surg. 2011; 
53(5): 1210-6.
5. Girardi LN, Krieger KH, Altorki NK, Mack CA, Lee LY, Isom OW. Ruptured descending 
and thoracoabdominal aortic aneurysms. Ann Thorac Surg. 2002; 74(4): 1066-70.
6. Barbato JE, Kim JY, Zenati M, Abu-Hamad G, Rhee RY, Makaroun MS, et al. Contem-
porary results of open repair of ruptured descending thoracic and thoracoabdominal 
aortic aneurysms. J Vasc Surg. 2007; 45(4): 667-76.
7. Semba CP, Kato N, Kee ST, Lee GK, Mitchell RS, Miller DC, et al. Acute rupture of the 
descending thoracic aorta: repair with use of endovascular stent-grafts. J Vasc Interv 
Radiol. 1997; 8(3): 337-42.
8. Dake MD, Miller DC, Semba CP, Mitchell RS, Walker PJ, Liddell RP. Transluminal place-
ment of endovascular stent-grafts for the treatment of descending thoracic aortic 
aneurysms. N Engl J Med. 1994; 331(26): 1729-34.
9. Doss M, Wood JP, Balzer J, Martens S, Deschka H, Moritz A. Emergency endovascular 
interventions for acute thoracic aortic rupture: four-year follow-up. J Thorac Cardio-
vasc Surg. 2005; 129(3): 645-51.
10. Scheinert D, Krankenberg H, Schmidt A, Gummert JF, Nitzsche S, Scheinert S, et al. 
Endoluminal stent-graft placement for acute rupture of the descending thoracic aorta. 
Eur Heart J. 2004; 25(8): 694-700.
11. Morishita K, Kurimoto Y, Kawaharada N, Fukada J, Hachiro Y, Fujisawa Y, et al. De-
scending thoracic aortic rupture: role of endovascular stent-grafting. Ann Thorac Surg. 
2004; 78(5): 1630-4.
12. Amabile P, Rollet G, Vidal V, Collart F, Bartoli JM, Piquet P. Emergency treatment of 
acute rupture of the descending thoracic aorta using endovascular stent-grafts. Ann 
Vasc Surg. 2006; 20(6): 723-30.
13. Mitchell ME, Rushton FW, Jr., Boland AB, Byrd TC, Baldwin ZK. Emergency procedures 
on the descending thoracic aorta in the endovascular era. J Vasc Surg. 2011; 54(5): 
1298-302; discussion 302.
14. Patel HJ, Williams DM, Upchurch GR, Jr., Dasika NL, Deeb GM. A comparative analysis 
of open and endovascular repair for the ruptured descending thoracic aorta. J Vasc 
Surg. 2009; 50(6): 1265-70.
15. Kilic A, Shah AS, Black JH, 3rd, Whitman GJ, Yuh DD, Cameron DE, et al. Trends in re-
pair of intact and ruptured descending thoracic aortic aneurysms in the United States: 
a population-based analysis. J Thorac Cardiovasc Surg. 2014; 147(6): 1855-60.
16. Gopaldas RR, Dao TK, LeMaire SA, Huh J, Coselli JS. Endovascular versus open repair 
of ruptured descending thoracic aortic aneurysms: a nationwide risk-adjusted study of 
923 patients. J Thorac Cardiovasc Surg. 2011; 142(5): 1010-8.
53
TEVAR for ruptured thoracic aortic aneurysms
2
17. Hong MS, Feezor RJ, Lee WA, Nelson PR. The advent of thoracic endovascular aortic 
repair is associated with broadened treatment eligibility and decreased overall mortal-
ity in traumatic thoracic aortic injury. J Vasc Surg. 2011; 53(1): 36-42; discussion 3.
18. Ultee KH, Soden PA, Chien V, Bensley RP, Zettervall SL, Verhagen HJ, et al. National 
trends in utilization and outcome of thoracic endovascular aortic repair for traumatic 
thoracic aortic injuries. J Vasc Surg. 2016.
19. National cause-specific age adjusted mortality data on the occurence of death due to 
thoracic aortic injury between 1999-2013 [Internet]. Centers for Disease Control and 
Prevention. [cited 06/29/2015]. Available from: http://wonder.cdc.gov/mcd-icd10.
html.
20. Goodney PP, Travis L, Lucas FL, Fillinger MF, Goodman DC, Cronenwett JL, et al. Survival 
after open versus endovascular thoracic aortic aneurysm repair in an observational 
study of the Medicare population. Circulation. 2011; 124(24): 2661-9.
21. Conrad MF, Ergul EA, Patel VI, Paruchuri V, Kwolek CJ, Cambria RP. Management of 
diseases of the descending thoracic aorta in the endovascular era: a Medicare popula-
tion study. Ann Surg. 2010; 252(4): 603-10.
22. Desai ND, Burtch K, Moser W, Moeller P, Szeto WY, Pochettino A, et al. Long-term 
comparison of thoracic endovascular aortic repair (TEVAR) to open surgery for the 
treatment of thoracic aortic aneurysms. J Thorac Cardiovasc Surg. 2012; 144(3): 604-
9; discussion 9-11.
23. Schermerhorn ML, Bensley RP, Giles KA, Hurks R, O’Malley A J, Cotterill P, et al. 
Changes in abdominal aortic aneurysm rupture and short-term mortality, 1995-2008: 
a retrospective observational study. Ann Surg. 2012; 256(4): 651-8.
24. Lederle FA, Freischlag JA, Kyriakides TC, Matsumura JS, Padberg FT, Jr., Kohler TR, 
et al. Long-term comparison of endovascular and open repair of abdominal aortic 
aneurysm. N Engl J Med. 2012; 367(21): 1988-97.
25. Walker KL, Shuster JJ, Martin TD, Hess PJ, Jr., Klodell CT, Feezor RJ, et al. Practice pat-
terns for thoracic aneurysms in the stent graft era: health care system implications. 
Ann Thorac Surg. 2010; 90(6): 1833-9.
26. Lawson EH, Louie R, Zingmond DS, Brook RH, Hall BL, Han L, et al. A comparison 
of clinical registry versus administrative claims data for reporting of 30-day surgical 
complications. Ann Surg. 2012; 256(6): 973-81.
27. Bensley RP, Yoshida S, Lo RC, Fokkema M, Hamdan AD, Wyers MC, et al. Accuracy of 
administrative data versus clinical data to evaluate carotid endarterectomy and carotid 
stenting. J Vasc Surg. 2013; 58(2): 412-9.
28. Fokkema M, Hurks R, Curran T, Bensley RP, Hamdan AD, Wyers MC, et al. The impact 
of the present on admission indicator on the accuracy of administrative data for carotid 
endarterectomy and stenting. J Vasc Surg. 2014; 59(1): 32-8 e1.
Chapter 2
54
3
supplemental Table 1. ICD-9 codes used for defining comorbid conditions, and adverse 
outcomes
Baseline characteristics ICD-9 codes
Hypertension 401.0-405.11
Coronary artery disease 412-414
Old myocardial infarction 412
Diabetes 250.x
Heart failure 428.x
COPD 492.x, 496.x
Chronic kidney disease 585.x
Cerebrovascular disease 433-438
Complications ICD-9 codes
Cardiac complication 997.1, 785.51, 427.41, 427.5, 410
Paraplegia 344.1
Stroke complication 997.02
Acute renal failure 584.5-584.9
Respiratory 481, 482, 518.5x, 518.7 518.81, 997.3x,
Wound dehiscence 998.30, 998.31, 998.32
Postoperative infection 998.51, 998.59
Bleeding complication 998.11-998.12
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3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
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ABsTRACT
Since its introduction more than two decades ago, endovascular aneurysm repair 
(EVAR) has become the primary choice for elective treatment of abdominal aortic 
aneurysms (AAA) in many medical centers. The (dis)advantages, including 30-day 
mortality and long-term survival, of both open and endovascular elective AAA 
repair have been studied extensively, including four randomized trials. On the 
contrary, the survival benefit of EVAR for ruptured AAAs is not as well established 
as in elective situations. In the absence of randomized trials, the best treatment 
modality for ruptured AAA has not been revealed. In this manuscript, we describe 
the design and (preliminary) results of recently completed and ongoing random-
ized trials. Furthermore, the trends in management and the results of the treat-
ment of ruptured AAA in our tertiary center over a 20-year period are presented. 
In the last decade, a progressive increase in the proportion of patients managed 
by EVAR was observed. This increase was associated with an overall increase in 
the number of treated patients and, simultaneously, a decrease in the overall 30-
day mortality (53% versus 39%) was seen when comparing the two last decades. 
The 30-day mortality rates were significantly lower in the patients treated with 
EVAR (24%) compared to open repair (52%). The survival advantage for EVAR 
after ruptured AAA persisted during the first 5 years after repair, but was lost after 
that period. The estimated 5-year survival was 44% and 39% for EVAR and open 
repair, respectively. These data support that endovascular repair is an effective 
and safe strategy as a primary treatment modality for ruptured AAA.
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InTRODUCTIOn
After the world’s first endovascular aneurysm repair (EVAR) in 1987 by Volodos, 
this less invasive treatment modality has been adapted in many medical centers 
and its use has expanded to approximately 60% of all elective abdominal aortic 
aneurysm (AAA) repairs.1, 2 Recent multicenter randomized controlled trials have 
confirmed that EVAR can be performed with three-fold reduction of periopera-
tive mortality compared with open repair.3 The reported 30-day mortality rates 
in four randomized trial (EVAR, DREAM, OVER and ACE) was 0.2-1.7% in the 
EVAR-treated patients versus 0.7- 4.7% after open repair. However, no significant 
differences were found in the long-term mortality rates (2-6 years).3
Since a ruptured aneurysm is nearly always fatal, the primary survival is of 
utmost importance for the critically ill patient with a ruptured AAA. Intuitively, it 
could be expected that these patients, in case of anatomical suitability, benefit 
most from the endovascular approach. However, since its first description, the 
introduction of endovascular treatment of ruptured AAA has faced significant re-
sistance.4, 5 Several single-center, mostly observational studies, report superior 
results, with a mean 38% decrease in 30-day mortality favoring EVAR in patients 
with ruptured AAAs.6 However, level I evidence from randomized trials which 
confirm these survival benefits of endovascular repair is still lacking.
This manuscript outlines the design and results of recently completed and 
ongoing randomized trials comparing EVAR to open repair for ruptured AAAs, 
and the most important published data so far will be discussed. Moreover, the 
trends in management and data of 20 years of ruptured AAA treatment in our 
tertiary center are discussed.
TRIALs
Currently, the results of one randomized trial have been published, two random-
ized trials are in progress (IMPROVE and ECAR) and the inclusion of the AJAX trial 
was completed in March 2011.5, 7-9
The nottingham Trial
Hinchliffe et al.5 described the results of the first, single-center, prospective ran-
domized controlled trial comparing EVAR with open aneurysm repair in patients 
with ruptured AAA. The primary endpoint was operative (30-day) mortality and 
secondary endpoints were moderate or severe operative complications, hospital 
stay and time between diagnosis and operation. Although 103 patients were admit-
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ted to the study between September 2002 and December 2004, only 32 patients 
were recruited. The trial was stopped because it was underpowered. No significant 
differences were found between the two groups in the 30-day mortality rates 
(53% in both groups) or other endpoints. The authors concluded that it is possible 
to perform a randomized trial of open and endovascular surgery in patients with 
ruptured AAA and that preoperative CT scanning does not delay treatment.
The Amsterdam Trial
The first results of the Acute Endovascular Treatment to Improve Outcome of Rup-
tured Aortoiliac Aneurysms (AJAX) Trial were presented at the 34th Charing Cross 
Symposium in London (April 2012).9 The objective of this multicenter randomized 
clinical trial was to study the outcome of open surgery versus endovascular treat-
ment for ruptured AAAs. All patients in the Amsterdam region with a ruptured 
abdominal aneurysm who were eligible for endovascular and conventional surgery 
were included. The primary endpoint was a combination of mortality and severe 
morbidity at 30 days. The secondary endpoints were length of hospital and inten-
sive care unit (ICU) stay, intubation/ventilation and use of blood products.
Between April 2004 and February 2011, 520 patients with ruptured AAAs 
were enrolled in the trial. Of these cases, 395 patients were evaluated with 
CT and 155 (39%) were found to have a suitable anatomy for endovascular 
repair. Eventually, only 116 patients (22%) were randomized (57 to EVAR and 
59 to open repair). Other patients were excluded for a variety of reasons. The 
preliminary data of this trial showed that there was no difference between EVAR, 
using an aorto-uni-iliac (AUI) graft with contralateral occlude and femorofemoral 
crossover bypass, and open repair in the treatment of ruptured AAAs. EVAR 
had a combined and severe complications rate of 42% (24/57) and in the open 
surgery group this rate was 47% (28/59) at 30 days. Also, the 30-day mortality 
rates showed no significant differences (EVAR: 21% and open repair: 25%). 
Regarding some of the secondary endpoints, EVAR performed slightly better. 
In the open repair group, ICU stay was 48 hours versus 28 hours in the EVAR 
group (P=0.14); hospital stay 9 days with EVAR and 13 days with open repair 
(P=0.57); mechanical ventilation: 39 versus 52 patients in the open repair group 
(P=0.002); blood loss with EVAR was 500 mL while it was 3500 mL with open 
repair (P<0.001) and 45 EVAR patients needed blood products during surgery 
versus 56 patients after open repair (P=0.01).
In conclusion, open repair performed much better than expected with low 
death rates in the randomized controlled trial, but also low death rates in the 
entire cohort. The absolute risk reduction (ARR) of EVAR versus open repair was 
5.4% (95% CI -11 to +23).
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It is remarkable that the AJAX Trial was initially based on the recruitment of 
just 80 patients. With these 80 patients, no significant difference in the primary 
endpoint was found. Therefore, the recruitment of patients was extended. The 
low death rates could not be explained by neither a selection of hemodynamically 
stable patients nor favorable anatomy. Of all patients, 17% was hemodynami-
cally] unstable, versus 20% in the randomized group (23/116). The death rate 
following open surgery in patients with unfavorable anatomy was 26% in the 
cohort (58/222) and the 30-day mortality of all patients who underwent surgery 
was 30% (138/454; 95% CI 26-35%).
The ECAR Trial
The inclusion of the multicentric randomized Endovasculaire vs. Chirurgie dans 
les Anévrysmes Rompus (ECAR) trial started in January 2008 and is still running.8 
This study was setup on 160 patients to compare EVAR versus open repair in 
patients with ruptured aortoiliac aneurysms in France. The study is powered for an 
expected 20% reduction in early mortality after endovascular repair. The design of 
the study is comparable to the AJAX trial and only patients who are hemodynamic 
stable and morphologically suitable for EVAR (including an infrarenal neck longer 
than 10 mm and smaller than 32 mm diameter) are included. Patients are ran-
domized according to the calendar week and the hospital at which they present. 
The primary endpoint is 30-days mortality.
The IMPROVE Trial
Also the Immediate Management of the Patient with Rupture: Open Versus Endo-
vascular repair (IMPROVE) Aneurysm Trial is still in progress.7 The objective of this 
international multicenter study is to determine whether a policy of endovascular 
repair improves the survival of all patients with ruptured AAA. The recruitment of 
patients started in October 2009. In this randomized trial, patients with a clinical 
diagnosis of ruptured AAA are randomized to immediate CT scan and endovascular 
repair whenever anatomically suitable (endovascular first), or to open repair, with 
CT scan being optional. The trialists expect that 600 patients are required to show 
a 14% reduction in 30-days mortality (primary outcome) for the endovascular 
first policy. Secondary endpoints include 24h, in-hospital and 1 year survival, 
complications, major morbidities, costs and quality of life.
As compared to the ECAR trial, the IMPROVE trial compares endovascular and 
open strategies in a more anatomically and hemodynamically heterogeneous 
group by this approach.
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RELEVAnT sTUDIEs
Many centers have published their data on endovascular treatment of rAAAs. In 
this part, two recent papers are summarized and some management strategies of 
rAAAs are enumerated.
Veith et al.10 collected data of 49 centers worldwide, which had used EVAR 
for rAAAs. The purpose of the study was to examine the role and value of the 
endovascular treatment of ruptured aneurysms and explain the variable results 
that have been published. Questionnaires were used to obtain the data. In 
total, 1037 patients treated by EVAR and 763 patients treated by open repair 
were included. Overall 30-day mortality after EVAR in 1037 patients was 21.2% 
versus 36.3% for 763 patients in the open repair group (P<0.0001). Centers 
performing EVAR as primary choice, treated patients with rAAAs endovascular in 
28-79% (mean 49%) of all cases. Furthermore, centers with the largest number 
of patients had a lower 30-day mortality after EVAR as compared to centers with 
low patient numbers (21% versus 35%). The authors concluded that in patients 
with a suitable anatomy, EVAR seems to be a superior way to treat rAAAs with 
lower 30-days mortality than open repair. Especially high risk patients who most 
probably will not survive open surgery, e.g. hemodynamic instable patients or 
patients with a hostile abdomen, will benefit most of EVAR. Furthermore, centers 
that treat this category of patients should be able to perform both techniques 
and additional surgical procedures. Finally, some recommendations on several 
key strategies, adjuncts and technical factors to perform EVAR for rAAAs are 
listed in this publication:
• a standard approach or protocol is indispensable for an efficient treatment 
and facilitates decision-making;
• hypotensive hemostasis: fluid resuscitation should be restricted and low 
systolic arterial pressure is well tolerated for short periods and limits internal 
bleeding;
• for optimal results, EVAR procedures should be performed in well equipped 
sites where open surgery is also possible;
• catheter-guidewire placement should be performed under local anesthesia. 
By this, circulatory collapse caused by the induction of general anesthesia 
can be prevented;
• supraceliac aortic balloon control can be used in case of severe circulatory 
collapse;
• both bifurcated and AUI grafts can be used successfully;
• a high index of suspicion for abdominal compartment syndrome (ACS) is 
mandatory as this is a major cause of morbidity and mortality after EVAR for 
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rAAAs. ACS can be managed by early laparotomy, hematoma evacuation and 
open abdomen treatment with suction/sponge (VAC) dressings
The group of Schermerhorn published their results on endovascular versus open 
repair for ruptured AAA very recently.11 In this study, perioperative mortality, mid-
term survival, and morbidity after EVAR and open surgical repair were compared 
in a period of 10 years (2000-2010). In this period, 74 infrarenal ruptured AAAs 
were treated (19 by EVAR and 55 by open repair). Although EVAR patients were 
significant older and faced more comorbidity, a large difference in perioperative 
mortality was found in favor of the EVAR patients (15.7% versus 49%; P=0.008). 
Also other endpoint as mid-term and one-year survival, mean length of stay and 
ventilator-dependent respiratory failure were more advantageous in the EVAR 
treated patients. Because of these results, EVAR should be considered the stan-
dard of care for ruptured AAAs.
The Erasmus University Medical Center Experience: endovascular 
versus open surgical repair of ruptured AAAs
In the Erasmus University Medical Center (Rotterdam, the Netherlands) we per-
formed a study to determine the trends in management for ruptured AAAs over 
a 20-year period. We also assessed the impact of treatment modality on early 
and late survival after ruptured AAA. The Erasmus University Medical Center is 
a tertiary institution, which provides endovascular and open vascular surgery in 
its full extent serving about one and a half million people living in the Rotter-
dam’s conurbation. In this study we only included the patients with a true AAA 
rupture. We defined rupture as either direct visualization of fresh blood in the 
retroperitoneal or peritoneal compartments during open surgery, or visualization 
of periaortic hematoma on the immediate preoperative CTA.12 Patients included 
were treated between 1991 and June 2012. All possible operation codes were 
retrieved retrospectively and the hospital charts and stored CTAs were manually 
searched to assess the presence of rupture. Due to the retrospective nature of 
this study, we were not able to determine the amount of patients with a ruptured 
AAA who were not operated on, either because they did not agree to surgery or 
because their surgical risk was unacceptably high. In the 1990s, open surgery was 
the only method to treat ruptured AAA but this changed in 2001 with the introduc-
tion of endovascular surgery for ruptured AAA in our facility. From the introduction 
onwards all patients suspected of ruptured AAA got a CTA to determine whether or 
not the aorta was suitable for endovascular repair, and the decision was individu-
alized, according to anatomical suitability and the surgeon’s preference.
In the last 5 years, logistics changed, making it possible to offer EVAR to 
any anatomically suitable patients at any day or time. This includes a CT scan 
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present in the emergency department, an endovascular team on call 24/7, and 
a full stock of endoprosthesis with a large selection of sizes and configurations. 
By institutional protocol, patients with a suspected ruptured AAA are kept on 
permissive hypotension and a CTA is performed immediately after confirmation 
of the presence of an AAA by ultrasound. The images are instantly transferred 
to the hospital’s patient management system, where it can be redirected to a 
dedicated postprocessing image workstation. If a rupture is confirmed and the 
patient is anatomically suitable, preference is generally given to endovascular 
repair. Immediate repair is performed in the operating theatre using a mobile 
C-arm. Whenever possible, the procedure is performed under local anesthesia.
The data from all these patients were retrieved from emergency reports, CT 
scans, operation — as well as anesthesia reports, patient files and discharge let-
ters. To obtain mortality rates, inquiry of national civil registry data was used to 
extract dates of death. The study endpoints were 30-day mortality and longterm 
survival. To compare 30-day mortality between EVAR and open surgery, χ2 test 
was used. Significant variables on univariable analysis were subsequently used 
in a multivariable logistic regression to determine the odds ratio (OR) and 95% 
confidence interval (CI) for 30-day mortality. Expected survival during follow-up 
was obtained using Kaplan-Meyer estimates, and survival after EVAR versus 
open repair was compared using the Log-rank (Mantel-Cox) statistical test. 
Kaplan-Meyer curves were plotted for 30-day, 5 year and overall survival.
The inclusion criteria were met in 314 patients with a mean age of 72±8 (88% 
male). Of these cases, 78 patients underwent EVAR and 236 patients open repair 
(Table 1). The mean age was not significantly different between the two groups. 
While in the first 10 years of the study open repair was used exclusively, a pro-
gressive increase in the proportion of patients managed by EVAR was observed 
in the last decade (Figure 1). The introduction of endovascular treatment was 
associated with an overall increase in the number of treated patients (119 in the 
first 10 years of the study versus 195 in the subsequent decade) and, simultane-
ously, a decrease in the overall 30-day mortality (from 52.6% in the period of 
1991- 2001 to 39.3% from 2002 to 2012). The 30-day mortality rates were 
significantly lower in the patients treated with EVAR (23.8%) compared to open 
repair (52.3%; P=0.016, Figure 2a-c). These results support that early survival 
Table 1. Baseline characteristics (N=314)
Variable Open surgery EVAR P-value
Age - mean ±SD 71.5±8.1 72.7±7.7 0.24
Female – N. (%) 29 (12.3) 9 (11.5) 0.52
63
Ruptured AAA: state of the art management
3
benefit for EVAR is not restricted to elective repair but also possible of the acute 
setting. 3 Both open repair (OR: 2.46, 95% CI: 1.29-4.68, P=0.006) and age 
at repair (OR: 1.08, 95% CI: 1.04-1.12 per year increase) were independent 
risk factors for 30-day mortality. In Figure 3, one can see the change in use 
of type of stent in the acute treatment of rAAA. At first, only bifurcated stents 
were used in rAAAs because those were the only type of stents in stock. In the 
latter years, this changed by adding the AUI stent, which caused a shift in use 
from bifurcated to AUI. Aneurysm exclusion using AUI is generally faster as 
compared with bifurcated stent-grafts, which is potentially advantageous when 
treating hemodynamically unstable patients. Availability of AUI devices may 
have resulted in expansion in the range of “amenable” patients for EVAR, and 
also contribute to the reduction in patients managed by open surgery. Within 
the open repair group, a shift was seen as well; with an increase of the usage of 
tube grafts in the latter decade. However, the type of open repair (tube versus 
bifurcated graft) or endovascular repair (bifurcated versus AUI configuration) 
was not a significant determinant of 30-day mortality in this study.
The survival advantage for EVAR after ruptured AAA persisted during the 
first 5 years after repair (Figure 4; P=0.026), but no significant difference was 
observed when the entire period of follow-up was analyzed (P=0.078). The 
Figure 1. Trends of type of repair for treatment of rAAA (1991-2012).
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Table I. Baseline characteristics (N=314) 
Variable Open surgery EVAR P-value 
Age - mean ±SD 71.5±8.1 72.7±7.7 0.24 
Female – N. (%) 29 (12.3) 9 (11.5) 0.52 
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Figure 2A. 30-day mortality for all patients (2003-2012) 
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estimated 5-year survival was 44.6% and 39.1% for EVAR and open repair, 
respectively. These late survival rates are remarkably good and compare favor-
ably to current literature.11-13 Importantly, these late results are encouraging 
for current management of ruptured AAA. In conclusion, our study shows a 
significant difference between the endovascular and open repair approach in 
short-term and long-term mortality for patients with ruptured AAA in favor of 
endovascular treatment.
Figure 2a. 30-day mortality for all patients 
(2003-2012)
Figure 2b. 30-day mortality for patient 
treated with open repair (2003-2012)
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Figure 2B. 30-day mortality for patient treated with open repair (2003-2012) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2C. 30-day mortality for patient treated with EVAR (2003-2012) 
 
 
 
 
 
  
Figure 2c. 30-day mortality for patient 
treated with EVAR (2003-2012)
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Figure 2B. 30-day mortality for patient treated with open repair (2003-2012) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2C. 30-day mortality for patient treated with EVAR (2003-2012) 
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Figure 3. Trends of type of operation and type of graft.
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Figure 4. Survival at 5-years (p=0.026) 
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COnCLUsIOns
With the growing worldwide application of EVAR for the treatment of elective 
AAAs, this endovascular treatment modality has also been adapted increasingly to 
the management of patients with ruptured AAAs. In contrast to elective aneurysm 
repair, up to now, the (short-term) survival benefit of EVAR for rAAAs has not been 
confirmed by randomized clinical trials. The ECAR and IMPROVE trials are not 
completed yet and in the Nottingham pilot trial no significant differences in the 30-
day mortality rates were found between open surgery and EVAR.5, 7, 8 However, as 
this study was underpowered, no final conclusion can be drawn, except that it is 
possible to perform a randomized controlled trial in patients with ruptured AAAs. 
Also the authors of the AJAX trial did not succeed to demonstrate the potential 
benefits of EVAR in ruptured AAA repair.9 In this study, only 22% (116/520) of 
all initial enrolled patients were randomized for EVAR or open surgery in a 7-year 
period. Moreover, in this small group, the open repaired patient performed much 
better than anticipated. These data endorse that is difficult to perform a random-
ized trial in patients with ruptured AAAs.
On the other hand, the majority of comparative, mostly observational, single-
center studies show a clear trend towards reduced perioperative mortality for 
endovascular treatment as compared to open repair.14, 15 The data from our 
tertiary institute, as described in this chapter, are in line with these reports. 
With both methods, randomized trials and observational studies, a potential 
selection bias can occur in selecting more hemodynamically stable patients or 
patient with a favorable anatomy. For the successful management of rAAAs by 
EVAR, it is a prerequisite that centers have dedicated teams, an extensive stock 
of materials and the rapid availability of CT-scan examination with appropriate 
planning software. Finally, it can be concluded that, within the limitations of the 
published studies and taking into account that not all patients are suitable for 
endovascular treatment due to anatomic constraints, endovascular repair is an 
effective and safe strategy as a primary treatment modality for ruptured AAAs.
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ABsTRACT
Objective
Endovascular aneurysm repair (EVAR) for ruptured abdominal aortic aneurysm 
(rAAA) has faced resistance owing to the marginal evidence of benefit over open 
surgical repair (OSR). This study aims to determine the impact of treatment mo-
dality on early mortality after rAAA, and to assess differences in postoperative 
complications and long-term survival.
Methods
Patients treated between January 2000 and June 2013 were identified. The 
primary endpoint was early mortality. Secondary endpoints were postoperative 
complications and long-term survival. Independent risk factors for early mortality 
were calculated using multivariate logistic regression. Survival estimates were 
obtained by means of Kaplan–Meier curves.
Results
Two hundred and twenty-one patients were treated (age 72 ± 8 years, 90% 
male), 83 (38%) by EVAR and 138 (62%) by OSR. There were no differences 
between groups at the time of admission. Early mortality was significantly lower 
for EVAR compared with OSR (odds ratio [OR]: 0.45, 95% confidence interval 
[CI]: 0.21–0.97). Similarly, EVAR was associated with a threefold risk reduction in 
major complications (OR: 0.33, 95%CI: 0.15–0.71). Hemoglobin level <11 mg/
dL was predictive of early death for patients in both groups. Age greater than 75 
years and the presence of shock were significant risk factors for early death after 
OSR, but not after EVAR. The early survival benefit of EVAR over OSR persisted 
for up to 3 years.
Conclusion
This study shows an early mortality benefit after EVAR, which persists over the 
mid-term. It also suggests different prognostic significance for preoperative vari-
ables according to the type of repair. Age and the presence of shock were risk 
factors for early death after OSR, while hemoglobin level on admission was a 
risk factor for both groups. This information may contribute to repair-specific risk 
prediction and improved patient selection.
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InTRODUCTIOn
Since the introduction of endovascular aneurysm repair (EVAR) in 1991 by Volodos 
et al.1 and Parodi et al.,2 the use of this less invasive treatment for infra-renal 
aortic aneurysms has expanded significantly. Nowadays, >60–70% of all elective 
abdominal aortic aneurysm (AAA) repairs are performed with EVAR.3 and 4 This 
is not the case for ruptured AAA (rAAA), for which the use of EVAR has not yet 
achieved generalized acceptance.5 and 6 In general, rAAA are frequently fatal 
with a mortality of up to 80%,7 but patients surviving until they receive hospital 
care, might expect to benefit from a minimally invasive technique.
For elective surgery, randomized trials have demonstrated a nearly uniform 
threefold reduction in peri-operative mortality and prolonged survival benefit for 
EVAR over open surgical repair (OSR), which is maintained for at least 2 years.8 
and 9 These results, also confirmed by large registries and national audits,10 
have justified a shift towards a preferential use of EVAR. For rupture, however, 
evidence of a similar advantage is still lacking.
The aim of this study was to determine the impact of treatment modality on 
early mortality after rAAA repair, and to evaluate the differences in the prog-
nostic capacity of preoperative variables in determining early survival for EVAR 
and OSR. Additionally, we investigated the differences in major postoperative 
complications and assessed any survival advantage related to treatment modal-
ity during follow-up.
METHODs
The study complied with the Declaration of Helsinki. According to our institutional 
guidelines, no formal ethical approval was required.
Patients
The study population consisted of all consecutive patients who underwent AAA re-
pair between January 2000 and June 2013 at a single, tertiary institution. For this 
study, only patients with confirmed rAAA were included. Some of these patients 
have previously been included in a published 20-year overview of institutional 
trends in the management of rAAA.7 Patients with infected aneurysms and those 
having had prior aneurysm repair were excluded from the analysis.
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Data collection
All possible operation codes and surgical reports were retrospectively retrieved, 
and hospital charts and computed tomography angiographies (CTAs) were checked 
for the presence of rupture. If confirmed, patient demographics, clinical baseline 
characteristics, intraoperative details, and clinical and laboratory outcome were 
obtained. Baseline characteristics on admission included age, gender, state of con-
sciousness, blood pressure, and pulse rate. Duration from the emergency room 
(ER) to the operating theatre, operation duration, body temperature, blood pres-
sure and pulse rate during operation, type of anesthesia, blood loss, and usage 
of blood products and fluids were derived from operative and anesthesia reports. 
Laboratory results on admission were also obtained. Postoperative complications 
and events were retrieved from hospital registries. Survival status and the exact 
date of death of treated patients were obtained via the national civil registry.
Missing data
Baseline data that were not retrievable were analyzed for differences between 
the OSR and EVAR groups. There were no significant differences in the number of 
missing data in either group, except for blood loss and the volume of intraopera-
tive transfusion, owing to a lack of documentation about minimal blood loss and 
transfusions needed with an EVAR procedure. Only variables with <3% missing 
data were included in multivariate models.
Institutional management of rAAA
The Erasmus University Medical Center is a tertiary teaching institution with full 
capacity for endovascular and open vascular surgery (24 hours a day/7 days a 
week), serving about 1.5 million people living in the Rotterdam and surrounding 
area. Owing to the characteristics of the institution, a relatively high proportion 
of AAA repairs are done for rupture. Although the logistics involved in EVAR have 
been adapted and improved over time, the capacity to offer both treatment op-
tions was present throughout the entire study period. This made EVAR available 
for any anatomically suitable patient on any day and at any time. The choice of 
treatment is individualized, but preference is generally given to EVAR in older 
patients.
If a patient presents at the ER with a suspected rAAA, the on-call surgical team is 
informed. On arrival of the patient in the ER, an ultrasound of the abdominal aorta 
is done to confirm the presence of an aortic aneurysm if the patient is not known 
to have an AAA. Otherwise, a CTA can be performed immediately. Patients are 
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managed by permissive hypotension in the ER, and resuscitation is started only if 
the patient becomes unconscious.
According to protocol, a multi-slice CT scanner is used for rAAA CTA. The patient 
is scanned from nipple to pubic symphysis with a collimation of 118*0.6, and plain 
and contrast series are acquired after administering 120 mL of Visipaque 320 
contrast. Anatomical suitability for EVAR is determined by the surgeon’s expecta-
tions and experience. In anatomically complex cases, or whenever time allows, a 
dedicated post-processing workstation (3Mensio Vascular 4.2 software; 3Mensio 
Medical Imaging, Bilthoven, the Netherlands) is available for sizing and planning. 
After diagnosis, informed consent is obtained whenever possible.
Aneurysm repair is performed either by consultant vascular surgeons or by 
residents during their vascular sub-specialization under the direct supervision of 
a consultant vascular surgeon. For EVAR, repair is performed in the operating 
theatre using a mobile C-arm. Preference is given to local anesthesia for EVAR, 
although the decision depends on the individual case.
For OSR, a midline transperitoneal approach is preferred, and aorto-aortic or 
aorto-bi-iliac reconstruction is performed depending on the presence of concomi-
tant iliac aneurysms. Postoperatively, intra-abdominal pressure using a vesical 
pressure probe is only checked when there is clinical suspicion of abdominal 
compartment syndrome.
Definitions
Rupture was defined by either direct visualization of fresh blood in the retro-
peritoneal or peritoneal compartments during OSR, or visualization of peri-aortic 
hematoma on the immediate preoperative CTA.11 Early mortality was defined 
by in-hospital mortality or death within 30 days of surgery. Major complications 
were defined as one of the following: respiratory; cardiac; cerebrovascular; renal 
failure (estimated glomerular filtration rate [eGFR] < 30); abdominal; wound; 
bleeding-related; lower limb ischemia; graft-related. Endovascular complications 
and EVAR-related adverse events were classified according to the reporting stan-
dards for EVAR by Chaikof et al.12 The shock index was calculated by dividing the 
heart rate by systolic blood pressure, and was calculated from the first heart rate 
and blood pressure recorded on arrival in the ER.13
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Endpoints
The primary study endpoint was early mortality. Secondary endpoints were early 
major complications and overall survival during follow-up.
statistical analysis
Categorical variables are presented as counts and percentages, and compared 
with chi-square tests. Continuous variables are presented as means ± standard 
deviation and compared with Student t tests; or as median and interquartile 
range, and compared with Mann–Whitney U tests if the distribution was non-
parametric. The influence of missing data on results was tested by comparing the 
outcome of patients with missing data to those with complete data sets. A logistic 
regression model was used to assess the proportional outcome risk associated 
with EVAR. Variables associated with 30-day in-hospital mortality were tested in 
univariate analysis by type of repair, and significant variables were introduced in 
a multivariate logistic regression model to determine independent significance. 
From the beginning of the study period the implementation of EVAR evolved and 
the number of patients undergoing the procedure increased. As a result, the year 
of operation was used as a co-variable to adjust for the growth in patients treated 
with EVAR every year. A graph of the proportion of the groups per year and the 
mortality rates per year of both groups is shown to illustrate the changes in both 
groups during the study period. Overall survival during follow-up was estimated 
using Kaplan–Meier tables, and survival after EVAR versus open repair was com-
pared using the log-rank (Mantel–Cox) statistical test.
REsULTs
From January 2000 to June 2013, 878 patients underwent AAA repair at our 
institution. The study sample of rAAA included 221 patients with a mean age of 72 
± 8 years (90% of whom were men). Of these 221 patients, 138 were treated with 
OSR and 83 with EVAR. The demographics and clinical characteristics of patients 
on admission did not differ significantly between groups (Table 1).
Intraoperative details
Within the OSR group, 13 (9%) intraoperative deaths occurred, while in the EVAR 
group four (5%) deaths occurred (p = .21; Table 2). Most deaths occurred as a 
result of severe hemorrhagic shock. Intraoperative complications were observed 
in 15 (11%) and 10 (13%) patients after OSR and EVAR, respectively (p = .48). 
These complications differed significantly between groups. Thrombosis (n = 7) and 
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iatrogenic arterial lesions or dissection (n = 6) were the most frequent intraopera-
tive complications for the OSR group; in the EVAR group, the main intraoperative 
complications were type I/III endoleaks (n = 6). Large differences were observed 
between the two treatment groups regarding the duration of operation, estimated 
intraoperative blood loss, and the intraoperative consumption of blood products 
and fluids (p < .001; Table 2).
Table 1. Preoperative baseline characteristics on admission.
Variable
OsR
n = 138
EVAR
n = 83 P
Age
Mean ± SD 71.9 ± 7.8 72.1 ± 8.2 .89
>75 y, n (%) 46 (33) 29 (35) .81
Male gender, n (%) 123 (89) 68 (93) .37
Unconsciousness, n (%) 4 (3) 1 (1) .65
Cardiopulmonary resuscitation before OR, n (%) 1 (1) 0 (0) 1
Hemodynamic statusa
Systolic blood pressure, mean ± SD 114 ± 37 115 ± 37 .81
Diastolic blood pressure, mean ± SD 69 ± 26 67 ± 21 .55
Heart rate (bpm), mean ± SD 85 ± 22 88 ± 25 .37
Shock index > 1b 31 (24) 29 (36) .05
Hemoglobin (g/dL)
Median (IQR) 11.1 (9.4–12.6) 11.8 (9.6–13.3) .10
<11, n (%) 60 (46) 31 (42) .59
Coagulation
INR ≥ 1.5, n (%)c 33 (28) 24 (33) .52
Platelet count (×103/μL), median (IQR)a 177 (135–235) 196 (154–256) .008
eGFR
Median (IQR) 61 (45–77) 63 (46–75) .96
< 60, n (%) 68 (53) 37 (51) .86
Leukocytes (×103/μL), median (IQR)c 12.0 (9.0–16.3) 12.5 (8.5–16.3) .69
CRP (mg/dL), median (IQR)c 11 (5–47) 14 (4–70) .58
Time from ER to OR (mins)d 50 36 .023
Note. OSR = open surgical repair; EVAR = endovascular aneurysm repair; OR = operating 
room; BPM = beats per minute; IQR = interquartile range; INR = international normalized 
ratio; eGFR = estimated glomerular filtration rate; CRP = C reactive protein; ER = emer-
gency room.
a Missing 1–3% of baseline data.
b Heart rate/systolic blood pressure.
c Missing 3–15% of baseline data.
d Missing >15% of baseline data.
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Early survival
Early death occurred in 55 patients (40%) and 20 patients (24%) for OSR and 
EVAR, respectively. After adjusting for age, gender, eGFR, hemoglobin (Hgb) and 
hemodynamic status, and year of operation, EVAR was associated with a twofold 
risk reduction of early death compared with OSR (odds ratio [OR]: 0.45; 95% 
confidence interval [CI]: 0.21–0.97; Table 3). In multivariate analysis of risk fac-
tors for early mortality (Fig. 1), significant differences were observed between 
groups. Only a low Hgb level was an independent risk factor for both types of 
repair. Being older than 75 years and the presence of shock were risk factors for 
OSR only and not for EVAR. Univariate analysis suggested coagulopathy on admis-
sion as a risk factor for EVAR (OR: 4.60, 95%CI: 1.49–14.18) instead of OSR (OR: 
1.69, 95%CI: 0.79–3.66), but the high number of missing values (12%) did not 
allow for inclusion of this variable in the multivariate model. Type of anesthesia 
(local vs. general) had no effect on mortality for EVAR patients (OR: 1.19, 95%CI: 
0.67–2.04). Fig. 2 shows the proportion per year of EVAR- or OSR-treated pa-
tients, as well as the 30-day mortality per year per treatment.
Table 2. Intraoperative characteristics.
Variable OsR EVAR p
Duration of surgery (h), median (IQR)a 3.42 (3.07–4.46) 2.46 (2.20–3.57) <.001
Blood loss (mL), median (IQR)b 4,500 (2,050–8,875) 200 (0–500) <.001
Red blood cell concentrates, median 
(IQR)b
6 (3–11) 2 (0–4.5) <.001
Plasma units, median (IQR)b 6 (2–10) 0 (0–2) <.001
Platelet units, median (IQR)b 1 (0–5) 0 (0–0) <.001
Crystalloids, median (IQR)b 4,000 (2,500–7,000) 1,500 (1,000–2,125) <.001
Colloids, median (IQR)b 1,500 (1,000–2,000) 500 (0–1,000) <.001
Body temperature at end of surgery, 
°C, median (IQR)b
35.9 (35.0–36.5) 36.00 (35.50–36.25) .21
Intraoperative death, n (%)a 13 (9) 4 (5) .21
Intraoperative complications, n (%)a 15 (11) 12 (14) .48
Endoleaks (type I/III), n (%) — 6 (7)
Graft occlusion 2 (1) 1 (1)
Peripheral embolization/thrombosis 7 (5) 0 (0)
Iatrogenic dissection 3 (2) 0 (0)
Arterial disruption with bleeding 3 (2) 2 (2)
Unintentional renal artery occlusion 0 (0) 2 (2)
Note. OSR = open surgical repair; EVAR = endovascular aneurysm repair; IQR = interquar-
tile range.
a Missing 1–3% of baseline data.
b Missing 3–15% of baseline data.
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Major postoperative complications
Median stay in the intensive care unit (ICU) was 4 (1–11) days for OSR and 1 
(1–5) days for EVAR (p = .001). Median hospital stay was 14 (6–33) days for OSR 
and 8.5 (4–21) days for EVAR (p = .001). More major complications occurred after 
OSR than after EVAR (76% vs. 58%, p = .007). Furthermore, OSR patients were 
more likely to suffer from more than one complication (42% vs. 24%, p = .047) 
and have more frequent fatal complications (30% vs. 16%, p = .033). The distri-
bution of complications is shown in Table 4. More abdominal, wound, and bleeding 
complications occurred after OSR, and more graft-related problems occurred after 
EVAR. Compared with OSR, EVAR was associated with a threefold risk reduction 
for major complications (OR: 0.33, 95%CI: 0.15–0.71), after adjusting for age, 
gender, Hgb, eGFR, hemodynamic status on admission, and year of surgery (Table 
3).
Table 3. Thirty-day/in-hospital outcome after ruptured abdominal aortic aneurysm repair.
Variable OsR EVAR ORa 95%CI
Mortality 55 (40) 20 (24) 0.45 0.21–0.97
Major complications 95 (76) 46 (58) 0.33 0.15–0.71
Systemic complications 80 (64) 42 (53) 0.69 0.34–1.38
Local complications 38 (30) 15 (19) 0.37 0.16–0.83
Fatal complications 37 (30) 13 (16) 0.39 0.17–0.90
Multiple complications 52 (42) 21 (27) 0.53 0.26–1.08
Note. ORs are given for EVAR compared with OSR. Significant values are presented in bold. 
OSR = open surgical repair; EVAR = endovascular aneurysm repair; OR = odds ratio; CI = 
confidence interval.
a Logistic regression is performed for each outcome measure, adjusting for age, gender, 
estimated glomerular filtration rate, preoperative hemoglobin level, hemodynamic status 
(shock index), and year of operation.
Figure 1. Multivariate logistic regression analysis of risk factors for early mortality, by type 
of repair (only including variables with <3% missing data).
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Figure 1. Multivariate logistic regression analysis of risk factors for early mortality, by type of 
repair (only including variables with <3% missing data).  
 
 
 
 
 
 
 
 
 
Note. eGFR = estimated glomerular filtration rate; OSR = open surgical repair; EVAR = 
endovascular aneurysm repair. 
 
 
 
 
Figure 2. Thirty-day mortality and relative amount of open surgical repair (OSR)- or 
endovascular aneurysm repair (EVAR)-treated patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Note. eGFR = estimated glomerular filtration rate; OSR = open surgical repair; EVAR = en-
dovascular aneurysm repair.
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Figure 2. Thirty-day mortality and relative amount of open surgical repair (OSR)- or endo-
vascular aneurysm repair (EVAR)-treated patients.
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Figure 1. Multivariate logistic regression analysis of risk factors for early mortality, by type of 
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Note. eGFR = estimated glomerular filtration rate; OSR = open surgical repair; EVAR = 
endovascular aneurysm repair. 
 
 
 
 
Figure 2. Thirty-day mortality and relative amount of open surgical repair (OSR)- or 
endovascular aneurysm repair (EVAR)-treated patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 4. Postoperative complications.
Variable OsR EVAR p
Days in ICU, median (IQR) 4 (1–11) 1 (1–5) .001
Total days of admission, median (IQR) 14 (6–33) 8.5 (4–21) .001
Major complications 95 (76) 46 (58) .007
Systemic complications 80 (64) 42 (53) .124
Cardiac 20 (16) 8 (10)
Cerebrovascular 6 (5) 3 (4)
Renal 49 (39) 25 (32)
Pulmonary 33 (26) 18 (23)
Local complications 38 (30) 12 (19) .070
Bowel ischemia 13 (10) 2 (3)
Abdominal compartment syndrome 10 (8) 4 (5)
Bleeding 7 (6) 1 (1)
Distal embolization/thrombosis 5 (4) 1 (1)
Wound infection 9 (7) 1 (1)
Graft-related 3 (2) 5 (6)
Multiple complications 52 (42) 19 (24) .047
Fatal complications 37 (30) 11 (16) .033
Note. OSR = open surgical repair; EVAR = endovascular aneurysm repair; ICU = intensive 
care unit; IQR = interquartile range.
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Late survival
The survival benefit after EVAR on early outcome was maintained during the mid-
term follow-up. The estimated survival after 2 years was 52% for OSR versus 65% 
for EVAR (p < .001; Fig. 3). After 3 years, the survival benefit after treatment with 
EVAR was no longer present.
DIsCUssIOn
In this study, EVAR was associated with a twofold reduction in early mortality after 
rAAA, after correcting for possible confounders. This benefit persisted for up to 
3 years after the index event. Moreover, risk factors for early mortality varied in 
type and importance according to which treatment modality was selected. These 
risk factors could have a potential impact on current clinical practice.
Figure 3. Kaplan–Meier curve of survival after ruptured abdominal aortic aneurysm repair, 
by type of repair (log rankp = .52). Note. OSR = open surgical repair; EVAR = endovascular 
aneurysm repair.
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In contrast to elective EVAR, which is widely accepted, EVAR for rAAA is far from 
accepted owing to a significant lack of level A evidence.5 and 6 To date, only two 
randomized controlled trials have been published on the subject. The Nottingham 
trial, which was only a pilot study, had difficulties with enrollment and was not 
able to show any differences in early mortality or complications. Recently, the 
results of the AJAX trial have been published.14 and 15 In this study, no differ-
ence in 30-day mortality and severe complications between EVAR and OSR were 
found. This could be explained, in part, by the unexpectedly good results from 
OSR, arguably difficult to achieve in most settings. With regard to the secondary 
endpoints of the AJAX study, EVAR generally performed better: mean ICU stay, 
mean hospital stay, mean blood loss, and the need for mechanical ventilation all 
favored the EVAR group. Both of the aforementioned studies were limited by low 
inclusion rates, which may result in significant bias, and are both considered to 
be underpowered.
Two other randomized trials are still in progress (IMPROVE16 and ECAR17). While 
the results of the ECAR trial are awaited, the IMPROVE investigators recently 
presented preliminary data.18 They were able to recruit 613 patients (about two-
thirds of all eligible patients) with a clinical diagnosis of ruptured aneurysm. Based 
on intention-to-treat analysis, no significant difference was found between the 
EVAR and OSR groups for 30-day mortality (35.4% and 37.4%, respectively), but 
there was a significant number of protocol variations (11%). In the endovascular 
first strategy group, patients who were actually treated by EVAR (n = 150) had 
a 30-day mortality of 25% compared with 37% for those treated in the OSR first 
strategy group (n = 220), results similar to those obtained in our study (24% 
and 40%, respectively). Subgroup analysis revealed a survival benefit for women 
treated with EVAR. After EVAR, patients had a shorter stay in hospital than OSR 
patients, and the costs related to both groups of patients after 30 days was com-
parable. They also found that the lowest measured systolic blood pressure was an 
independent risk factor for 30-day mortality, and that the use of local anesthesia 
during EVAR reduced the 30-day mortality. In this study shock and use of local 
anesthesia had no effect on mortality after EVAR.
In contrast to published randomized trials, retrospective data are generally more 
favorable for EVAR. Inclusion of symptomatic non-ruptured aneurysms in retro-
spective series could contribute to this difference between trials and retrospective 
studies. To avoid such a bias in our study, we individually assessed the presence of 
true rupture in all cases. Veith19 has published collected data from 49 institutions 
that routinely use EVAR for the treatment of rAAA. One thousand and thirty-seven 
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patients treated by EVAR and 763 patients treated by OSR were included in the 
review. The study showed a significant reduction in early mortality favoring EVAR 
(21% vs. 36%, p < .001). The author concluded that EVAR is superior to OSR for 
patients with suitable anatomy, especially those who are more hemodynamically 
unstable, which is in line with the findings in this study. A population-based study 
by Mandawat et al. 20 showed that EVAR is superior to OSR in regard to short-
term clinical outcomes (36% vs. 18%, p < .01). Nedeau et al. 21 published a 
retrospective study comparing EVAR with OSR. Although their patient sample was 
smaller than in this study (19 EVAR and 55 OSR patients), their conclusions were 
very similar, with EVAR conferring an early and mid-term survival benefit. A recent 
publication by Mehta et al.22 also compared early mortality for EVAR versus OSR 
in rAAA patients.22 In a sample of 283 patients, of whom 120 underwent EVAR, 
the authors reached a similar conclusion regarding an early mortality benefit for 
EVAR, which was maintained over time. However, the study by Mehta et al.22 
found a higher risk for EVAR in elderly patients, which was only present for OSR 
in this study. In addition to survival analysis, more insight is provided into the 
complications after rAAA, suggesting important differences on the number and 
type of complications found after OSR and EVAR.
A low Hgb level on admission was associated with adverse early prognosis after 
rAAA. This seems logical, as it suggests more extensive bleeding and a more 
prolonged evolution, increasing the chance of cardiac ischemia due to inadequate 
oxygen delivery. This is potentially aggravated by the fact that OSR is associated 
with greater blood loss. Age more than 75 years was associated with a higher risk 
of early death after OSR, but not after EVAR. This could be the result of reduced 
physiological reserve in elderly patients, which is insufficient to withstand the 
added insult of open surgery. Similarly, the presence of shock on admission was 
an independent predictor for early outcome after OSR, but not after EVAR. This 
interesting observation may be explained by the less invasive nature of EVAR and 
the maintenance of higher peripheral resistance during endovascular operations. 
Another interesting observation is that coagulopathy on admission was associated 
with increased mortality after EVAR, but not after OSR. Although this could not 
be tested for confounders, it may be explained by persistent bleeding followed 
by abdominal compartment syndrome, and by a higher threshold for transfusion 
after EVAR.
The difference in early survival could also be explained by patient selection prior 
to the operation.22 A common argument is that the most unstable patients would 
not undergo a CTA and, as a consequence, not be offered EVAR. In our population, 
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however, admission hemodynamic status was similar for both groups, and the 
presence of shock was only found to influence outcome after OSR. It could be 
argued that the difference of admission time suggests that OSR patients are more 
unstable as theirs is shorter. We think that this difference is mainly due to the 
need for CTA in EVAR patients and not directly to patients’ hemodynamic status. 
Furthermore, admission information was missing 16.7% of the data, which makes 
it less reliable than the shock index (<3%). These findings support the prior 
suggestion by Hinchliffe et al.6 that the most unstable patients may be the ones 
to obtain the greatest benefit from EVAR. Also, it is possible that anatomically 
suitable patients for EVAR have a better outcome than those who are anatomically 
unsuitable, independent of the type of repair, as suggested by Ioannidis et al.23 
and Dick et al.24 However, this effect was not observed in a study by Ten Bosch 
et al.,25 in which anatomical suitability did not influence results in a cohort of 
patients who all underwent preoperative CTA irrespective of hemodynamic status. 
We could not confirm the hypothesis of anatomical suitability because some pa-
tients undergoing OSR did not undergo a preoperative CTA, and performing this 
analysis would inevitably incur bias. However, no supra-renal or type IV thoraco-
abdominal aneurysm patients were included in our series.
Postoperatively, the total admission period and ICU period for patients treated 
with EVAR was significantly lower than that of OSR-treated patients. This suggests 
a quicker recovery and less severe postoperative complications for EVAR. In paral-
lel with mortality, EVAR was associated with a threefold reduction in the risk of 
major complications, and the occurrence of multiple and fatal complications were 
more frequent after OSR, contributing to better early survival rates for EVAR.
Over time, the prognosis of patients treated with EVAR gradually converged with 
that of OSR patients. In this series, the benefit of EVAR was maintained up to 
3 years; beyond this point, the survival of the two groups was similar. No clear 
explanation for this effect could be found, but it is hypothesized that it may reflect 
the less aggressive nature of EVAR, therefore minimizing the “second hit” after 
rupture. In patients with severe comorbidities, the additional surgical aggression 
of OSR could result in early death. Similarly, frail patients may survive the acute 
period after EVAR, but succumb to their comorbidities at mid-term. We found no 
evidence that EVAR-related complications could explain the observed pattern.
The results of this study are limited by the retrospective design and individualized 
treatment selection, which could result in bias. Also, the time span of the study 
may have influenced results, with inevitable management and referral modifica-
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tions occurring over time. For the outcome analysis, year of operation was used 
as a co-variable, therefore adjusting for this potential confounder. Because of 
the relatively small sample, and because many patients died very early after the 
start of follow-up owing to the rupture, there was not sufficient statistical power 
to determine differences in long-term survival, and restricted the analysis to 4 
years after repair. Finally, accurate turn-down rates for repair, which are known 
to significantly influence the overall survival after rAAA, could not be provided. 
This important limitation probably has less impact on direct comparison between 
treatment modalities than on the overall results of rAAA repair.
In conclusion, this study shows a twofold early mortality risk reduction for rAAA 
patients undergoing EVAR, which is maintained over the mid-term. Old age and 
the presence of shock were significant predictors of early mortality for OSR only, 
suggesting that EVAR may be particularly beneficial for patients presenting with 
these factors.26 Also, OSR patients were at higher risk of major postoperative 
complications, required longer ICU and hospital stays, and appeared more likely 
to suffer from multiple and fatal complications after surgery. These results support 
the preferential use of EVAR for rAAA, and suggest a potential improvement in risk 
prediction by introducing the type of repair into the equation.
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ABsTRACT
Objective
Historically symptomatic AAAs were found to have intermediate mortality com-
pared to asymptomatic and ruptured AAAs but, with wider EVAR use, a more 
recent study suggested mortality of symptomatic aneurysms were similar to 
asymptomatic AAAs. These prior studies were limited by small numbers. The 
purpose of this study is to evaluate the mortality and morbidity associated with 
symptomatic AAA repair in a large contemporary population.
Methods
All patients undergoing infrarenal AAA repair were identified in the 2011-2013 
ACS-NSQIP, Vascular Surgery targeted module. We excluded acute conversions to 
open repair and those for whom the surgical indication was embolization, dissec-
tion, thrombosis, or not documented. We compared 30-day mortality and major 
adverse events (MAE) for asymptomatic, symptomatic, and ruptured AAA repair, 
stratified by EVAR and open repair, with univariate analysis and multivariable 
logistic regression.
Results
5502 infrarenal AAAs were identified, 4495 asymptomatic (830 open repair, 3665 
[82%] EVAR), 455 symptomatic (143 open, 312 [69%] EVAR), and 552 ruptured 
aneurysms (263 open, 289 [52%] EVAR). Aneurysm diameter was similar be-
tween asymptomatic and symptomatic AAAs, when stratified by procedure type, 
but larger for ruptured aneurysms (EVAR symptomatic 5.8cm ±1.6 vs. ruptured 
7.5cm ±2.0, P<.001; open repair symptomatic 6.4cm ±1.9 vs. ruptured 8.0cm 
±1.9, P<.001). The proportion of females was similar in symptomatic and rup-
tured AAA (27% vs. 23%, P=.14, respectively), but lower in asymptomatic AAA 
(20%, P<.001). Symptomatic AAAs had intermediate 30-day mortality compared 
to asymptomatic and ruptured aneurysms after both EVAR (asymptomatic 1.4% 
vs. symptomatic 3.8%, P=.001; symptomatic vs. 22% ruptured, P<.001) and 
open repair (asymptomatic 4.3% vs. symptomatic 7.7% , P=.08; symptomatic 
vs. 57% ruptured, P<.001). After adjustment for age, gender, repair type, di-
alysis dependence, and history of severe COPD, patients undergoing repair of 
symptomatic AAAs were twice as likely to die within 30-days compared to those 
with asymptomatic aneurysms (OR 2.1, 95%CI 1.3-3.5). When stratified by repair 
type the effect size and direction of the odds ratios were similar (EVAR OR 2.4, 
CI 1.2-4.7; open repair OR 1.8, CI 0.86-3.9), although not significant for open 
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repair. Patients with ruptured aneurysms had a seven-fold increased risk of 30-
day mortality compared to symptomatic patients (OR 6.5, CI 4.1-10.6).
Conclusion
Patients with symptomatic AAAs had a two-fold increased risk of perioperative 
mortality, compared to asymptomatic aneurysms undergoing repair. Furthermore, 
patients with ruptured aneurysms have a seven-fold increased risk of mortality 
compared to symptomatic aneurysms.
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InTRODUCTIOn
The 30-day mortality rate for abdominal aortic aneurysm (AAA) repair can range 
from approximately 1% to over 70% depending on whether the aneurysm is 
intact, symptomatic, or ruptured.1-6 3% to 15% of treated aneurysms have been 
described as symptomatic in prior studies.7-10 Symptomatic abdominal aortic an-
eurysms present with symptoms of abdominal or back pain, often associated with 
tenderness to palpation of the aneurysm itself, and are thought to represent an 
intermediate risk group between elective and ruptured aneurysms.
Historically, many single institution studies showed that patients with symp-
tomatic AAAs had higher rates of mortality and major adverse events compared 
to asymptomatic AAA repairs.7, 10-14 However, most of these studies predated 
the wide use of EVAR and had small numbers of symptomatic AAAs. De Martino 
et al, using a contemporary clinical registry, the Vascular Study Group of New 
England (VSGNE), from 2003-2009, showed that there was no difference in 
in-hospital mortality between symptomatic and elective infrarenal AAA repairs, 
when stratified by procedure type.8 This study had the largest cohort of symp-
tomatic AAAs treated with EVAR at the time. Prior to this study, Cambria et al. 
reported that deferral of operation to medically optimize the patient and ensure 
appropriate staff are available, instead of immediate repair within the first 4 
hours, improved outcomes for the symptomatic AAAs.7 This led to an increased 
focus on preoperative management of the symptomatic patient and was thought 
to contribute to the lack of difference in perioperative mortality between elective 
and symptomatic patients in De Martino’s study. However, many still believe 
that symptomatic AAAs continue to have an intermediate operative mortality 
risk in the short-term but there have been no studies with a current-practice 
distribution of EVAR and open repair and an adequate number of symptomatic 
AAA patients to address this ongoing question.
The purpose of this study was to analyze the differences in mortality and mor-
bidity between patients with symptomatic AAAs compared to both asymptomatic 
and ruptured aneurysms in a contemporary population where EVAR was the 
preferred treatment modality for elective repair.
METHODs
Dataset
Using the American College of Surgeons National Surgical Quality Improvement 
Program (NSQIP) Vascular Surgery targeted module from 2011-2013, we identi-
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fied all patients undergoing endovascular (EVAR) and open AAA repair. The NSQIP 
vascular targeted module is an extension of the original NSQIP with 72 participating 
hospitals in the AAA module as of 2013. It is a multi-institutional collaboration that 
continues to collect all the preoperative, intraoperative, and 30-day outcomes that 
were contained in the original NSQIP as well as further clinical detail selected by 
vascular surgeons in an effort to better risk adjust and determine best practices. 
Trained clinical nurse reviewers complete all data collection, and each hospital has 
a surgeon champion, available to answer any questions related to data entry for 
cases submitted. Additional information on the NSQIP is available at www.facs.
org/quality-programs/acs-nsqip.
Patients and Cohorts
All 6703 patients undergoing AAA repair in the targeted NSQIP were identified. 
For direct comparison to prior studies the primary analysis of this paper focused 
on repair of infrarenal aneurysms, as identified by proximal aneurysm extent. Jux-
tarenal aneurysms were included in the analysis with adjustment in multivariable 
analysis. A subset of patients who were documented to have infrarenal aneurysm 
extent yet had a suprarenal clamp position were re-classified as juxtarenal. All 
those with a proximal aneurysm extent listed as pararenal, suprarenal, or Type IV 
thoracoabdominal were excluded from the analysis. Patients with no documented 
proximal aneurysm extent or operative indication were excluded (n= 439 and n= 
81 respectively). Patients with an operative indication of dissection, thrombosis, 
or embolization or those undergoing conversion from EVAR to open repair (n=33) 
were also excluded.
Patients with symptomatic AAAs were defined as those without evidence of 
rupture but presenting with abdominal or back pain, or symptoms from local 
compression by the aneurysm causing early satiety, hydronephrosis, or deep 
venous thrombosis. Ruptured aneurysms were divided into 2 groups based on 
hemodynamic status: hypotensive (defined as systolic blood pressure <90mmHg 
or drop in systolic blood pressure of >40mmHg from baseline or need for pres-
sors preoperatively), and non-hypotensive. The asymptomatic non-ruptured 
group consisted of those with a surgical indication for repair listed as diameter, 
prior open repair with unsatisfactory result, or prior endovascular repair with 
unsatisfactory result. The latter two indications were accepted because it was 
thought likely that the symptomatic and rupture groups contained some of these 
patients as well, as only one indication can be entered per patient.
All variable definitions captured by the NSQIP can be found at www.facs.org/
quality-programs/acs-nsqip. New or aggregate variables used in this analysis 
included, obesity, defined as a body mass index >30, and a binary variable for 
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diabetes mellitus, defined as both insulin and non-insulin dependent diabetes. 
For EVAR, percutaneous access included attempted but failed percutaneous ac-
cess attempts. We consolidated the main body devices analyzed and created 
an “Other” group that included Cook Zenith Fenestrated (1.9%), Cook Zenith 
Renu (1.4%), Lombard Aorfix (<0.1%), Medtronic Aneurx (0.2%), Medtronic 
Talent (0.6%), Trivascular Ovation (0.9%), and other (4.1%). 10% of patients 
were missing data on lower extremity revascularization but these patients were 
considered as not having revascularization in our analysis. Time from admission 
to operation was recorded in days with day 0 representing operation on day of 
admission. We identified patients undergoing surgery after the day of admission 
to highlight the number of symptomatic patients who have a delay in their repair 
since this has been shown to affect outcomes in prior literature.7 Operative de-
tails and outcomes were presented for EVAR and open repair separately.
All outcomes were within 30 days of the index operation. A major adverse 
event was defined as a myocardial infarction (diagnosed as new Q waves on ECG 
and documentation stating diagnosis of MI), intraoperative cardiac arrest, pneu-
monia, prolonged intubation (defined as >48 hours), worsening renal function 
(defined as a rise in creatinine of >2.0mg/dl or new requirement for dialysis), 
bowel ischemia as stated in the medical record whether intervention was nec-
essary or not, lower extremity ischemia requiring intervention, or subsequent 
rupture after repair.
statistical Analysis
Continuous variables were presented as mean ± standard deviation, or as median 
and interquartile range based on distribution. Categorical variables were presented 
as counts and percentages. Univariate differences between cohorts were assessed 
using χ2 and Fisher’s exact tests for categorical variables and Student’s t-test and 
Mann Whitney U test for continuous variables, where appropriate. Comparisons 
were made between asymptomatic and symptomatic AAAs and symptomatic to 
ruptured AAAs, stratified by repair type. To identify independent risk factors for 
30-day mortality and major adverse events we used purposeful selection, which 
utilizes both univariate analysis and previously identified predictors for the end-
point of interest, to fill the multivariable model for the comparison of asymptomatic 
to symptomatic and symptomatic to ruptured AAAs.15 Certain variables, such as 
emergency repair and aneurysm diameter were not included in the model as they 
were collinear with symptomatic aneurysms. We listed the Hosmer and Lemeshow 
statistic for all steps of model optimization to support the stability of our model 
given the limited number of total events. P-value < .10 on univariate analysis was 
used for inclusion into each model. All tests were two-sided and significance was 
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considered when P-value was < .05. IBM SPSS Statistics version 22.0 (IBM Inc., 
Chicago, IL) was used for all analysis. Permission to use deidentified data from the 
NSQIP, without the need for informed consent, was obtained from the Institutional 
Review Board at Beth Israel Deaconess Medical Center.
REsULTs
From a total of 6703 patients undergoing AAA repair in the vascular targeted 
NSQIP from 2011-2013, we excluded 516 (7.7% of total) pararenal/suprarenal 
aneurysms, 439 (6.5%) patients without documentation of aneurysm extent, 213 
(3.2%) for indication of dissection, embolization, thrombosis, or no documenta-
tion, and 33 (0.5%) for acute conversion from EVAR to open repair. This left 5502 
patients undergoing repair of infrarenal (85%, 92% EVAR) or juxtarenal (15%; 
20% EVAR) aneurysms. The final cohort included 4495 asymptomatic patients 
(82% EVAR), 455 symptomatic patients (69% EVAR), and 552 ruptured patients 
(52% EVAR). Within the asymptomatic group there were 138 (3.1%) patients 
with prior unsatisfactory endovascular repair (72% EVAR) and 19 (0.4%) with 
unsatisfactory open repair (79% EVAR).
Patient Characteristics
Asymptomatic vs. Symptomatic
Symptomatic patients in general were younger (mean 72.6 SD ±10.1 vs. 73.6 
±8.6, p=.01), and less likely to be white (80% vs. 87%, P < .001), male (73% 
vs. 80%, P < .001), or obese (25% vs. 32%, P = .01)(Table 1). They were more 
likely to be current smokers (43% vs. 32%, P < .001), have preoperative acute 
renal failure (0.9% vs. 0.2%, P = .03) or hemodialysis (2.6% vs. 0.8%, P < 
.001), and have a preoperative transfusion (3.1% vs. 0.9%, P < .001). Patients 
with symptomatic AAAs had larger mean aneurysm diameter overall compared to 
asymptomatic aneurysms (asymptomatic 5.8 SD ±1.2 vs. 6.0 ±1.7, P = .045). 
Figure 1 illustrates a higher proportion of asymptomatic AAA repairs occurring 
between 5.0-5.9cm compared to symptomatic AAAs, which coincides with guide-
lines for elective repair in this group. As expected there was a higher proportion 
of symptomatic patients listed as emergent compared to asymptomatic patients 
(EVAR 26% vs. 2.1% P < .001; open repair 39% vs. 3.0%, P < .001). Symptomatic 
patients were more likely to have surgery deferred and to not undergo surgical 
repair on the same calendar day as admission (EVAR 44% vs. 12%, P < .001; 
open repair 42% vs. 23%, P < .001), which we hypothesized to represent time 
spent medically optimizing the patient and avoiding off-hour operations, although 
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5
a delay in diagnosis of a symptomatic aneurysm could also be contributing. Out 
of the 198 symptomatic patients who underwent repair after the day of admission 
50% were operated on the next calendar day and 79% were operated on within 
three calendar days of admission.
Symptomatic vs. Ruptured
When compared to those with ruptured aneurysms, symptomatic patients were 
less likely to be obese (25% vs. 32%, P = .03), intubated prior to the OR (0.4% 
vs. 11%, P < .001), have dependent baseline functional status (1.8% vs. 5.8%, 
P = .001), preoperative creatinine elevation (5.2% vs. 17%, P = .001), preopera-
tive transfusion (3.1% vs. 26%, P < .001), ASA score of 4 or 5 (43% vs. 86 %, 
P < .001)(Table 1). Symptomatic patients were more likely to have preoperative 
dyspnea on exertion (19% vs. 10%, P < .001) and hypertension (79% vs. 71%, 
P < .001). Aneurysm diameter was significantly smaller in symptomatic patients 
(6.0 ±1.7 vs. 7.7 ±2.0, P < .001), (Figure 1). As expected, there was a lower 
proportion of emergent cases amongst the symptomatic patients compared to 
those with rupture (EVAR 26% vs. 88%, P < .001; open repair 39% vs. 92%, P < 
.001), and greater deferment of cases to the following days after admission (EVAR 
44% vs. 13%, P < .001; open repair 42% vs. 12%, P < .001).
Operative details
EVAR
The use of EVAR was highest in asymptomatic patients followed by symptom-
atic patients (asymptomatic 82% vs. symptomatic 69%, P < .001), and lowest 
in ruptures (52%, P < .001)(Table 2). Comparing EVAR for asymptomatic and 
symptomatic presentations, symptomatic patients were less likely to have a per-
cutaneous attempt for access (20% vs. 27%, P = .01), had longer operative times 
(median 140 minutes [Inter-quartile range 110-178] vs. 133 [102-175], P = .02), 
and were more likely to require a concomitant access vessel conduit or repair 
(11% vs. 7.4%, P = .04).
When comparing symptomatic to ruptured EVAR, symptomatic EVAR cases had 
shorter operative times (140 [110-178] vs. 157 [116-205], P = .01) and were 
less likely to have an access vessel conduit or repair (11% vs. 18%, P = .01)
(Table 2). There was a difference in main body devices used between groups. 
Excluder was the most common device used for asymptomatic, symptomatic, 
and ruptured aneurysms. Excluder was followed by Endurant then Zenith for 
asymptomatic and symptomatic aneurysms, but was followed by Zenith then 
Endurant for ruptures.
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5
Open Repair
Comparing symptomatic to asymptomatic patients there was no difference in 
operative time (246 [173-290] vs. 232 [178-302], P = 0.8 respectively), distal 
aneurysm extent, aneurysm diameter, proportion of juxtarenal aneurysms, or 
concomitant procedures performed (Table 3).
When comparing symptomatic to ruptured open repairs there was no differ-
ence in operative time (246 [173-290] vs. 235 [178-296], P = 0.9 respectively), 
distal aneurysm extent, proportion of juxtarenal aneurysms, or concomitant 
procedures performed (Table 3). A retroperitoneal approach was more com-
monly used in symptomatic patients compared to those with rupture (26% vs. 
14%, P = .01).
30-day Outcomes
Symptomatic vs. Asymptomatic
The overall 30-day mortality rate was higher in symptomatic patients (5.1% vs. 
1.9%, P < .001). For EVAR, symptomatic patients had a higher 30-day mortality 
rate (3.8% vs. 1.4%, P = .001) compared to asymptomatic patients (Table 4a). 
For open repair the mortality difference did not reach statistical significance (7.7% 
vs. 4.3%, P = .08)(Table 4b). There was also no difference in 30-day mortality for 
patients with symptomatic aneurysms whose surgery was not performed on day 
of admission (EVAR- day of admission 3.4% vs. not on day of admission 4.3%, P 
= .68; open repair 8.4 vs. 6.7, P = .76).
The rate of major adverse events was higher for symptomatic, compared to 
asymptomatic, patients after EVAR (9.3% vs. 3.7%, P < .001)(Table 4a). How-
ever, no significant difference was seen following open repair (19% vs. 20%, P = 
.64)(Table 4b). After EVAR, rates of bleeding, myocardial infarction, cardiac ar-
rest, and prolonged intubation were also higher in symptomatic patients. Among 
those surviving through hospital discharge, symptomatic patients undergoing 
EVAR had a longer length of stay than asymptomatic patients (3 days [2-6] vs. 
2 [1-3], P < .001). After open repair there were no differences in peri-operative 
morbidity or length of stay.
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Symptomatic vs. Ruptured
As expected, patients with symptomatic aneurysms had a lower 30-day mortality 
rate than those with ruptured aneurysms (5.1% vs. 27%, P < .001; OR 0.14, 
95% CI 0.1-0.22). When stratified by type of repair, mortality was lower in the 
symptomatic group for both EVAR (3.8% vs. 22%, P < .001)(Table 4a) and open 
repair (7.7% vs. 34%, P < .001)(Table 4b).
Symptomatic patients had lower major adverse event rates compared to rup-
tured patients (EVAR 9.3% vs. 31%, P < .001 and open repair 18% vs. 57%, P 
< .001)(Table 4a and 4b respectively). Symptomatic patients also had a lower 
rate of bowel ischemia (EVAR 1.0% vs. 8.3%, P < .001; Open 2.1% vs. 11%, P 
= .001) and subsequent rupture after repair (EVAR 0.0% vs. 4.8%, P < .001; 
Open 1.4% vs. 9.1%, P = .002).
Multivariable Models
After adjustment symptomatic patients had twice the operative mortality com-
pared to asymptomatic patients (OR 2.1, 95% CI 1.3-3.5)(Table 5). Additional 
predictors included increasing age, female sex, open repair (vs. EVAR), history of 
severe COPD, and on dialysis preoperatively. When stratified by procedure, this 
same model showed an increased risk for mortality after EVAR (OR 2.4, CI 1.2-
4.7) and a similar effect size and direction for open repair (OR 1.8, CI 0.86-3.9), 
although not significant in the open repair group. Since method of repair may be 
influenced by presence of symptoms we ran the overall model without adjusting 
for this and found a similar risk of 30-day mortality associated with symptomatic 
Table 5. Independent Predictors of 30-day Mortality in Elective and Symptomatic AAAs
OR 95% CI P-value
Symptomatic aneurysm 1.49 1.07-2.08 .02
EVAR (vs. open) 0.23 0.17-0.30 <.001
Age increase (by decade) 1.25 1.07-1.44 .004
Female 1.51 1.17-1.95 .002
Current smoker 1.24 0.97-1.60 .09
Baseline Cr > 1.78 mg/dl 2.14 1.63-2.82 <.001
Pre-op Wound 2.48 1.11-5.51 .03
Pre-op Transfusion 2.37 1.15-4.88 .02
Juxtarenal aneurysm 1.64 1.22-2.20 .001
*Also adjusted for diabetes, CHF, pre-op dialysis
Hosmer and Lemeshow test .13 (> .13 throughout all steps)
EVAR repairs only: Symptomatic aneurysm OR 2.42 (CI 1.57-3.74, P < .001)
Open repairs only: Symptomatic aneurysm OR 0.91 (CI 0.56-1.48, P = .70)
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aneurysms (OR 2.3, CI 1.4-3.8). Symptomatic aneurysm was independently pre-
dictive of major adverse events as well (OR 1.5, CI 1.07-2.08)(Table 6).
After similar adjustment for age, repair type, history of congestive heart fail-
ure, history of COPD, dialysis dependence, and juxtarenal aneurysms, ruptured 
aneurysms were at a 7-fold increased risk of 30-day mortality compared to 
symptomatic aneurysms (OR 6.5,CI 4.1-10.6) and 5-fold increased risk of a 
major adverse event (OR 5.1, CI 3.6-7.2).
DIsCUssIOn
In this large contemporary series of symptomatic AAAs we found that symp-
tomatic patients have a 2-fold increased risk of 30-day mortality compared to 
asymptomatic patients. Comparing ruptured and symptomatic patients we also 
found those with rupture have a 7-fold increased risk of 30-day mortality.
The distribution of symptomatic aneurysms in our study, 8.3%, lies well within 
the incidence previously reported in the literature, of 3% to 15%.7-10 Many of the 
studies on symptomatic AAA repairs are outdated and under-represent the con-
temporary utilization of EVAR. We found that 69% of patients with symptomatic 
infrarenal aneurysms had EVAR in the NSQIP from 2011-13, which is quite dif-
ferent from the majority of prior studies on this topic in which open surgery was 
primarily or solely used.14, 16-18 Studies that reported higher proportions of EVAR 
repair for symptomatic AAAs were limited by low numbers and were from single 
centers.19, 20 From the Vascular Study Group of New England (VSGNE) in 2010, 
De Martino et al reported that 38% of symptomatic AAA repairs were completed 
Table 6. Independent Predictors of MAE in Elective and Symptomatic AAAs
OR 95% CI P-value
symptomatic aneurysm 2.14 1.3-3.3 .003
EVAR (vs. open) 0.40 0.2-0.7 .001
Age increase (by decade) 1.81 1.4-2.3 <.001
Female 1.83 1.2-2.8 .004
Dialysis dependent 8.28 3.2-21.2 <.001
Hx of severe COPD 1.85 1.2-2.8 .01
Juxtarenal aneurysm 1.68 0.99-2.9 .06
Initial model also included CHF episode within prior 30 days and elevated baseline creatinine 
>1.78mg/dl but not on dialysis
Hosmer and Lemeshow test 0.52 (> 0.51 throughout all steps of model optimization)
EVAR repairs only: Symptomatic aneurysm OR 2.42 (CI 1.2-4.7, P=.01)
Open repairs only: Symptomatic aneurysm OR 1.83 (CI 0.9-3.9, P=.12)
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using EVAR (60 EVARs of 156 symptomatic AAAs).8 They found no difference 
in in-hospital mortality between asymptomatic and symptomatic infrarenal 
aneurysm repairs, for EVAR (asymptomatic 0.4% and symptomatic 0.0%) and 
open repair (asymptomatic 2.9% and symptomatic 2.1%). Their study, however, 
was limited both by smaller numbers and the ability to detect only in-hospital-
mortality rather than 30-day. However, over 1- and 4-years they did show 
reduced survival in symptomatic compared to asymptomatic patients. We have 
previously demonstrated that in-hospital mortality misses a substantial number 
of post discharge deaths that occur within 30 days, particularly after EVAR.21 We 
found a significant difference in the larger EVAR subgroup (n=312) but not in 
the open repair subgroup (n=143), likely due to the smaller number of patients. 
Given the similar magnitude and direction of the effect size (odds ratio) in both 
the open and EVAR subgroups, it is reasonable to make the general statement 
from our larger multivariable model, that includes procedure type, that repair 
of symptomatic AAA is associated with twice the operative mortality compared 
to asymptomatic AAA repair. Subsequent to the VSGNE study, the ENGAGE reg-
istry for Endurant post-market surveillance reported similar 30-day mortality in 
185 symptomatic AAAs compared to 1015 asymptomatic AAAs (0.5% vs. 1.5% 
respectively, p=.31).9 However, it is difficult to compare real-world results from 
the NSQIP to a post-marketing surveillance study where most patients met strict 
eligibility criteria and received the same endograft. Our 30-day mortality rate 
for patients with asymptomatic aneurysms undergoing EVAR or open repair were 
consistent with rates previously reported for the NSQIP.22
Cambria et al reviewed the Mayo Clinic experience with symptomatic AAA and 
highlighted the importance of preoperative optimization of patients presenting 
with symptomatic AAA.7 In that analysis patients with symptomatic AAAs under-
going operation within the first 4 hours of admission accounted for all deaths 
compared to those with surgery delayed either 4-24 hours or 24 hours to 7 days. 
The authors recommended delay to optimize fluid and electrolyte status, evalu-
ation and limited preoperative improvement of cardiac and pulmonary status 
when necessary, and semi-elective repair when an experienced operating room 
staff was available. Unfortunately, the NSQIP does not track time from admission 
to operation in hours but instead by days. We were able to show that 42% of 
open repair and 44% of EVAR treated symptomatic patients underwent surgery 
at least one calendar day after the day of admission. We believe this is a sur-
rogate for surgeons choosing to not operate on symptomatic AAAs emergently 
but allowing optimization and semi-elective repair as advocated by the Mayo 
Clinic group. We did not find a benefit to delayed surgery, but this may reflect 
our inability to quantify delay in hours rather than calendar days.
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Symptomatic patients had higher rates of major adverse events after EVAR as 
well, when compared to asymptomatic patients, similar to VSGNE, where major 
adverse events were found to be approximately 7% and 28% after EVAR in 
asymptomatic and symptomatic patients respectively.8
Similar to prior studies, we had a higher proportion of females in the symp-
tomatic group compared to the asymptomatic but there was no difference 
between symptomatic and ruptured.7-9, 23 The reason for this remains unclear 
from this analysis; however, our previous work has shown that women are being 
repaired at relatively larger aneurysm sizes when diameter is indexed to body 
size.24 Patients presenting with symptomatic or ruptured AAA were also more 
likely to be non-white. This could be from issues related to unequal access to 
care, screening, or differences in natural history of aneurysm disease between 
different races. Unfortunately further delineation between races could not be 
adequately assessed due to small numbers.
There was a difference in main body device preference between ruptured 
aneurysm repair and symptomatic/asymptomatic AAAs, with higher rates of the 
Cook Zenith and “other” devices being used compared to elective utilization, 
although the Gore Excluder was the most commonly used device for all 3 groups. 
Whether this is due to surgeon preference related to indication or what is avail-
able on the shelf for the more emergent situations is not clear from this analysis.
This study has several limitations. It was a retrospective analysis of a large 
clinical dataset. Also, despite the large number of symptomatic AAAs our mul-
tivariable models were limited by the number of total events. In addition, only 
one surgical indication could be chosen for recording purposes in the targeted 
NSQIP and because of this we could not identify the proportion of patients in 
the symptomatic and ruptured groups who had prior unsuccessful EVAR or open 
repair. However, those with prior unsuccessful aneurysm repair represented a 
very small percentage of the asymptomatic group, where it could be identi-
fied, and were unlikely to influence the results of this analysis. In addition, the 
definition of ruptured and symptomatic aneurysms are taken directly from the 
surgeon’s operative note and we believe the larger than expected proportion 
of non-emergent ruptured aneurysms is likely from miscoding of the emergent 
status, and may also include some contained ruptures that for undocumented 
reasons were not repaired emergently. We expected and confirmed that some 
small aneurysms were being repaired for symptoms but NSQIP lacks data for 
other potential reasons for repair of small AAA including rapid growth, large con-
current iliac aneurysm, saccular shape, pseudoaneurysm, infected aneurysm, or 
strong family history of rupture. Similarly, rupture of small AAA could be a result 
of the above factors as well. Finally, patients could be reported as symptomatic 
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if their aneurysm caused local compression symptoms; this subgroup of symp-
tomatic patients is presumably not at risk for imminent rupture but we could not 
differentiate them from the patients presenting with pain. However, inclusion of 
these patients would likely lower the mortality in this group.
COnCLUsIOn
In this large contemporary study of symptomatic AAA patients, in which the ma-
jority were treated with EVAR, we found that symptomatic patients have twice the 
perioperative mortality compared to asymptomatic patients. Despite this we also 
find a reduction in perioperative mortality for symptomatic aneurysms compared 
to prior reports where the majority were treated by open repair, and believe 
this supports an EVAR-first approach for symptomatic aneurysms with suitable 
anatomy.
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ABsTRACT
Objective
Concomitant procedures during endovascular repair (EVAR) of an abdominal aortic 
aneurysm (AAA) are performed to either facilitate endograft delivery, simultane-
ously treat unrelated conditions, or to resolve intraoperative pitfalls. The frequency 
and perioperative impact of these procedures are not well described. This study 
aims to assess the frequency and perioperative impact of various concomitant 
procedures performed at the time of EVAR
Methods
We included all elective EVARs in the Vascular Study Group of New England be-
tween January 2003 and November 2014, and identified those with and those 
without concomitant procedures. Multivariable logistic regression analysis was 
used to establish the independent association between concomitant procedures 
and perioperative outcomes.
Results
4033 patients were included in the study, with 1168 (29.0%) patients undergoing 
one or more additional procedure. Independent risk factors for 30-day mortality 
were concomitant femoral endarterectomy (OR: 4.8, 95% CI: 2.1-11.2) and renal 
angioplasty or stenting (3.1, 1.2-8.3). Postoperative bowel ischemia was associ-
ated with hypogastric embolization (3.8, 1.1-13.4) and iliac angioplasty or stenting 
(3.5, 1.3-9.6). Leg ischemia was associated with unplanned graft extension (2.3, 
1.02-5.0), other artery reconstruction (5.2, 1.8-15.1), thrombo-embolectomy 
(5.2, 1.3-20.8), and repair of arterial injury (4.6, 1.2-18.3). Risk factors for de-
terioration of renal function were ilio-femoral bypass (3.9, 1.3-12.2), other artery 
reconstruction (2.7, 1.3-5.8), renal angioplasty or stenting (2.5, 1.3-4.6), and 
repair of arterial injury (4.5, 1.6-12.2). Myocardial infarction was associated with 
femoro-femoral bypass (3.9, 1.7-8.7), other artery reconstruction (3.9, 1.6-9.2) 
and repair of arterial injury (6.1, 1.8-21.0). Wound complications were predicted 
by femoro-femoral bypass (13.4, 5.8-31.1).
Conclusions
Concomitant procedures during EVAR are associated with increased postoperative 
morbidity and mortality. The need for performing concomitant procedures should 
be carefully considered. The morbidity associated with intraoperative complica-
tions highlights the importance of avoidance of arterial injury and thrombo-embolic 
events where possible.
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InTRODUCTIOn
Endovascular repair (EVAR) has become the primary mode of treatment for elec-
tive abdominal aortic aneurysms (AAA).1 EVAR is often performed in conjunction 
with additional procedures. These adjunctive procedures are done for various 
reasons, such as gaining adequate access to aorto-iliac vessels, establishing 
adequate endograft seal, but also to resolve intraoperative pitfalls, or to treat 
unrelated conditions. As EVAR is increasingly utilized for patients with complex 
anatomy, who more often undergo concomitant procedures, the need for evidence 
determining the perioperative implications of these interventions is rising.1, 2
Several studies have assessed the influence of various types of concomitant 
procedures on outcome.3-5 The largest and most recent report by Hobo et al. 
showed that concomitant endovascular procedures were associated with low 
additional risks, while surgical interventions for peripheral vascular disease 
significantly worsened outcome.6 Although interesting, the clinical implications 
of these results may be limited, as outcomes were provided for the overall 
procedural categories only (e.g., endovascular, surgical, etc.), and devices, 
treatment strategies, and outcomes have changed since the study’s last enroll-
ment in 2003.7, 8 More recently, several studies have reported on the safety 
of procedures facilitating EVAR, such as concomitant hypogastric embolization 
and femoral endarterectomy.9-12 However, these reports described only single 
institution experiences and were limited to relatively small numbers of patients.
In addition, the role of EVAR as an opportunity to treat concurrent vascular 
diseases is largely unclear, despite a high prevalence of occlusive vascular dis-
ease in the AAA population.13-16. Moreover, it has been shown that a substantial 
proportion of AAA patients later require non-aortic vascular surgery,17 which 
will likely increase as life expectancy is improving. By sparing a second opera-
tion, total morbidity, hospitalization and costs may decline. The purpose of this 
study is to assess the frequency and perioperative impact of various concomitant 
vascular interventions performed at the time of EVAR.
METHODs
Database
For this study, we used data from the Vascular Study Group of New England 
(VSGNE). The VSGNE is a regional multidisciplinary collaboration of 30 academic 
and non-academic centers, which prospectively gather data for 12 commonly per-
formed vascular procedures, including EVAR. The group aims to improve regional 
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outcomes in vascular surgery through monitoring and evaluation of 140 detailed 
patient demographic, operative, and clinical outcome variables. Trained nurses 
or clinical data abstractors enter the data in the registry. Surgeons are respon-
sible for the documentation of operative details and intraoperative complications. 
Researchers employing the VSGNE are blinded to patient, surgeon, and hospital 
identity. The data are validated through comparisons of submitted hospital data 
to discharge claims from each of the participating institutions.18 Patients in the 
VSGNE are individually matched to administrative data using unique identifiers to 
assess completeness and accuracy. Previous audits have demonstrated complete 
data capture for 99% of procedures and in-hospital mortality was correctly en-
tered for all patients. More details on this regional registry can be found at http://
www.vsgne.org. As the VSGNE contains de-identified data only without protected 
health information, Institutional Review Board approval and patient consent were 
waived.
Patients
We identified all patients undergoing elective endovascular AAA repair between 
January 2003 and November 2014. Patients with symptomatic AAA were excluded 
from the analysis. The following concomitant procedures at the time of EVAR are 
captured by the VSGNE: hypogastric embolization, unplanned graft extension, 
femoro-femoral bypass, femoral endarterectomy, iliac angioplasty or stenting, 
ilio-femoral bypass, renal angioplasty or stenting, other artery reconstruction, 
thrombo-embolectomy and repair of arterial injury. Patients undergoing multiple 
concomitant procedures were grouped in each of the procedure groups.
Clinical and outcome variables
The additional procedure groups were compared to those without concomitant 
procedures on baseline characteristics, intraoperative data, and postoperative 
outcomes. Baseline characteristics consisted of demographics, co-morbidities, 
and aneurysm diameter. Intraoperative details included operative time, blood 
loss, contrast media volumes, arterial injury, the occurrence of endoleaks and 
conversion to open repair. Postoperative outcomes were in-hospital events with 
the exception of 30-day mortality, and included deterioration of renal function, leg 
ischemia, cardiac complications, pneumonia, bowel ischemia, wound complica-
tions, postoperative blood transfusions, return to the operating room, prolonged 
postoperative length of stay, and prolonged length of stay in the intensive care 
unit (ICU). Deterioration of renal function was defined as an increase in postop-
erative creatinine >0.5mg per dl and/or need for dialysis. Prolonged length of 
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stay was considered when a patient remained hospitalized longer than 2 days 
postoperatively.
statistical analyses
Categorical variables are presented as counts and percentages. Normally distrib-
uted continuous variables are presented as mean ± standard deviation and non-
parametric distributions as median and interquartile range. Differences between 
those with and those without concomitant procedures were initially assessed us-
ing χ2 and Fisher’s exact testing for categorical variables and Student’s t-test, and 
Mann Whitney U test for continuous variables, where appropriate. Multivariable 
logistic regression was subsequently used to assess the independent associations 
between additional procedures and postoperative outcomes. For the adjusted 
analyses, baseline characteristics were first univariately tested. Variables with a 
P-value ≤ .1 were subsequently entered into the multivariable model. To avoid 
overfitting while maintaining adjustment for potential confounding procedures, 
the concomitant procedures were entered into the multivariate model using a 
conditional forward inclusion approach (p-value for entry <0.05, exit >0.10). To 
clarify, the association between all concomitant procedures and the outcome was 
tested, but only predictive procedures were entered into the multivariable model. 
Different models were constructed for each of the outcomes. All tests were two-
sided and significance was considered when p-value <0.05. Statistical analysis 
was performed using the SPSS Statistics 21 (IBM Inc., Chicago, IL).
REsULTs
A total of 4033 patients were included in the study, with 1168 patients (29.0%) 
undergoing one or more concomitant procedure. In addition to EVAR, 228 (5.7 %) 
patients received hypogastric embolization, 357 (8.9%) unplanned graft exten-
sion, 118 (2.9%) femoro-femoral bypass, 175 (4.3%) femoral endarterectomy, 
403 (10.0%) iliac angioplasty or stenting, 29 (0.7%) ilio-femoral bypass, 134 
(3.3%) renal angioplasty or stenting, 96 (2.4%) other artery reconstruction, 31 
(0.8%) thrombo-embolectomy, and 37 (0.9%) repair of arterial injury. Of the 
1168 patients undergoing concomitant procedures, 337 (28.9%) underwent mul-
tiple procedures (Supplemental Table 1).
Baseline characteristics
Baseline characteristics are detailed in Table 1. Compared to patients undergo-
ing isolated EVAR, concomitant hypogastric embolization patients were less 
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often female (17.5% vs. 11.4%, P=.019), while all other concomitant procedure 
groups –except other artery reconstruction– had a higher proportion of women 
(22.4% – 48.4%, P-value range <.001 to .023). Also, patients receiving un-
planned graft extensions, renal angioplasty or stents, and those undergoing a 
thrombo-embolectomy were older (73.8 years vs. 74.9, 76.6, and 76.7; P=.017, 
P<.001, and P=.024, respectively). Patients undergoing additional femoral end-
arterectomy more often suffered from obstructive pulmonary disease (33.4% vs. 
41.7%, P=.025). Iliac and renal angioplasty or stenting patients more commonly 
had renal insufficiency (5.3% vs. 8.5% and 10.4%, P=.009 and P=.010) and 
hypertension (84.2% vs. 89.8% and 91.8%, P=.003 and P=.018, respectively). 
Finally, as expected, smoking was more frequently observed in patients undergo-
ing concurrent treatment of atherosclerotic disease (i.e. femoral endarterectomy: 
28.1% vs. 44.0%, P<.001; iliac angioplasty or stenting: 36.7%, P=.001).
Intraoperative characteristics
Operative time was significantly longer (140 min. vs. 193 – 286 min., P<.001 for 
all, Table 2) and blood loss higher for all concomitant procedure groups (209 mL 
vs. 297 – 885 mL, P ≤.001 for all). Similarly, patients undergoing combined pro-
cedures more often required blood transfusions (3.0% vs. 10.4 – 37.9%, P<.001 
for all) and had higher rates arterial injury (0.6% vs. 3.0 – 70.3%, P-value range 
<.001 to .014). Not surprisingly, type I endoleak occurred more often in patients 
undergoing concomitant unplanned graft extension (1.9% vs. 7.3%, P<.001), but 
also in those undergoing iliac angioplasty or stenting (3.5%, P=.032), femoral 
endarterectomy (4.0%, P=.048), renal angioplasty or stenting (9.0%, P<.001) 
or repair of arterial injury (13.9%, P<.001). Type III was more common in those 
undergoing hypogastric embolization (0.2% vs. 1.8%, P=.003) and unplanned 
graft extension (1.4%, P<.001). In contrast, fewer type II endoleaks were found 
in patients undergoing procedures to treat atherosclerotic occlusive disease, such 
as concomitant iliac angioplasty or stenting (22.7% vs. 13.4%, P<.001), ilio-
femoral bypass (6.9%, P=.044), renal angioplasty or stenting (12.7%, P=.006) 
and thrombo-embolectomy (6.5%, P=.030).
Postoperative outcomes
Increased 30-day mortality rates were found in patients undergoing concomi-
tant femoro-femoral bypass (0.8% vs. 3.4% P=.018, Table 3), femoral endar-
terectomy (4.6%, P<.001), iliac angioplasty or stenting (2.7%, P<.001), renal 
angioplasty or stenting (3.7%, P<.001), other artery reconstruction (3.1%, 
P=.045), thrombo-embolectomy (6.5%, P=.026), and repair of arterial injury 
(5.4%, P=.037). Postoperative bowel ischemia was more frequently observed 
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6
after unplanned graft extension (0.3% vs. 1.1%, P=.047) and iliac angioplasty 
or stenting (1.7%, P<.001), with a trend for hypogastric embolization (1.3%, 
P=.053). Myocardial infarction occurred more often after all concomitant pro-
cedures except for iliac angioplasty or stenting (1.0% vs. 2.2 – 10.3%, P-value 
range: <.001 to .040), and heart failure after all but hypogastric embolization 
and femoral endarterectomy (0.6% vs. 2.0 – 12.9%, P-value range: <.001 to 
.015). Postoperative renal function deterioration was more frequently observed in 
all concomitant procedure groups except for the hypogastric embolization group 
(2.5% vs. 4.8 – 13.8%, P-value range: <.001 to .022), and leg ischemia in all but 
the hypogastric embolization and ilio-femoral bypass group (0.6% vs. 2.5 – 9.7% 
<.001 to P=0.013). Patients undergoing concomitant procedures, except for other 
artery reconstruction, were also more likely to return to the operating room (1.0% 
vs. 3.1% – 8.5%, P-value range: <.001 to .045), and all concomitant procedure 
patients were more likely to be hospitalized for longer than 2 days (17.8% vs. 
31.1 – 82.8%, P<.001 for all).
Multivariable analyses
Independent risk factors for 30-day mortality were concomitant femoral endar-
terectomy (OR: 4.8, 95% CI: 2.1-11.2, Table 4) and renal angioplasty or stenting 
(OR: 3.1, 95% CI: 1.2-8.3). Risk factors for postoperative bowel ischemia were 
hypogastric embolization (OR: 3.8, 95% CI: 1.1-13.4) and iliac angioplasty or 
stenting (OR: 3.5, 95% CI: 1.3-9.6). Leg ischemia was predicted by simultaneous 
unplanned graft extension (OR: 2.3, 95% CI: 1.02-5.0, P=.046), other artery 
reconstruction (OR: 5.2, 95% CI: 1.8-15.1), thrombo-embolectomy (OR: 5.2, 
95% CI: 1.3-20.8), and repair of arterial injury (OR: 4.6, 95 CI: 1.2-18.3). Risk 
factors for deterioration of the renal function were ilio-femoral bypass (OR: 3.9, 
95% CI: 1.3-12.2), renal angioplasty or stenting (OR: 2.5, 95% CI: 1.3-4.6), 
other artery reconstruction (OR: 2.7, 95% CI: 1.3-5.8), and repair of arterial 
injury (OR: 4.5, 95% CI: 1.6-12.2). Postoperative myocardial infarction was as-
sociated with femoro-femoral bypass (OR: 3.9, 95% CI: 1.7-8.7), other artery 
reconstruction (OR: 3.9, 95% CI: 1.6-9.2) and repair of arterial injury (OR: 6.1, 
95% CI: 1.8-21.0), while a trend was found for hypogastric embolization (OR: 2.2, 
95% CI: 1.0-4.8, p=0.051). Femoro-femoral bypass was additionally predictive of 
wound complications (OR: 13.5, 95% CI: 5.8-31.1). All concomitant procedures 
except iliac angioplasty or stenting were predictive of prolonged postoperative 
length of stay.
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DIsCUssIOn
With 29% of patients undergoing one or more additional procedure, this study 
demonstrates that concomitant procedures are commonly performed during elec-
tive EVAR.6 In line with previous reports, 6, 19-21 we found that women were more 
likely to undergo concomitant procedures. This is most likely due to smaller artery 
diameters in women, which more often requires access-related and revasculariza-
tion procedures.19-21 Depending on type of intervention, performing concomitant 
procedures during EVAR proved to be associated with increased intraoperative 
complications, as well as higher risks of morbidity and mortality in the postopera-
tive period. Femoral endarterectomy and renal angioplasty or stenting were inde-
pendently associated with perioperative mortality, while hypogastric embolization 
and iliac angioplasty or stenting were predictors of postoperative bowel ischemia. 
Unplanned graft extension, other artery reconstruction, and the interventions to 
treat intraoperative complications (i.e., thrombo-embolectomy and repair of arte-
rial injury) were associated with lower extremity ischemia, and femoro-femoral 
bypass was a risk factor for wound complications. These, and other concomitant 
procedures were additionally associated with various other perioperative complica-
tions, including renal function deterioration, myocardial infarction, and prolonged 
length of stay.
Concomitant femoral endarterectomy during EVAR was found to be associ-
ated with increased mortality following surgery. While evidence on performing 
concomitant femoral endarterectomy is limited, one report showed that femoral 
artery reconstruction (i.e., femoral endarterectomy and femoro-femoral bypass) 
during EVAR did worsen outcomes as compared to direct closure.11 However, 
the conclusions are hampered by limited numbers and consequent lack of sta-
tistical power. In line with our study, Nguyen et al. recently reported in a large 
series that the risks of death following femoral endarterectomy, albeit as an 
isolated intervention, are not insignificant.22 In addition, Hobo et al. determined 
that surgical intervention for PAD, which included femoral endarterectomy, was 
associated with increased perioperative mortality.6 The need for femoral end-
arterectomy is a reflection of extensive PAD, which is a well-established risk 
for adverse outcomes following surgery. Several other concomitant procedures 
to treat atherosclerotic occlusive disease (ilio-femoral bypass, iliac angioplasty 
or stenting, femoro-femoral bypass, renal angioplasty or stenting, other artery 
reconstruction) were also associated with complications, particularly of ischemic 
nature. Conversely, these procedure groups had lower rates of type II endoleak, 
which is likely related to occlusive disease affecting aortic side branches.23 In 
addition, procedures that are indicative of extensive atherosclerotic disease, 
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including femoral endarterectomy, were more likely to have a type I endoleak. 
This is most likely caused by extensive aortic atherosclerotic disease and par-
ticularly calcified aneurysm necks, hampering adequate proximal seal.24
The other independent risk factor for 30-day mortality was concomitant renal 
artery stenting. Renal angioplasty or stenting is performed to either to treat 
a pre-existing renal artery stenosis, or to preserve renal perfusion after renal 
artery overstenting (planned or unplanned). In contrast to the present results 
showing more than 3 times the risk of 30-day mortality, renal stenting has previ-
ously been determined a safe and effective means to treat patients with short 
infrarenal necks and inadvertent renal artery coverage.12 However, it should be 
considered that this single center study may not have been adequately powered 
to detect small differences in outcome, and the lack of single center studies 
demonstrating increased risk may be due to publication bias. Also, it is likely 
that apart from the procedure itself, chronic kidney disease, which has been 
identified as a predictor of worse outcome after EVAR, has contributed to the 
worse outcome in this particular patient group.25, 26
Hypogastric artery embolization and iliac artery stenting were associated with 
increased risks of bowel ischemia. While complications such as buttock and 
spinal claudication are well-defined complications of hypogastric embolization, 
bowel ischemia is not.27, 28 Several studies have reported on the importance 
of the hypogastric circulation for mesenteric blood flow.29, 30 However, it was 
concluded that bowel ischemia following EVAR is mostly caused by widespread 
micro-embolization, of which dislodged atheromatous debris from access vessels 
has been determined an important source. 31, 32 This provides a valid explana-
tion for the increased risks of bowel ischemia after iliac artery angioplasty and 
stenting. In addition, performing iliac angioplasty o stenting indicates extensive 
atherosclerotic disease, which is likely to also affect the mesenteric vessels and 
collaterals. As colonic ischemia significantly worsens the postoperative progno-
sis, the present data highlight the importance of using caution when performing 
iliac angioplasty or stenting. Coil embolization of the hypogastric may also cause 
micro-embolization, in addition to a global decrease in flow. It is unclear whether 
placement of a more proximal plug has a decreased risk of colonic ischemia 
compared to placement of coils, but it seems reasonable to try to maintain as 
much collateral flow as possible. The fact that hypogastric artery embolization 
was associated with increased risks of bowel ischemia highlights the need to 
assess patency of the superior mesenteric artery and evaluate any history of 
colonic surgery that could impact collateral flow in the colon when this procedure 
is considered.
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Apart from planned concomitant procedures, thrombo-embolectomy and repair 
of arterial injury were also associated with various adverse outcomes, including 
postoperative leg ischemia, myocardial infarction, and prolonged length of stay. 
In contrast to most concomitant procedures, consideration of operative risks 
before intervening is less of an option for these procedures. Therefore, the need 
for these procedures should be avoided through appropriate patient selection, 
adequate intraoperative anticoagulation, and careful consideration of performing 
additional procedures that are associated with increased risks of arterial injury.
This study has several limitations that should be addressed. First, as the 
VSGNE collects data through a registry, underreporting of events is a possibil-
ity. Second, the rates of adverse outcomes following EVAR are generally low, 
thereby limiting the statistical power of multivariable analyses. As a result, 
univariate associations between less common procedures and complications, 
such as the association between ilio-femoral bypass and leg ischemia, could not 
be established in multivariable analyses. Third, we were unable to distinguish 
between patients undergoing concomitant renal stenting to treat renal artery 
stenoses or re-establish blood flow after renal artery coverage (planned or 
unplanned). As the clinical implications of the procedure depend on the indica-
tion, this information would be valuable. Similarly, for several other concomitant 
procedures we were unable to determine whether the procedure was planned 
or performed to resolve an intraoperative complication. However, it is unlikely 
that all planned concomitant procedures were uncomplicated, and only bailout 
procedures were associated with worse outcome. Therefore, the present data 
should be considered when a concomitant procedure is planned. Fourth, the lack 
of data on proximal extent of the aneurysm precluded stratification of outcomes 
based on the type of aneurysm. Finally, it should be noted that patients were 
not randomized to undergo concomitant procedures or not. Since the patient 
dictates which concomitant procedures are indicated, patients undergoing one 
or more concomitant procedure are more likely to have extensive disease than 
those not undergoing additional interventions. Therefore, confounding by indica-
tion should be considered, despite adjustment for baseline characteristics in 
multivariable analysis.
In conclusion, this study shows that various additional procedures during EVAR 
are associated with increased intraoperative complications and postoperative 
morbidity and mortality. Careful patient selection and deliberation of the need 
for the intervention are advised for procedures performed electively. The mor-
bidity associated with the treatment of intraoperative complications highlights 
the importance of avoidance of these events where possible.
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ABsTRACT
Objective
Open repair of abdominal aortic aneurysms (AAA) is occasionally performed in 
conjunction with additional procedures. However, it is unclear how these concomi-
tant procedures affect outcome. This study aims to determine the frequency of 
additional procedures during elective open AAA repair and the impact on periop-
erative outcomes.
Methods
Between January 2003 and November 2014, all elective infrarenal open AAA 
repairs in the Vascular Study Group of New England (VSGNE) were identified. 
Patients were grouped by concomitant procedures, which included: no concomi-
tant procedure, renal artery bypass, lower extremity bypass, other abdominal 
procedure or thrombo-embolectomy. Analyses were performed using multivari-
able logistic regression.
Results
1314 patients underwent elective AAA repair, of whom 153 (11.6%) had a con-
comitant procedure, including renal bypass 27 (2.1%), lower extremity bypass 
28 (2.1%), other abdominal procedures 64 (4.9%), and thrombo-embolectomy 
48 (3.7%). Independent risk factors for 30-day mortality were renal bypass (OR: 
7.2, 95% CI: 1.9 – 27.7), other abdominal procedures (OR: 4.8, 95% CI: 1.6 – 
14.1) and thrombo-embolectomy (OR: 8.8, 95% CI: 3.1 – 24.9). Deterioration 
of renal function was predicted by renal bypass (OR: 5.1, 95% CI: 2.1–12.4) and 
thrombo-embolectomy (OR: 3.7, 95% CI: 1.8 – 7.6). Lower extremity bypass 
and thrombo-embolectomy were predictive of postoperative leg ischemia (OR: 
8.9, 95% CI: 2.7 – 29.0; OR: 11.2, 95% CI: 4.4 – 28.8, respectively), while 
thrombo-embolectomy was also predictive of postoperative myocardial infarction 
(OR: 4.4, 95% CI: 1.6 – 12.0).
Conclusions
Performing additional procedures during infrarenal open AAA repair is associated 
with increased morbidity and mortality in the postoperative period. Careful delib-
eration of both the operative risks and the necessity of the additional interventions 
are therefore advised during operative planning. This study also highlights the 
importance of avoiding perioperative thrombo-embolic events.
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InTRODUCTIOn
Considering that abdominal aortic aneurysm (AAA) is generally a disease of the 
elderly,1 AAA patients commonly have coexisting medical conditions, such as 
peripheral artery disease and gastrointestinal pathologies.2-6 Open AAA repair 
provides the opportunity to simultaneously treat some of these coexisting medical 
conditions in a single-staged procedure. By sparing the need for a second pro-
cedure, outcomes may improve, while total hospital stay and costs decrease.5, 7 
However, clinicians are generally hesitant to attempt one-stage procedures,4, 5, 8 
as evidence supporting the safety and feasibility of contemporaneous procedures 
is largely lacking.
The prevalence of concurrent nonvascular intra-abdominal pathologies (e.g. 
malignancies, cholecystopathology) in AAA patients has been reported to be as 
high as 32%.3, 4, 6 Several studies have assessed the benefits of a combined pro-
cedure over a sequential approach for concomitant nonvascular intra-abdominal 
disease with mixed conclusions and recommendations.5, 9-12 With up to one-third 
of AAA patients suffering from renal artery stenoses and a prevalence of pe-
ripheral artery disease (PAD) of over 50%,13-16 occlusive vascular disease in 
particular is often present in the AAA population. Despite this high prevalence, 
the safety and feasibility of concurrent surgical treatments remain largely un-
clear. The limited studies available for one-stage repairs of AAA and renal artery 
stenosis are conflicting, with some reporting an increase in adverse events,16, 17 
while others did not.18-20 Furthermore, these studies mostly described small 
series of combined procedures and were all conducted prior to the introduction 
of EVAR, after which the characteristics of patients selected for open repair have 
likely changed.21, 22 There are no studies to date investigating the outcomes of 
open AAA repair with concurrent peripheral revascularization.
The purpose of this study, therefore, is to determine the frequency and out-
comes of procedures that are concomitantly performed with open AAA repair and 
to aid clinicians in deciding whether or not a combined procedure can be safely 
attempted.
METHODs
Database
Data from the Vascular Study Group of New England (VSGNE) were used for this 
study. The VSGNE is a regional collaboration of 30 academic and community hospi-
tals in the six New England states, involving more than 180 physicians. The group 
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aims to study and improve regional outcomes in vascular surgery and documents 
140 detailed patient demographic, operative, and clinical outcome variables for 
12 commonly performed vascular procedures, including AAA repair.23 The data are 
prospectively gathered and entered in the registry by trained nurses or clinical data 
abstractors. Surgeons enter operative details. Research analysts are blinded to 
patient, surgeon, and hospital identity. The VSGNE database has been validated for 
completeness using audits of discharge claims data from each participating institu-
tion.23 Institutional Review Board approval and patient consent were waived, as 
the VSGNE contains de-identified data only without protected health information. 
Further details about this registry can be found at http://www.vsgne.org.
Patients
The study cohort included patients undergoing elective open infrarenal AAA repair 
between January 2003 and November 2014. The following concomitant procedures 
during open AAA are documented in the VSGNE: ‘renal bypass’, ‘lower extremity 
bypass’, ‘other abdominal procedures’, and ‘thrombo-embolectomy’. Patients un-
dergoing isolated open AAA repair were assigned to the ‘no concomitant procedure’ 
group. When a patient underwent more than one concomitant procedure, they 
were allocated to multiple concomitant procedure groups. Since the incidence of, 
indication for, and outcomes of concomitant procedures likely differ for juxtarenal 
and suprarenal aneurysms compared to infrarenal, in particular for renal artery 
bypass surgery, only patients undergoing infrarenal AAA repair were included.
Clinical and outcome variables
Patients receiving combined surgery were compared to those undergoing infrarenal 
AAA repair alone on patient characteristics, intraoperative data, and postoperative 
outcomes. Patient characteristics included age, gender, co-morbidities, and aneu-
rysm diameter. Intraoperative details analyzed were operative time, blood loss, re-
nal/visceral ischemia time, and procedural details, including surgical approach (i.e. 
transabdominal vs. retroperitoneal), target vessel for the distal anastomosis, and 
management of the hypogastric and inferior mesenteric artery. Postoperative out-
comes were in-hospital events with the exception of 30-day mortality, and included 
deterioration of renal function, lower extremity ischemia, cardiac complications, 
pneumonia, bowel ischemia, wound complications, prolonged postoperative length 
of stay, and prolonged length of stay in an intensive care unit (ICU). Deterioration 
of renal function was defined as an increase in postoperative creatinine >0.5mg per 
dl and/or need for dialysis. Myocardial infarction was considered when one of the 
following was documented: isolated troponin elevation, electrocardiogram change, 
or clinical evidence of myocardial infarction. Prolonged postoperative length of stay 
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was defined as longer than 7 days and prolonged length of ICU stay was longer 
than 2 days, definitions that have been used previously.24
statistical analyses
Discrete variables are presented as counts and percentages, and continuous 
variables as mean ± standard deviation, if normally distributed, or as median 
and interquartile range if the distribution is non-parametric. To assess differences 
between patients undergoing concomitant procedures and those who did not, we 
used χ2 and Fisher’s exact tests for categorical variables, and Student’s t-test for 
continuous variables, where appropriate. Multivariable logistic regression analy-
sis was used to determine the independent associations between concomitant 
procedures and outcomes. Baseline characteristics were first univariately tested 
and significant predictors were added to the multivariable model. Concomitant 
procedures with a p-value ≤ .1, when compared to the no concomitant procedure 
group, were subsequently entered. A separate model was constructed for each of 
the studied outcomes. All tests were two-sided and significance was considered 
when P-value < .05. Statistical analysis was performed using the SPSS Statistics 
21 (IBM Inc., Chicago, IL).
REsULTs
A total of 1314 patients receiving elective open AAA repair were included in the 
study, with 153 (11.6%) undergoing one or more additional procedures. Concomi-
tant renal bypass surgery was performed in 27 (2.1%) patients, lower extremity 
bypass surgery in 28 (2.1%) patients, other additional abdominal procedures in 
64 (4.9.%) patients, and thrombo-embolectomy in 48 (3.7%) patients. Of the 
153 patients undergoing concomitant procedures, 13 (8.5%) underwent multiple 
procedures (Supplemental Table 1).
Baseline characteristics
Patients solely treated for AAA and those undergoing additional procedures were 
generally similar (Table 1). However, concomitant renal bypass patients were 
more likely to have never smoked compared to those not undergoing concomi-
tant procedures (22.2% vs. 8.2%, P = .020), while lower extremity bypass and 
thrombo-embolectomy patients were more frequently current smokers (75.0% vs. 
40.9%, P = .001; 58.3% vs. 40.9%, P = .051, respectively). In addition, patients 
requiring a thrombo-embolectomy had a smaller mean aneurysm diameter (52.9 
mm vs. 59.2 mm, P = .024).
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Intraoperative characteristics
All combined procedures were accompanied by a longer procedure time, adding 
between 80 and 121 min. compared to patients with no concomitant procedures 
(mean: 199 min., P ≤ .001 for all, Table 2). Blood loss more than 1L occurred 
more frequently with renal bypass surgery (73.1% vs. 46.2, P = .007), other 
abdominal procedures (60.9%, P = 021) and thrombo-embolectomy (64.6%, 
P = .012). In lower extremity bypass and thrombo-embolectomy patients the 
aortic graft was more often anastomosed to vessels distal to the aorta (71.4% vs. 
48.5%, P = .016; 68.7% vs. 48.5%, P < .001, respectively). Further, there was 
a trend for retroperitoneal approach to be more frequently used for simultaneous 
renal bypass procedures (25.9% vs. 13.3%%, P = .057). Renal and/or visceral 
ischemia time longer than 30 minutes was observed in 30.8% of renal bypass 
patients, and 10.6% of those undergoing a thrombo-embolectomy.
Postoperative outcomes
Thirty day mortality ranged from 7.1% to 12.5% for those undergoing concomi-
tant procedures while those without concomitant procedures had a mortality rate 
of 1.1% (P <.05 for all, Table 3). Similarly, acute kidney failure occurred more 
often after all concomitant procedures (17.2% – 30.8% vs. 7.2%, P < .05 for 
all). Patients undergoing lower extremity bypass and thrombo-embolectomy more 
commonly experienced postoperative leg ischemia (18.5% vs. 1.3%, P < .001; 
17.0% vs. 1.3%, P < .001, respectively) and pneumonia (21.4% vs. 5.8%, P 
= .001; 18.8% vs. 5.8%, P = .001, respectively). Lower extremity bypass was 
also associated with higher rates of heart failure (17% vs. 4%, P < .001). In 
addition, thrombo-embolectomy patients more often suffered a postoperative MI 
(14.6% vs. 4.2%, P = .001) and required an unplanned return to the operating 
room (14.9% vs. 5.9%, P = .012). Finally, ICU stay was more often prolonged 
(>2 days) in patients undergoing lower extremity bypass surgery (67.9% vs. 
38.7%, P = .002), other abdominal procedures (54.7%, P = .011) and thrombo-
embolectomy (62.5%, P = .002), while postoperative length of hospital stay was 
prolonged (>7 days) in those undergoing other abdominal procedures 50.0% vs. 
32.9%, P = .005) and thrombo-embolectomy (58.3%, P < .001).
Multivariable analyses
In adjusted analyses (Table 4), risk factors for 30-day mortality were renal bypass 
(OR: 7.2, 95% CI: 1.9 – 27.7) other abdominal procedure (OR: 4.8, 95% CI: 
1.6 – 14.1) and thrombo-embolectomy (OR: 8.8, 95% CI: 3.1 – 24.9). Concomi-
tant procedures associated with deterioration of renal function were renal bypass 
surgery (OR: 5.1, 95% CI: 2.1 – 12.4) and thrombo-embolectomy (OR: 3.7, 
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95% CI: 1.8 – 7.6). Predictors for postoperative limb ischemia were concomitant 
lower extremity bypass surgery (OR: 8.9, 95% CI: 2.7 – 29.0) and thrombo-
embolectomy (OR: 11.2, 95% CI: 4.4 – 28.8). Thrombo-embolectomy was addi-
tionally found to be a risk factor for bowel ischemia (OR: 4.4, 95% CI: 1.6 – 12.0) 
and postoperative MI (OR: 3.5, 95% CI: 1.5 – 8.3). ICU stay longer than 2 days 
was predicted by lower extremity bypass (OR: 3.5, 95% CI: 1.5 – 8.2), other 
abdominal procedures (OR: 1.9, 95% CI: 1.1 – 3.3) and thrombo-embolectomy 
(OR: 2.4, 95% CI: 1.3 – 4.5).
Table 4. Adjusted associations between concomitant procedures and postoperative out-
comes
30-day mortalityα Renal deteriorationβ
OR 95% CI P-value OR 95% CI P-value
Renal bypass 7.2 1.9 – 27.7 .004 5.1 2.1 – 12.4 <.001
Lower extremity bypass 3.2 0.6 – 17.0 .17 2.5 0.9 – 6.6 .075
Other abdominal 4.8 1.6 – 14.1 .005 2.0 0.9 – 4.0 .070
Thrombo-embolectomy 8.8 3.1 – 24.9 <.001 3.7 1.8 – 7.6 .001
Leg ischemiaγ Bowel ischemiaδ
OR 95% CI P-value OR 95% CI P-value
Renal bypass - - - - - -
Lower extremity bypass 8.9 2.7 – 29.0 <.001 - - -
Other abdominal - - - - - -
Thrombo-embolectomy 11.2 4.4 – 28.8 <.001 4.4 1.6 – 12.0 .003
Myocardial infarctionε ICU stay >2 daysζ
OR 95% CI P-value OR 95% CI P-value
Renal bypass - - - - - -
Lower extremity bypass - - - 3.5 1.5 – 8.2 .005
Other abdominal - - - 1.9 1.1 – 3.3 .015
Thrombo-embolectomy 3.5 1.5 – 8.3 .005 2.4 1.3 – 4.5 .006
OR: odds ratio; CI: confidence interval
Concomitant procedures without odds ratio’s did not reach a p-value ≤ .1 in univariable 
analysis, and were therefore not included in the
multivariable model.
α adjusted for: age; β adjusted for: diabetes, renal insufficiency; γ adjusted for: gender; δ 
adjusted for: age; ε adjusted for: age, coronary artery disease, obstructive pulmonary dis-
ease; ζ adjusted for: age, gender, renal insufficiency, obstructive pulmonary disease
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DIsCUssIOn
This study demonstrates that performing additional procedures during open AAA 
surgery is associated with increased morbidity and mortality in the postopera-
tive period. Concomitant renal bypass, other concurrent abdominal procedures, 
and thrombo-embolectomy were independent predictors for 30-day mortality and 
multiple other postoperative adverse events. Lower extremity bypass surgery was 
not established as a risk factor for 30-day mortality, but was associated with 
postoperative complications, including leg ischemia and prolonged length of ICU 
stay.
Some studies conducted prior to the introduction of EVAR recommended an 
aggressive approach towards renal bypass surgery at the time of AAA repair, as 
they found similar mortality rates between concurrent aortic and renal artery 
reconstruction versus aortic surgery alone. 18-20, 27, 28 In our study, we found that 
patients with renal disease severe enough for concomitant renal bypass surgery 
to be performed, had a 7-fold increase in 30-day mortality risk. This is in agree-
ment with the largest series to date by Benjamin et al,16 and adds support to 
performing renal stenting before or after the AAA repair, rather than combined 
surgery when correction of the renal artery lesion is indicated. Moreover, it has 
been demonstrated that normotension was less often achieved after combined 
aortorenal reconstruction as compared to a staged approach.16, 18 The present 
results additionally highlight the potential benefit of utilizing endovascular treat-
ment approaches in these patients, which can be performed simultaneously, 
but also prior or subsequent to the AAA repair. However, two randomized trials 
comparing endovascular renal artery revascularization to medical therapy rec-
ommended a conservative approach over revascularization.25, 26
Abdominal aneurysmal disease and PAD share a number of etiologic risk fac-
tors.13 As a result, PAD is present in a majority of AAA patients.2 Yet, concomitant 
lower extremity bypass during open AAA repair was only performed in 2.1% 
of all cases. In addition to treatment of comorbid peripheral artery disease, 
concomitant lower extremity bypass surgery may be performed to improve out-
flow following clamp release and prevent graft thrombosis. Although the 30-day 
mortality rate was significantly higher compared to infrarenal AAA repair only 
(7.1% vs. 1.1%), no mortality risks associated with concomitant lower extremity 
bypass could be established in adjusted analyses. A low number of patients and 
the consequent lack of statistical power, rather than a lack of association, is 
likely to be responsible for these results. Although extensive occlusive disease 
in these patients may also have contributed to their poor outcome, we believe 
a cautionary note on concomitant lower extremity bypass surgery during AAA 
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repair is fitting. Additionally, the present results warrant consideration of per-
forming angioplasty or stenting rather than bypass surgery, particularly since 
these interventions can be performed prior or subsequent to the AAA repair with 
limited additional operative risk.
Since the majority of intra-abdominal procedures involve gastrointestinal 
structures with potentially infectious contents, the biggest concern of intra-
abdominal concomitant procedures is graft contamination.9 In the present study, 
performing other abdominal procedures in conjunction with open AAA repair was 
predictive of increased morbidity and mortality in the perioperative period. The 
results from prior studies are conflicting. Some studies have demonstrated that 
additional intra-abdominal interventions during open AAA repair, such as colorec-
tal resections and cholecystectomies, worsen the perioperative outcome.9, 11, 12 
As a result, Lin et al. recommended treating the symptomatic lesion first in case 
of concurrent colorectal cancer.12 Conversely, other studies that covered similar 
concomitant interventions encouraged combined surgery, as they deemed it safe 
and went a step further to say it reduces the risk of AAA rupture between opera-
tive procedures.5, 9, 10 Unfortunately, we were unable to obtain further details 
on the nature of the interventions included in the other abdominal procedures 
group as we do not know what procedures were performed. Nevertheless, the 
fact that these procedures were associated with such a clear increase in periop-
erative mortality warrants careful deliberation by the surgeon when considering 
performing any additional abdominal procedure during open AAA repair.
Apart from other abdominal procedures, concomitant thrombo-embolectomy 
was a major risk factor for multiple adverse outcomes in the postoperative 
period, including death. Since the need for thrombo-embolectomy is not some-
thing planned pre-operatively, this demonstrates the problems associated with 
thrombo-embolic events that complicate open AAA repair. The results from this 
study highlight the importance of minimizing the likelihood of thrombo-embolic 
events. Patients undergoing a thrombo-embolectomy were more severely bur-
dened by occlusive disease in addition to their known aneurysmal disease, as 
indicated by the fact that in these patients the prosthesis was more often anas-
tomosed to vessels distal to the aorta. Since dislodged atherothrombotic debris 
is often the cause of thrombo-embolic events, careful consideration should be 
given to the clamp location in order to reduce clamp trauma and consequent 
plaque embolism. Inadequate intraoperative anticoagulation may also play a 
role. However, heparin dose and activated clotting time were not documented in 
this data set.
This study has several potential limitations that must be addressed. First, as 
the VSGNE collects data through a registry, underreporting of events is possible. 
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Second, since endovascular repair is currently the primary mode of treatment 
for infrarenal AAA, it is likely that certain patient characteristics either precluded 
an endovascular approach, or made open repair the better alternative for these 
patients. Unfortunately, these reasons for performing open repair instead of 
EVAR are not documented in this data set. Third, concomitant procedures during 
open repair are grouped into only four categories, with one category consisting 
of all other abdominal procedures. As a result of the limited specificity of this 
group, the conclusions and clinical implications are bounded. In addition, this 
data set does not include operative characteristics specific to each of the con-
comitant procedures, which precluded us from performing subanalyses within 
the different concomitant procedure categories. Similarly, data on whether the 
procedure was planned or not were not documented. However, it is unlikely that 
all planned concomitant procedures were uncomplicated, and only procedures 
to resolve intraoperative complications were associated with worse outcome. 
Therefore, the present data should be considered when a concomitant procedure 
is planned. Due to the lack of adverse outcome data, we were unable to deter-
mine whether any differences in outcomes existed outside the in-hospital period 
with the exception of mortality. Finally, it should be noted that patients were 
not randomized to undergo either AAA repair only or combined surgery. Despite 
the use of multivariable analysis to minimize the potential of confounding by 
indication, residual confounding should always be considered.
In conclusion, this study demonstrates that combining open AAA repair with 
additional interventions is associated with increased morbidity and mortality 
in the perioperative period. Renal bypass surgery, other abdominal procedures 
and the need for concurrent thrombo-embolectomy were all independent risk 
factors for mortality and multiple other in-hospital complications. Concomitant 
lower extremity bypass surgery was also associated with worse mortality and 
in-hospital outcomes, although the independent risks could not be established 
for mortality. Careful deliberation of the operative risks and the necessity of 
additional procedures is advised during operative planning. The poor outcome 
of thrombo-embolectomy highlights the importance of adequate intraoperative 
anticoagulation and prevention of intraoperative thrombo-embolic events where 
possible.
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supplemental Table 1. Incidence of infrarenal AAA repairs performed in conjunction with 
more than one concomitant procedure
Renal 
bypass
Lower 
extremity 
bypass
Other 
abdominal
Thrombo-
embolectomy
One 
concomitant 
procedure
Total
Renal bypass - 0 4 (15%) 0 23 (85%) 27 (100%)
Lower extremity bypass 0 - 2 (7%) 5 (18%) 21 (75%) 28 (100%)
Other abdominal 4 (6%) 2 (3%) - 4 (6%) 54 (84%) 64 (100%)
Thrombo-embolectomy 0 (0) 5 (10%) 4 (8%) - 39 (81%) 48 (100%)
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ABsTRACT
Objective
As endovascular techniques (EVAR) continue to advance, eligibility of patients 
with anatomically complex abdominal aortic aneurysms (AAA) for EVAR is increas-
ing. However, it remains largely unclear whether complex EVAR is associated with 
favorable outcome over conventional open repair and how outcomes compare to 
infrarenal EVAR. The purpose of this study was to examine perioperative outcomes 
of patients undergoing complex EVAR, focusing on differences with complex open 
repair and standard infrarenal EVAR.
Methods
We identified all patients undergoing non-ruptured complex EVAR, complex open 
repair, and infrarenal EVAR in the Targeted Vascular Module from the American 
College of Surgeons National Surgical Quality Improvement Program. Aneurysms 
were considered complex if the proximal extent was juxta- or suprarenal, and/or 
when the Cook Zenith Fenestrated endograft was used. Independent risks were 
established using multivariable logistic regression analysis.
Results
A total of 4584 patients were included, with 411 (9.0%) undergoing complex 
EVAR, 395 (8.6%) complex open repair, and 3778 (82.4%) infrarenal EVAR. Peri-
operative mortality following complex EVAR was 3.4% vs. 6.6% after open repair 
(P=.038), and 1.5% after infrarenal EVAR (P=.005). Postoperative acute kidney 
injuries occurred in 2.3% of complex EVAR patients vs. 9.5% of those undergoing 
complex open repair (P<.001), and 0.9% of infrarenal EVAR patients (P=.007). 
Compared to complex EVAR, complex open repair was an independent predictor 
of 30-day mortality (OR: 2.2, 95% CI:1.1–4.4), renal function deterioration (5.0, 
2.3–10.7), and any complication (3.9, 2.7–5.8). When comparing complex to 
infrarenal EVAR, infrarenal EVAR was associated with favorable 30-day mortality 
(0.5, 0.3–0.9), and renal outcome (0.4, 0.2–0.9).
Conclusions
Complex EVAR has fewer perioperative complications compared to complex open 
repair, but –in turn– does carry a higher risk of adverse outcomes than infrarenal 
EVAR. Further research is warranted to determine whether the benefits of EVAR 
compared to open repair for complex AAA treatment are maintained during long-
term follow-up.
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InTRODUCTIOn
Endovascular repair (EVAR) of an abdominal aortic aneurysm (AAA) is associated 
with lower perioperative mortality, as well as lower rates of complications, need for 
transfusions, and length of stay compared to open repair.1-4 Because of these ben-
efits, the utilization of EVAR has rapidly increased since its introduction in 1996,5 
with over 80% of infrarenal AAA repairs now being performed using endovascular 
treatment.6-8 Due to inadequate proximal seal zone, standard endovascular repair 
cannot be used for juxta- and suprarenal aneurysms (complex AAA), which has 
been reported to make up as much as 20% of all AAAs.9-11
Through advancements in endovascular treatment techniques, including chim-
ney, fenestrated and branched stent grafts, EVAR can now be offered to patients 
with complex proximal neck anatomy.12 A large national series from the United 
Kingdom demonstrated that fenestrated endovascular repair can be performed 
with a high degree of technical and clinical success.13 However, most feasibility 
studies are institutional based and therefore often limited to small numbers of 
patients.14-18 Moreover, they usually did not compare outcome of complex EVAR 
to that of conventional open repair. Efforts that did compare complex EVAR to 
open repair yielded conflicting results. While one study demonstrated favorable 
perioperative outcomes after open repair,19 two other studies showed reduced 
30-day morbidity and mortality associated with EVAR.20, 21 Adding to the confu-
sion, two systematic reviews found perioperative benefits favoring EVAR,22, 23 
while another review demonstrated a pooled perioperative mortality of 4.1% 
after both EVAR and open repair, with no difference in the complication rate.24
In addition, it has been suggested that complex EVAR is associated with in-
creased risk of postoperative renal failure compared to uncomplicated infrarenal 
EVAR.25, 26 However, limited comparative data exist for infrarenal versus complex 
EVAR, and the presumed differences in renal complications could previously not 
be confirmed.27
The purpose of this study was to assess the perioperative outcome following 
EVAR for complex aneurysms, focusing on differences with complex open repair, 
the alternative treatment option, and standard infrarenal EVAR using the newly 
available Targeted Vascular data set of the National Surgical Quality Improve-
ment Program.
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METHODs
For this study, we used the Targeted Vascular data set from the American College 
of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) data-
base. The ACS NSQIP is a multi-institutional collaboration with 102 participating 
hospitals in the United States that prospectively collect clinical data of patients 
undergoing major surgery. The NSQIP database includes demographics, comor-
bidities, intraoperative characteristics, and 30-day postoperative outcomes. The 
Targeted Vascular data set is a recently added module, which includes additional 
disease and procedure specific characteristics, and procedure-related outcomes 
chosen by vascular surgeons. All data collection is performed by trained clinical 
nurse reviewers and data abstractors. The validity of the ACS NSQIP has been 
confirmed in previous reports.28-30 The database contains de-identified data only 
without any protected health information. Therefore, Institutional Review Board 
approval and patient consent were waived. Additional information on the ACS 
NSQIP and the Targeted Vascular data set are available on www.acsnsqip.org.
From the Targeted Vascular data set for years 2011 to 2013, we identified all 
elective open and endovascular abdominal aortic aneurysm repairs, by the treat-
ment indication variable. Thoracoabdominal aneurysms were excluded from this 
study. Additionally, procedures coded as repair of a ruptured AAA (CPT: 38082, 
35092, 35103), cases with a postoperative diagnosis code for a ruptured AAA 
(ICD-9: 441.3), and procedures coded as conversions to open repair (CPT: 34830, 
34831, 34832) were excluded. The remaining cohort was subsequently divided in 
three groups in accordance with both treatment modality and proximal aneurysm 
extent: complex EVAR, complex open repair, and infrarenal EVAR. A complex 
aneurysm was defined as an aneurysm with either a juxtarenal or suprarenal 
proximal extent (i.e. all pararenal AAA). All aneurysms treated using the Cook 
Zenith Fenestrated endograft, which is currently the only fenestrated graft ap-
proved by the Food and Drug Administration, were considered complex. Complex 
open repair patients with infrarenal aortic clamping were excluded. For patients 
undergoing open repair, a visceral vessel reconstruction was defined as mention-
ing of a CPT code for visceral vessel reconstruction (CPT: 35361), or mentioning 
of a visceral vessel reconstruction in the Targeted module.
Groups were compared on baseline and operative characteristics, as well as 
postoperative outcomes. Postoperative outcomes included 30-day mortality, and 
in-hospital adverse outcomes such renal function deterioration, ischemic colitis, 
leg ischemia, wound complications, shock, sepsis, and length of ICU and hospital 
151
EVAR for complex AAA
8
stay. Renal function deterioration was defined as a rise in creatinine of >2 mg/dl 
from preoperative value, and/or requirement of hemodialysis, peritoneal dialysis, 
hemofiltration, hemodiafiltration, or ultrafiltration within 30 days of the operation. 
Patients on dialysis preoperatively were excluded for analysis of renal outcomes. 
Ischemic colitis was defined as having symptoms of ischemic colitis and/or confir-
mation of the diagnosis on diagnostic sigmoidoscopy or colonoscopy. Patients with 
SIRS, sepsis, or septic shock prior to surgery were not included for postoperative 
sepsis and shock analysis. Wound complications included superficial, deep, and 
organ space infections. In order to identify differences in postoperative morbid-
ity aside from death, 30-day mortality was not included in the any complication 
variable.
statistical analyses
Categorical variables are presented as counts and percentages, and continuous 
variables as mean ± standard deviation. Differences between treatment groups 
were assessed using χ2 and Fisher’s exact tests for categorical variables and Stu-
dent’s t-test for continuous variables, where appropriate. To assess independent 
risks associated with treatment approaches, we used multivariable logistic regres-
sion analysis. Baseline characteristics were univariately tested, and predictors 
with a P-value <.1 were added to the multivariable model. Age was included in 
all models, regardless of the univariable association. Risk-adjusted comparisons 
of complex EVAR to complex open repair and infrarenal EVAR were performed 
separately, and different models were constructed for each analysis. All tests were 
two-sided and significance was considered when P-value < .05. Statistical analysis 
was performed using the IBM SPSS Statistics 21 (IBM Inc., Chicago, IL).
REsULTs
A total of 4584 patients were included, with 411 (9.0%) undergoing complex 
EVAR, 395 (8.6%) complex open repair, and 3778 (82.4%) underwent EVAR for 
an infrarenal (noncomplex) AAA.
Baseline characteristics
Baseline characteristics are detailed in Table 1. The complex EVAR group was older 
than the complex open repair group (74.9 vs. 72.2 years, P<.001), consisted of 
fewer females (22.4% vs. 33.2%, P=.001), and more non-white patients (11.1% 
vs. 5.4%, P=.005). In terms of comorbidities, we found that complex EVAR 
patients more often had insulin-dependent diabetes (3.9% vs. 1.3% P=.019), 
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had a higher preoperative creatinine (1.22 vs. 1.09 mg/dl, P=.006), and were 
more commonly on dialysis (2.9% vs. 0.8%, P=.034). Conversely, complex EVAR 
patients were less often current smokers (29.2% vs. 45.6%, P<.001).
Comparing the complex EVAR patients to the infrarenal EVAR patients, those 
undergoing repair for a complex AAA were more commonly dialysis depen-
Table 1. Baseline characteristics
EVAR 
complex
OR 
complex
EVAR 
infra p-value
N=411 N=395 N=3778 C
om
pl
ex
 
EV
A
R
 
vs
. 
O
R
In
fr
a 
vs
. 
co
m
pl
ex
 
EV
A
R
Age – years (sd) 74.9 (8.1) 72.2 (8.3) 74.2 (8.6) <.001 .160
Categories – N (%) <.001 .788
<59 years 17 (4.1) 24 (6.1) 191 (5.1) <.001 .788
60-69 90 (21.9) 125 (31.6) 898 (23.8)
70-79 181 (44.0) 165 (41.8) 1573 (41.6)
80-89 112 (27.3) 80 (20.3) 1015 (26.9)
90+ 11 (2.7) 1 (0.3) 101 (2.7)
Female gender – N (%) 92 (22.4) 131 (33.2) 699 (18.5) .001 .056
Race .007 .006
American Indian/ Alaska Native 1 (0.2) 2 (0.5) 3 (0.1)
Asian 15 (3.6) 4 (1.0) 85 (2.2)
Black or African American 26 (6.3) 14 (3.5) 185 (4.9)
Native Hawaiian or Pacific Islander 2 (0.5) 0 (0) 2 (0.1)
White 352 (85.6) 347 (87.8) 3255 (86.2)
Unknown 15 (3.6) 28 (7.1) 248 (6.6)
Comorbidities
Hypertension – N (%) 343 (83.5) 336 (85.1) 3046 (80.6) .531 .166
Diabetes – N (%) 63 (15.3) 44 (11.1) 618 (16.4) .080 .591
Insulin-dependent diabetes – N (%) 16 (3.9) 5 (1.3) 105 (2.8) .019 0.20
COPD – N (%) 80 (19.5) 93 (23.5) 674 (17.8) .158 .416
Heart failure – N (%) 17 (4.1) 8 (2.0) 62 (1.6) .084 <.001
Renal insufficiency – N (%) 79 (19.7) 59 (15.1) 622 (16.9) .087 .167
Preoperative creatinine – N (%) 1.22 (.85) 1.09 (.43) 1.14 (.57) .006 .055
Dialysis– N (%) 12 (2.9) 3 (0.8) 34 (0.9) .034 <.001
BMI >30 – N (%) 110 (26.8) 99 (25.1) 1198 (31.7) .582 .040
Current smoking – N (%) 120 (29.2) 180 (45.6) 1137 (30.1) <.001 .706
OR: open repair; COPD: chronic obstructive pulmonary disease; BMI: Body Mass Index
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dent (2.9% vs. 0.9%, P<.001), more often had heart failure (4.1% vs. 1.6%, 
P<.001), and tended towards a higher preoperative creatinine (1.22 vs. 1.14 
mg/dl, P=.055). In addition, obesity, defined as a BMI higher than 30 kg/m2, 
was less common among complex EVAR patients compared to infrarenal EVAR 
patients (26.8% vs. 31.7%, P=.040).
Operative and anatomical characteristics
Complex EVAR was associated with shorter operative time compared to complex 
open repair (184 vs. 269 min., P<.001), while taking significantly longer than in-
frarenal EVAR (146 min, P<.001, Table 2a). Complex EVAR patients had a smaller 
aneurysm diameter compared to complex open repair patients (5.9 vs. 6.2 cm, 
P=.015), but not significantly different from those undergoing infrarenal EVAR 
(5.7 cm, P=.058). In addition, the aneurysm of complex EVAR patients more 
often extended into the iliac arteries compared to open complex repair (69.7% vs. 
43.2%, P<.001), and infrarenal EVAR (52.9%, P<.001). The complex EVAR group 
included 22 (5.4%) patients with an infrarenal aneurysm treated using the Cook 
Zenith Fenestrated graft. Among complex AAA patients undergoing open repair, 
Table 2a. Anatomical and intraoperative characteristics for all study groups
EVAR 
complex
OR
complex
EVAR
infra p-value
N=411 N=395 N=3778
Complex 
EVAR vs. 
OR
Infra vs. 
complex 
EVAR
Operative time – min (sd) 184 (100) 269 (108) 146 (70) <.001 <.001
Diameter – cm (sd) 5.9 (2.6) 6.2 (1.4) 5.7 (1.6) .015 .058
Indication – N (%) .074 .108
Diameter 348 (88.1) 328 (83.9) 3304 (88.6)
Dissection 2 (0.5) 1 (0.3) 28 (0.8)
Embolization 2 (0.5) 1 (0.3) 20 (0.5)
Symptomatic 23 (5.8) 47 (12.0) 281 (7.5)
Thrombosis 10 (2.5) 9 (2.3) 43 (1.2)
Prior unsatisf. EVAR 7 (1.8) 0 (0) 40 (1.1)
Prior unsatisf. OR 3 (0.8) 5 (1.3) 12 (0.3)
Distal extent – N (%) <.001 <.001
Aortic 112 (30.3) 204 (56.8) 1539 (47.1)
Common iliac 171 (46.2) 137 (38.2) 1304 (39.9)
External iliac 38 (10.3) 9 (2.5) 181 (5.5)
Internal iliac 49 (13.2) 9 (2.5) 242 (7.4)
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18.8% had a clamp location above the celiac artery, 45.4% between the superior 
mesenteric artery and the renal arteries, and 35.9% above one renal artery. A 
visceral vessel reconstruction during open repair was performed in 27.1% of 
patients.
Not surprisingly, complex EVAR patients more often received renal revascu-
larization than those undergoing EVAR for an infrarenal AAA (30.4% vs. 4.1%, 
P<.001, Table 2b). No difference existed in main body device used between 
complex and infrarenal EVAR patients (P=.121).
Table 2b. EVAR specific intraoperative characteristics
EVAR 
complex
OR 
complex
EVAR
infra p-value
N=411 N=395 N=3778
Infra vs. 
complex EVAR
Acute conversion – N (%) 3 (0.7) - 21 (0.6) .506
Access – N (%) .100
Attempted percutaneous 5 (1.2) - 33 (0.9)
Bilateral cutdown 277 (67.4) - 2441 (64.7)
One groin cutdown 23 (5.6) - 348 (9.2)
Percutaneous bilateral 106 (25.8) - 950 (25.2)
Renal revascularization – N (%) 125 (30.4) - 156 (4.1) <.001
Lower extrem revasc – N (%) 19 (5.5) - 138 (4.2) .247
Access vessel repair – N (%) 42 (10.2) - 284 (7.5) .052
Hypogastric embolization – N (%) 27 (6.6) - 248 (6.6) .997
Main body device – N (%) .121α
Cook Zenith 72 (17.5) - 795 (21.0)
Cook Zenith Fenestrated 84 (20.4) - 0 (0)
Cook Zenith Renu 3 (0.7) - 39 (1.0)
Endologix Powerlink 26 (6.3) - 292 (7.7)
Gore Excluder 95 (23.1) - 1281 (33.9)
Lobard Aorfix 0 (0) - 2 (0.1)
Medtronic AneuRx 1 (0.3) - 7 (0.2)
Medtronic Endurant 95 (23.1) - 1130 (29.9)
Medtronic TALENT 1 (0.2) - 18 (0.5)
TriVascular Ovation 4 (1.0) - 36 (1.0)
other 26 (6.3) - 149 (3.9)
not documented 4 (1.0) - 29 (0.8)
α analysis did not include patients receiving a Cook Zenith Fenestrated endograft.
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Postoperative outcomes
Postoperative outcomes are detailed in Table 3a. Mortality within 30-days was sig-
nificantly lower after complex EVAR compared to complex open repair (3.4% vs. 
6.6%, P=.038). Similarly, deterioration of renal function (2.3% vs. 9.5%, P<.001) 
and new dialysis requirement (1.3% vs. 6.1%, P<.001) occurred less frequently 
after complex EVAR than complex open repair. In addition, complex EVAR was 
associated with lower rates of ischemic colitis (1.0% vs. 4.6%, P=.002), myo-
cardial infarction (0.7% vs. 4.3%, P=.001), pneumonia (1.2 vs. 7.6%, P<.001), 
prolonged ventilator dependence (1.9% vs. 14.4%, P<.001), reintubation (2.2% 
vs. 9.4%, P<.001), wound dehiscence (0.2% vs. 3.0%, P=.001), shock (0.7% 
vs. 2.8%, P=.031, respectively), return to the operating room (5.4% vs. 13.9%, 
P<.001), and postoperative blood transfusions (16.3% vs. 78.7%, P<.001). Also, 
length of ICU stay and hospital stay were significantly shorter for those undergo-
ing complex EVAR compared to complex open repair (1.0 vs. 4.7, P<.001; 4.1 
days vs. 11.3 days, P<.001, respectively).
In comparison to infrarenal EVAR, 30-day mortality was significantly higher 
after complex EVAR (3.4% vs. 1.5%, P=.005). Similarly, complex EVAR was 
associated with a higher rate of renal function deterioration (2.3 % vs. 0.9%, 
P=.007), postoperative blood transfusion (16.3%, vs. 10.2%, P<.001), and 
prolonged ventilator dependence (1.9% vs. 0.9%, P=.036). In addition, ICU 
length of stay (1.0 vs. 0.6, P=.003), and hospital length of stay (4.1 days vs. 
2.9 days, P=.001) were both significantly longer after complex EVAR compared 
to infrarenal EVAR.
Outcomes of patients receiving the Cook Zenith Fenestrated endograft are 
shown in Table 3b. Although not significant, this subanalysis demonstrated that 
patients undergoing placement of a Cook Zenith fenestrated graft had a similar, 
if not lower, 30-day mortality rate compared to all other complex EVAR patients 
(1.2% vs. 4.0%, P=.318). However, patients treated with the Cook Zenith 
Fenestrated endograft more frequently received blood transfusions postopera-
tively (25.0% vs. 14.1%, P=.016). Similar to the other complex EVAR patients, 
low occurrence rates were found for various adverse outcomes, such as renal 
function deterioration (2.4% vs. 2.2%, P=1.000), ischemic colitis (1.2% vs. 
0.9%, P=1.000), leg ischemia (0% vs. 1.8%, P=.354), and pneumonia (1.2% 
vs. 1.2%, P=1.000). Hospital and ICU length of stay were also comparable to 
the other complex EVAR patients (4.6 vs. 4.0 days, P=.488; 1.4 vs. 0.9 days, 
P=.208, respectively).
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Multivariable analyses
In multivariable analysis (Table 4), open repair for complex AAA was found to be 
an independent predictor of 30-day mortality (OR: 2.2, 95% CI: 1.1 – 4.4), renal 
function deterioration (OR: 5.0, 95% CI: 2.3 – 10.7), and any complication (OR: 
3.9, 95% CI: 2.7 – 5.8) compared to complex EVAR. When comparing complex to 
infrarenal EVAR, infrarenal EVAR was associated with favorable 30-day mortality 
(OR: 0.5, 95% CI: 0.3 – 0.9), and renal outcome (OR: 0.4, 95% CI: 0.2 – 0.9), 
while no difference was found in the occurrence of any complication (OR: 0.9, 
Table 3a. Postoperative outcomes for all study groups
EVAR 
complex
OR 
complex
EVAR 
infra p-value
N=411 N=395 N=3778
Complex 
EVAR vs. 
OR
Infra vs. 
complex 
EVAR
30-day mortality 14 (3.4) 26 (6.6) 57 (1.5) 0.038 .005
Creat rise >2 mg/dl – N (%) 9 (2.3) 37 (9.5) 32 (0.9) <.001 .007
Requiring dialysis – N (%) 5 (1.3) 24 (6.1) 21 (0.6) <.001 .096
Ischemic colitis – N (%) 4 (1.0) 18 (4.6) 19 (0.5) .002 .276
Leg ischemia – N (%) 6 (1.5) 7 (1.8) 49 (1.3) .725 .783
Pneumonia – N (%) 5 (1.2) 30 (7.6) 32 (0.8) <.001 .447
>48 hour on ventilator 8 (1.9) 57 (14.4) 33 (0.9) <.001 .036
Reintubation – N (%) 9 (2.2) 37 (9.4) 51 (1.3) <.001 .174
Myocardial infarction – N (%) 3 (0.7) 17 (4.3) 52 (1.4) .001 .364
CPR – N (%) 2 (0.5) 10 (2.5) 22 (0.6) .019 1.000
Wound infection – N (%) 6 (1.5) 11 (2.8) 60 (1.6) .191 .860
Wound dehiscence – N (%) 1 (0.2) 12 (3.0) 8 (0.2) .001 .606
Return to OR – N (%) 22 (5.4) 55 (13.9) 148 (3.9) <.001 .161
Pulmonary embolism 1 (0.2) 2 (0.5) 8 (0.2) .617 .606
Stroke – N (%) 3 (0.7) 3 (0.8) 9 (0.2) 1.000 .106
Sepsis – N (%) 3 (0.7) 10 (2.5) 22 (0.6) .051 .731
Shock – N (%) 3 (0.7) 11 (2.8) 14 (0.4) .031 .229
Rupture 30-day – N (%) 0 (0) 1 (0.3) 2 (0.1) .490 1.000
≥1 postoperative transfusion 67 (16.3) 311 (78.7) 385 (10.2) <.001 <.001
Any complication – N (%) 47 (11.4) 133 (33.7) 333 (8.8) <.001 .085
Any complication – N (%)α 97 (23.6) 328 (83.0) 614 (16.3) <.001 <.001
Hospital length of stay – days 
(sd) 4.1 (6.8) 11.3 (10.0) 2.9 (5.1) <.001 .001
ICU length of stay – days (sd) 1.0 (2.4) 4.7 (4.9) 0.6 (1.7) <.001 .003
α incidence of any complication when postoperative blood transfusions are included
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95% CI: 0.6 – 1.2). Given the invasive nature of open AAA repair and the routine 
need for postoperative blood transfusions, a postoperative transfusion was not 
included as a complication in this analysis. However, when a blood transfusion is 
considered a complication, complex EVAR is associated with an increased risk of 
any complication compared to infrarenal EVAR as well (OR: 0.7, 95% CI: 0.5 – 
0.9). Within the complex EVAR group, no differences were found between patients 
treated with the Cook Zenith Fenestrated endograft and those treated using other 
grafts in multivariable analysis.
Table 3b. Postoperative outcomes for complex EVAR patients treated with the Cook Zenith 
Fenestrated graft and those treated otherwise
Cook Zenith 
Fenestrated
Other Complex 
EVAR
P-valueN=84 N=327
30-day mortality 1 (1.2) 13 (4.0) .318
Creat rise >2 mg/dl – N (%) 2 (2.4) 7 (2.2) 1.000
 Requiring dialysis – N (%) 2 (2.4) 3 (1.0) .284
Ischemic colitis – N (%) 1 (1.2) 3 (0.9) 1.000
Leg ischemia – N (%) 0 (0) 6 (1.8) .354
Pneumonia – N (%) 1 (1.2) 4 (1.2) 1.000
>48 hour on ventilator 2 (2.4) 6 (1.8) .669
Reintubation – N (%) 3 (3.6) 6 (1.8) .397
Myocardial infarction – N (%) 1 (1.2) 2 (0.6) .497
CPR – N (%) 0 (0) 2 (0.6) 1.000
Wound infection – N (%) 1 (1.2) 6 (1.8) 1.000
Wound dehiscence – N (%) 0 (0) 1 (0.3) 1.000
Return to OR – N (%) 5 (6.0) 17 (5.2) .784
Pulmonary embolism 0 (0) 1 (0.3) 1.000
Stroke – N (%) 1 (1.2) 2 (0.6) .497
Sepsis – N (%) 2 (2.4) 1 (0.3) .108
Shock – N (%) 1 (1.2) 2 (0.6) .497
Rupture 30-day – N (%) 0 (0) 0 (0) 1.000
≥1 postoperative transfusion 21 (25.0) 46 (14.1) .016
Any complication – N (%) 10 (11.9) 37 (11.3) .880
Any complication – N (%)α 25 (29.8) 72 (22.0) .136
Hospital length of stay – days 
(sd)
4.6 (6.5) 4.0 (6.9) .488
ICU length of stay – days (sd) 1.4 (3.5) 0.9 (2.1) .208
α incidence of any complication when postoperative blood transfusions are included
Chapter 8
158
DIsCUssIOn
This study demonstrates that endovascular repair provides a good alternative 
to open repair for the treatment of complex AAA. In addition to lower 30-day 
mortality, we found that EVAR was associated with a lower incidence of various 
adverse outcomes, including acute renal failure, ischemic colitis, return to the 
operating room, and length of stay. In comparison to infrarenal EVAR, complex 
EVAR was associated with a significantly increased perioperative mortality risk, as 
well as a higher frequency of several other adverse outcomes, most importantly 
an increased incidence of postoperative renal dysfunction.
At 3.4%, the mortality following complex EVAR is comparable to previous 
reports.22, 31-33 Despite the fact that complex EVAR patients were older and in 
more frail health than those undergoing open repair, mortality was almost half 
of that following open repair (3.4% vs. 6.6%). After adjustment for the various 
health disparities, treatment of a complex AAA through open repair proved to 
Table 4. Adjusted associations between treatment groups and outcomes
30-day mortalityα OR 95% CI p-value
EVAR complex Reference - -
Open complexα 2.2 1.1 – 4.4 0.025
EVAR infrarenalβ 0.5 0.3 – 0.9 0.019
Renal complicationβ OR 95% CI p-value
EVAR complex Reference - -
Open complexγ 5.0 2.3 – 10.7 <.001
EVAR infrarenalδ 0.4 0.2 – 0.9 .017
Any complicationγ OR 95% CI p-value
EVAR complex Reference - -
Open complexε 3.9 2.7 – 5.8 <.001
EVAR infrarenalζ 0.9 0.6 – 1.2 .369
α: adjusted for: age, gender, obstructive pulmonary disease
β adjusted for: age, gender, hypertension, insulin-dependent diabetes, preoperative renal 
insufficiency, preoperative dialysis, heart failure, obstructive pulmonary disease, obesity, 
current smoking
γ adjusted for: age, preoperative renal insufficiency, obstructive pulmonary disease, obesity
δ adjusted for: age, gender, insulin-dependent diabetes, preoperative renal insufficiency, 
obstructive pulmonary disease, obesity
ε adjusted for: age, gender, hypertension, preoperative renal insufficiency, obstructive pul-
monary disease
ζ adjusted for: age, gender, nonwhite race, hypertension, insulin-dependent diabetes, pre-
operative renal insufficiency, preoperative dialysis, heart failure, obstructive pulmonary dis-
ease, obesity
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be associated with two-and-half times higher mortality risk compared to EVAR. 
This is in line with the results of previously conducted studies by Canavati et 
al. and Tsilimparis et al., which found a similar mortality benefit for fenestrated 
EVAR.20, 34 In contrast to what has been shown for open repair,35 endovascular 
complex AAA repair was associated with increased mortality risks over infrarenal 
EVAR. A difference in operative stress between EVAR for infrarenal and complex 
AAA, as indicated by the longer operative time, may have contributed to the ob-
served difference in occurrence of adverse outcomes in the perioperative period.
Our results indicated that complex EVAR was associated with lower rates of 
complications compared to complex open repair. Despite worse preoperative 
renal function, the avoidance of suprarenal clamping and the resulting renal 
ischemia led to fewer kidney injuries and fewer patients requiring new dialysis 
with complex EVAR. This favorable renal outcome of EVAR for complex AAA is 
in line with previous studies.22, 23 A recent case-controlled study, however, dem-
onstrated a higher frequency of acute kidney injury after complex endovascular 
repair with similar 1-year results as open repair.36 When comparing absolute 
rates of postoperative renal dysfunction to prior reports, the occurrence of kid-
ney injuries in this study is relatively low.22, 23, 37, 38 The present results most likely 
underestimate the actual incidence in our cohort, which is the result of the rela-
tive strict definition for postoperative renal dysfunction employed by the NSQIP. 
In regards to mid-term and late renal outcomes, previous studies have reported 
good patency results of renal stents and chimneys.13, 25, 26, 37, 39 Although close 
monitoring of the renal function is required, this further highlights the benefit of 
EVAR over open repair, particularly for patients with renal impairment.40
Similar to established short-term perioperative benefits of EVAR for infrarenal 
AAA, the incidence of adverse events such as respiratory and wound complica-
tions, ischemic colitis, leg ischemia, myocardial infarction, and return to the 
operating room were lower for complex EVAR versus open repair. Due to the 
less complicated postoperative period and invasiveness of procedure, length 
of stay following complex EVAR was almost one-third of that following open 
repair. It should be noted that as a result of the exclusion of conversions, the 
incidence of adverse outcomes in the complex open repair might be relatively 
low. However, since complex EVAR was superior over open repair despite the ex-
clusion of these patients, this only strengthens the conclusions of this study. As 
previously suggested,25, 26 complex EVAR was associated with a higher frequency 
of postoperative renal dysfunction compared to infrarenal EVAR, although this 
did not translate into a higher need for dialysis in the postoperative period. 
This is in contrast to the study by Glebova et al., which showed no difference 
in renal complications between infrarenal EVAR and fenestrated EVAR using the 
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non-Targeted NSQIP dataset.27 This difference may be related to the fact that 
the definition for complex EVAR in the present study is based on the specific 
Targeted NSQIP variable for proximal aneurysm extent, while the definition in 
the Glebova study was established from billing coding prior to the commercial 
availability of fenestrated endografts.
Several studies have reported on differences in outcome between chimney and 
fenestrated grafts. These studies determined that no difference exists in mor-
tality or in renal endpoints between chimneys and fenestrated endografts.32, 41 
Unfortunately, we were unable to identify the exact technical approach that was 
used beyond the type of main body device. Although not significantly differ-
ent, selective analysis of patients receiving the Cook Zenith Fenestrated graft 
revealed that these patients had a similar to lower mortality rate as compared 
to the other complex EVAR patients. However, this may simply reflect that those 
treated otherwise have more complex anatomy, and were therefore ineligible 
for the Cook Zenith Fenestrated graft, which led to the trend towards worse 
outcomes. Unfortunately we did not have this level of anatomic detail. For other 
perioperative complications, we found that the Cook Zenith Fenestrated patients 
had comparable occurrence rates to other complex EVAR patients, including 
adverse renal outcomes, despite an increased transfusion requirement. This is 
in line with results from a pooled data analysis on fenestrated stent grafts.32
This study has several limitations. First, since the Targeted Vascular dataset of 
the NSQIP is gathered through a registry, underreporting of events is possible. 
Second, we were unable to fully distinguish between treatment approaches in 
patients undergoing complex EVAR. However, as previously addressed, reports 
have shown no differences in perioperative outcomes between fenestrated en-
dografts and chimney grafts, making the group more generalizable.32, 41 Third, 
as evidenced by the lower than expected proportion of complex EVARs undergo-
ing concurrent renal stenting, the capture of this data point was thought to be 
unreliable and therefore limited our ability to identify snorkel repairs. However, 
we know they are complex aneurysms because of the clearly defined proxi-
mal extent of the aneurysm in this data set, as captured by operative report 
review. Furthermore, NSQIP clinical reviewers are instructed to capture renal 
revascularization for renal artery stenosis, which we believe leads to variable 
reporting based on interpretation of this definition. For complex open repair, we 
found that 27% of patients underwent visceral artery reconstruction, which is 
similar to previous reports.42 Unfortunately, the exact number of visceral artery 
reconstructions is not documented in this data set. Fourth, the NSQIP database 
lacks data on perioperative endoleaks and long-term outcomes, which precluded 
us from assessing differences in the occurrence of endoleaks and late reinter-
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ventions, as well as long-term renal function. This highlights the need for future 
studies investigating the long-term outcome of EVAR for complex AAA. Also, 
since we did not have access to postoperative serum creatinine values, we were 
unable to redefine renal dysfunction or use standardized formulas consistent with 
previous studies. In addition, due to the novelty of this recently added vascular 
module, validation studies have yet to be conducted for it. However, the ability of 
these same nurse reviewers to accurately abstract data from the medical record 
for the NSQIP in general has been confirmed previously.28-30 Finally, it should 
be noted that patients were not randomized to undergo open repair or EVAR. 
Nevertheless, this study provides valuable new data on the operative outcome of 
complex AAA repair in both the open and endovascular setting, which may add 
to prospectively conducted research efforts.
In conclusion, this study demonstrates that as a result of advancements in 
endovascular treatment techniques, EVAR has become a good alternative to 
conventional open repair for treatment of anatomically complex aneurysms. 
Complex EVAR has fewer perioperative complications compared to complex open 
repair, but –in turn– is associated with increased perioperative risks compared 
to infrarenal EVAR. Further research is warranted to determine whether the 
favorable outcome of EVAR for complex AAA is maintained during long-term 
follow-up.
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ABsTRACT
Objective
We sought to compare current practices in patient selection and 30-day outcomes 
for transperitoneal and retroperitoneal abdominal aortic aneurysm (AAA) repairs.
Methods
All patients undergoing elective transperitoneal or retroperitoneal surgical repair 
for AAA between January 2011 and December 2013 were identified in the Targeted 
Vascular National Surgical Quality Improvement Program database. Emergency 
cases were excluded. Baseline characteristics, anatomic details, and intraopera-
tive and postoperative outcomes were evaluated among those with infrarenal or 
juxtarenal AAA only.
Results
We identified 1135 patients: 788 transperitoneal (69%) and 347 retroperitoneal 
(31%). When only infrarenal and juxtarenal AAAs were evaluated, the retro-
peritoneal patients were less likely to have an infrarenal clamp location (43% 
vs 68%) and had more renal revascularizations (15% vs 6%; P < .001), more 
visceral revascularizations (5.6% vs 2.4%; P = .014), and more lower extremity 
revascularizations (11% vs 7%; P = .021) compared with the transperitoneal 
approach. Postoperative mortality and return to the operating room were similar. 
Transperitoneal patients had a higher rate of wound dehiscence (2.4% vs 0.4%; 
P = .045), and retroperitoneal patients had higher incidence of pneumonia (9% 
vs 5%; P = .034), transfusion (77% vs 71%; P = .037), and reintubation (11% 
vs 7%; P = .034), and a longer median length of stay (8 vs 7 days; P = .048). 
After exclusion of all concomitant procedures, only transfusions remained more 
common in the retroperitoneal approach (78% vs 70%; P = .036). Multivariable 
analyses showed only higher rates of reintubation in the retroperitoneal group 
(odds ratio, 1.7; 95% confidence interval, 1.0-3.0; P = .047).
Conclusions
The retroperitoneal approach is more commonly used for more proximal aneu-
rysms and was associated with higher rates of pneumonia, reintubation, and 
transfusion, and a longer length of stay on univariate analyses. However, mul-
tivariable analysis demonstrated similar results between groups. The long-term 
benefits and frequency of reinterventions remain to be proven.
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InTRODUCTIOn
Despite the development of endovascular techniques for abdominal aortic aneu-
rysm (AAA) repair in recent years, open surgical repair remains necessary to treat 
anatomically complex aneurysms and may be beneficial for younger patients and 
those unable to comply with long-term surveillance.1 Medicare data show that 
open surgical repair was used in 23% of intact AAA repairs in the United States in 
2008, but also highlighted higher rates of medical and surgical complications com-
pared with endovascular AAA repair.2, 3 In addition, lower rates of late bowel and 
hernia complications were demonstrated with retroperitoneal surgery compared 
with intraperitoneal surgery for nonaortic surgical procedures.4
The transperitoneal approach is most familiar to surgeonsand provides exten-
sive intra-abdominal access.5, 6 The time from skin incision to aortic clamping 
was shown to be shorter in the transperitoneal group than in the retroperitoneal 
group.7, 8 However, complications associated with this approach leading to pro-
longed ileus have been reported.9 In an attempt to avoid complications associated 
with entrance into the peritoneal cavity, the retroperitoneal approach was adopted 
and also offers improved access to the suprarenal and supraceliac aorta.5, 10
Several studies comparing perioperative outcomes of the transperitoneal and 
retroperitoneal approach for AAA repair suggest that the retroperitoneal ap-
proach may result in lower rates of ileus, shortened hospital length of stay, and 
improved respiratory function than transperitoneal procedures.6, 7, 9, 11, 12, 13, 14, 15 
Conversely, other studies have found no differences in respiratory complications, 
return of bowel function, and length of stay.16, 17 This study aimed to identify the 
demographic and anatomic differences between patients currently selected for 
elective transperitoneal vs retroperitoneal AAA repair and to assess differences 
in intraoperative details, perioperative mortality, and complications.
METHODs
Data source
The patient cohort for this study was identified using the Targeted Vascular 
American College of Surgeons National Surgical Quality Improvement Program 
(ACS NSQIP) database. The NSQIP is a national clinical registry of self-selected 
hospitals with an interest in quality improvement and improved risk adjustment. 
This data set contains prospectively collected clinical data on preoperative, opera-
tive, and postoperative variables. To ensure quality, data are collected by trained 
clinical nurse reviewers.
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The more clinically detailed Targeted Vascular module was created from the 
general NSQIP in 2011 to collect additional anatomic and operative charac-
teristics from >60 participating hospitals. The Targeted Vascular ACS NSQIP 
database contains unidentifiable patients only; therefore, Institutional Review 
Board approval and patient consent were waived. Details of quality control and 
data collection have been described extensively on the ACS NSQIP Web site.18 
Definitions for the specific Targeted Vascular ACS NSQIP collected data points 
may be found in the user guide available online.19
We identified all patients undergoing elective transperitoneal or retroperitoneal 
open surgical repair for AAA from January 2011 to December 2013. Emergency 
cases were excluded from analyses.
Outcomes
Patients with transperitoneal surgical repair (midline and transverse incisions) 
were compared with patients undergoing retroperitoneal repair. A subgroup 
analysis found no differences between midline and transverse incisions; there-
fore, they were grouped for this analysis. Data were collected on relevant patient 
demographics, comorbidities, operative details, and postoperative course. Obesity 
was defined at body mass index >30 kg/m2. Baseline characteristics were com-
pared for all AAA, including infrarenal, juxtarenal, pararenal, suprarenal, and type 
IV thoracoabdominal aneurysms. This database defines pararenal as AAAs that 
involve the origin of the renal arteries and is distinct from juxtarenal (AAAs that 
do not involve the renal arteries but because of proximity require clamping above 
the renal arteries to complete the proximal anastomosis) and suprarenal (AAAs 
that begin above at least one main renal artery but below the visceral segment).
Renal revascularization included bypass or reimplantation of one or both of 
the renal arteries. Visceral revascularization included endarterectomy of celiac 
or superior mesenteric artery or reimplantation of a visceral vessel. Lower ex-
tremity revascularizations were defined as infrainguinal bypass or endovascular 
stent placement. All lower extremity, renal, and visceral revascularizations were 
considered concomitant procedures.
Operative time was defined as the time from incision to skin closure. For com-
parison of intraoperative and postoperative outcomes, pararenal, suprarenal, and 
thoracoabdominal aneurysms were excluded. Intraoperative anatomic details in-
cluded clamp location, extent of aneurysm, and extent of distal iliac involvement, 
and concomitant renal, visceral, or lower extremity revascularization performed. 
Concomitant procedures were excluded in the comparison of operative time. Any 
wound complication was defined as a composite variable inclusive of any surgical 
site infection (SSI), superficial SSI, deep SSI, organ/space SSI, or dehiscence.
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statistical analysis
Analyses were conducted with SPSS 20 software (IBM Corp, Armonk, NY). Cat-
egorical variables were compared using the Pearson χ2 or Fisher exact test, and 
continuous variables were analyzed by two-tailed independent samples t-test or 
the Mann-Whitney test, where appropriate. Clinically relevant factors shown to be 
predictive of adverse outcomes in previous studies were selected for inclusion in 
multivariable logistic regression. These factors included gender, age, race, prior 
abdominal surgery, concomitant procedure, aneurysm extent, bifurcated grafts, 
and management of the inferior mesenteric artery. To evaluate potential interac-
tion between outcomes and concomitant procedures, multivariable models were 
run with and without adjusting for concomitant procedures, with no significant 
differences identified. Statistical significance was defined as P < .05.
REsULTs
A cohort of 1135 patients was identified, including 788 patients (69%) with a 
transperitoneal approach, and 347 (31%) with a retroperitoneal approach for 
repair. Patients who underwent the retroperitoneal approach were less likely to 
have an infrarenal aneurysm (31% vs 61%) and more likely to have juxtarenal 
(41% vs 28%), pararenal (9% vs 4%), suprarenal (14% vs 5%), and type IV 
thoracoabdominal aneurysms (5% vs 1%; Table 1).
Baseline characteristics
The retroperitoneal approach was used less often in men (67% vs 74%; P = 
.018) and more often in those of white race (90% vs 81%; P < .001) or with prior 
abdominal operations (35% vs 21%; P < .001). There were no significant differ-
ences in mean age (71 vs 71 years; P = .228), American Society of Anesthesiolo-
gists (ASA) Physical Status Classification ≥4 (36 % vs 34%; P = .505), or mean 
aneurysm diameter (6.3 vs 6.2 cm;P = .261). The same significant differences in 
baseline characteristics persisted when the analysis was confined to infrarenal and 
juxtarenal aneurysms only.
Analysis of intraoperative characteristics among infrarenal and juxtarenal 
repairs only (Table 2) indicated that patients undergoing retroperitoneal repairs 
were more likely to have a more renal revascularization (15% vs 6%; P < 
.001), lower extremity revascularization (11% vs 7%; P = .021), and visceral 
revascularization (6% vs 2%; P = .014). When all concomitant procedures were 
combined, this rate was higher in the retroperitoneal approach (26% vs 16%; 
P = .001). There was no difference in the management of the inferior mesen-
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teric artery, whether reimplantation (2.8% vs 6.0%), ligation, or observation of 
chronic occlusion.
Table 1. Baseline characteristics of patients with abdominal aortic aneurysms undergoing 
open repair (transperitoneal vs. retroperitoneal approach)
Variable
Transperitoneal 
(n=788)
Retroperitoneal 
(n=347)
P Value
Male gender 74% 67% 0.02
Race or ethnic group <.001
Other/Unkown 12% 5%
White 81% 90%
Black/African American 4.7% 4.0%
American Indian/Alaska Native 0.4% 0.6%
Asian 2.8% 0.6%
White Race 81% 90% <.001
Age (mean) 70.6 71.3 0.23
Age Category (years) 0.31
18-59 11% 7.8%
60-69 33% 33%
70-79 39% 42%
80+ 17% 18%
Prior Open Abdominal Surgery 21% 35% <.001
ASA 4 Classification 34% 36% 0.51
Aneurysm diameter (cm) 6.16 6.27 0.26
Coexisting conditions
Congestive heart failure 2.2% 1.4% 0.42
Hypertension 84% 83% 0.62
Diabetes 13% 12% 0.84
History of severe COPD * 20% 22% 0.48
Dialysis (pre-op) 0.8% 0.9% 0.86
Obesity 27% 30% 0.29
Proximal Aneurysm Extent <.001
Infrarenal 61% 31%
Juxtarenal 28% 41%
Pararenal 4.3% 9.2%
Supra-renal 5.2% 14%
Type IV Thoracoabdominal aneurysm 1.4% 4.9%
ASA, American Society of Anesthesiologists; COPD, chronic obstructive pulmonary disease.
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Table 2. Intra-operative outcomes of patients with infrarenal or juxtarenal abdominal aortic 
aneurysms undergoing transperitoneal vs. retroperitoneal open surgical repair
Outcomes
Transperitoneal 
(n=702)
Retroperitoneal 
(n=248)
P Value
Surgical Approach <.001
Retroperitoneal 100%
Transperitoneal-midline 95%
Transperitoneal-transverse 5%
Aneurysm Extent <.001
Infrarenal 68% 43%
Juxtarenal 32% 57%
Indication for surgery 0.21
Diameter 81% 78%
Dissection 0.9% 0.4%
Embolization 0.3% 1.6%
Non-ruptured symptomatic 8.5% 11%
Not documented 0.6% 0.8%
Prior endovascular intervention w/ 
unsatisfactory result
3.1% 4.4%
Prior open intervention w/ unsatisfactory 
result
0.6% 0%
Rupture w/ or w/out hypotension 2.3% 2.0%
Thrombosis 3.3% 2.0%
Proximal Clamp Location <.001
Supraceliac 4.6% 15%
Between SMA & renals 16% 28%
Above one renal 16% 17%
Infrarenal 58% 34%
Not documented 6.0% 6.9%
Distal Extent <.001
Aortic 39% 53%
Common Iliac 44% 30%
External Iliac 4.4% 6.5%
Internal Iliac 4.1% 1.2%
Not documented 8.4% 9.3%
Management of Inferior Mesenteric Artery <.001
Chronically occluded 11% 4.8%
Implanted 6.0% 2.8%
Ligated 42% 36%
Not documented 41% 57%
Renal Revascularization 6.4% 15% <.001
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Intra-operative characteristics
The overall operative time was similar in the two cohorts. However, more tube 
grafts were placed in the retroperitoneal group. Median operative time was sig-
nificantly longer for the retroperitoneal approach among patients with tube grafts 
alone (235 vs 211 minutes;P = .027). Operative time was 250 vs 243 minutes (P 
= .180) for bifurcated configurations without concomitant procedures.
Post-operative outcomes
Analysis of the unadjusted postoperative outcomes demonstrated that the retro-
peritoneal group had significantly higher rates of transfusion (77% vs 71%;P = 
.037), sepsis (3.2% vs 1.3%; P = .047), pneumonia (8.9% vs 5.1%; P = .034), 
reintubation (11% vs 7%; P = .034), and median length of stay (8 vs 7 days; P 
= .048;Table 3a). Prolonged length of stay >10 days was similar in both groups 
(28% vs 27%;P = .735). The rate of wound dehiscence was lower in the retro-
peritoneal cohort (0.4% vs 2.4%; P = .045). There were no significant differences 
in mortality (3.6% vs 3.8%; P = .878) or return to the operating room (12% vs 
10%; P = .382).
Multivariable analysis
Because concomitant procedures were more common in the retroperitoneal 
patients, we performed an analysis limited to those without concomitant proce-
dures. After exclusion of any concomitant procedures during AAA repair, only the 
Table 2. (continued)
Outcomes
Transperitoneal 
(n=702)
Retroperitoneal 
(n=248)
P Value
Visceral (SMA & Celiac) Revascularization 2.4% 5.6% 0.01
Lower Extremity Revascularization 6.7% 11% 0.02
Abdominal, non-arterial repair or excision 3.3% 1.6% 0.18
Any Concomitant Procedure 16.2% 25.8% 0.001
Median OR time (min) 234 238 0.12
Median OR time (all concomitant procedures 
excluded)
219 227 0.25
Median OR time for bifurcated grafts only 243 250 0.18
Median OR time for bifurcated grafts only 
(all concomitant procedures excluded)
235 236 0.42
Median OR time for tubegrafts only 211 235 0.03
Median OR time for tubegrafts only (all 
concomitant procedures excluded)
193 223 0.02
SMA = superior mesenteric artery,
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transfusion rate remained higher in the retroperitoneal group (78% vs 70%; P = 
.036; Table 3b). A separate multivariable analyses, with adjustment for baseline 
characteristics, showed that only reintubation remained significantly higher with 
the retroperitoneal approach (odds ratio, 1.7; 95% confidence interval, 1.0-3.0; 
Table 3a. Post-operative outcomes of patients with infrarenal and juxtarenal abdominal 
aortic aneurysms undergoing transperitoneal vs. retroperitoneal open surgical repair
Outcomes
Transperito-
neal (n=702)
Retroperito-
neal (n=248)
P 
Value
Odds Ratio 
(95% CI)
Mortality 3.8% 3.6% 0.88 0.9 (0.4-2.0)
Medical complications (% of patients)
Myocardial Infarction 2.6% 2.8% 0.83 1.1 (0.5-2.7)
Cardiac Arrest requiring CPR 2.1% 2.8% 0.54 1.3 (0.5-3.3)
Pneumonia 5.1% 8.9% 0.03 1.8 (1.0-3.1)
Pulmonary Embolism 0.4% 0.4% 0.96 0.9 (0.1-9.1)
Progressive Renal Insufficiency 1.7% 2.4% 0.48 1.4 (0.5-3.8)
Acute Renal Failure 3.4% 6.0% 0.07 1.8 (0.9-3.5)
Urinary Tract Infection 3.0% 1.6% 0.24 0.5 (0.2-1.6)
Stroke / CVA 0.4% 0.8% 0.48 1.9 (0.3-11.4)
DVT 2.1% 1.6% 0.61 0.8 (0.2-2.3)
Transfusion 71% 77% 0.04 1.4 (1.0-2.0)
Sepsis 1.3% 3.2% 0.05 2.6 (1.0-6.7)
Surgical complications (% of patients)
Prolonged Intubation > 48 hours 9.1% 13% 0.06 1.5 (1.0-2.4)
Reintubation 6.7% 11% 0.03 1.7 (1.0-2.8)
Return to OR 9.5% 12% 0.25 1.3 (0.8-2.1)
Any Wound Complication 5.6% 2.8% 0.09 0.5 (0.2-1.1)
 Wound dehiscence 2.4% 0.4% 0.05 0.2 (0.0-1.2)
 Superficial SSI 2.1% 1.6% 0.61 0.8 (0.2-2.3)
 Deep SSI 0.7% 0.4% 0.58 0.6 (0.1-4.9)
 Organ/Space SSI 1.1% 0.4% 0.30 0.4 (0.0-2.8)
Ischeamic colitis 3.7% 2.4% 0.34 0.6 (0.3-1.6)
Lower Extremity Ischemia 2.4% 2.0% 0.72 0.8 (0.3-2.3)
Mean length of hospital stay
(no. of days)
9.6 10.5 0.17
Median length of hospital stay
(no. of days)
7 8 0.05
Length of stay ≥ 10 days 28% 27% 0.74 1.3 (0.9-1.7)
Discharged home 77% 74% 0.34 0.9 (0.6-1.2)
CI, Confidence interval; CPR, cardiopulmonary resuscitation; CVA, cerebrovascular acci-
dent; OR, odds ratio; SSI, surgical site infection.
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P = .047; Table 4a). After adjusting for baseline characteristics and concomitant 
procedures, there were no differences between groups (Table 4b).
Table 3b. Post-operative outcomes of patients with infrarenal and juxtarenal abdominal 
aortic aneurysms undergoing transperitoneal vs. retroperitoneal open surgical repair (all 
concomitant procedures excluded)
Outcomes
Transperitoneal 
(n=588)
Retroperitoneal 
(n=184)
P Value
Mortality 4.6% 2.7% 0.27
Rupture of Aneurysm 0.9% 0.5% 0.68
Medical complications (% of patients)
Myocardial Infarction 2.0% 2.2% 0.91
Cardiac Arrest requiring CPR 2.2% 2.2% 0.98
Pneumonia 4.9% 7.1% 0.27
Pulmonary Embolism 0.3% 0.5% 0.70
Progressive Renal Insufficiency 1.9% 1.6% 0.83
Acute Renal Failure 3.6% 4.3% 0.63
Urinary Tract Infection 2.7% 1.6% 0.41
Stroke / CVA 0.3% 0.5% 0.70
DVT 2.2% 1.1% 0.34
Bleeding Transfusions 69.7% 77.7% 0.04
Sepsis 1.0% 2.7% 0.09
Surgical complications (% of patients)
Prolonged Intubation > 48 hours 9.2% 9.8% 0.81
Reintubation 6.8% 8.7% 0.39
Return to OR 9.0% 8.2% 0.72
Any Wound Complication 5.4% 2.7% 0.13
 Wound dehiscence 2.4% 0.5% 0.12
 Superficial SSI 1.9% 1.6% 0.83
 Deep SSI 0.9% 0.5% 0.68
 Organ/Space SSI 1 0 0.17
Ischeamic colitis 3.2% 2.2% 0.46
Lower Extremity Ischemia 2.2% 1.6% 0.63
Mean length of hospital stay (no. of days) 239.9 244.2 0.63
Median length of hospital stay (no. of days) 219.0 227.0 0.34
LOS ≥ 8 days 40.5% 46.2% 0.17
Discharged home 76.5% 78.1% 0.65
CPR, Cardiopulmonary resuscitation; CVA, cerebrovascular accident; SSI, surgical site infec-
tion.
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DIsCUssIOn
Our study found that as expected, the retroperitoneal approach was more com-
monly used for aneurysms with more proximal extent and was associated with 
higher rates of concomitant procedures as well as pneumonia, reintubation, and 
transfusion, and longer length of stay. The transperitoneal approach, however, 
Table 4a. Adjusted outcomes of patients with infrarenal and juxtarenal abdominal aortic 
aneurysms undergoing transperitoneal vs. retroperitoneal open surgical repair
Outcome Odds Ratio (95% CI) P-value
Mortality 0.9 0.4-2.1 0.89
Pneumonia 1.8 1.0-3.2 0.07
Reintubation 1.7 1.0-3.0 0.05
Acute Renal Failure 1.8 0.8-3.9 0.14
Return to the OR 0.7 0.4-1.3 0.27
Any Wound Complication 0.7 0.3-1.6 0.40
Wound Infection 0.9 0.1-8.3 0.94
Length of stay ≥ 10 days 1.4 1.0-2.0 0.08
CI, Confidence interval; OR, odds ratio.
a Variables included in the regression were male gender, age, white race, prior abdominal 
surgery, any concomitant procedure, aneurysm extent, bifurcated graft, management of 
inferior mesenteric artery, and retroperitoneal approach.
Table 4b. Adjusted outcomes of patients with infrarenal and juxtarenal abdominal aortic an-
eurysms undergoing transperitoneal vs. retroperitoneal open surgical repair (all concomitant 
procedures excluded)
Outcome Odds Ratio (95% CI) P-value
Mortality 0.6 0.2-1.6 0.27
Pneumonia 1.5 0.7-3.1 0.27
Reintubation 1.3 0.7-2.5 0.47
Acute Renal Failure 1.2 0.5-3.1 0.72
Return to the OR 0.9 0.5-1.7 0.76
Any Wound Complication 0.7 0.3-1.9 0.46
Wound Infection 0.9 0.1-8.4 0.95
Length of stay ≥ 10 days 1.3 0.8-1.9 0.30
CI, Confidence interval; OR, odds ratio.
a Variables included in the regression were male gender, age, white race, prior abdominal 
surgery, any concomitant procedure, aneurysm extent, bifurcated graft, management of 
inferior mesenteric artery, and retroperitoneal approach.
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had a higher rate of wound dehiscence. After multivariable analysis, however, 
most of these differences were simply related to concomitant procedures.
Data from previous randomized control trials have demonstrated antithetical 
outcomes.9, 17, 20, 21, 22 Arya et al found that retroperitoneal surgery shortened the 
length of stay in a study of 35 patients,20 whereas Sieunarine et al (n = 100) 
found no differences in length of stay.17 Sicard et al,9 (n = 145) also found that 
retroperitoneal surgery was associated with shorter hospial stays and excluded 
patients who required concomitant mesenteric or renal artery revascularization 
in their analysis. Our analysis found no differences in length of stay between 
surgical groups, emphasizing that this difference was after adjustment for con-
comitant procedures.
Sicard et al demonstrated that patients undergoing the retroperitoneal ap-
proach had fewer postoperative complications (including bowel obstruction, 
wound, pulmonary, and cardiac complications).9 Sieunarine et al found higher 
rates of wound complications in the retroperitoneal group but no differences in 
any other postoperative complication.17 Our data showed lower rates of wound 
dehiscence with the retroperitoneal approach, higher rates of pneumonia, rein-
tubation, and transfusion, and longer length of stay. However, only reintubation 
was significantly higher in the retroperitoneal group after accounting for other 
patient and procedural characteristics.
Although published before 1990, several larger retrospective reviews of 299, 
270, and 213 patients have also demonstrated mixed results.23, 24, 25 Leather et 
al (n = 299) demonstrated a reduction of pulmonary complications and length 
of stay favorable for the retroperitoneal approach.23 Peck et al (n = 270) also 
showed a shorter length of stay with the retroperitoneal approach and fewer 
complications, including pneumonia, the need for nasogastric suction, and at-
electasis, in the retroperitoneal group.25 They did not demonstrate significant 
differences in wound infections or postoperative myocardial infarctions.25 Sicard 
et al (n = 213) showed that the retroperitoneal approach was preferable with 
respect to blood loss.24
Our study demonstrates that the retroperitoneal approach is more commonly 
used for more proximal aneurysms because this approach is generally consid-
ered to provide better exposure of the suprarenal abdominal aorta. Our analysis 
showed that concomitant procedures were more common in the retroperitoneal 
group. After excluding all concomitant procedures, all differences in outcomes 
were similar except for transfusion. In our multivariable model, which allowed 
inclusion of greater numbers and still accounted for concomitant procedures as 
well as differences in anatomic and comorbid conditions, there were no differ-
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ences in outcomes. These results suggest that concomitant procedures drive the 
observed increase in complications and length of stay.
The use of the Targeted Vascular ACS NSQIP database is limited by the lack of 
randomization and defined variables. The surgeon’s preference and the experi-
ence of the surgeon or center performing open AAA repair cannot be captured 
with this database but likely played a roll in the choice of treatment. In addi-
tion, data on choice of anesthesia and the use of epidurals, which may affect 
outcomes, are not available in the NSQIP. The NSQIP also does not have data 
describing postoperative ileus or bowel obstruction. However, length of stay is 
likely a reasonable proxy for this, and we did not see any difference. Finally, the 
database does not provide information on outcomes >30 postoperative days. As 
a result, we are unable to draw conclusions on the potential late effects of open 
surgical approach on hernia and bowel obstruction or on survival. Despite these 
limitations, our study provides a large cohort, including anatomic detail, and 
demonstrates current outcomes with open AAA repair in centers participating in 
the recently released Targeted Vascular ACS NSQIP.
Conclusions
The retroperitoneal surgery was more commonly used for a more proximal aneu-
rysm extent and with concomitant renal, visceral, and lower extremity revascu-
larization procedures. When controlling for concomitant procedures, no significant 
differences were found between the transperitoneal and retroperitoneal approach 
for AAA repair. Further long-term data regarding late survival, bowel obstruction, 
and hernia formation will be useful to guide treatment selection. For the time 
being, the choice should be driven by anatomy and surgeon preference.
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ABsTRACT
Objective
Abdominal aortic aneurysm (AAA) repair has been performed by various surgical 
specialties for many years. Endovascular aneurysm repair (EVAR) may be a disrup-
tive technology, impacting which specialties care for patients with AAA. Therefore, 
we examined the proportion of AAA repairs performed by various specialties over 
time in the United States and evaluated the impact of the introduction of EVAR.
Methods
The Nationwide Inpatient Sample, 2001-2009, was queried for intact and ruptured 
AAA and for open repair and EVAR. Specific procedures were used to identify 
vascular surgeons (VS), cardiac surgeons (CS), and general surgeons (GS) as well 
as interventional cardiologists (IC), and interventional radiologists (IR) for states 
that reported unique treating physician identifiers. Annual procedure volumes 
were subsequently calculated for each specialty.
Results
We identified 108,587 EVAR and 85,080 open AAA repairs (3,011 EVAR and 12,811 
open repairs for ruptured AAA). VS performed an increasing proportion of AAA 
repairs over the study period (52% in 2001 to 66% in 2009, P < .001). GS and CS 
performed fewer repairs over the same period (25% to 17%, P < .001 and 19% 
to 13%, P < .001, respectively). EVAR was increasingly utilized for intact (33% to 
78% of annual cases, P < .001) as well as ruptured AAA repair (5% to 28%, P < 
.001). The proportion of intact open repairs performed by VS increased from 52% 
to 65% (P < .001), while for EVAR the proportion went from 60% to 67% (P < 
.001). For ruptured open repairs, the proportion performed by VS increased from 
37% to 53% (P < .001) and for ruptured EVAR repairs from 28% to 73% (P < 
.001). Compared to treatment by VS, treatment by a CS (0.55 [0.53-0.56]) and 
GS (0.66 [0.64-0.68]) was associated with a decreased likelihood of undergoing 
endovascular rather than open AAA repair.
Conclusions
VS are performing an increasing majority of AAA repairs, in large part driven by 
the increased utilization of EVAR for both intact and ruptured AAA repair. However, 
GS and CS still perform AAA repair. Further studies should examine the implica-
tions of these national trends on the outcome of AAA repair.
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InTRODUCTIOn
During the late 20th century, surgery has become a technology driven profes-
sion.1 Since then, innovations such as endoscopic and endovascular surgery have 
transformed clinical medicine. Besides changing the procedure itself, these disrup-
tive technologies have had their effect on the type of physicians performing the 
procedures. Percutaneous coronary intervention, for example, has diminished the 
proportion of coronary revascularizations performed by cardiac surgeons, while 
the proportion of interventional cardiologists increased dramatically with the use of 
this technique.2 For abdominal aortic aneurysm (AAA) repair, it is unclear how the 
introduction and widespread adoption of endovascular repair (EVAR) has changed 
the distribution of specialties performing elective and ruptured AAA repair.
Prior to the introduction of EVAR, open surgical repair was the primary method 
of treatment. Using Medicare data, Birkmeyer et al. showed that between 1998 
and 1999, prior to the widespread adoption of EVAR, vascular surgeons (VS) 
performed 39% of all elective AAA repairs, while cardiac and general surgeons 
(CS, GS) performed 33% and 28%, respectively.3 In contrast to elective AAA re-
pair, general surgeons performed the largest proportion of ruptured AAA repairs 
at 39%, followed by vascular surgeons at 33% and cardiac surgeons at 29%.4 
Currently, as with coronary revascularization, the endovascular approach has 
also led to the inclusion of nonsurgical specialties in treating patients with AAA, 
such as interventional cardiology (IC) and interventional radiology (IR). Since 
the performance of EVAR requires a specific skill set that has not been mastered 
by many surgeons from other specialties, we hypothesize that the proportion of 
surgical specialties other than VS (i.e., GS and CS) has declined, while VS, IR, 
and IC are responsible for an increasing number of patients due to a shift from 
open repair towards EVAR.
The purpose of this study is to analyze how the introduction of EVAR has 
influenced which specialties are providing care for AAA patients for both elective 
and ruptured AAA repair in the United States.
METHODs
Database
The Nationwide Inpatient Sample (NIS) is the largest national administrative 
database and represents a 20% sample of all payer (insured and uninsured) 
hospitalizations. The NIS is maintained by the Agency for Health Care Research 
and Quality as part of the Healthcare Cost and Utilization Project. Years 2001 
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to 2009 were queried using International Classification of Diseases, 9th revision 
(ICD-9) codes to identify patients with diagnosis codes for intact (i.e. elective, 
symptomatic and mycotic aneurysms) AAA (441.4) and ruptured AAA (441.3). 
ICD-9 coding does not distinguish infrarenal from juxtarenal or suprarenal AAA. 
More recent years could not be interrogated due to discontinuation of the surgeon 
identification variables in the NIS database after 2009.5 Patients who underwent 
open AAA repair (38.44, 39.25) or EVAR (39.71) were selected. Patients with pro-
cedural codes for both open repair and EVAR were considered to have undergone 
EVAR, as they likely represent conversions to open repair. Patients with codes for 
a thoracic aneurysm (441.1 or 441.2), thoracoabdominal aneurysm (441.6 or 
441.7) or aortic dissection (441.00-441.03) were excluded. As the NIS contains 
de-identified data only without protected health information, Institutional Review 
Board approval and patient consent were waived.
The primary outcome was proportional procedure volume by physician specialty 
over time for intact and ruptured AAA repair. We evaluated the uptake of EVAR 
overall and by specialty over time. Additionally, we assessed the likelihood of 
receiving EVAR rather than open repair by specialty.
Physician specialty
For AAA repair, we were interested in the following type physicians: vascular 
surgeons (VS), general surgeons (GS), cardiac surgeons (CS), interventional 
cardiologists (IC), and interventional radiologists (IR). The NIS provides unique 
physician identifiers per state that allow tracking of procedures performed by 
that physician during that specific year in that state. Of the available states, 27 
provide 2 unique physician identifiers, with 22 of the 27 specifically detailing 
which physician performed the primary procedure (Supplemental Table 3). For the 
remaining 5 states, the identifiers were only used when both identifiers were the 
same to ensure that the identified physician was the one performing the primary 
procedure. We composed a list of specific procedures (Supplemental Table 1) that 
we used to determine the specialty of each physician (VS, GS, CS, IC, or IR). 
The top 15 procedures identified for each of the physician specialties are listed 
in Supplemental Table 2. Similar approaches have been previously reported.6-8 
Subsequently, a hierarchical model was created: each physician that performed 
>10 cardiac surgery procedures was labeled a CS; the remaining physicians that 
performed >10 interventional cardiology procedures (e.g. coronary stenting) were 
labeled IC; physicians with >10 interventional radiology procedures not typically 
performed by VS (e.g. liver biopsy, nephrostomy, etc.) were identified as IR; the 
remaining physicians whose procedures consisted of 75%-100% of vascular pro-
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cedures with >10 in number, were classified as VS; physicians whose procedures 
consisted of 0-75% of vascular procedures and performed >10 general surgery 
procedures were classified as GS. Similar approaches have been previously de-
scribed.9, 10 Two hundred and ten procedures labeled as open repairs were coded 
as being performed by IC or IR (0.1% of total procedures). We felt these were 
most likely miscoded endovascular procedures and excluded these patients from 
further analyses.
statistical approach
Mean and standard deviation are reported for parametric data. Baseline variables 
were compared using Chi-square tests or t-tests, where appropriate. We exam-
ined the proportional volume of open AAA repairs and EVAR for each specialty and 
how this changed over the study period. Trends over time were assessed using 
the Cochran-Armitage test for trend. A P-value less than .05 indicates that annual 
procedural volumes followed a significant upward or downward (i.e., non-random) 
trend over time. Multivariable logistic regression analysis was conducted to exam-
ine the influence of physician specialty type on the type of procedure performed, 
whether open or endovascular. Analyses were considered statistically significant 
when P < .05. Statistical analyses were performed using SAS 9.2 software (SAS 
Institute, Cary, NC) and SPSS Statistics 21 (IBM Inc., Chicago, IL).
REsULTs
Overall, 108,587 EVAR and 85,080 open AAA repairs were identified in the study 
period, of which 3,011 EVAR and 12,811 open repairs were for ruptured AAA. 
The annual overall volume increased from 20,134 in 2001 to 22,541 in 2009 (P 
< .001). Patient and hospital characteristics are detailed in Table 1. Of all AAA 
repairs, 61% of AAA repairs were performed by VS, 20% by GS and 16% by CS, 
while the remainder was performed by IC and IR (3% combined). Figure 1 illus-
trates changes over time for each physician specialty. VS performed an increasing 
proportion of AAA repairs over the study period (52% in 2001 to 66% in 2009, 
P < .001, Supplemental Table 4). During the same period, GS and CS performed 
fewer repairs (25% to 17%, P < .001 and 19% to 13%, P < .001, respectively). 
Similarly, the absolute number of VS performing AAA repair increased with 30% 
over the study period, while the number of GS and CS decreased over time (46% 
and 30%, respectively).
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Intact AAA Repair
With 55%, VS performed the majority of open AAA repairs (increasing from 52% 
to 65% from 2001 to 2009, P < .001). Over this same time period GS performed 
24% of all intact open repairs (decreasing from 25% to 16%, P < .001), followed 
by CS with 22% of cases (24% to 19%, P <. 001, Figure 2a). VS also performed 
the majority of EVARs at 67%, (increasing from 60% to 67% from 2001 to 2009), 
followed by 16% performed by GS (19% to 17%, P < .001), 13% by CS (10.5% 
to 11.3%, P = .009) and 4% by IC and IR combined (10% to 6%, P = .015, 
Figure 2b). The absolute number of EVARs increased from 5,906 in 2001 (33% 
of the annual intact AAA repairs) to 16,252 in 2009 (78%). Over the same pe-
riod, the number of open repairs decreased from 12,188 (67%) to 4,678 (22%). 
Consequently, EVAR has become the primary treatment method for intact AAA 
in all three surgical specialties (Figure 3). Since VS perform a greater proportion 
of endovascular procedures, the rise in EVAR utilization has in part led to VS 
performing an increasing majority of overall intact AAA repairs (54% in 2001 to 
66% in 2009, P < .001).
Rupture AAA Repair
VS performed 49% of open ruptured AAA repairs (increasing from 37% to 53%, P 
< .001, Figure 4A), followed by GS with 35% (44% to 33%, P < .001) and 16% 
by CS (19% to 14%, P = .001). With 73%, VS also carried out the majority of 
ruptured EVAR (rEVAR) (28% to 73%, P < .001, Figure 4B), while GS performed 
Figure 1. Proportion of all abdominal aortic aneurysm repairs (both open and endovascular) 
performed by each physician specialty from 2001-2009 in the Nationwide Inpatient Sample 
(totals sum to 100%)
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Figure 2A. Proportion of all open repairs for intact abdominal aortic aneurysms performed by 
physician specialty from 2001-2009 in the Nationwide Inpatient Sample (totals sum to 100%) 
 
  
52% 
66% 
25% 
17% 
19% 13% 
3% 4% 
0% 
10% 
20% 
30% 
40% 
50% 
60% 
70% 
80% 
90% 
100% 
2001 2002 2003 2004 2005 2006 2007 2008 2009 
IC + IR   (P < .001) 
CS          (P < .001) 
GS          (P < .001) 
VS          (P < .001) 
52% 
65% 
25% 
16% 
24% 19% 
0% 
10% 
20% 
30% 
40% 
50% 
60% 
70% 
80% 
90% 
100% 
2001 2002 2003 2004 2005 2006 2007 2008 2009 
CS         (P = .001) 
GS          (P < .001) 
VS          (P < .001) 
Chapter 10
188
15% (54% to 16%, P < .001) and CS 9% (18% to 8%, P = .008). IC and IR 
together are responsible for 3% of rEVARs (0% to 3%, P = .095). A dramatic 
overall increase in the utilization of rEVAR was observed (5% to 38% of the annual 
ruptured volume). This was most pronounced for VS, where the utilization of 
rEVAR went from 4% in 2001 to 46% in 2009 (P < .001, Figure 5).
Figure 2a. Proportion of all open repairs for intact abdominal aortic aneurysms performed 
by physician specialty from 2001-2009 in the Nationwide Inpatient Sample (totals sum to 
100%)
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physician specialty from 2001-2009 in the Nationwide Inpatient Sample (totals sum to 100%) 
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Figure 2b. Proportion of all endovascular repairs for intact abdominal aortic aneurysms per-
formed by physician specialty from 2001-2009 in the Nationwide Inpatient Sample (totals 
sum to 100%)
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Figure 2B. Proportion of all endovascular repairs for intact abdominal aortic aneurysms 
performed by physician specialty from 2001-2009 in the Nationwide Inpatient Sample (totals 
sum to 100%) 
 
Figure 3. Proportion of intact abdominal aortic aneurysms treated by endovascular repair 
within each specialty from 2001-2009 in the Nationwide Inpatient Sample 
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Likelihood of receiving EVAR
Compared to treatment by VS, treatment by CS and GS was associated with a 
signifi cantly lower likelihood of receiving EVAR (OR: 0.55, 95% CI: 0.53 – 0.56 
for CS and OR: 0.66, 95% CI: 0.64 – 0.68 for GS, Table 2). Additionally, women 
(OR: 0.57, 95% CI: 0.55 – 0.58) those with non-white race (OR: 0.88 95% CI: 
0.84 – 0.91), and emergency admission (OR: 0.14, 95% CI: 0.14 – 0.15) were 
signifi cantly less likely to undergo EVAR. Advanced age (OR: 1.42, 95% CI: 1.40 
– 1.44, per 10 years), treatment in a teaching hospital (OR: 1.27, 95% CI: 1.25 
– 1.30) and urban designation of the hospital (OR: 1.33, 95% CI: 1.27 – 1.40) 
were predictive of EVAR. Over the study period, the probability for receiving EVAR 
increased annually (OR: 1.33, 95% CI: 1.32 – 1.34, per year).
DIsCUssIOn
The main fi nding of this study is that with the introduction of EVAR, the proportion 
of AAA repairs being performed by each physician specialty has changed. Vascular 
surgeons performed an increasing majority of both open and endovascular intact 
AAA repairs, while the proportion carried out by CS and GS has steadily declined. 
The distribution of specialties performing rAAA repair shifted from predominantly 
GS in the fi rst years of the study towards VS in later years. Over the study period, 
EVAR has become the dominant treatment for intact AAA repair and is being 
utilized for an increasing number of ruptured AAA repairs as well. As EVAR is most 
likely performed by VS, the overall proportion of repairs done by VS –intact and 
ruptured– increased substantially with the widespread adoption of EVAR.
Figure 3. Proportion of intact abdominal aortic aneurysms treated by endovascular repair 
within each specialty from 2001-2009 in the Nationwide Inpatient Sample
 
 218
Figure 2B. Proportion of all endovascular repairs for intact abdominal aortic aneurysms 
performed by physician specialty from 2001-2009 in the Nationwide Inpatient Sample (totals 
sum to 100%) 
 
Figure 3. Proportion of intact abdominal aortic aneurysms treated by endovascular repair 
w thin ach specialty from 2001-2009 in the N tionwide Inpatient Sample
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Regarding intact AAA repair, our results are in line with a study by Birkmeyer et 
al., showing that between 1998 and 1999 intact open repairs were predominantly 
performed by VS. However, Birkmeyer et al. found a relatively even distribution 
with 39% being done by VS, 33% by CS and 28% by GS, while our results showed 
that VS already performed a majority of the open repairs in the early years of 
the study and this difference continued to increase over time. Regionalization of 
open AAA repairs to high-volume centers during the turn of the century is likely 
Figure 4a. Proportion of all open ruptured AAA repairs performed by physician specialty 
from 2001-2009 in the Nationwide Inpatient Sample (totals sum to 100%)
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Figure 4A. Proportion of all open ruptured AAA repairs performed by physician specialty from 
2001-2009 in the Nationwide Inpatient Sample (totals sum to 100%) 
 
 
Figure 4B. Proportion of all EVARs for ruptured AAA repairs performed by physician specialty 
from 2001-2009 in the Nationwide Inpatient Sample (totals sum to 100%) 
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Figure 4b. Proportion of all EVARs for ruptured AAA repairs performed by physician spe-
cialty from 2001-2009 in the Nationwide Inpatient Sample (totals sum to 100%)
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Figure 4A. Proportion of all open ruptured AAA repairs performed by physician specialty from 
2001-2009 in the Nationwide Inpatient Sample (totals sum to 100%) 
 
 
Figure 4B. Proportion of all EVARs for ruptured AAA repairs performed by physician specialty 
from 2001-2009 in the Nationwide Inpatient Sample (totals sum to 100%) 
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to have contributed to VS being increasingly responsible for AAA surgery.11 In 
addition, retirement of senior surgeons who were trained at a time when GS 
and CS customarily performed repair of abdominal aortic aneurysms and may 
have been less likely to obtain endovascular skills may have added to the shift 
towards VS. Similar to the early years of our study, previous reports show that 
GS performed the majority of ruptured AAA repairs at 39%, followed by VS 
at 33%, and CS at 29% before the introduction of EVAR.12 As EVAR became 
Figure 5. Proportion of ruptured abdominal aortic aneurysms treated by endovascular re-
pair within each specialty from 2001-2009 in the Nationwide Inpatient Sample
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Figure 5. Proportion of ruptured abdominal aortic aneurysms treated by endovascular repair 
within each specialty from 2001-2009 in the Nationwide Inpatient Sample 
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Table 2. Multivariable predictors for the likelihood of receiving EVAR (OR >1 predicts EVAR)
Variable Odds ratio 95% CI P-value
Surgeon Specialty
Vascular surgeons Reference - -
Cardiac surgeons 0.55 0.53 – 0.56 < .001
General surgeons 0.66 0.64 – 0.68 < .001
Emergent admission 0.14 0.14 – 0.15 < .001
Age (per 10 y) 1.42 1.40 – 1.44 < .001
Female sex 0.57 0.55 – 0.58 < .001
Non-white race 0.88 0.84 – 0.91 < .001
Year of surgery (per y) 1.33 1.32 – 1.34 < .001
Teaching hospital 1.27 1.25 – 1.30 < .001
Hospital location 1.33 1.27 – 1.40 < .001
Hospital Bed size
Small Reference - -
Medium 0.72 0.69 – 0.76 < .001
Large 0.98 0.94 – 1.02 < .319
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more widely used in the emergency setting, this distribution changed towards a 
growing proportion of emergency repairs being performed by VS. Since VS also 
performed an increasing proportion of open rAAA repairs separately from trends 
in endovascular repair, centralization of rAAA care is likely to have contributed 
to the shift from GS towards VS as well. Yet a persistent presence of GS treating 
open rAAA repair remained, which could be due to geographic location where 
the presence of VS may be lacking.13 In these areas, the emergent nature of 
a ruptured AAA may preclude the transfer of the patient to a center with VS 
necessitating immediate treatment by an available GS.
The phenomenon of disruptive technologies in healthcare is not new. In coro-
nary artery disease, the number of coronary revascularizations performed with 
coronary stenting rapidly increased after the first coronary stent was introduced 
in 1994, while the utilization of coronary bypass grafting declined.2 As a result, 
interventional cardiologists rather than cardiac surgeons currently perform the 
majority of coronary revascularizations. A similar shift was seen in vascular 
surgery with the introduction of carotid stenting. Before its introduction, carotid 
revascularization through endarterectomy was predominantly done by VS and, 
to a lesser extent GS, CS and neurosurgeons.14 We noted that GS and CS practice 
included a substantial percentage of carotid endarterectomies (8.6% and 10.0% 
of the selected procedures we identified, respectively) (Supplemental Table 2). 
However, we did not evaluate changes in carotid revascularization over time in 
this study. After FDA approval in 2004, carotid stenting is increasingly utilized 
with rapid adoption by not only surgeons, but also interventional radiologists and 
interventional cardiologists.15, 16 Currently, carotid endarterectomy use is still 
declining, while some patients are being treated through stenting predominantly 
by interventional cardiologists.17, 18 EVAR has certainly changed how AAA is being 
treated but contrary to the examples above, VS have only increased their role as 
the treating surgeon for intact and ruptured AAA.
Our study has several limitations that should be addressed. Since administra-
tive databases were used, important clinical data such as anatomical informa-
tion or hemodynamic status, which could influence the choice of procedure and 
subsequent outcomes, could not be assessed. Additionally, the difficulty of dis-
tinguishing a pre-existing comorbid condition from a post-operative complication 
in this dataset makes an adequate risk-adjustment model difficult. Therefore, we 
chose not to perform outcomes analysis using NIS. However, the NIS does afford 
national representation of all age groups thus making it an optimal source of epi-
demiologic data. Also, as the NIS database does not include the specialty of the 
attending physician, we employed an algorithm incorporating specialty specific 
procedures similar to what has been described before.7, 19, 20 Our algorithm for 
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identifying vascular surgeons is arbitrary (75% vascular surgery cases), sug-
gesting that some board certified VS may have been mistakenly classified as GS 
or vice versa. However, our methodology reflects what physicians were actually 
doing routinely in practice and focused on the change over time. Additionally, 
our algorithm generated similar distributions of physician’s specialty performing 
open repair in the early years of the current studied period when compared to a 
previously published large study using physician self identification of specialty.4 
Further, procedures coded as open repairs performed by IC or IR (0.1%) were 
excluded from this study, as they are, most likely, miscoded endovascular pro-
cedures. Unfortunately, it is not possible to identify similar procedural coding 
errors for the remaining open repairs. Consequently, a very small proportion 
of miscoded procedures may have remained. Finally, the discontinuation of the 
surgeon-identifying variable after 2009 prevented the inclusion of more recent 
years. However, as is demonstrated in this study, the major shift from open 
repair to EVAR was already well established by 2009.21
COnCLUsIOns
Our results show that VS are performing an increasing majority of AAA repairs, in 
large part driven by the increased utilization of EVAR for both intact and ruptured 
AAA repair. However, GS and CS still perform AAA repair. Treatment by GS and 
CS, as well as emergent admission, female sex and non-white race are associ-
ated with a decreased likelihood of receiving EVAR. Advanced age, more recent 
year of surgery, treatment in a teaching hospital and urban designated area of 
the hospital increased the probability of receiving EVAR. Further studies should 
examine the implications of these national trends on the outcome of AAA repair.
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supplemental Table 1. Procedures used to identify physician specialty
Vascular surgeon
ICD-9 Description
38.12 Carotid endarterectomy
39.29 Peripheral vascular bypass
84.15 Below knee amputation
84.17 Above knee amputation
General surgeon
ICD-9 Description
17.11-24; 53.00-9 Hernia repair
47.01-19 Appendectomy
51.21-24 Cholecystectomy
Cardiac surgeon
ICD-9 Description
36.10-19 Coronary artery bypass grafting
35.20-28 Heart valve replacement
39.61 Cardiopulmonary bypass
Interventional Cardiologist
ICD-9 Description
00.66; 36.01-02; 36.05 Percutaneous transmural coronary angioplasty
36.04 Intracoronary thrombolysis
36.06-07 Intracoronary stenting
37.21-23 Heart catheterization
Interventional Radiologist
ICD-9 Description
33.26 Closed lung biopsy
39.1 Transjugular intrahepatic portosystemic shunt
50.11 Closed liver biopsy
55.03-04 Percutaneous nephrostomy
78.49; 81.65 Percutaneous vertebroplasty
99.25 Chemoembolization
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supplemental Table 2. Top 15 procedures performed per physician specialty
Vascular surgeon
ICD-9 % Description
38.12 17.6% Carotid endarterectomy
39.29 10.0% Peripheral vascular bypass
39.5 7.7% Angioplasty or atherectomy of other non-coronary vessel(s)
39.71 5.2% Endovascular implantation of graft in abdominal aorta
38.7 3.4% Interruption of the vena cava
39.49 3.3% Revision of anastomosis of blood vessel or vascular procedure
39.27 3.0% Arteriovenostomy for renal dialysis
38.44 2.8% Resection of vessel with replacement, aorta, abdominal
86.22 2.5% Excisional debridement of wound, infection, or burn
39.25 2.4% Aorta-iliac-femoral bypass
84.15 2.2% Other amputation below knee
84.17 2.2% Amputation above knee
38.95 2.1% Venous catheterization for renal dialysis
38.18 1.8% Endarterectomy, lower limb arteries
84.11 1.7% Amputation of toe
General surgeon
ICD-9 % Description
51.23 10.2% Laparoscopic cholecystectomy
38.12 8.6% Carotid endarterectomy
39.29 4.1% Peripheral vascular bypass
47.09 3.8% Other appendectomy
47.01 3.1% Laparoscopic appendectomy
45.73 2.5% Open and other right hemicolectomy
38.93 2.5% Venous catheterization
86.22 2.4% Excisional debridement of wound, infection, or burn
45.76 2.1% Open and other sigmoidectomy
39.5 2.0% Angioplasty or atherectomy of other non-coronary vessel(s)
51.22 1.9% Cholecystectomy
39.27 1.8% Arteriovenostomy for renal dialysis
38.7 1.7% Interruption of vena cava
86.04 1.6% Other incision with drainage of skin and subcutaneous tissue
54.59 1.6% Other lysis of peritoneal adhesions
Cardiac surgeon
ICD-9 % Description
38.12 10.0% Carotid endarterectomy
36.12 9.1% (Aorto)coronary bypass of two coronary arteries
36.13 8.9% (Aorto)coronary bypass of three coronary arteries
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supplemental Table 2. (continued)
36.14 4.2% (Aorto)coronary bypass of four or more coronary arteries
36.11 3.5% (Aorto)coronary bypass of one coronary artery
36.15 3.2% Single internal mammary-coronary artery bypass
39.29 3.1% Peripheral vascular bypass
35.22 2.9% Other replacement of aortic valve
35.21 2.9% Replacement of aortic valve with tissue graft
38.44 1.7% Resection of vessel with replacement, aorta, abdominal
32.4 1.7% Lobectomy of lumg
39.71 1.5% Endovascular implantation of graft in abdominal aorta
39.5 1.3% Angioplasty or atherectomy of other non-coronary vessel(s)
32.29 1.3% Other local excision or destruction of lesion
35.12 1.1% Open heart valvuloplasty of mitral valve without replacement
Interventional Cardiologist
ICD-9 % Description
0.66 21.4% Percutaneous transmural coronary angioplasty
37.22 13.7% Left heart cardiac catheterization
39.5 11.7% Angioplasty or atherectomy of other non-coronary vessel(s)
36.01 11.6% Percutaneous transmural coronary angioplasty
39.71 2.5% Endovascular implantation of graft in abdominal aorta
36.05 2.3% Percutaneous transmural coronary angioplasty
0.61 2.1% Percutaneous angioplasty or atherectomy of precerebral extracranial vessel(s)
37.23 2.1% Combined right and left heart cardiac catheterization
37.72 1.9% Initial insertion of transvenous leads [electrodes] into atrium and ventricle
37.61 1.2% Implant of pulsation balloon
88.72 1.1% Diagnostic ultrasound of heart
64 1.0% Circumcision
57.94 0.9% Insertion of indwelling catheter
35.52 0.9% Repair of atrial septal defect with prosthesis, closed technique
88.56 0.7% Coronary arteriography using two catheters
Interventional Radiologist
ICD-9 % Description
38.9 18.3% Venous catheterization, not elsewhere classified
39.5 11.9% Angioplasty or atherectomy of other non-coronary vessel(s)
38.7 7.0% Interruption of the vena cava
54.91 6.8% Percutaneous abdominal drainage
34.91 6.1% Thoracentesis
38.95 2.9% Venous catheterization for renal dialysis
55.03 2.4% Percutaneous nephrostomy without fragmentation
50.11 2.1% Closed (percutaneous) [needle] biopsy of liver
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supplemental Table 2. (continued)
88.41 2.1% Arteriography of cerebral arteries
39.71 2.0% Endovascular implantation of graft in abdominal aorta
33.26 2.0% Closed (percutaneous) [needle] biopsy of lung
81.66 1.7% Percutaneous vertebral augmentation
34.04 1.3% Insertion of intercostal catheter for drainage
88.42 1.3% Aortography
99.29 1.2% Injection or infusion of other therapeutic or prophylactic substance
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supplemental Table 3. Proportion of the cohort per state
state Proportion of cohort (%)
Arkansas 1.1%
Arizona 5.3%
Colorado 2.0%
Florida 17.6%
Georgia 0.4%
Iowa 2.1%
Kansas 0.7%
Kentucky 3.2%
Maryland 4.6%
Maine 0.1%
Michigan 4.2%
Minnesota 0.9%
Missouri 5.9%
Montana 0.1%
Nebraska 0.9%
New Hampshire 2.0%
New Jersey 5.8%
Nevada 0.8%
New York 14.4%
Oregon 0.6%
Pennsylvania 5.8%
Rhode Island 0.2%
South Carolina 1.4%
South Dakota 0.1%
Tennessee 5.4%
Texas 8.9%
Virginia 4.3%
Washington 1.4%
West Virginia <0.1%
Wyoming <0.1%
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ABsTRACT
Objective
Life expectancy and causes of death after abdominal aortic aneurysm (AAA) repair 
are not well characterized. Population aging and improved secondary prevention 
may have modified the prognosis of these patients. We designed a retrospective 
cohort study to determine the vital prognosis, causes of death, and differences in 
outcome after intact and ruptured AAA.
Methods
All patients with AAA treated from 2003 to 2011 at a single university institution 
in the Netherlands were analyzed. Survival status was derived from civil registry 
data. Causes of death were obtained from death certificates. The primary end 
point was overall mortality. Secondary end points were cardiovascular, cancer-
related, and AAA-related mortality. Predictors for perioperative and late survival 
were obtained by logistic regression and Cox regression models, respectively.
Results
The study included 619 consecutive AAA patients (12% women; mean age, 72 
years), of whom 152 (24.5%) had ruptured AAAs. Endovascular repair was per-
formed in 390 (63%). Rupture (odds ratio [OR], 10.63; 95% confidence interval 
[CI], 4.80-23.5), open repair (OR, 3.59; 95% CI, 1.69-7.62), renal insufficiency 
(OR, 2.94; 95% CI, 1.51-3.46), and age (OR, 1.08 per year; 95% CI, 1.09-1.15) 
were predictors of 30-day mortality. Five-year survival expectancy was 65% for 
intact AAA and 41% for ruptured AAA (P < .001). Cardiovascular deaths unrelated 
to the AAA occurred in 35% and cancer-related deaths in 29% of deceased pa-
tients. Predictors for late mortality were history of prior malignant disease (hazard 
ratio, 2.83; 95% CI, 1.99-4.03) and age (hazard ratio, 1.08 per year; 95% CI, 
1.05-1.10). After 30 days, only six deaths (1.1%) were AAA related.
Conclusions
Endovascular repair reduced perioperative mortality by threefold, but no survival 
benefit was observed at long term. After the perioperative period, survival of 
ruptured AAA and intact AAA patients was not different. Deaths were distributed 
in similar proportions between cardiovascular and cancer-related causes.
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InTRODUCTIOn
The prognosis of patients with abdominal aortic aneurysm (AAA) undergoing re-
pair is of major importance for decision-making, in both elective and acute situa-
tions. Whereas rupture contributes significantly to the mortality of untreated AAA 
patients,1, 2 those undergoing successful repair are considered to have a worse life 
expectancy than the background population. This is thought to be mainly due to 
a high prevalence of occult or overt atherosclerotic disease (especially coronary 
artery disease).3, 4 In addition, conflicting data have been published about the 
impact of rupture on survival expectancy beyond 30 days, with large studies 
suggesting worse prognosis for those surviving rupture and more recent data 
suggesting no difference.5-7
The evolution of AAA repair in the last decades has resulted in improved early 
outcomes for elective and ruptured situations alike. However, it is unclear if 
these improvements have been accompanied by a similar improvement in long-
term prognosis for AAA patients. The effects of superior secondary prevention 
for atherosclerosis and modification of environmental and behavioral character-
istics may have resulted in better survival and a shift away from cardiovascular 
deaths. On the other hand, changes in postoperative surveillance brought about 
by endovascular repair (frequently including repeated radiation exposure and 
nephrotoxic contrast agents) may have worsened the expected prognosis of this 
specific population.
The purpose of this study was to determine the contemporary prognosis of pa-
tients undergoing AAA repair, focusing on the possible differences between intact 
and ruptured AAAs and analyzing specific risk factors for overall, cardiovascular, 
and cancer-related mortality. In addition, we explore differences in prognosis 
after endovascular and open AAA repair.
METHODs
Institutional approval for this study was obtained, and no informed consent was 
required according to local directives for retrospective studies. The study complies 
with the Helsinki Declaration on research ethics.
study design
This was a retrospective, single-center cohort study.
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Patients
The study sample was derived from the population of patients consecutively 
treated for AAA at the Erasmus University Medical Centre (EMC), Rotterdam, the 
Netherlands, from January 2003 to November 2011. These were included in a pro-
spective AAA database, which was queried. The latest follow-up period considered 
was December 2011, therefore ensuring that all patients had at least an expected 
follow-up of 30 days. This limit to follow-up was determined by the latest available 
data sets for causes of death (see later). Patients with infectious aneurysms and 
patients with a prior history of abdominal aortic repair were excluded.
Definitions
Ruptured aneurysms were defined as either evidence of retroperitoneal blood 
on computed tomography angiography immediately before intervention or clear 
mention of periaortic hematoma in the operative report. AAAs were otherwise 
considered intact. Renal insufficiency at admission was considered present if the 
estimated glomerular filtration rate, calculated by the Modification of Diet in Renal 
Disease formula,8 was <60. Anemia at admission was considered if the serum 
hemoglobin level was <13 mg/dL (12 mg/dL in a female patient), according to the 
World Health Organization definition.9
Institutional management of AAA
The Erasmus University Medical Centre is a tertiary teaching institution performing 
around 100 aortic procedures yearly. Elective AAA repair is routinely performed 
for AAAs with a maximum diameter >5.5 cm or growth >5 mm in 6 months 
or whenever symptoms are present. Selection for endovascular aneurysm repair 
(EVAR) is individualized, considering the patient’s comorbidities, anatomic char-
acteristics, and informed consent. In the latter half of the study, preference was 
generally given to EVAR for both intact and ruptured AAAs.
survival status
Survival status was derived from inquiry of civil registry database information. 
Only deaths occurring within the study time frame (2003-2011) were considered 
to capture the cause of death for each event.
Causes of death
The causes of death were obtained by inquiry of the Dutch Central Bureau of 
Statistics (study ID: 7465). To obtain information on cause of death, a data-
base with all patients deceased within the study interval was anonymized and 
matched to the official death certificate reports using International Classification 
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of Diseases, Tenth Revision codes. According to Dutch privacy legislation, data 
analysis was allowed only to authorized researchers (K.U., F.B.G.) inside a secure 
environment, and all output was checked by the Central Bureau of Statistics for 
privacy violation before it was allowed for publication purposes. Autopsy was not 
routinely performed, and the expected cause leading to health deterioration be-
fore death was considered the true cause of death, in parallel to the strategy used 
for the overall Dutch population. The causes of death were grouped according to 
the International Classification of Diseases, Tenth Revision. The following codes 
were used: for cardiovascular death, I10-I79; for cancer-related death, C00-C43, 
C45-C97, D00-D03, and D05-09; and for AAA-related death, I71.3, I71.4, I71.8, 
I71.9, and I72.3. The proportion of coding based on autopsy vs clinical evaluation 
could not be determined.
End points
The primary end points are overall early and late mortality. Secondary end points 
are AAA-related, cardiovascular, and cancer-related mortality.
statistical methods
Baseline characteristics were described as counts and percentages (dichotomous 
variables) or means and standard deviations (continuous variables). Differences 
at baseline were assessed using Pearson χ2 or Student t-test, where appropri-
ate. Estimates of survival were obtained using Kaplan-Meier plots and tabulated 
with the respective 95% confidence intervals (CIs) at yearly intervals. General 
population survival estimates were generated after age and gender matching. 
Independent risk factors for 30-day death after AAA repair were obtained by a 
logistic regression model using variables selected a priori on the basis of clinical 
relevance, which included age, gender, renal function at admittance, anemia at 
admittance, maximum preoperative AAA diameter, indication for treatment (rup-
ture vs intact), type of anesthesia (general vs locoregional), and type of repair 
(open vs EVAR). For long-term outcome, a Cox regression model was constructed 
to determine risk factors for all-cause, cardiovascular, and cancer-related death. 
Similarly, variables were selected a priori and included age, gender, prior history 
of cardiovascular disease (cardiac, cerebrovascular, or peripheral ischemic dis-
ease), prior history of diabetes mellitus, prior history of cancer, renal insufficiency 
at admittance, anemia at admittance, indication for treatment, and type of repair. 
To determine the influence of radiation exposure resulting from postoperative 
surveillance strategies after endovascular repair, we performed a subanalysis of 
patients without a prior history of cancer and compared cancer-related mortal-
ity between endovascular and open surgery using a χ2 test. All tests were two 
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sided, and significance was considered a P value < .05. Statistical analysis was 
performed using the IBM SPSS Statistics 20 (IBM Inc, Chicago, Ill).
REsULTs
From January 2003 to November 2011, 619 patients underwent primary repair 
for noninfected AAA at our institution. Survival status was available for all but one 
patient (because of emigration), who was excluded from further analysis. Mean 
age was 71.9 ± 7.6 years, 74 (12%) were female, and 152 (25%) were ruptured 
AAAs. Endovascular repair was performed in 390 patients (63%).
Baseline characteristics
A greater proportion of patients undergoing repair for intact AAA had a prior 
history of ischemic heart disease (46% vs 35% for ruptured AAA) and diabetes 
(15% vs 8%;Table 1). Other demographics and past medical history were not 
different between these two groups. More patients in the ruptured AAA group had 
Table 1. Baseline characteristics by surgical indication
Intact AAA
N=466
Ruptured AAA
N=152
P-value
Demographics
Female gender – N (%) 56 (12) 18 (12) 0.954
Age (years, mean ± SD) 71.8 ± 7.5 72.3 ± 7.7 0.553
Prior medical history
Ischemic heart disease – N (%) 216 (46) 50 (35)* 0.016
Cerebrovascular disease – N (%) 91 (19) 22 (15)* 0.279
Diabetes mellitus – N (%) 72 (15) 12 (8)* 0.036
History of cancer – N (%) 97 (21) 17 (12)* 0.023
PAD – N (%) 87 (19) 16 (11)* 0.040
Preoperative eGFR<60 – N (%) 142 (30) 75 (49) <0.001
Preoperative anaemia– N (%) 116 (25) 113 (75) <0.001
AAA characteristics
Max AAA diameter, mm – mean ± SD 62 ± 12 77 ± 17 † <0.001
Operative details
Loco-regional anaesthesia – N (%) 97 (21) 25 (16) 0.198
Open surgical repair – N (%) 137 (29) 91 (60) <0.001
Legend * 11 rAAA patients (2%) missing baseline data; † 20 patients missing baseline di-
ameter; PAD – Peripheral arterial obstructive disease; eGFR – estimated glomerular filtration 
ratio
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estimated glomerular filtration rate <60 (49% vs 30% for intact AAA; P < .001) 
and were anemic (75% vs 25%; P < .001) at admittance, as expected because 
of their acute presentation. Also, the maximum AAA diameter of ruptured cases 
was generally greater (77 ± 17 mm vs 62 ± 12 mm; P < .001). The choice of 
anesthetic technique did not differ for intact and ruptured AAA patients. Patients 
with intact AAA, however, were less likely to undergo open surgical repair (29% vs 
60% for ruptured cases; P < .001). Baseline characteristics are detailed in Table 1.
Early postoperative mortality
Overall, there were 66 deaths within 30 days. As expected, patients with ruptured 
AAA had a higher early mortality rate (n = 50 [32.9%] vs n = 16 [3.4%] for 
intact aneurysms;P < .001). Age (odds ratio [OR], 1.08 per year increase; 95% 
CI, 1.09-1.15), renal insufficiency at admittance (OR, 2.94; 95% CI, 1.51-3.46), 
rupture as indication (OR, 10.63; 95% CI, 4.80-23.5), and open surgical repair 
(OR, 3.59; 95% CI, 1.69-7.62) were independent predictors of death within 30-
days after surgery (Table 2).
Late overall mortality
During a median follow-up of 2.4 years (range, 8.9 years), there were 157 deaths 
after 30 days. The estimated survival after operation for intact AAA was 78% and 
65% at 3 and 5 years, respectively. For ruptured AAA, the estimated survival was 
48% and 41%, respectively (Fig 1). The independent predictors for late overall 
mortality after AAA repair were age (hazard ratio [HR], 1.08 per year increase; 
95% CI, 1.05-1.10) and prior history of cancer (HR, 2.83; 95% CI, 1.99-4.03; 
Table 3). If 30-day deaths were not considered, there would be no difference in 
prognosis for intact and ruptured AAA patients during the first 5 years (Fig 2).
Table 2. Risk factors for early mortality (logistic regression)
Univariable Multivariable
Risk factor OR (95% CI) OR (95% CI)
Age * 1.08 (1.04 to 1.12) 1.09 (1.04 to 1.15)
Female gender 0.93 (0.66 to 2.80) 1.01 (0.39 to 2.62)
Renal insufficiency 3.50 (2.06 to 5.94) 2.94 (1.5 to 5.71)
Anaemia 5.94 (3.33 to 10.61) 1.66 (0.79 to 3.46)
Baseline AAA † 1.02 (1.01 to 1.04) 0.99 (0.96 to 1.01)
Rupture 13.79 (7.55 to 25.2) 10.63 (4.80 to 23.5)
General anaesthesia 3.47 (1.36 to 8.83) 1.48 (0.47 to 4.60)
Open repair 4.68 (2.69 to 8.14) 3.59 (1.69 to 7.62)
Legend: * per unit (year) increase; † per unit (mm) increase. OR: Odds Ratio
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Figure 1. Kaplan-Meier survival estimates after abdominal aortic aneurysm (AAA) repair 
compared with an age- and gender-matched general population.
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Figure 1. Kaplan-Meier survival estimates after abdominal aortic aneurysm (AAA) 
repair compared with an age- and gender-matched general population. 
 
 
 
 
  
Figure 2. Estimated proportion of deaths beyond 30 days of abdominal aortic aneurysm 
(AAA) repair.
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Figure 2. Estimated proportion of deaths beyon  30 days of ab inal aortic aneurysm 
(AAA) repair. 
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Late cardiovascular and cancer-related mortality
During follow-up, there were 55 (35%) cardiovascular deaths. Only age (HR, 1.08 
per year increase; 95% CI, 1.04-1.13) was identified as an independent predictor 
of cardiovascular death after AAA surgery. Cancer-related deaths occurred in 46 
patients (29%). Lung cancer was the most common type (22 of 46), followed by 
neoplasms of the digestive tract (11 of 46). Age (HR, 1.05 per year increase; 95% 
CI, 1.01-1.09) and prior history of cancer (HR, 5.06; 95% CI, 2.73-9.38) were in-
dependent predictors of cancer-related death. When patients with a prior history of 
cancer were excluded, there was no difference in cancer-related mortality between 
endovascular and open surgery patients (4.6% vs 5.6%, respectively; P = .83)
AAA-related late mortality
After 30 days, six (1.1%) deaths were coded as being AAA related (Table 4). 
Three of these occurred in the intact AAA group (0.7%), and three occurred in the 
ruptured AAA group (3.0%; P = .042). Only one of these six events was coded 
as a direct consequence of rupture, which was a patient on postoperative day 34 
after EVAR for ruptured AAA. One death in the intact AAA group and two deaths 
in the ruptured AAA group occurred within 3 months of operation, which suggests 
a possible association with the primary event. There was no difference in AAA-
related late mortality in patients undergoing open repair (2 deaths of 182 30-day 
survivors [1.1%]) or EVAR (4 deaths of 370 [1.1%]; P = .951).
Other causes of death
For the remaining 32% of patients, causes of death were diverse and not easily 
grouped. The most common alternative causes were infection, respiratory failure, 
and dementia.
DIsCUssIOn
Determining the vital prognosis of patients after AAA repair is paramount for 
selection of patients and informed consent. In the presented results, it is clear 
that AAA patients undergoing repair have a worse vital prognosis compared with 
the age- and gender-matched population. Interestingly, the predominant causes 
of death beyond 30 days are cardiovascular and cancer related, in similar propor-
tions. The results also suggest that life expectancy after ruptured AAA is similar 
to that of those treated electively, once a patient endures the critical periopera-
tive period. Last, our findings confirm the early survival benefit of EVAR (in both 
ruptured and intact patients), which is lost at long term.
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Comparison of overall survival to previous literature
The benchmark randomized studies and large observational studies comparing 
EVAR and open surgery have shown us that the survival of AAA patients after 
repair is worse than survival of the age- and gender-matched background popula-
tion. In a recent meta-analysis including four large randomized trials and data 
from the Medicare and Swedvasc databases, Stather et al reported a 14% to 15% 
mortality at 2 years and 33% to 34% mortality at 4 years or more for elective AAA 
repair.1 In a large Swedvasc-based publication on long-term survival after AAA 
repair spanning 1987 to 2005, Mani et al have reported a 69% and 42% crude 
5-year survival after intact and ruptured AAA repair.7 The estimated survival in our 
series was 65% at 5 years for intact AAAs and 41% for ruptured AAAs. Although 
these estimates appear relatively similar, they may not be entirely comparable 
populations; it is likely that before EVAR was generalized, patients with less physi-
ologic reserve (elderly or higher risk patients) were not offered treatment. In our 
study, the proportion of EVAR patients is much greater.
Cardiovascular mortality shift
Contemporary epidemiologic studies have shown that life expectancy continues to 
increase and that there is a proportional trend toward a decrease in cardiovascular 
deaths in the overall population.10 Although aortic aneurysmal disease typically 
Table 4. AAA-related late mortality
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home
3 Male 73 90 Sequelae of complications of surgical 
and medical care (T98.3), Embolism 
or thrombosis of arteries of the lower 
extremities (I74.3)
Open Rupture Nursing 
home
4 Male 75 147 Sequelae of complications of surgical and 
medical care (T98.3), Atherosclerosis of the 
aorta (I70.0)
Open Rupture Nursing 
home
5 Male 62 223 Sequelae of complications of surgical and 
medical care (T98.3), Sepsis (A41.9)
EVAR Intact Nursing 
home
6 Male 71 772 Vascular graft infection (T82.7) EVAR Intact Hospital
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coexists with atherosclerosis,4 the proportion of our patients dying of any cardio-
vascular cause was relatively low (35%). A historical study of 1112 AAA patients 
operated on between 1970 and 1975 reported cardiovascular-related deaths in 
more than two-thirds of patients, a proportion much greater than observed in this 
study.11 In a more contemporary series, dating from 1999 to 2004, Brown et al 
reported 256 cardiovascular deaths of 524 deaths in patients randomized for the 
EVAR 1 trial during 5.5 years.12 This corresponds to 49% cardiovascular mortality, 
a proportion much greater than we observed. The same group reported 46 (32%) 
fatal myocardial infarctions or strokes in 145 deaths of patients randomized to 
EVAR for the EVAR 2 trial and observed for 2 to 8 years.13 These results suggest 
a greater contribution of cardiovascular causes for death in these trial popula-
tions compared with the cohort of our study. The Dutch Randomized Endovascular 
Aneurysm Management (DREAM) trial reported cardiovascular deaths in 32 of 106 
(30.1%), a proportion closer to the one found in this study.14 These disparities 
may be explained by geographic differences and recent evolution in secondary 
prevention for this population, particularly with the generalized use of antiplatelet 
and statin therapy. Although we could not obtain exact figures on the proportion of 
patients receiving appropriate secondary prevention, it is likely that most received 
lifelong antiplatelet and statin therapy as part of our local protocol. Naturally, both 
the DREAM and EVAR 1 trials included only patients considered fit for prophylactic 
open repair and do not reflect the real-life population of AAA patients included in 
the present study.
Cancer-related mortality in AAA patients
Cancer-related mortality is an important cause of mortality for AAA patients, 
responsible for almost one-third of deaths in our population and second only to 
cardiovascular disease. If coronary ischemic disease, stroke, and peripheral arte-
rial disease were considered separately, malignant disease would be the most 
frequent cause of death by a large margin. Aside from age, only a prior history 
of cancer was a strong predictor of overall death, increasing the risk by nearly 
threefold, and of cancer-related death, increasing the risk by fivefold. This sug-
gests that a prior history of cancer has a strong impact on the overall survival 
of AAA patients and may need to be considered in the decision process for elec-
tive treatment. Despite an apparent decrease in incidence of cancer in Western 
populations,15 this pathologic process has a marked impact on the prognosis of 
patients with AAA.
Cancer-related mortality was similar between EVAR and open surgery patients. 
This remained true after exclusion of patients without a prior history of cancer, 
suggesting that the effect of cumulative radiation of a typical post-EVAR surveil-
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lance protocol did not result in an increase in incidence of cancer during the 
study period. We cannot conclude that repeated radiation exposure resulting 
from postoperative surveillance has no impact on survival at long term because 
stochastic effects of exposure may become clinically evident only many years 
later. However, the relatively limited life expectancy of AAA patients is likely to 
obscure possible carcinogenic effects of ionizing radiation.
AAA-related deaths
Previous publications suggest a yearly risk of AAA-related death of 0.5% to 1%.1 
In a publication by Wyss et al,16 the authors even suggest that these are respon-
sible for the midterm survival catch-up effect of endovascular vs open repair, in a 
way canceling the early survival benefit of EVAR. The proportion of patients dying 
of an AAA-related cause is smaller in this study, however. This may be explained 
by selection of patients or by the time period involved (improved planning, proce-
dural skills, and device technology). Interestingly, infection was the primary event 
in the majority of AAA-related deaths, a matter that deserves consideration in 
the future. We could not determine if patients suffering from graft infection could 
be at higher risk because of sterility breach or operation outside the operation 
theater (in an angiography suite), but this could be a possible explanation for late 
infections.
Because of the paucity of events and the chance of misinterpretation (poten-
tially leading to both underestimation and overestimation), data on AAA-related 
deaths must be interpreted with special care and in light of the aforementioned 
intrinsic limitation.
Impact of rupture on outcome for AAA patients
The timing of surgery had a strong impact on early survival after AAA repair, with 
ruptured AAA patients having an expected 10-fold increase in mortality. More 
important, timing had no influence on late mortality, as illustrated by the paral-
lel evolution of the survival curves beyond 30 days. This similarity in long-term 
prognosis may seem counterintuitive, especially considering that the intact AAA 
group had a higher incidence of coronary disease, diabetes, and peripheral arte-
rial disease at baseline in our study. However, it confirms the similar long-term 
survival expectancy between intact and ruptured AAA patients observed by Mani 
et al.7 This interesting finding suggests that an increment in perioperative survival 
for ruptured AAA patients is the most influential attitude for improving vital prog-
nosis of AAA patients.
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Impact of treatment alternatives on survival
The choice of treatment (endovascular vs open) had a strong impact on 30-day 
outcome, as already demonstrated extensively in the literature.1 Specifically, open 
repair was associated with a 3.6-fold increased mortality risk irrespective of pre-
sentation. However, the type of repair had no influence on overall or AAA-related 
late mortality. Although endovascular patients are known to require a higher 
number of secondary interventions and to have a persistent (yet small) risk of 
late ruptures, these appear to have no important influence on survival expectancy. 
There were six AAA-related deaths in our series. Four of these were after endo-
vascular repair, of which three had septic complications, suggesting endograft 
infection to be the predominant cause of AAA-related death after endovascular 
repair. These results challenge the suggestion by Wyss et al that postimplantation 
ruptures were mainly responsible for the convergence of survival expectancy be-
tween open repair and EVAR observed in the EVAR 1 trial.16 Globally, however, our 
results show no long-term prognostic difference between open and endovascular 
repair, which supports a previous publication by Schermerhorn et al.17
Limitations
There are limitations to consider in this study. First, this is a retrospective study 
of a single institution and therefore subject to selection and reporting bias. Also, 
postmortem examinations are not routinely done in the Netherlands, limiting the 
diagnostic acuity of codification. This may be especially concerning in the case of 
AAA-related deaths because of the paucity of events and the chance of misinter-
pretation. We are unable to determine the proportion of patients in the study in 
whom autopsies were performed. The causes of death reported, however, were 
obtained through the Central Bureau of Statistics, had an availability of 100%, and 
represent the most accurate way available to acquire information on mortality. The 
Netherlands has a strict and sustained policy of rigor in reporting causes of death. 
Reliability of cause of death coding in the Netherlands for major causes of death 
including cancer and myocardial infarction has been investigated by Harteloh et al 
and was found to be higher than 90% for the period of this study.18 These authors 
concluded that accuracy was especially high for cardiovascular causes. In light of 
this, overall survival data were used as primary end points (hard end points), and 
causes of death were considered secondary end points (soft end points). Careful 
interpretation of the cause of death data is required, taking into account the 
degree of uncertainty present.
Finally, the study’s generalizability may be compromised by the predominantly 
western European origin of included patients, by the level of secondary preven-
tion and incidence of cancer observed in the study setting, and by the local 
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expertise in aneurysm treatment. Genetic and environmental modifications may 
result in different outcome for AAA patients.
Conclusions
The results of this study suggest a trend toward improved overall and cardiovas-
cular-related survival after AAA repair compared with historical series, with ma-
lignant disease assuming growing preponderance in the long term. Endovascular 
repair reduced 30-day mortality by threefold, but no survival benefit or increased 
mortality was observed in the long term. After the early postoperative period, the 
prognosis of patients after ruptured AAA is favorable and similar to that observed 
after intact AAA repair.
On the basis of these observations, an increased awareness for malignant 
disease in this specific population is necessary. Also, efforts should focus on 
improving perioperative mortality for ruptured AAA.
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ABsTRACT
Objective
Bowel ischemia is a rare but devastating complication following abdominal aortic 
aneurysm (AAA) repair. Its rarity has prohibited extensive risk factor analysis, 
particularly since the widespread adoption of endovascular repair (EVAR). There-
fore, the purpose of this study was to assess the incidence of postoperative bowel 
ischemia following AAA repair in the endovascular era, and identify risk factors for 
its occurrence.
Methods
All patients undergoing AAA repair, either intact or ruptured, in the Vascular Study 
Group of New England between January 2003 and November 2014 were included. 
We compared patients with postoperative bowel ischemia to those without, and 
stratified by indication (intact and ruptured) and treatment approach (open repair 
and EVAR). Criteria for diagnosis were endoscopic or clinical evidence of ischemia, 
including bloody stools in patients who died before diagnostic procedures were 
performed. Independent predictors of postoperative bowel ischemia were estab-
lished using multivariable logistic regression analysis.
Results
A total of 7312 patients were included, with 6668 intact (67.0% EVAR), and 644 
ruptured AAA repairs (31.5% EVAR). The incidence of bowel ischemia following 
intact repair was 1.6% (open repair: 3.6%, EVAR: 0.6%), and 15.2% following 
ruptured repair (open repair: 19.3%, EVAR: 6.4%). Ruptured AAA was the most 
important determinant of postoperative bowel ischemia (OR:6.4, 95%CI:4.5 – 
9.0), followed by open repair (OR:2.9, 95%CI:1.8 – 4.7). Additional predictive 
patient factors were advanced age (OR:1.4 per 10 years, 95%CI:1.1 – 1.7), 
female gender (OR:1.6, 95%CI:1.1 – 2.2), hypertension (OR:1.8, 95%CI:1.1 – 
3.0), heart failure (OR:1.8, 95%CI:1.2 – 2.8), and current smoking (OR:1.5, 
95%CI:1.1 – 2.1). Other risk factors included unilateral interruption of the hypo-
gastric artery (OR:1.7, 95%CI:1.0 – 2.8), prolonged operative time (OR:1.2 per 
60 min. increase, 95%CI:1.1 – 1.3), blood loss >1L (OR:2.0, 95%CI:1.3 – 3.0), 
and a distal anastomosis to the femoral artery (OR:1.7, 95%CI:1.1 – 2.7). Bowel 
ischemia patients had a significantly higher perioperative mortality after both in-
tact (open repair: 20.5% vs. 1.9%, P<.001; EVAR: 34.6% vs. 0.9%, P<.001), as 
well ruptured AAA repair (open repair: 48.2% vs. 25.6%, P<.001; EVAR: 30.8% 
vs. 21.1%, P<.001).
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Conclusion
This study underlines that although bowel ischemia following AAA repair is rare, 
the associated outcomes are very poor. The cause of postoperative bowel ischemia 
is multifactorial in nature, and can be attributed to patient factors, as well as 
operative characteristics. These data should be considered during pre-operative 
risk assessment, and optimization of both patient and procedure in an effort to 
reduce the risk of postoperative bowel ischemia.
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InTRODUCTIOn
Bowel ischemia is a well-known complication following abdominal aortic aneurysm 
(AAA) repair. After elective AAA surgery the occurrence of bowel ischemia is rare, 
with a reported incidence of 1-3% for open repair and 0.5-3% for endovascular 
repair (EVAR).1-9 Yet the importance of postoperative bowel ischemia should not be 
underestimated, as the associated perioperative mortality has been reported to be 
as high as 50%.2, 9 Furthermore, the incidence of bowel ischemia is substantially 
higher in patients undergoing repair of a ruptured AAA, with similar increases in 
resulting mortality.1, 9-11
Previous studies have identified several risk factors, including rupture, age, 
renal insufficiency, operative time, (micro) embolizations in supplying vessels, 
and proximal clamp location during open repair.2, 9, 12, 13 However, the rarity of 
postoperative bowel ischemia has prohibited extensive risk factor analysis, par-
ticularly among EVAR patients. Aside from limited evidence, the role of several 
other factors that have previously been implicated remains disputed. While some 
studies determined that hypogastric artery interruption –either through ligation/
occlusion during open repair or embolization during EVAR– is an innocuous pro-
cedure,4, 14-16 other studies determined that disruption of hypogastric blood flow 
is associated with ischemic complications, including bowel ischemia.2, 5, 12, 17-19 
There is also conflicting evidence on the benefits of EVAR compared to open 
repair. Perry et al. determined that EVAR was associated with significantly lower 
bowel ischemia rates.13 Becquemin et al., however, reported no difference in the 
risk of bowel ischemia between open repair and EVAR patients, and concluded 
that other factors such as rupture and operative time are more important predic-
tors.9
The primary aim of this study was to assess the incidence of postoperative 
bowel ischemia following AAA repair in the endovascular era, and identify overall 
and procedure-specific risk factors for its occurrence. As a secondary aim, we 
sought out to determine the impact of bowel ischemia on the perioperative 
prognosis.
METHODs
For this study, we used the Vascular Study Group of New England (VSGNE) data-
base. The Vascular Study Group of New England is a voluntary, cooperative group 
of clinicians, hospital administrators, and research personnel from 30 academic 
and non-academic centers, who prospectively gather data for 12 commonly per-
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formed vascular procedures, including AAA repair. The group strives to improve 
quality, safety, effectiveness, and costs of caring for patients with vascular disease 
through monitoring and evaluation of 140 detailed patient demographic, opera-
tive, and clinical outcome variables. Trained nurses or clinical data abstractors 
enter the data in the registry, and surgeons are responsible for the documentation 
of operative details and intraoperative complications. Researchers utilizing the 
VSGNE database are blinded to patient, surgeon, and hospital identifiers. The data 
are validated through audits of discharge claims from each of the participating 
institutions.20 More details on this regional registry can be found at http://www.
vsgne.org. The institutional review board of Beth Israel Deaconess Medical Center 
approved this study and patient consent was waived, due to the de-identified 
nature of the data.
All patients undergoing AAA repair, either intact or ruptured, between January 
2003 and November 2014 were included. Criteria for the diagnosis of bowel isch-
emia were either colonoscopic evidence of ischemia, bloody stools in a patient 
who died before colonoscopy or laparotomy could be performed, or a clinical 
diagnosis of bowel ischemia treated with medical management only, as defined 
by the Vascular Quality Initiative.
Patients with and without postoperative bowel ischemia were compared on 
baseline and intraoperative characteristics, as well as postoperative outcomes. 
Baseline characteristics included demographics, comorbidities, and maximal an-
eurysm diameter. Heart failure was defined as any documented congestive heart 
failure. Intraoperative characteristics included operative time, blood loss, (un)
intentional hypogastric artery coverage by the endograft, and interruption of a 
hypogastric artery, because of ligation/occlusion during open repair or emboliza-
tion during EVAR. Additional procedure-specific variables were evaluated, which 
included concomitant procedures, proximal clamp location, type of graft (tube vs. 
bifurcation), and inferior mesenteric artery (IMA) management for open repair, 
and concomitant procedures, arterial injury, and endoleak at completion for EVAR.
Postoperative outcomes included 30-day mortality and in-hospital adverse 
outcomes, including renal deterioration, leg ischemia, wound complication, myo-
cardial infarction, congestive heart failure, respiratory complications, >3 units 
of transfusion, return to the OR, (prolonged length of) stay in the intensive care 
unit (ICU), and prolonged length of postoperative hospital stay. Deterioration of 
renal function was defined as an increase in postoperative creatinine >0.5mg 
per dl and/or need for dialysis (peritoneal dialysis, hemodialysis, or hemofil-
tration). Leg ischemia was considered in case of loss of a previously palpable 
pulse, previously measurable Doppler signals, decrease in the ankle-brachial 
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index greater than .15, blue toe, or tissue loss. Wound complications ranged 
between a superficial wound separation or infection, and return to the operat-
ing room. Myocardial infarction was considered when one of the following was 
documented: isolated troponin elevation, electrocardiogram change, or clinical 
evidence of myocardial infarction. Congestive heart failure was defined as a new 
onset of pulmonary edema requiring transfer or treatment in an intensive care 
unit. Respiratory complications included pneumonia (lobar infiltrate on chest 
radiography and pure growth of recognized pathogen), or need for reintubation 
after initial weaning from the ventilator. Prolonged length of stay was defined as 
longer than 7 days postoperatively for open repair and 2 days for EVAR, in accor-
dance with the Center for Medicare and Medicaid Services clinical benchmarks.8 
Prolonged ICU length of stay for open repair was considered when ICU stay was 
longer than 48 hours following open repair.
statistical analysis
Comparisons between those with and those without postoperative bowel ischemia 
were performed using Pearson’s χ2 and Fisher’s exact testing for categorical vari-
ables, and student t-testing and Mann-Whitney U test for continuous data, where 
appropriate. Analyses were stratified by indication for the procedure (intact and 
ruptured) and treatment approach (open repair and EVAR). Independent predic-
tors of postoperative bowel ischemia were established using multivariable logistic 
regression analysis. Individual factors were first tested by univariate analysis. 
Variables with P-value ≤ .1 were subsequently entered into the multivariable mod-
el, after which the final model was obtained using stepwise backward elimination 
(exit P > .05). EVAR patients were assigned a separate category for open repair 
specific procedure characteristics, and vice versa, to avoid exclusion of patients 
when including procedure-specific variables into the multivariable model. All tests 
were two-sided and significance was considered when p-value <0.05. Statistical 
analysis was performed using SPSS Statistics 21 (IBM Inc., Chicago, IL).
REsULTs
A total of 7389 patients were identified, of which 77 (1.0%) were excluded be-
cause of missing data on bowel ischemia occurrence. The remaining 7312 patients 
(intact 91.2%, rupture 8.8%) were included, with 4675 (63.9%) undergoing EVAR 
and 2637 (36.1%) undergoing open repair. Among open repairs, 441 (16.7%) 
were performed for ruptured AAA, and 203 (4.3%) patients underwent EVAR for 
rupture. Bowel ischemia was diagnosed in 202 (2.8%) patients, with 91 (1.2%) 
229
Bowel ischemia following AAA repair
12
requiring surgical treatment. The incidence of bowel ischemia was significantly 
higher following open repair compared to EVAR (6.2% vs. 0.8%, P<.001). After 
stratification by indication, this difference remained for both intact (3.6% vs. 
0.6%, P<.001), and ruptured AAA repair (19.3% vs. 6.4%, P<.001).
Baseline characteristics
Baseline characteristics are detailed in Table 1. Among intact open repair patients, 
those with postoperative bowel ischemia were significantly older than those with-
out (73.1 vs. 70.0 years, respectively, P<.001), while a trend was observed for 
intact EVAR (77.2 vs. 74.0, P=.054). Patients with bowel ischemia following intact 
AAA repair more often had hypertension (Open: 93.6% vs. 82.8%, P=.012; EVAR: 
100% vs. 84.9%, P=.025), heart failure (Open: 16.7% vs. 5.8%, P<.001; EVAR: 
26.9% vs. 10.9%, P=.009), and were more frequently on dialysis preoperatively 
(Open: 2.6% vs. 0.5%, P=.003; EVAR: 7.7% vs. 0.7%, P<.001). Patients with 
bowel ischemia treated with EVAR for intact aneurysms also had increased rates 
of coronary artery disease (61.5% vs. 33.4%, P=.002). Finally, among ruptured 
open repair patients, COPD was more frequently present in those with postopera-
tive bowel ischemia (48.8% vs. 37.1%, P=.048).
Intraoperative characteristics
For both intact and ruptured open repair, operative time was significantly longer 
among patients with postoperative bowel ischemia (Intact: 261 vs. 220 minutes, 
P=.001; Rupture: 227 vs. 199 minutes, P=.011, respectively, Table 2a). Similarly, 
blood loss exceeding 1L (Intact: 67.9% vs. 53.5%, P=.012; Rupture: 96.4% vs. 
83.9%, P=.001), and intraoperative blood transfusion (Intact: 49.4% vs. 29.3%, 
P<.001; Rupture 95.3% vs. 85.9%, P=.016) occurred more frequently among 
those with postoperative bowel ischemia. In addition, patients with bowel ischemia 
more frequently had the graft anastomosed to the femoral artery (Intact: 25.6% 
vs. 14.5%, P=.049; Rupture: 21.4% vs. 11.0%, P=.022). Among the intact open 
repair patients, those with postoperative bowel ischemia were more likely to have 
had the IMA reimplanted (10.3% vs. 3.6%, P=.012), and the proximal clamp 
placed above the renal arteries (45.5% vs. 32.2%, P<.001). Also, in patients 
undergoing open repair for ruptured AAA, bowel ischemia was associated with 
a higher rate of hypogastric artery ligation (12.0% vs. 5.2%, P=.036), although 
this relation could not be established for bilateral hypogastric ligation (1.2% vs. 
4.0%).
Similar to open repair, intact EVAR patients with postoperative bowel ischemia 
had a longer operative time (255 min. vs. 158 min., P=.003, Table 2b), exten-
sive blood loss (15.4% vs. 2.4%, P=.003), and intraoperative blood transfusion 
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(30.8% vs. 6.0%, P<.001) compared to those without bowel ischemia. In ad-
dition, arterial injury (19.2% vs. 2.6%), and type III endoleak at completion 
(7.7% vs. 0.3%P=.004) occurred more often among those with bowel ischemia. 
Further, an iliac angioplasty or stenting procedure, and a thrombo-embolectomy 
were also more often performed in patients with postoperative bowel ischemia 
(26.9% vs. 9.9%, P=.004; 11.5% vs. 0.8%, P=.001, respectively).
Postoperative outcomes
Postoperative outcomes are listed in Table 3. Considerably higher rates of 30-day 
mortality were found in patients with postoperative bowel ischemia after open 
repair for intact aneurysms (20.5% vs. 1.9%, P<.001), intact EVAR (34.6% 
vs. 0.9%, P<.001), as well as open repair for ruptured AAA (48.2% vs. 25.6%, 
P<.001). Following EVAR for ruptured aneurysms, mortality was increased among 
patients with bowel ischemia, although significance was not achieved (30.8% vs. 
21.1%, P=.49). Bowel ischemia was also associated with various other compli-
cations, including wound-, cardiovascular-, and respiratory complications, acute 
kidney injury, leg ischemia, requirement for return to OR, and need for >3 post-
operative transfusions.
Predictors of bowel ischemia
In adjusted analysis (Table 4), surgery for a ruptured AAA proved to the most 
important determinant of postoperative bowel ischemia (OR: 6.4, 95% CI: 4.5 
– 9.0). Also, open repair was associated with a considerable higher risk of bowel 
ischemia compared to EVAR (OR 2.9, 95% CI: 1.8 – 4.7). Predictive demographic 
factors included advanced age (OR: 1.4 per 10 years, 95% CI: 1.1 – 1.7), as well 
as female gender (OR: 1.6, 95: CI: 1.1 – 2.2). Other patient factors associated 
with bowel ischemia included hypertension (OR: 1.8, 95% CI: 1.1 – 3.0), heart 
failure (OR: 1.8, 95% CI: 1.2 – 2.8), and current smoking (OR: 1.5, 95% CI: 1.1 
– 2.1). Interruption of the hypogastric artery, because of ligation/occlusion during 
open repair or embolization during EVAR, was also associated with an increased 
risk of postoperative bowel ischemia (OR: 1.7, 95% CI: 1.0 – 2.8), although this 
association could not be established for bilateral occlusion. Additional operative 
risk factors for bowel ischemia were prolonged operative time (OR: 1.2 per 60 
min. increase, 95% CI: 1.1 – 1.3), blood loss >1L (OR: 2.0, 95% CI: 1.3 – 3.0), 
and aorto-femoral artery anastomosis during open repair (OR: 1.7, 95% CI: 1.1 
– 2.7).
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DIsCUssIOn
This study demonstrates that although the incidence of bowel ischemia following 
AAA repair is low, it is associated with very poor outcomes. In addition to various 
complications, 30-day mortality was much worse in those with postoperative bowel 
ischemia, ranging between a factor of two among patients undergoing open repair 
for ruptured AAA, and a factor of 38 among those undergoing EVAR for intact AAA. 
Adjusted analysis demonstrated that repair for a ruptured AAA and open repair 
were the most dominant predictors of bowel ischemia. Other factors included 
patient factors such as age, gender, hypertension, heart failure, and smoking, as 
well as operative factors, such as prolonged operative time, and increased blood 
loss. Further, interruption of the hypogastric artery, because of ligation/occlusion 
during open repair or embolization during EVAR, and using the femoral artery for 
the distal anastomosis during open repair were also independent predictors of 
bowel ischemia.
Since the risks of bowel ischemia differ according to the indication of the AAA 
repair (intact vs. ruptured), and the operative approach (open repair vs. EVAR), 
the reported incidence varies based on the composition of the studied cohort. 
The study by Becquemin et al. with similar proportions in terms of operative 
approach and ruptures as the present study found an overall bowel ischemia rate 
of 2.9%, which is comparable to the 2.8% in this study.9 When comparing our 
results to studies conducted among open repair patients only, the incidence of 
Table 4. Independent predictors of bowel ischemia following AAA repair
Variable OR 95% CI P-value
Age (per 10 years) 1.4 1.1 – 1.7 .002
Female gender 1.6 1.1 – 2.2 .008
Hypertension 1.8 1.1 – 3.0 .015
Heart Failure 1.8 1.2 – 2.8 .008
Current smoking 1.5 1.1 – 2.1 .010
Open repair 2.9 1.8 – 4.7 <.001
Rupture 6.4 4.5 – 9.0 <.001
Hypogastric interruption
Unilateral 1.7 1.0 – 2.8 .040
Bilateral 0.7 0.2 – 2.1 .55
Procedure time (per 60 min) 1.2 1.1 – 1.3 <.001
Blood loss >1L 2.0 1.3 – 3.0 .002
Distal anastomosis
Femoral artery 1.7 1.1 – 2.7 .012
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3.6% for intact AAA is on the higher end with previous studies showing occur-
rence rates between 1-3%.1-3 This may be related to the fact that the diagnosis 
of bowel ischemia in our study could be established based on either clinical basis 
or colonoscopy, while other studies required confirmation through colonoscopy 
for all cases. For open repair of ruptured AAA, the rate of 19.3% falls well within 
the reported range of 7 – 36%.1, 9, 10, 22 Furthermore, our results for EVAR are on 
the lower end of what has previously been reported for EVAR series, with 0.6% 
vs. 0.5 – 3% for intact, and 6.4% vs. 4 – 23% for ruptured EVAR.4-8, 11
While crude analysis in the study by Becquemin et al. demonstrated that open 
repair was followed by a higher rate of bowel ischemia compared to EVAR, no 
relation was established in adjusted analysis.9 A study utilizing the Nationwide 
Inpatient Sample, however, did show that open repair was an independent risk 
factor for bowel ischemia.13 In line with the latter report, open surgery was as-
sociated with a 2.7-fold increase risk of bowel ischemia in our study. Confirming 
previous studies,9, 12 longer operative time and excessive blood loss were also 
established as predictive of bowel ischemia. As addressed previously, this risk 
should not be attributed to the duration of the procedure, but rather the techni-
cal difficulty it represents.9 Apart from operative stress, our adjusted analysis 
demonstrated that women were at a higher risk of bowel ischemia than men. 
The relation between female gender and higher risks of bowel ischemia has 
been demonstrated before,13 and is most likely due to the fact that women are 
more likely to encounter intraoperative difficulties as a result of their smaller 
vasculature.23-25 These difficulties include embolic complications, which have 
been implicated as an important cause of postoperative bowel ischemia after 
both open repair and EVAR.4, 6, 26
The role of the hypogastric arteries and their management remains disputed. 
While some studies demonstrated that interruption the hypogastric arteries, 
either because of ligation/occlusion during open repair or embolization or coiling 
during EVAR, can safely be performed,4, 14-16 others concluded that hypogastric 
artery interruption is associated with ischemic complications, including spinal, 
pelvic, and bowel ischemia.2, 5, 7, 12, 17-19 In the present study, we found that dis-
ruption of one hypogastric artery was associated with increased risks of bowel 
ischemia postoperatively. Although the relation was demonstrated for unilateral 
interventions, the relation could not be confirmed for two-sided interruption. 
This is most likely the result of the limited number of patients receiving bilateral 
hypogastric artery interruption (N=98), the rarity of bowel ischemia (N=4), and 
consequent lack of statistical power, rather than a lack of association. These 
demonstrated risks emphasize the need to assess patency of the superior mes-
enteric artery and to evaluate any history of colonic surgery that could impact 
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collateral flow in the colon. Also, these data highlight the potential benefit of 
utilizing iliac branch graft systems in those with a high a priori risk of bowel 
ischemia. Of note, coverage of the hypogastric artery by the endograft during 
EVAR –uni- or bilateral– was not associated with an increased risk of bowel 
ischemia. This is likely related to the fact that this group included a large number 
of patients that did not undergo hypogastric embolization, indicating that their 
hypogastric artery may not have been patent at the time of surgery, or that 
with a short seal zone in the distal common iliac and no hypogastric aneurysm, 
embolization was not needed and collateral circulation was maintained. Notably, 
no distinction could be made between the use of coils and plugs in this database.
Similar to previous studies,9, 12 we found that the femoral artery as the target 
for the distal anastomosis was also predictive of bowel ischemia. The choice 
for femoral anastomosis is often related to aneurysmal or occlusive disease in 
the common and/or external iliac arteries. Although the hypogastric artery is 
typically not ligated in case of aorto-femoral anastomosis, occlusive disease in 
the external iliac may limit retrograde flow into the hypogastric arteries. Pa-
tients with a femoral anastomosis also typically have a more advanced state of 
atherosclerosis generally, with the potential of (micro)embolization of dislodged 
atherothrombotic debris, atherosclerosis of the mesenteric vessels, and poor 
collateral flow through the marginal artery in case of IMA or hypogastric inter-
ruption. 4, 6, 26 Since smoking is a strong etiologic contributor to atherosclerosis, 
these factors may also explain the increased risks associated with current smok-
ing. Interestingly, Brewster et al. found that IMA ligation was the most important 
predictor for bowel ischemia following open repair.2 Yet in our study, not ligation, 
but rather reimplantation of the IMA was associated increased risks of bowel 
ischemia. Although this association was lost in multivariable analysis, our results 
indicate that IMA reimplantation is currently not standard practice, and that it is 
only performed in those at the highest risk of suffering from postoperative bowel 
ischemia.
This study has several limitations. First, as the VSGNE collects data through 
a registry, the potential exists for underreporting of data. Second, the severity 
of the bowel ischemia beyond need for surgery, and the extent of the bowel 
resection were unknown. Third, we were unable to distinguish patients with a 
clinical diagnosis of postoperative bowel ischemia from those who underwent 
endoscopic diagnostic procedures, which precluded sub- or sensitivity analy-
sis between these patients. Also, the importance of prior abdominal surgery, 
particularly previous bowel resection, has been addressed in prior studies,4, 6, 9 
but remains unclear. Unfortunately, data on prior abdominal surgery were not 
documented, precluding its consideration in the multivariable model. In addition, 
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although many operative characteristics were evaluated on their association with 
postoperative bowel ischemia, other factors, including hypogastric artery revas-
cularization and mesenteric vessel stenting, were unfortunately not documented 
in this data set. It should also be noted that the bowel ischemia was presumed 
to be in the colon, but the data set did not distinguish small bowel ischemia 
from colonic ischemia. Finally, due to the limited follow-up data, we were unable 
to determine the incidence of late laparotomy, and the impact of perioperative 
bowel ischemia on long-term survival.
In conclusion, this study underlines that although bowel ischemia following 
AAA repair is rare, the associated outcome is very poor. The cause of post-
operative bowel ischemia is multifactorial. In contrast to some previous work, 
open repair proved to be an important predictor. Other risk factors included 
age, gender, hypertension, heart failure, and factors indicative of more operative 
stress, including longer operative time, and extensive blood loss. Interruption of 
the hypogastric artery and the distal anastomosis to the femoral artery were also 
established as risk factors for bowel ischemia. These data should be considered 
during operative planning in an effort to adequately assess patient risk for bowel 
ischemia, and undertake efforts to reduce it.
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ABsTRACT
Objectives
Renal complications following repair of abdominal aortic aneurysms (AAA) have 
been associated with increased morbidity and mortality. However, limited data 
have assessed risk factors for renal complications in the endovascular era. This 
study aims to identify predictors of renal complications following endovascular 
(EVAR) and open repair.
Methods
Patients who underwent EVAR or open repair of a non-ruptured infrarenal AAA 
between 2011 and 2013 were identified in the Targeted Vascular module of the 
National Surgical Quality Improvement Project. Patients on hemodialysis preop-
eratively were excluded. Renal complications were defined as new postopera-
tive dialysis or creatinine increase greater than 2mg/dL. Patient demographics, 
comorbidities, glomerular filtration rate (GFR), operative details, and outcomes 
were compared using univariate analysis between those with and without renal 
complications. Multivariable logistic regression was utilized to identify independent 
predictors of renal complications.
Results
We identified 4503 patients who underwent elective repair of infrarenal AAA 
(EVAR: 3869, Open: 634). Renal complication occurred in 1% of patients follow-
ing EVAR and 5% of patients following open repair. There were no differences in 
comorbidities between patients with and without renal complications. A preopera-
tive GFR < 60 occurred more frequently among patients with renal complications 
(EVAR: 81% vs. 37%, P < .01; Open: 60% vs. 34%, P < .01). 30-day mortality 
was also significantly increased (EVAR: 55% vs. 1% P < .01; Open: 30% vs. 4% 
P < .01). After adjustment, renal complications were strongly associated with 30-
day mortality (Odds Ratio (OR): 38.3 95% Confidence Interval (CI): 20.4-71.9). 
Independent predictors of renal complications included: GFR < 60 (OR: 4.6, 95% 
CI: 2.4-8.7), open repair (OR: 2.6, 95% CI: 1.3-5.3), transfusion (OR: 6.1, 95% 
CI: 3.0-12.6), and prolonged operative time (OR: 3.0, 95% CI: 1.6-5.6).
Conclusion
Predictors of renal complications include elevated baseline GFR, open approach, 
transfusion, and prolonged operative time. Given the dramatic increase in mortal-
ity associated with renal complications, care should be taken to employ renal 
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protective strategies, achieve meticulous hemostasis to limit transfusions, and to 
utilize an endovascular approach when technically feasible.
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InTRODUCTIOn
Renal complications following surgery are associated with increased mortality, 
prolonged hospital length of stay, and higher healthcare costs.1-3 Following open 
repair of abdominal aortic aneurysms (AAA), both 30-day and long-term mortality 
have been strongly associated with post-operative renal complications.4 Prior work 
has shown predictors of renal complications after AAA repair include pre-operative 
kidney dysfunction and chronic obstructive pulmonary disease.4 Additional opera-
tive factors such as urgency of presentation, supra-renal clamping, and operative 
time have also been associated with renal complications.2, 4 Despite these findings, 
previous studies have included predominantly open aneurysm repairs with varying 
proximal extent of aneurysms and operative urgency. The effects of renal dysfunc-
tion on mortality in the endovascular era, and the predictors of such complications 
following endovascular repair (EVAR) remain unclear.
Therefore, this study aims to identify the rate of post-operative renal com-
plications and subsequent mortality associated with this adverse event among 
patients undergoing EVAR and open repair of intact infrarenal aneurysms in the 
endovascular era. Additionally, we intend to identify predictors of renal dysfunc-
tion among patients.
METHODs
Patients
The Targeted Vascular Module of the American College of Surgeons National Sur-
gical Quality Improvement Program (NSQIP) was utilized to identify all patients 
undergoing elective repairs for intact infrarenal AAAs from 2011-2014. Patients 
with juxtarenal, pararenal, and suprarenal AAAs were excluded to minimize the 
effect of clamp time. Additionally, those on dialysis pre-operatively were excluded 
from this analysis (n=88). The targeted NSQIP is a national clinical registry 
developed in 2011, which collects patient demographics, operative details, and 
30-day outcomes from patients undergoing surgical procedures at more than 65 
self-selected hospitals. Further information is available at www.facs.org/quality-
programs/acs-nsqip.
Variables
Patient demographics, age, and comorbid conditions were compared between 
those with and without renal complications. Smoking was defined as current to-
bacco use. Glomerular filtration rate (GFR - mL/minute per 1.73m2) was calculated 
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in accordance with the Modification of Diet in Renal Disease (MDRD) equation, 
and chronic kidney disease was identified according the Kidney Disease: Improv-
ing Global Outcomes (KDIGO) and Acute Kidney Injury Network (AKIN) Clinical 
Practice Guidelines.5-7
The operative variables compared are listed in Table 2 and include: aneurysm 
diameter, transfusion, renal revascularization, and lower extremity revascular-
ization, as defined by NSQIP. Transfusion was defined as any transfusion within 
72 hours of the initial operation. Prolonged operative time was defined as greater 
than 2 standard deviations from the mean (greater than 180 minutes for EVAR 
and greater than 360 minutes for open repair).
All outcomes measured occurred within 30-days of operation. A renal complica-
tion was defined as a creatinine increase greater than 2 mg/dL from baseline or 
new dialysis in the 30-day post-operative period, as defined by NSQIP. A pulmo-
nary complication was defined as pneumonia, failure to wean from mechanical 
ventilation within 48 hours, re-intubation, or pulmonary embolism. Prolonged 
length of stay was defined as great than 2 days following EVAR and greater than 
7 days following open repair.
statistics
All statistical analyses were performed using the SPSS statistical package (version 
21.0). Univariate analysis was stratified by EVAR or open repair, and patients with 
and without renal complications were compared using chi-square and Fisher’s ex-
act tests for categorical variables, as appropriate. The Student’s t-test and Mann-
Whitney U-test were utilized to assess continuous variables, as appropriate. All 
pre-operative variables and outcomes compared had less than 2% missing data, 
with the exception of lower extremity revascularization (10.9% missing data). 
Independent predictors of renal complications, mortality, and prolonged length of 
stay were established using multivariable logistic regression. Purposeful selection 
was utilized to select variables for inclusion.8 This included all variables with P < 
0.1 on univariate analysis as well as those variables shown to be predictive of 
the outcome of interest in previous studies. The Hosmer-Lemeshow goodness 
of fit test was used to evaluate each model. A P-value < 0.05 was considered 
significant. The institutional review board of Beth Israel Deaconess Medical Center 
approved this study and consent was waived due to the de-identified nature of 
the NSQIP database.
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REsULTs
We identified 4503 patients, 3869 of whom underwent EVAR and 634 had open 
repair. Renal complications, as defined by NSQIP, occurred in 33 patients (1%) 
following EVAR and 30 patients (5%) after open repair. Dialysis was initiated in 
22 (0.6%) patients following EVAR and 26 (4%) of patients following open repair.
Baseline Characteristics
Among those treated with EVAR, patients with renal complications were older (80 
years vs. 75 years, P = 0.01), less commonly male (67% vs. 81%, P = 0.03), 
and more commonly had a GFR < 60 (81% vs. 37%, P < .01). Among patients 
undergoing open repair, only GFR < 60 differed between patients with and without 
renal complications (60% vs. 34%, P < .01, respectively) (Table 1).
Operative Characteristics
Following EVAR, patients with renal complications had longer operative times 
(183 minutes vs. 132 minutes, P < .01), more lower extremity revascularizations 
(13% vs. 4% P < .01) and transfusions (70% vs. 10%, P < .01). There were no 
significant differences in AAA diameter or proportion of patients undergoing renal 
revascularization.
Table 1 – Baseline Demographics and Comorbidities
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Age: median (SD) 75 (8.6) 80 (9.3) 0.01 70 (9.3) 69 (10.3) 0.46
Male Gender 3121 (81%) 22 (67%) 0.03 451 (75%) 24 (80%) 0.51
White Race 3318 (87%) 27 (82%) 0.43 484 (80.1) 25 (83%) 0.67
GFR < 60 1435 (37%) 27 (81%) <.01 203 (34%) 18 (60%) <.01
Diabetes 616 (16%) 6 (18%) 0.74 693 (16%) 8 (13%) 0.53
COPD 106 (18%) 6 (20%) 0.81 796 (18%) 15 (24%) 0.23
CHF 9 (2%) 1 (3%) 0.39 67 (2%) 1 (2%) 0.96
Hypertension 493 (82%) 25 (83%) 0.81 3590 (81%) 55 (87%) 0.20
Smoking 259 (43%) 14 (47%) 0.71 1410 (32%) 26 (41%) 0.11
SD: Standard Deviation
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Following open repair, patients with renal complications had longer operative 
times (374 minutes vs. 221 minutes, P <. 01), larger AAA diameters (6.6 cm vs. 
5.8 cm, P < .01), and more lower extremity revascularizations (15% vs. 5%, P 
= 0.03). There were no differences in transfusions or proportion with concurrent 
renal revascularization (Table 2).
Outcomes
Both morbidity and mortality increased among patients with renal complications. 
Among EVAR patients, 30-day mortality was 55% in patients with renal complica-
tions compared to 1% without renal complications (P < .01). Major complications, 
including myocardial infarction (21% vs. 1%, P < .01), pulmonary complications 
(49% vs. 2%, P < .01), ischemic colitis (15% vs. 0.3%, P < .01), and lower ex-
tremity ischemia (15% vs. 1%, P < .01) were also more common among patients 
with renal complications. Median hospital stay was 8 days among patients with 
renal complications and 2 days among those without (P < .01).
Following open repair, 30-day mortality was 30% among those with renal com-
plications and 4% among those without (P < .01). Similar to EVAR, pulmonary 
complications (80% vs. 13%, P < .01), ischemic colitis (23% vs. 2%, P < .01), 
and lower extremity ischemia (17% vs. 2%, P < .01) were increased among 
patients with renal complications. The median hospital stay was 19 days among 
patients with renal complications compared to 7 days among patients without (P 
< .01) (Table 3).
Table 2 – Operative Characteristics
Outcome EVAR Open
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Operative Time: min, 
median (IQR)
132 (103-
171)
183 (130-
275)
< 
.01
221 (168-
285)
374 (220-
457)
<.01
Diameter: cm, med. 
(IQR)
5.5 (5.1-
6.0)
5.8 (5.1-
7.7)
0.15
5.8 (5.2-
6.7)
6.6 (5.8-
8.6)
<.01
Transfusion 373 (10%) 24 (72%) <.01 417 (69%) 23 (77%) 0.38
Renal Revascularization 170 (4%) 4 (12%) 0.06 25 (4%) 2 (7%) 0.50
LE Revascularization 138 (4%) 4 (13%) 0.04 39 (7%) 5 (17%) 0.04
IQR: Interquartile Range, cm: centimeters, LE: Lower Extremity
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In multivariable analysis, adjusting for patient demographics, comorbidities, 
and operative approach, renal complications were predictive of both 30-day 
mortality (Odds Ratio (OR): 38.3 95% Confidence Interval (CI): 20.4-71.9) and 
prolonged length of stay (OR: 8.3, CI: 4.2-16.4).
Table 4 – Multivariable Predictors of Renal Complications
Odds Ratio
95%
Confidence Interval
P-Value
Open Repair 2.6 1.3-5.3 <.01
GFR < 60 4.6 2.4-8.7 <.01
Transfusion 6.1 3.0-12.6 <.01
Prolonged Operative Time 3.0 1.6-5.6 <.01
Age (decade) 0.9 0.7-1.3 0.63
Female gender 1.0 0.5-1.9 0.93
CHF 0.7 0.1-5.3 0.71
COPD 1.4 0.7-2.7 0.33
Diabetes 0.9 0.4-2.0 0.73
Diameter 1.0 0.9-1.1 0.23
Renal Revascularization 1.4 0.5-3.9 0.48
Lower Extremity Revascularization 1.2 0.5-3.0 0.73
Table 3 – Univariate Outcomes
Outcome
Number (%)
EVAR Open
n
o
 R
e
n
a
l 
C
o
m
p
li
ca
ti
o
n
N
=
38
36
R
e
n
a
l 
C
o
m
p
li
ca
ti
o
n
N
=
33
P
-V
a
lu
e
n
o
 R
e
n
a
l 
C
o
m
p
li
ca
ti
o
n
 
N
=
60
4
R
e
n
a
l 
C
o
m
p
li
ca
ti
o
n
N
=
30
P
-V
a
lu
e
30-day Mortality 38 (1%) 18 (55%) <.01 23 (4%) 9 (30%) <.01
Pulmonary 
Complication 73 (2%) 16 (49%)
<.01
81 (13%) 24 (80%)
<.01
Ischemic Colitis 13 (0.3%) 5 (15%) <.01 10 (2%) 7 (23%) <.01
Lower Extremity 
Ischemia 45 (1%) 5 (15%)
<.01
11 (2%) 5 (17%)
<.01
Myocardial Infarction 46 (1%) 7 (21%) <.01 12 (2%) 1 (3%) 0.47
Re-operation 22 (1%) 1 (3%) 0.18 12 (2%) 1 (3%) 0.47
Hospital Stay: median 
(IQR) 2 days (1-3)
8 days (4-
20)
<.01
7 days (5-9)
19 days (12-
29)
<.01
IQR: Interquartile Range
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Predictors of Renal Complications
Following multivariable adjustment for only those characteristics available to 
surgeons pre-operatively, GFR < 60 (OR: 5.7, 95% CI: 3.0-10.6), AAA diameter 
(OR: 1.1, 95% CI: 1.02-1.2), and open repair (OR: 6.0, 95% CI: 3.5-10.3) were 
predictive of renal complications. When intraoperative characteristics were added 
to the same model, GFR < 60 (OR: 4.6, 95% CI: 2.4-8.7), open repair (OR: 
2.6, 95% CI: 1.3-5.3), transfusion (OR: 6.1, 95% CI: 3.0-12.6), and prolonged 
operative time (OR: 3.0, 95% CI: 1.6-5.6) were independently predictive of renal 
complications (Table 4).
DIsCUssIOn
This study found that post-operative renal complications, defined as an increase in 
creatinine of 2.0mg/dL from baseline or new dialysis, occur in 1% of elective infra-
renal EVARs and 5% of open repairs and are associated with a significant increase 
in mortality, morbidity, and prolonged length of stay compared to those patients 
without renal complications. Moreover, a baseline GFR < 60, open operative ap-
proach, transfusion, and prolonged operative time are independently predictive of 
renal complications.
The reported rates of renal complications vary in current literature. Following 
open repair, reported rates have ranged from 5-11%.2, 4, 9 Lower rates have been 
reported following EVAR, occurring in 2-7% of patients. 9-11 Our study found a 
similar rate of renal complications following open repair to that reported by Grant 
et al., in a study of 2347 consecutive repairs, (6%) but was lower than other 
prior studies.2 This variation was likely due to differences in study population and 
the definition of renal dysfunction. Our study evaluated infrarenal aneurysms 
only, with a renal complication defined by NSQIP as an increase in creatinine > 
2.0mg/dL from baseline or new onset dialysis. This differs from previous work by 
both Patel and Ellenberg, who had a less stringent definition of renal complica-
tions, defined as all those with a creatinine increase > 0.5 mg/dL, and included 
all elective open repairs including those utilizing a suprarenal clamp, which is 
known to be independently associated with increased renal complications.4, 12 
Fewer studies have directly addressed renal function following EVAR, however 
Mehta reported rates of 3-7% following EVAR among patients treated in the first 
years of EVAR utilization (1996-2000) and also included physician-made grafts 
for patients with complex anatomy, both of which likely explain the increased 
renal complication rate compared to our study.10 In a more recent study, Saratzis 
found a rate of renal complications of 19%. This rate was likely higher than 
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our work, and previous studies, due to their use of the highly sensitive KDIGO 
definition of renal dysfunction which included: increase in creatinine > 0.3mg/dL 
or well as low urine output.13
Given the infrequency of renal complications large databases are necessary to 
adequately power studies on acute kidney injury. However, a common definition 
of renal complications has not been widely utilized by any major databases 
including Vascular Quality Initiative, NSQIP, Medicare, or NIS leading to variable 
reports of such complications. The 2012 KDIGO and Acute Kidney Injury Net-
work (AKIN) guidelines define acute kidney injury as an increase in creatinine 
> 0.3mg/dL, 50% increase in creatinine from baseline, or reduction in urine 
output to less than 0.5mL/kg per hour for more than 6 hours, are the most 
widely utilized guidelines for acute kidney injury.7, 14 However, like many alterna-
tive definitions, the utility of this definition is challenged by the difficulty and 
reliability or urine collection at many institutions and the potential for fluid shifts 
among surgical patients. Nonetheless, NSQIP and other large databases would 
be improved by reporting of post-operative creatinine and GFR levels to more 
uniformly evaluate post-operative renal dysfunction.
Increased mortality among patients with renal complications following open 
AAA repair was also demonstrated in prior work.2, 4, 13, 15, 16 Our study found 30-day 
mortality rates of 30% following open repair and 55% following EVAR amongst 
patients with renal complications. These rates are similar to those reported by 
Grant et al. who found a 30-day mortality rate of 35% in their study of 2378 
open repairs. However, mortality rates among patients with renal complications 
vary tremendously in the literature and range from 9-58% following open repair. 
Much of this variation is likely due to differing definitions of renal dysfunction, 
with lower mortality rates seen in those studies that used the lower cutoff of 0.5 
mg/dL increase from baseline as their definition of renal complication. Following 
EVAR, few studies have evaluated the mortality rates among patients with renal 
complications, and additional research is warranted to confirm our findings. 
Saratzis et al. found a mortality rate of 32% following EVAR; however this study 
utilized more sensitive definition of acute kidney injury including a significantly 
lower increase of serum creatinine.5
Despite differing rates of renal complications, we found similar predictors 
of this adverse outcome compared to prior work in patients undergoing open 
repair.2, 4, 12, 16, 17 Only one previous study, from Wald et al., identified predictors 
following EVAR and open repair using the Nationwide Inpatient Sample (NIS) 
and found open repair, chronic kidney disease, and congestive heart failure to be 
associated with post-operative renal complications. However, due to limitations 
of the NIS database, the authors were unable to account for operative and 
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anatomic characteristics including transfusion, operative time, and aneurysm 
extent.16 Additionally, the NIS is considered a suboptimal dataset for evaluation 
of post-operative morbidity, as it is an administrative dataset reliant on coding, 
rather than chart review, and cannot identify events occurring after discharge. 
Finally, previous work has shown administrative databases to be inferior to 
NSQIP and chart review in identifying perioperative complications.18, 19 Following 
open repair, other authors have identified baseline kidney dysfunction, transfu-
sion, urgency, clamp location, and renal ischemia as other predictors of renal 
complications; however such studies included suprarenal and ruptured aneu-
rysms which have significantly different risks as compared to elective infrarenal 
aneurysms, and as such we elected to exclude them for this study.2, 4, 12, 16, 17
There are important clinical implications to the results in this study. Both chronic 
kidney disease and operative approach are characteristics known to the surgeon 
in the pre-operative period and should be utilized for patient education and risk 
assessment pre-operatively. Furthermore, given the risk of open repair in those 
with chronic kidney disease, surgeons should utilize an EVAR-first approach for 
patients with suitable anatomy. Additionally, in all patients, but particularly those 
with a GFR < 60, surgeons should take care to limit the volume of contrast used 
to avoid further renal deterioration and contrast nephropathy. Transfusion and 
operative time are characteristics reflective of challenging cases and may not 
be avoidable; however, given their strong association with renal complications, 
particular care to minimize blood loss and to ensure complete hemostasis at the 
closure of the case should be taken.
This study has multiple limitations, which must be noted. First, it is subject to 
generic limitations of a clinical registry including errors in coding, missing data, 
and limited variable definitions. Therefore, it is possible that other confounders 
including blood loss, clamp time, neck length, angulation, and thrombus may 
impact this study and cannot be accounted for. In the current era, open repairs 
are often more technically challenging due to poor anatomy for EVAR; however, 
in this analysis we excluded those patients with short necks (suprarenal, parare-
nal, and juxtarenal clamps). As a result the rates of renal dysfunction following 
open repair may not be reflective of all open AAA repairs. Additionally, this study 
was unable to assess the long-term effects of renal complications. This study 
was also unable to account for the volume of contrast used; however, contrast 
volume is often not known in the pre-operative period and as such does not 
assist with pre-operative risk stratification. Finally, in this study renal dysfunc-
tion is restricted to the VSGNE definition of renal dysfunction and characterized 
by a large increase in creatinine of > 2mg/dL, which neglects to include those 
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patients with less severe renal dysfunction; therefore, the effects of mild kidney 
injury and exact cause of dysfunction are unable to be evaluated.
Conclusions
Predictors of renal complications include elevated baseline GFR, open approach, 
transfusion, and prolonged operative time. Given the dramatic increase in mortal-
ity associated with renal complications, care should be taken to employ renal 
protective strategies, achieve meticulous hemostasis to limit transfusions, and to 
utilize an endovascular approach when technically feasible.
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ABsTRACT
Objective
Previous studies have found conflicting results regarding the operative risks as-
sociated with conversion to open abdominal aortic aneurysm (AAA) repair after 
failed endovascular treatment (EVAR). The purpose of this study was to assess the 
outcome of patients undergoing a conversion, and compare outcomes to standard 
open AAA repair and EVAR. Additionally, we sought out to identify factors associ-
ated with conversion.
Methods
All patients undergoing a conversion to open repair, and those undergoing 
standard EVAR and open repair between 2005 and 2013 were included from the 
National Surgical Quality Improvement Program (NSQIP). Multivariable logistic 
regression analysis was used to identify factors associated with conversion, and 
to assess independent perioperative risks associated with conversion compared 
to standard AAA repair. Subanalysis for factors associated with conversion was 
performed among patients additionally included in the more detailed Targeted 
Vascular Module of the NSQIP.
Results
A total of 32,164 patients were included, with 300 conversions, 7188 standard 
open repairs, and 24,676 EVARs. Conversion to open repair was associated with a 
significantly higher 30-day mortality than standard open repair (10.0% vs. 4.2%, 
P<.001, OR: 2.4, 95% CI: 1.6 – 3.6), and EVAR (10.0% vs. 1.7%, P<.001, OR: 
7.2, 95% CI: 4.8 – 10.9). Conversion surgery was additionally followed by an in-
creased occurrence of any complication (OR: 1.5, 95% CI: 1.2 – 1.9 (open); OR: 
7.8, 95% CI: 6.1 – 9.9 (EVAR)). Factors associated with conversion were young 
age (OR: 1.2 per 10 years decrease, 95% CI: 1.1 – 1.4), female gender (OR: 1.5, 
95% CI: 1.2 – 2.0), and non-white race (OR: 1.8, 95% CI: 1.3 – 2.6). Conversely, 
BMI > 30 was negatively associated with (OR: 0.7, 95% CI: 0.5 – 0.9). Among 
anatomic characteristics captured in the Targeted Vascular data set (N=4555), 
aneurysm large diameter demonstrated to be strongly associated with conversion 
(OR: 1.1 per 1 cm increase, 95% CI: 1.03 – 1.1).
Conclusion
Conversion to open repair after failed EVAR is associated with substantially in-
creased perioperative morbidity and mortality compared to standard AAA repair. 
Factors associated with conversion are large diameter of the aneurysm, young 
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age, female gender, and non-white race, while obesity is inversely related to 
conversion surgery.
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InTRODUCTIOn
Owing to the perioperative benefits over open repair,1-4 the use of endovascular 
treatment modalities (EVAR) for abdominal aortic aneurysm (AAA) repair has 
rapidly increased since its introduction.5-7 EVAR is currently the primary mode 
of treatment for AAA, with over 80% of elective cases being performed through 
endovascular repair.8-10 Although rare, a conversion to open repair is sometimes 
required.11, 12 A conversion can either be performed acutely, necessitated by intra-
operative complications during EVAR, such as access-related problems and errors 
in endograft deployment,13-16 or as a late reintervention following graft migration, 
persistent endoleak, graft thrombosis, or infection.15-19
Due to the rarity of the procedure, evidence on the frequency and prognostic 
implications of performing a conversion is largely limited to small retrospective 
series from mostly single-institution experiences.13, 16, 20-24 These studies did show 
that conversion surgery was associated with substantial perioperative mortality, 
averaging 12% and 10% after acute and late conversion respectively.11 Con-
sequently, many of these studies concluded that having to convert from EVAR 
to open repair is associated with worse outcomes than either standard open 
AAA repair or EVAR. Yet in the largest study to date using the National Quality 
Improvement Program (NSQIP) from 2005 to 2008 with 72 conversion patients, 
Newton et al. found no differences in perioperative outcomes between patients 
undergoing a conversion and those undergoing standard open AAA repair.25 
The purpose of this study was to assess the outcome of patients undergoing 
conversion, and compare outcomes to standard open AAA repair and EVAR. 
Additionally, we aim to identify factors associated with conversion to open AAA 
repair using the regular NSQIP, as well as the newly available Targeted Vascular 
module.
METHODs
Data source
For this study, we used the American College of Surgeons National Surgical Quality 
Improvement Program (ACS NSQIP) database. The NSQIP is a quality improve-
ment initiative of the American College of Surgeons, and is designed to provide 
robust, reliable and risk-adjusted surgical outcomes intended to identify elements 
in current healthcare practice for quality improvement purposes. Dedicated surgi-
cal clinical nurse reviewers at each hospital prospectively collect preoperative and 
procedural risk factors, as well as 30-day postoperative outcomes according to 
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standardized definitions.26, 27 The validity of the ACS NSQIP has been confirmed 
previously. The database contains de-identified data only without any protected 
health information. Therefore, Institutional Review Board approval and patient 
consent were waived. In order to identify anatomy-related factors associated with 
conversion, we performed a subanalysis among patients who are also captured 
in the Targeted Vascular data set of the ACS NSQIP. The Targeted Vascular data 
set is a newly available module, which includes additional disease and procedure 
specific characteristics, and procedure-related outcomes chosen by vascular sur-
geons. Additional information on the ACS NSQIP and the Targeted Vascular data 
set are available at www.acsnsqip.org.
Patients undergoing a conversion to open repair between January 2005 and 
December 2013 were included in the study. Procedures were identified using Cur-
rent Procedural Terminology coding (CPT). CPT codes for conversion to open AAA 
repair are: 34830, 3481, and 34832, which respectively correspond to open AAA 
repair using tube, aortobiiliac, and aortobifemoral prostheses after unsuccessful 
EVAR. Since these same CPT codes are used for both acute and late conver-
sions, we were unable to distinguish between conversions performed immediately 
after failed EVAR and those performed as late reinterventions.28 Therefore, we 
considered our cohort to comprise of both acute and late conversions. The CPT 
codes for conversion also encompass the attempted EVAR in case of an acute 
conversion, which precluded us from determining whether the conversion was 
immediate or not based on the time between the EVAR and conversion. Standard 
EVAR (CPT: 34800, 34802, 34803, 34804, 34805), and non-ruptured open AAA 
repair (CPT: 35081, 35102) patients were also included for comparison. Cases 
with a postoperative diagnosis indicating the treatment of a ruptured aneurysm, 
as defined by the International Classification of Diseases – 9th revision (ICD-9), 
were excluded (ICD-9: 441.3).
Conversion patients were compared to open repair and EVAR patients on baseline 
and intraoperative characteristics, as well as 30-day postoperative outcomes. 
Age was considered both as a categorical variable, and as a continuous vari-
able, with 90+ coded as 90 to prevent individual patient identification. Body mass 
index (BMI) was calculated using height and weight data (kg/m2). Postoperative 
outcomes included 30-day mortality and morbidity including acute kidney injury, 
respiratory complications, wound complications, myocardial infarction, sepsis, 
septic shock, and return to the operating room. Acute kidney injury was defined 
as a rise in creatinine of >2 mg/dl from preoperative value, and/or requirement of 
hemodialysis, peritoneal dialysis, hemofiltration, hemodiafiltration, or ultrafiltra-
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tion within 30 days of the operation. A respiratory complication was defined as 
prolonged ventilator dependence (>48 hours), reintubation, or a postoperative 
pneumonia. Wound complications included superficial, deep, and organ space 
infections. Patients with systemic inflammatory response syndrome (SIRS), 
sepsis, or septic shock prior to surgery were not considered for postoperative 
sepsis and septic shock analysis. Additional anatomical characteristics assessed in 
the subanalysis among patients captured in the Targeted Vascular data set were 
aneurysm diameter, and distal aneurysm extent. In order to identify differences 
in postoperative morbidity aside from death, 30-day mortality was not included in 
the any complication measure.
statistical analyses
Categorical variables are presented as counts and percentages. Normally distrib-
uted continuous variables are presented as mean ± standard deviation and non-
parametric distributions as median and interquartile range. Differences between 
treatment groups were assessed using χ2 and Fisher’s exact testing for categorical 
variables and Student’s t-test, and Mann Whitney U test for continuous variables, 
where appropriate. Trend analyses were performed with the Cochran-Armitage 
test for trend. Independent associations between conversion and adverse postop-
erative outcomes were established using multivariable logistic regression analysis. 
Baseline characteristics were univariately tested, and variables with a P-value ≤ 
.1 were subsequently entered into the multivariable model. Separate models were 
constructed for 30-day mortality, acute kidney injury, and the occurrence of any 
complication. To identify factors associated with conversion, differences in de-
mographics, comorbidities, and aneurysm diameter were assessed using logistic 
regression analysis. Similar to the outcomes analysis, variables with a P-value ≤ 
.1 were added to the multivariable model. To avoid over-fitting in the subanalysis 
among patients captured in the Targeted Vascular data set (N=4555), a separate 
model was constructed. All tests were two-sided and significance was considered 
when P-value <0.05. Statistical analysis was performed using the SPSS Statistics 
21 (IBM Inc., Chicago, IL).
REsULTs
A total of 32,164 patients were included, with 300 patients who underwent a 
conversion to open repair, 7188 open repairs, and 24,676 EVARs. During the study 
period, the conversion rate was 1.2 per 100 EVAR cases (range: 0.8 – 1.5), with 
no apparent upward or downward trend over time (P=0.836).
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Baseline characteristics
Baseline characteristics are listed in Table 1. Compared to open repair patients, 
those undergoing a conversion were older (72.6 vs. 70.5, P<.001), but were 
comparable in terms of gender (P=.801), and race (P=.072). Similarly, no dif-
ferences were found in comorbidities. However, those undergoing a conversion 
were less frequently current smokers than standard open repair patients (32.7% 
vs. 43.8%, P<.001), and were more often classified as a class 4 or greater on 
the American Association of Anesthesiologists (ASA) physical status classification 
system (37.1% vs. 29.3%, P=.004).
When comparing the conversions to EVAR patients, we found that those under-
going conversion were younger (72.6 vs. 74.0 years, P=006), more often female 
(25.8% vs. 18.6%, P=.002), and more frequently of non-white race (12.0% vs. 
6.8%%, P=.002). In addition, the conversion patients were less likely to have 
diabetes (11.0% vs. 15.7%, P=.026) or obesity (24.6% vs. 31.4%, P=.012). 
Also, conversion patients more often had a ASA class of 4 or greater (37.1% vs. 
22.6%, P<.001).
Intraoperative differences
Operative details are listed in Table 2. Conversion was associated with a sig-
nificantly longer operative time compared to standard open repair (275 min. vs. 
232 min, P<.001). In addition, conversion cases were more often classified as 
emergent compared to standard open repairs (10.0% vs. 6.4%, P=.013), and 
EVARs (3.9%, P<.001). There was no difference in proportion of cases performed 
by vascular surgeons with the vast majority for conversions and standard open 
repairs (96.3% vs. 96.1%, P=.832), as well as EVARs (96.5%, P=.892) being 
performed by this specialty.
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Postoperative outcomes
Compared to standard open repair, 30-day mortality following a conversion was 
significantly higher (10.0% vs. 4.2%, P<.001, Table 3). In addition, conversion 
patients were more likely to undergo new dialysis (6.0% vs. 3.5%, P=.024), 
cardiopulmonary resuscitation (5.3% vs. 1.9%, P<.001), postoperative blood 
transfusion (42.3% vs. 31.6%, P<.001), and have a myocardial infarction (5.0% 
vs. 2.2%, P=.001).
When comparing conversion patients to those undergoing EVAR, we found 
that 30-day mortality after a conversion was substantially higher (10.0% vs. 
1.7%, P<.001). Similarly, conversion to open repair was associated with a 
higher rate of various adverse events, including acute kidney injury (7.3% vs. 
1.4%, P<.001), respiratory complications (16.3% vs. 2.2%, P<.001), cardiac 
complications (8.7% vs. 1.4%, P<.001), wound complications (4.7% vs. 2.3%, 
P=.008), return to the operating room (9.3% vs. 4.5%, P<.001), and postop-
erative septic shock (3.7% vs. 0.6%, P<.001).
After adjustment for potential confounders, conversion to open repair proved 
to be associated with almost two-and-a-half times higher mortality risk com-
pared to standard open repair (OR: 2.4, 95% CI: 1.6 – 3.6). Conversion surgery 
was additionally associated with increased risks for the occurrence of any com-
plication (OR: 1.5, 95% CI: 1.2 – 1.9). Compared to EVAR, conversion to open 
repair was an independent predictor of 30-day mortality (OR: 7.2, 95% CI: 4.8 
– 10.9), acute kidney injury (OR: 5.6, 95% CI: 3.5 – 8.9), and any complication 
(OR: 7.8, 95% CI: 6.1 – 9.9).
Factors associated with conversion
For multivariable analysis, demographics, comorbidities, and aneurysm diameter 
were considered. In the overall cohort, young age (OR: 1.2 per 10 years decrease, 
α Odds ratio conversion vs. open repair: 2.4 (95% CI: 1.6 – 3.6); Odds ratio conversion 
vs. EVAR: 7.2 (95% CI: 4.8 – 10.9) (adjusted for: age, gender, race, hypertension, insulin 
dependent diabetes, obstructive pulmonary disease, heart failure, estimated GFR <30 ml/
min/1.73m2, preoperative dialysis, and obesity (BMI>30), emergency procedure)
β Odds ratio conversion vs. open repair: 1.3 (95% CI: 0.8 – 2.0), Odds ratio conversion 
vs. EVAR: 5.6 (95% CI: 3.5 – 8.9) (adjusted for: age, gender, race, hypertension, insulin 
dependent diabetes, obstructive pulmonary disease, heart failure, estimated GFR <30 ml/
min/1.73m2, and current smoking, emergency procedure)
γ Odds ratio conversion vs. open repair: 1.5 (95% CI: 1.2 – 1.9), Odds ratio conversion 
vs. EVAR: 7.8 (95% CI: 6.1 – 9.9) (adjusted for: age, gender, race, hypertension, insu-
lin dependent diabetes, obstructive pulmonary disease, heart failure, estimated GFR <30 
ml/min/1.73m2, preoperative dialysis, obesity (BMI>30), and current smoking, emergency 
procedure)
δ incidence of any complication excluding postoperative blood transfusion
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95% CI: 1.1 – 1.4, Table 4), female gender (OR: 1.5, 95% CI: 1.2 – 2.0), and 
non-white race (OR: 1.8, 95% CI: 1.3 – 2.6) were associated with conversion. 
Conversely, BMI over 30 had a negative association with conversion (OR: 0.7, 
95% CI: 0.5 – 0.9). For patients captured in the more detailed Targeted Vascular 
module (N=50 and N=4505, respectively for conversion and EVAR cases), ad-
ditional subanalysis was performed. Among these patients, large diameter was 
strongly associated with conversion (mean diameter: 6.8cm vs. 5.7cm, P=.001; 
OR: 1.1 per 1 cm increase, 95% CI: 1.03 – 1.1).
DIsCUssIOn
This study demonstrates that conversion to open repair is independently associ-
ated with an increased risk of mortality and other adverse outcomes during the 
postoperative period compared to standard open repair. In addition to almost a 
two-and-a-half fold increase in perioperative mortality, patients undergoing a con-
version more often suffered adverse events, such as myocardial infarction, acute 
kidney injury requiring dialysis, need for CPR, and postoperative blood transfusion. 
Multivariable analysis showed that younger age, female gender, and non-white 
race were associated with conversion surgery, while obesity was inversely related 
to conversion. Inclusion of targeted module variables established that aneurysm 
diameter is also an important determinant of conversion.
The first study assessing the outcome following a conversion from endovas-
cular to open repair was published in 1997.20 With an incidence of almost 16% 
(11.5% acute, 4.5% late), the conversion rate was substantially higher than the 
1.2% in the present study. The reduction is most likely the result of improved 
Table 4. Factors associated with conversion
Overall cohort OR 95% CI P-value
Age (per 10 year decrease) 1.2 1.1 – 1.4 .001
Female gender 1.5 1.2 – 2.0 .002
Race
non-white 1.8 1.3 – 2.6 .001
unknown 1.1 0.8 – 1.7 .531
Diabetes 0.7 0.5 – 1.0 .074
BMI >30 0.7 0.5 – 0.9 .008
Targeted Variablesα
Aneurysm diameter 1.1 1.0 – 1.1 0.002
α subanalysis of patients captured in the Targeted NSQIP (N=50 and N=4505, respectively 
for conversion and EVAR cases)
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patient selection and surgeon experience, as well as technical advances in en-
dovascular repair allowing for patients with more challenging anatomy to be 
successfully treated using endovascular treatment modalities. This is supported 
by a decline in conversion rates in more recent reports.12, 13 In the 1997 study 
by Jacobowitz et al., the perioperative mortality following conversion –acute or 
chronic– was 17%. Mortality rates in subsequent studies have ranged between 
0% and 28.5%. This variability is likely the result of the small sample sizes of 
these single-center studies.13, 16, 24, 29 A pooled data-analysis by Moulakakis et 
al. determined the perioperative mortality to be 12% and 10%, respectively for 
acute and late conversion. This is comparable to the 10% found in our study. 
Considering that this is over twice the norm for standard open AAA repair, our 
results –not surprisingly– showed that conversion surgery was associated with 
a significantly increased perioperative mortality risk compared to open repair, 
as well as EVAR. However, in the largest reported conversion cohort to date, 
which was obtained from the same database as the present study and included 
the same patients for the years 2005 to 2008, Newton et al. found no difference 
in mortality between conversion patients and those undergoing standard open 
AAA repair (4.2% vs. 3.2%, respectively). This difference in outcome appears to 
be result of a higher perioperative mortality following conversion to open repair 
in the later years of the past decade in this database. In the study by Newton 
et al., the mortality rate of 4.2% in a cohort of 72 patients corresponds to only 
3 deaths in the perioperative period. Considering the consequent susceptibility 
to sample variability, the discrepancy with the present study may simply be the 
result of an increase in sample size. This highlights the value of reexamination 
when more data are available. An actual increase in mortality over time may be 
caused by an increase in the proportion of suprarenal bare-metal stents being 
explanted due to the rise in utilization of these stents in more recent years.
In regards to factors associated with conversion, some studies found no rela-
tion between patient factors and conversion to open repair.14, 25 However, in 
the Lifeline registry, which described both acute and late conversions, it was 
found that female gender was strongly associated with conversion, in addition 
to large aneurysm diameter.7 Both of these factors were also associated with 
conversion in the present study. The relation between gender and conversion in 
the Lifeline registry was in large part driven by acute conversion rates, which 
fits with studies showing higher intraoperative complication rates among woman 
during EVAR –particularly access-related– due to complex anatomy and smaller 
artery diameters.30-32 However, subsequent studies have also determined female 
gender to be a predictor of late conversion,29 which may also be the result of 
more complex aneurysm anatomy in females, as well as more late complications 
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requiring reintervention, such as graft thrombosis.33, 34 The positive correlation 
between diameter and conversion risk may also be different for acute and late 
conversions. For acute conversions the correlation is likely to represent the 
technical difficulty of establishing adequate seal in patients with large diam-
eter aneurysms, while the larger diameter observed in late conversion patients 
is more likely the result of sac growth, which has prompted the decision for 
conversion to open repair. Cuypers et al. reported that low body weight was 
associated with higher conversion rates in a cohort consisting of both acute and 
late conversions.35 In the present study, we also found an inverse association be-
tween BMI and conversion. This may be related to a greater comorbidity burden 
and technical difficulty in obese patients with consequent higher complication 
rates. Cuypers et al. additionally showed that advanced age was a risk factor for 
conversion. In our study, however, young age was associated with an increased 
likelihood of conversion. The correlation with young age could suggest that our 
cohort consisted more of patients undergoing late conversions, as younger pa-
tients will live long enough to benefit from conversion surgery. The difference 
with the study by Cuypers et al. may therefore be related to the proportion of 
acute versus late conversions in each cohort. Similar to the explanation for the 
correlation between BMI and conversion, the association with young age may 
also be mediated by the fact that younger patients are more often deemed 
healthy enough to undergo conversion surgery compared to older patients.
This study has several limitations that should be addressed. First, since the 
data for this study were gathered through a prospective data registry, the po-
tential exists for underreporting of events. Second, as the American Medical 
Association recommends the CPT coding for conversion to be used for acute and 
late conversions,28 we assumed our cohort to consist of both. Unfortunately, 
we were unable to differentiate between conversions performed immediately 
and those performed as a late reintervention. However, multicenter studies, 
as well as meta-analysis have shown the perioperative outcomes to be similar 
between these two groups.11, 15 Third, previous studies have demonstrated that 
some older stent grafts are associated with graft migration, and other untoward 
events during follow-up. Since these grafts are no longer used, it should be 
noted that the possible inclusion of these grafts in the present study may have 
affected our results on the current conversion rate, as well as the factors as-
sociated with conversion. Also, baseline characteristics of conversion patients 
were obtained at the time of the conversion procedure. A more appropriate 
comparison would have included age and comorbidity at the time of the original 
EVAR. Unfortunately, these data were not available. Additionally, conversion to 
open repair may be an indicator of complex anatomy and more severe comorbid-
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ity. Despite adjustment for potential confounders in multivariable analysis, these 
factors may also have contributed to the poor outcome of conversion patients. 
In addition, the ACS NSQIP does not include long-term follow-up data, which 
precludes analysis on reintervention rates, late ruptures, and long-term survival. 
Finally, the anatomic-characteristics provided by the Targeted Vascular module 
were only available for a subset of our cohort. Consequently, we were unable 
to adjust for all the initially identified predictive factors in the subanalysis to 
avoid over-fitting the model. However, sensitivity analysis demonstrated that 
aneurysm diameter remained significant when adjusting for factors that were 
most predictive in the overall cohort (i.e. age, gender, non-white race, obesity).
In conclusion, this study demonstrated that conversion to open repair after 
failed EVAR is associated with substantially increased perioperative mortality, as 
well as a higher rate of complications such as myocardial infarction and need for 
dialysis. Multivariable analysis showed that in addition to large diameter of the 
aneurysm, young age, female gender, and non-white race are associated with 
conversion surgery, while obesity is inversely related to conversion.
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ABsTRACT
Objective
The association between socioeconomic status (SES), presentation and outcome 
after vascular surgery is largely unknown. This study aims to determine the influ-
ence of SES on postoperative survival and severity of disease at presentation 
among vascular surgery patients in the Dutch setting of equal access to and provi-
sion of care.
Methods
Patients undergoing surgical treatment for peripheral artery disease (PAD), ab-
dominal aortic aneurysm (AAA) or carotid artery stenosis (CS) between January 
2003 and December 2011 were retrospectively included. The association between 
SES, quantified by household income, disease severity at presentation and survival 
was studied using logistic and Cox regression analysis adjusted for demographics, 
medical and behavioral risk factors.
Results
A total of 1178 patients were included. Low income was associated with worse 
postoperative survival in the PAD cohort (n=324, HR: 1.05, 95% CI: 1.00 – 1.10, 
per 5,000 euro decrease) and AAA cohort (n=440, quadratic relation, p = .006). 
AAA patients in the lowest income quartile were more likely to present with a 
ruptured aneurysm (OR: 2.12 95% CI: 1.08 – 4.17). Lowest income quartile 
PAD patients presented more frequently with symptoms of critical limb ischemia, 
although no significant association could be established (OR: 2.02, 95% CI: 0.96 
– 4.26).
Conclusions
The increased health hazards observed in this study are caused by patient related 
factors rather than differences in medical care, considering the equality of care 
provided by the study setting. Although the exact mechanism driving the associa-
tion between SES and worse outcome remains elusive, consideration of SES as 
a risk factor in preoperative decision-making and focus on treatment of known 
SES-related behavioral and psychosocial risk factors may improve the outcome of 
patients with vascular disease.
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InTRODUCTIOn
The association between socioeconomic deprivation and poor health in the general 
population is well documented. Low socioeconomic status (SES) also negatively 
impacts the prognosis of a variety of diseases, such as colon carcinoma and pul-
monary disease, and treatment outcomes.1, 2 A limited number of studies have 
demonstrated a similar association between low SES and poor outcome for vas-
cular diseases, including stroke and critical limb ischemia, as well as for vascular 
surgery.2-5
Many of these studies have been performed in the United States, where SES-
related disparity in access to and provision of healthcare exists and is extensively 
affected by income.2, 6, 7 Consequently, the relationship between low SES and poor 
outcome is often ascribed to healthcare disparities.5, 7, 8 Alternatively, since the 
prevalence of conventional cardiovascular risk factors and poor lifestyle is higher 
in socially deprived regions, the association between SES and outcome may 
be mediated through patient factors as well.9 Due to healthcare inequality, the 
impact of SES-related patient factors on outcome remains largely undetermined.
Healthcare in the Netherlands is publicly provided and has been credited the 
most equally accessible healthcare system in the world.10, 11 Therefore, mini-
mal differences could be expected in access to and provision of care, including 
screening and access to medication, both in hospital and in primary care settings. 
Hence, as opposed to the US system, the Dutch healthcare system provides the 
opportunity to study the association between SES and outcome irrespective of 
healthcare disparities.
The objective of this study is to determine SES as a predictor for survival 
following surgical treatment for peripheral artery disease, abdominal aortic an-
eurysm and carotid artery stenosis. Additionally, we aim to assess whether SES 
is associated with severity of disease at presentation.
METHODs
Patients undergoing elective open or endovascular surgery under general or 
locoregional anesthesia for peripheral artery disease (PAD), abdominal aortic 
aneurysm (AAA) or carotid artery stenosis (CS) in the Erasmus University Medical 
Center between January 2003 and December 2011 were retrospectively included. 
Patients undergoing completely percutaneous procedures under local infiltration 
analgesia (i.e., carotid artery stenting, lower extremity angioplasty and/or stent-
ing, or percutaneous EVAR) or open surgical procedures performed under local 
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infiltration analgesia were not included in this study. Identification was done using 
operation codes and surgical reports. When a patient underwent multiple vascular 
procedures within the study period, the first operation in this period was defined 
as the index operation and survival was assessed from that moment onward. 
Baseline characteristics were obtained from the medical records and included age 
at index operation, gender, comorbidities, prior vascular interventions, smoking 
status (current, former or never), and body mass index (BMI). Patients without 
registered and/or obtainable household income (e.g. due to illegal residency) 
were excluded. Institutional approval for this study was obtained, and no informed 
consent was required according to local directives for retrospective studies. The 
study complies with the Helsinki declaration on research ethics.
Definitions
Diabetes mellitus was recorded if diabetes was mentioned in the medical history 
or if patients used insulin or oral anti-diabetics. Hypertension was defined as blood 
pressure >140/90 mmHg or use of anti-hypertensive medication, and a history 
of cancer was defined as past or current malignant neoplastic disease, except for 
basal cell carcinoma. Further, severity of PAD at presentation was classified as 
claudication or critical limb ischemia (Fontaine stages III and IV), and smoking 
alludes to all active and former smokers. Cerebrovascular disease was defined 
as mentioning of symptomatic cerebrovascular disease (i.e., transient ischemic 
attack (TIA) or stroke) and/or a carotid endarterectomy or stenting procedure in 
the medical history. Ischemic heart disease was considered if one of the following 
was present: reference to previous cardiac ischemic events in cardiology notes, 
prior coronary intervention or evidence of myocardial ischemia in provocative pre-
operative tests (dobutamine stress echocardiography or myocardial scintigraphy). 
Finally, prior vascular interventions were defined as either surgical or percuta-
neous vascular treatment prior to the index operation, not including coronary 
revascularization.
Follow-up
Survival status was obtained by inquiry of the civil registry. The latest date of 
follow up was considered December 31st 2012.
socioeconomic status
Income is one of the most widely accepted and used methods to quantify SES and 
was found to provide a superior reflection of SES-related health disparities com-
pared to other approaches such as educational status.12-14 The income data used 
for this study was the gross household income earned in 2003, which included 
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every form of income of all people sharing a household or place of residence 
combined. The household income was not adjusted for household size. However, 
it has been demonstrated that adjustment for number of members in a household 
does not improve predictability of the associated health disparities.13 Incomes 
were assigned percentiles and quartiles in accordance with the national income 
distributions, with the first quartile being the lowest income group and the fourth 
quartile including households with the highest incomes. The annual earnings were 
obtained by inquiry of the Dutch Central Bureau of Statistics (CBS) – study ID: 
7465. To obtain information on SES, a database consisting of medical data on 
all study participants was anonymized by authorized data managers employed 
by CBS and matched to the household income dataset maintained by this entity. 
Income data is documented on an individual and household basis. According to 
Dutch privacy legislation, data analysis was only allowed to authorized researchers 
(KU, FBG) from designated institutions inside a secure environment after approval 
from the institutional ethical committee. Furthermore, output was checked by the 
CBS for privacy violations before it was allowed for publication purposes.
Endpoints
The primary endpoint was overall postoperative mortality. Secondary endpoints 
were severity of disease at presentation for AAA patients (i.e. rupture vs. non-
rupture) and PAD patients (i.e. critical limb ischemia vs. claudication). Severity 
of disease at presentation was not studied among CS patients, because carotid 
revascularization in asymptomatic patients is only rarely performed in our hospital 
in accordance with clinical guidelines.15
statistical methods
Income percentiles corresponding to the national gross income distribution were 
separated in quartiles. To clarify, first income quartile patients included members 
of a household with an annual salary that corresponds to 0-25% gross household 
incomes of the Dutch population. Baseline characteristics were described as counts 
and percentages (dichotomous variables), or means and standard deviations 
(continuous variables). Income is presented as median and interquartile ranges, 
because of the skewness of the data distribution. Differences between quartiles at 
baseline were determined using Pearson’s chi-square analysis and ANOVA, where 
appropriate.
Cox regression analyses were used to assess the predictive value of income for 
survival following treatment. The multivariate analyses were performed in two 
stages: in the first stage the model was adjusted for demographics only (age and 
gender), whereas in the second stage the full model included comorbidities and 
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behavioral risk factors (diabetes, cancer, ischemic heart disease, hypertension, 
smoking status, and BMI). In order to determine the type of association between 
income and postoperative survival, analyses were done both continuously, by 
hazard ratio per 5,000 euro decrease in gross household income, and categorical, 
by hazard ratio of the individual income quartiles compared to the fourth quartile 
(75-100%). Exponential properties in the relation between annual earnings and 
outcome were tested by including the quadratic term of household income in the 
regression model.
To investigate the relationship between income and severity of disease, odds ra-
tios (OR) and 95% confidence intervals (CI) were calculated by logistic regression 
analyses. Similar to the primary endpoint, multivariate analyses for the secondary 
objective were done using a two-stage method. Covariates included in the mul-
tivariable model were identical to the Cox proportional hazards model. Ruptured 
AAA cases were only included in univariate and step 1 multivariate analyses for se-
verity of disease at presentation, due to the number of missing values at baseline. 
Both regression models were tested for interactions. All tests were two-sided and 
significance was considered when p-value < .05. Statistical analysis was performed 
using the IBM SPSS Statistics 20 (IBM Inc., Chicago, IL, USA).
REsULTs
A total number of 1260 patients underwent surgical treatment for AAA, CS or 
PAD between January 2003 and December 2011. The inquiry yielded the income 
of 1178 patients (93.5%): 577 with AAA, 277 with CS, and 324 with PAD. The 
cohort consisted of 915 men (78%) and 263 women (22%). The median gross 
household income was 30 889 euro annually (IQR: 21 779 – 51 620). The overall 
5-year survival was 69% with a median follow-up time of 3.84 years (excluding 
patients treated for rAAA).
Baseline characteristics
Patients in the first and second income quartiles were older compared to the 
higher two quartiles (p ≤ .001, Table 1a, b, c). Additionally, BMI differed across 
the income quartiles in the PAD cohort (p = .014), although no clear pattern was 
observed. In the AAA cohort, patients in the first quartile were more frequently 
female as compared to the higher three quartiles (22% vs. 11%, 9%, 9%, p 
= .020, Table 1b). Further, the third income quartile AAA patients more often 
suffered from PAD (28% vs. 15%, 14, 16%, p = .030). No additional differences 
were found in the PAD and CS cohorts at baseline (Tables 1a and 1c).
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Peripheral artery disease
Surgical revascularization for limb ischemia was performed in 324 patients. During 
a median follow-up of 3.60 years, 96 deaths occurred with a 5-year survival rate 
of 69% (Table 2). The median income among the PAD patients was 33 248 euro 
(IQR: 19 802 – 55 353). With income as a continuous variable, adjusted analysis 
proved that low income was significantly associated with worse survival (step 2 
HR: 1.05, 95% CI: 1.00 – 1.10, per 5,000 euro decrease, Table 3). Regarding 
the hazard expressed per income quartile, a similar linear relation with increasing 
hazard as income decreased was observed in the first two quartiles compared to 
the fourth quartile (step 2 HR: 3.05, 95% CI: 1.25 – 7.44 and HR: 2.50, 95% CI: 
1.03 – 6.07, for the first and second quartiles, respectively), while no significant 
association was found for the third quartile (HR: 2.47, 95% CI: .98 – 6.24, p = 
.056).
In terms of disease severity, patients in the first income quartile presented 
more often with critical limb ischemia, although no significant association could 
be established in step 2 multivariable analysis (OR: 2.02, 95% CI: .96 – 4.26, 
p = .064, Table 4).
Abdominal aortic aneurysm
Of the 577 included AAA patients, 440 (76%) received treatment for non-ruptured 
AAA. During a median follow-up of 3.17 years, 159 patients died, which resulted 
in a 5-year survival of 62% among elective AAA patients. The median income was 
31 232 euro (IQR: 22 653 – 51 230). In multivariate quartile analyses, low income 
was not significantly associated with worse survival following AAA repair. With 
income as a continuous variable, however, there was an exponential increase in 
mortality hazard associated with a decrease in income (p = .006). The quadratic 
relation implies that the negative effect on survival for which low SES is respon-
sible, is more severe in the lowest percentiles and diminishes exponentially as 
income increases. This indicates that only survival of non-ruptured AAA patients 
in the lowest income regions within the first quartile is affected by low SES.
Table 2. Follow-up of the study cohort (N=1041, excluding rAAA patients)
Indication Death (%) 5-year survival (±SE)
Median follow-up
(years, IQR)
PAD 96 (27.2) 69.2% (± 3.0) 3.60 (1.90 – 5.60)
AAA 159 (36.1) 62.1% (± 2.8) 3.17 (1.75 – 5.17)
CS 64 (23.1) 78.8% (± 2.7) 4.77 (3.39 – 6.04)
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Regarding the relationship between income and severity of disease at presen-
tation, low household income was associated with more severe presentation. 
After adjusting for demographics, patients in the first quartile were more likely 
to present with a ruptured aneurysm as compared to those in the fourth quartile 
(OR: 2.12 95% CI: 1.08 – 4.17). The second step multivariate analysis was not 
performed because of the missing baseline characteristics in the rAAA group.
Carotid artery stenosis
The median follow-up period of the 277 patients who underwent a carotid end-
arterectomy was 4.77 years, during which 64 patients died, resulting in a 5-year 
survival of 79%. The median income was 31 796 euro (IQR: 22 054 – 51 604). 
Low income was not associated with worse survival. Severity of disease at presen-
tation was not studied, since carotid revascularization is only rarely performed in 
asymptomatic patients in the Netherlands, according to clinical guidelines.15
Table 3. The association between income and survival (hazard ratio per quartile, relative to 
the fourth quartile [75-100%])
Continuous Quartile 1 Quartile 2 Quartile 3 Quartile 4
PAD
Deaths – N (%) 38 (40) 32 (32) 20 (27) 6 (11)
Univariate 1.08
(1.03 – 1.13)
4.74
(2.00 – 11.22)
3.29
(1.38 – 7.87)
3.01
(1.21 – 7.50)
-
Multivariate 
step 1
1.06
(1.01 – 1.11)
3.89
(1.62 – 9.33)
3.05
(1.27 – 7.32)
3.23
(1.30 – 8.07)
-
Multivariate 
step 2
1.05
(1.00 – 1.10)
3.05
(1.25 – 7.44)
2.50
(1.03 – 6.07)
2.47
(0.98 – 6.24)
-
AAA
Deaths – N (%) 41 (48) 76 (40) 26 (28) 16 (22)
Univariate Quadratic
(P<0.001)
2.07
(1.16 – 3.69)
1.76
(1.03 – 3.02)
1.14
(0.61 – 2.12)
-
Multivariate 
step 1
Quadratic
(P=0.001)
1.56
(0.86 – 2.85)
1.32
(0.76 – 2.29)
1.15
(0.62 – 2.14)
-
Multivariate 
step 2
Quadratic
(P=0.006)
1.50
(0.80 – 2.81)
1.33
(0.75 – 2.38)
1.34
(0.71 – 2.55)
-
CS
Deaths – N (%) 17 (27) 24 (25) 15 (21) 8 (17)
Univariate 1.03
(0.98 – 1.09)
1.39
(0.60 – 3.23)
1.31
(0.59 – 2.91)
1.03
(0.44 – 2.43)
-
Multivariate 
step 1
1.02
(0.96 – 1.07)
1.06
(0.44 – 2.58)
0.97
(0.42 – 2.25)
0.97
(0.41 – 2.30)
-
Multivariate 
step 2
1.02
(0.96 – 1.07)
1.02
(0.41 – 2.50)
1.00
(0.43 – 2.33)
1.05
(0.44 – 2.49)
-
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DIsCUssIOn
Previous reports of socioeconomic deprivation and its association with cardio-
vascular disease (CVD) have demonstrated increased lifetime cumulative risks 
of acute myocardial infarction, stroke, heart failure, coronary death, and PAD in 
deprived subjects.16 The current study demonstrates that, in addition to increased 
risk of a range of CVD presentations, socioeconomic status –as determined by 
income– also negatively impacts survival after vascular surgery.
The different income quartiles, as defined by the national income distribution, 
were –by approximation– equally represented in our cohort, indicating that this 
patient group is a good reflection of the national socioeconomic situation. Low 
SES was associated with worse postoperative survival among PAD and AAA pa-
tients, even after adjusting for demographics, conventional cardiovascular risk 
factors, and comorbidities. The relation between low SES and poor outcome was 
strongest in patients who underwent surgical revascularization for PAD. Patients 
in the lowest income quartile were 3 times more likely to die after surgery as 
compared to those in the highest income group. Although the exact reasons 
are unclear, the importance of SES for especially PAD patients has been dem-
onstrated in previous studies.16 In AAA patients a similar relation was present, 
albeit only in patients with the lowest income. Although it has been reported that 
SES affects mortality after stroke,17 we found no association between mortality 
Table 4. The association between income and the severity of symptoms at presentation 
(Odds ratio per quartile, relative to the fourth quartile [75-100%])
Quartile 1 Quartile 2 Quartile 3 Quartile 4
PAD
CLI – N (%) 61 (67) 51 (53) 40 (55) 26 (47)
Univariate 2.27
(1.14 – 4.51)
1.26
(0.65 – 2.46)
1.35
(.67 – 2.73)
-
Multivariate step 1 2.00
(0.99 – 4.02)
1.18
(0.60 – 2.31)
1.38
(0.68 – 2.79)
-
Multivariate step 2 2.02
(0.96 – 4.26)
1.16
(0.58 – 2.34)
1.28
(0.61 – 2.70)
-
AAA Reference
Ruptures – N (%) 40 (32) 55 (23) 25 (21) 17 (19)
Univariate 2.03
(1.06 – 3.87)
1.27
(0.69 – 2.34)
1.18
(0.60 – 2.35)
-
Multivariate step 1 2.12
(1.08 – 4.17)
1.30
(0.69 – 2.47)
1.18
(0.59 – 2.35)
-
Legend: CLI: critical limb ischemia (Fontaine stage III, IV)
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hazard and gross household income in patients undergoing carotid endarterec-
tomy for symptomatic CS.
The present data underlines the importance of socioeconomic deprivation as 
a risk factor for the prognosis of people with established cardiovascular disease 
(CVD). But which factors drive the relationship between low SES and poor health? 
Studies conducted in the US showed a clear link between income, insurance 
status and outcome. For example, uninsured patients were 4 times more likely 
to die following AAA repair.8, 18, 19 Discrepancies in mortality hazards associated 
with insurance status and low SES are generally attributed to poor access to 
and/or low quality of healthcare. However, the present study was conducted in 
the Dutch setting with equal access to and quality of healthcare, irrespective 
of income.10 Hence, the association between income and postoperative survival 
that was demonstrated in our study cannot be attributed to inequality in health-
care resources. In addition, low income as a predictor of poor outcome was 
found to be independent of conventional cardiovascular risk factors, such as 
age, smoking status, diabetes, and obesity, as well as common comorbidities, 
including cancer and ischemic heart disease, since we corrected for these factors 
in multivariate analyses.
Several alternative factors may mediate the association between SES and poor 
survival. Psychosocial risk factors implicated in the etiology of cardiovascular 
disease, such as psychological stress, depression and social isolation, are more 
often observed in low SES individuals.20-23 In addition, socioeconomic disadvan-
tage has been established as a risk factor for poor compliance with medication, 
diet, and lifestyle restrictions.24-28 Also, SES has been shown to be an important 
determinant of physical activity and exercise,29 which –in turn– is associated 
with health status and life-expectancy.29, 30 Fourth, even in developed countries, 
material deprivation in people from disadvantaged backgrounds is increasingly 
associated with poorer dietary quality.31-34 Fifth, lower SES patients more often 
live in disadvantaged neighborhoods with higher concentrations of harmful air 
pollutants and worse housing conditions, which are associated with worse health 
outcomes.35-37 Additionally, physical demand, low decision latitude and high job 
strain, which are more common in lower employment grades, may explain some 
of the excess risk among disadvantaged groups.38 Finally, a recent study suggests 
that perhaps even epigenetical factors among lower socioeconomic classes may 
play a role in SES-related health disparities.39 Although the interaction between 
SES and poor prognosis is complex, a better understanding of these acquired 
health hazards may attenuate the health inequalities. In addition, increased 
physician awareness and consideration of SES in clinical practice, for example by 
incorporating a number of –voluntary– questions to existing questionnaires (e.g. 
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employment of the patient and his or her partner, residential area and household 
income category), and focus on treatment of these established SES-related risk 
factors may help to improve outcome of low SES vascular patients. Although 
this study shows the relation of SES with outcome and the potential benefit of 
its consideration, further study is needed on how to integrate SES with current 
decision-models for risks of restenosis, amputation, and survival.
In line with previous reports,4, 5, 19, 40 AAA patients with low income were more 
likely to present with a ruptured aneurysm, while PAD patients with lower an-
nual earnings more often presented with symptoms of critical limb ischemia. 
These results indicate that the severity of disease at presentation is affected 
by SES as well. Since patients with lower SES tend to postpone seeking health-
care even in the absence of financial barriers, a lack of disease awareness and 
knowledge in lower socioeconomic classes is likely to be responsible for delayed 
presentation.41 Regarding PAD patients, it is well recognized that the prognosis 
for patients presenting with critical limb ischemia is worse than for those with 
claudication. Therefore, additional analyses to determine the relative influence 
of SES and disease severity were performed. These analyses showed that both 
income and disease severity at presentation independently influenced survival 
in our cohort (data not shown). Considering that delayed presentation appeared 
to be associated with SES as well, a lack of awareness and knowledge may also 
partially account for SES-related disparities in the outcome of vascular surgery 
patients.
This study has several limitations that must be considered. First, the study 
was performed retrospectively, which comes with its inherent disadvantages. 
Second, local law prohibits the documentation of ethnicity, unless explicit ap-
proval is provided. Although we assume most patients to be of Western European 
origin, the ethnicity was not obtainable for this study, making racial differences 
in our analyses inaccessible. Another limitation was the missing data among the 
ruptured AAA patients. Due to a high number of missing baseline data, we could 
not include these patients in multivariable analysis beyond step one (age and 
gender adjusted). Also, it should be considered that only patients who underwent 
surgery were identified. Patients who were treated conservatively, or patients 
with prohibitive surgical risks due to severe comorbidity were not included in this 
study. As a result, a selection bias towards patients suited for surgery may be 
present. Further, patients undergoing endovascular procedures under local infil-
tration analgesia were not included in this study. Since endovascular treatment 
approaches are increasingly utilized, further study is warranted to assess the 
importance of SES for outcome of patients undergoing less invasive endovas-
cular procedures. In addition, treatment indication for carotid revascularization 
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(i.e. TIA or stroke) was not graded in this study. Some studies have noticed 
different perioperative complication rates for different treatment indications.42, 43 
However, for long-term survival, which was the primary endpoint in the pres-
ent study, the impact of treatment indication is not well-established.44-46 Finally, 
gross household income was acquired for all patients in 2003, suggesting that 
the income used for analyses may be the income earned several years prior to 
surgery. However, the mean age in the cohort was 69 years, meaning that major 
differences between the income used in the analyses and the actual income at 
the time of surgery are not very likely.
In conclusion, this study demonstrates that socioeconomic deprivation is a pre-
dictor of adverse outcome after vascular surgery independent from conventional 
risk factors, in particular for peripheral artery disease. For AAA patients, the 
association was of an exponential nature, indicating that the mortality hazards 
rapidly decrease as income rises, while for PAD patients the relation followed a 
linear path. Although the precise mechanisms accounting for this risk remain 
elusive, the increased health hazards observed in this study are caused by 
patient related factors rather than differences in medical care, considering the 
equality of care provided by the study setting. Consideration of SES, for example 
assessed by household income, as a risk factor in preoperative decision-making 
and focus on treatment of the associated behavioral and psychosocial risk fac-
tors may improve the outcome of patients with vascular disease.
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ABsTRACT
Objective
The impact of socioeconomic disparities on surgical outcome in the absence of 
healthcare inequality remains unclear. Therefore, we set out to determine the 
association between socioeconomic status (SES) and overall survival after surgery 
in the Dutch setting of equal access and provision of care. Additionally, we aim to 
assess whether SES is associated with cause-specific survival and major 30-day 
complications.
Methods
Patients undergoing surgery between March 2005 and December 2006 in a general 
teaching hospital in the Netherlands were prospectively included. Adjusted logistic 
and cox regression analyses were used to assess the independent association of 
SES –quantified by gross household income– with major 30-day complications 
and long-term postoperative survival.
Results
A total of 3929 patients were included, with a median follow-up of 6.3 years. 
Low SES was associated with worse survival in continuous analysis (HR: 1.05 per 
10.000 euro decrease in income, 95% CI: 1.01 – 1.10) and in income quartile 
analysis (HR: 1.58, 95% CI: 1.08 – 2.31, first [i.e. lowest] quartile relative to the 
fourth quartile). Similarly, low SES patients were at higher risk of cardiovascular 
death (HR: 1.26 per 10.000 decrease in income, 95% CI: 1.07 – 1.48, first income 
quartile: HR: 3.10, 95% CI: 1.04 – 9.22). SES was not independently associated 
with cancer-related mortality and major 30-day complications.
Conclusions
Low SES is associated with increased overall and cardiovascular mortality risks 
among surgical patients. Considering the equality of care provided by this study 
setting, the associated survival hazards can be attributed to patient factors, rather 
than disparities in healthcare. Increased physician awareness of SES as a risk 
factor in preoperative decision-making and focus on improving established SES-
related risk factors may improve surgical outcome of low SES patients.
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InTRODUCTIOn
The relation between socioeconomic status (SES) and outcome of medical treat-
ment has been the subject of many studies over the past years, and SES-related 
risks of poor outcome have been demonstrated previously.1-9 However, these stud-
ies were predominantly performed in the United States, where health care is not 
publicly provided. Differences in outcome between socioeconomic classes were 
therefore predominantly attributed to differences in accessibility and provision 
of care, rather than patient factors.1, 6, 9, 10 Hence, the role of SES on surgical 
outcome in the absence of healthcare disparities remains unclear.
As a result of governmental regulation, medical care in the Netherlands is 
equal among all layers of society, and has even been credited the most equally 
accessible healthcare system in the world.11, 12 This characteristic of the present 
study setting provides a new and unique opportunity to assess the role of SES on 
outcome of care. Due to the healthcare equality, differences in outcome associ-
ated with SES can under these circumstances be attributed to patient factors, 
rather than healthcare disparities. We have previously demonstrated in a vas-
cular surgery population that SES implicated significant postoperative survival 
risks, independent from conventional medical and environmental risk factors.13 
These findings suggest that SES encompasses a wide variety of risk factors and 
behaviors that are not adequately captured by conventionally considered risk 
factors.
The association between SES and prognosis in a non-vascular general surgical 
population remains unexplored. Moreover, it is well known that vascular dis-
ease and vascular patients are relatively more susceptive to environmental risk 
factors, which limits the generalizability of the previous study to non-vascular 
patients.
The primary objective of this study is to determine the association between 
SES and survival after surgery in a general surgical population. Additionally, 
we aim to establish whether SES is associated with cause-specific survival and 
major 30-day complications.
METHODs
study population
Patients undergoing elective or acute surgery between March 2005 and Decem-
ber 2006 in a medium-sized general teaching hospital in the Netherlands were 
prospectively included.14 Procedures are detailed in Supplemental Table 1. Since 
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the association between low SES and worse outcome among vascular surgery 
patients has been established in the previous study,13 vascular procedures were 
excluded. Additional exclusion criteria were surgical interventions performed 
under local anesthesia, and patients younger than 14 years at the time of the 
procedure. Bariatric surgery was not performed in this hospital. When a patient 
underwent multiple surgical procedures within the study period, the first operation 
was included for analysis and survival was assessed from that moment onward. 
The institutional review board of Zuyderland Medical Center approved this study, 
and patient consent was waived due to the de-identified nature of the data. The 
study complies with the Helsinki declaration on research ethics.
Baseline characteristics
Medical characteristics were obtained by a surgeon or a surgical resident during a 
routine visit prior to surgery. Pulmonary disease was defined as an illness of the 
lung or respiratory system (i.e. asthma, lung cancer, chronic infections, previous 
pulmonary embolisms, chronic obstructive pulmonary disease (COPD)). Cardiac 
disease was considered when the medical history included coronary artery disease 
(with or without coronary revascularization), heart failure, arrhythmias, valvular 
heart disease or cardiomyopathy. Cerebrovascular disease was defined as either 
a Transient Ischemic Attack (TIA) or ischemic stroke in the medical history. A 
patient was considered diabetic when diabetes mellitus was mentioned in the prior 
history or medical records show use of insulin or oral anti-diabetics. Hypertension 
was considered when hypertensive disease was mentioned in the medical history 
or the patient received anti-hypertensive medication. A history of cancer was 
defined as malignant neoplastic disease in the prior medical history.
Gathered surgery-related data included the type of anesthesia (locoregional 
or general) and the surgical setting (inpatient or outpatient). The risk of the 
performed procedure was defined as low, intermediate or high risk conform 
the surgical risk classification system by Boersma et al. (Supplemental Table 
1).15 High-risk surgical procedures solely consist of major vascular procedures 
and were not included in this study for previously mentioned reasons. Finally, 
all events following surgery were documented. A surgical resident as well as a 
member of the surgical staff independently scored all complications. To ensure 
complications were interpreted objectively and systematically, a classification 
proposed by Clavien et al. was used as guidance.16 A major complication was 
defined as a complication requiring surgical, endoscopic or radiological inter-
vention with or without residual organ dysfunction. Validation of the database 
using a random sampling audit procedure confirmed a high level of accuracy and 
completeness of the data.
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Endpoints: The primary endpoint was overall mortality. Secondary endpoints were 
major 30-day complications, cardiovascular and cancer-related mortality.
socioeconomic status
In this study, SES was defined as gross household income. Household income 
is one of the most widely accepted and used methods to quantify SES, and was 
found to provide a superior reflection of SES-related health disparities compared 
to other approaches such as educational status.17-19 To avoid missing income data 
due to a patients’ death in the year of surgery, gross household income in the year 
prior to the year of surgery was used to quantify SES. Annual earnings were ob-
tained at the Dutch Central Bureau of Statistics (CBS), and encompassed all types 
of income of people sharing a household or place of residence combined, including 
salary, (state) pension, social compensation, and investment revenues. Patients 
were assigned income percentiles and quartiles in accordance with the national 
income distribution. To clarify, first income quartile patients included members of 
a household with an annual salary that corresponds to 0-25% gross household 
incomes of the Dutch population.
Cause of death
Causes of death obtained through national death registries, which are also main-
tained by the CBS. The high accuracy of Dutch cause-of-death registration has 
been demonstrated previously.20 The cause of death was defined as the cause 
for the initial health deterioration, which subsequently resulted in death. This 
approach is similar to the strategy employed for the overall Dutch population 
death registrations and reports. Autopsy was not routinely performed. The causes 
of death were coded in accordance with International Classification of Diseases, 
10th Revision (ICD-10). Cardiovascular death was defined as I10-I79, and cancer-
related death as C00-C43, C45-C97.
To obtain information on SES and causes of death, a database consisting of medi-
cal data on all study participants was anonymised and matched to the household 
income and death registry data sets maintained by the CBS. Dutch privacy legisla-
tion stipulates that data analysis with national data is only allowed by authorized 
researchers (KU, FBG) from designated institutions inside a secure environment 
after approval from the institutional ethical committee. Furthermore, output was 
checked by the CBS for privacy violations before it was allowed for publication 
purposes.
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Statistical methods: Baseline characteristics are presented as counts and per-
centages (dichotomous variables), means and standard deviations (continuous 
variables), or medians and interquartile ranges. Patients were grouped in quartiles 
in correspondence with the national gross household income distribution. Differ-
ences at baseline between income quartiles were tested using Pearson’s chi-square 
analysis and ANOVA, where appropriate. The predictive value of SES for long-term 
survival was assessed using Cox-regression analysis. In order to determine both 
the type (i.e. linear or exponential) and the clinical significance of the relation 
between income and survival, analyses were performed with income as a continu-
ous variable as well as categorical per income quartile. Exponential properties 
were tested by including higher-order terms of income in the regression model in 
continuous analysis. In income quartile analysis, the highest income quartile was 
designated reference category. The multivariable model included surgery risk, 
demographics (age, gender), medical characteristics (diabetes, hypertension, 
cerebrovascular disease, cardiac disease, malignant disease, pulmonary disease) 
and behavioral risk factors (smoking and BMI). Cause specific mortality hazards 
(i.e. cardiovascular and cancer-related) associated with SES were established with 
the same Cox model. The association between SES and major 30-day complica-
tions and death following surgery was studied using logistic regression analysis. 
The multivariable model consisted the same covariates as the long-term survival 
models. Sensitivity analyses were performed to assess whether the association 
between SES and postoperative survival existed among all patients, including 
vascular patients. All tests were two-sided and significance was considered when 
P-value <0.05. Statistical analysis was performed using the IBM SPSS Statistics 
20 (IBM Inc., Chicago, IL).
REsULTs
A total of 4153 patients were suitable for analysis. The gross household income 
could be retrieved for 3929 patients (94.6%).
Baseline characteristics
Baseline characteristics are detailed in Table 1. Low SES patients were younger 
(P<0.001) and were more frequently female (P<0.001). All medical conditions 
were more common among lower income quartile patients (P<0.001 for all medi-
cal conditions). Similarly, higher income patients were less often current or former 
smokers (P<0.001). BMI also significantly differed between the income quartiles 
(P<0.001).
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Major 30-day complications
In the first 30 days following surgery, 206 patients suffered a major complica-
tion requiring additional interventions (either surgical, endoscopic or radiological) 
(Table 2). Within this group, 37 patients (18%) were left with residual organ 
dysfunction. Income was associated with the occurrence of major complications 
in univariate continuous analysis (OR: 1.05, 95% CI: 1.004 – 1.11), as well as 
in income quartile analysis for the first quartile (OR: 1.99, 95% CI: 1.30 – 3.04) 
compared to the fourth quartile (Table 3). However, no association could be es-
tablished in adjusted analysis.
Overall mortality
During a median follow-up of 6.3 years 570 deaths occurred (Table 2). Regarding 
the relation between SES and overall survival, a significant association was found 
Table 1. Baseline characteristics
Quartile 1
(n=708)
Quartile 2
(n=1122)
Quartile 3
(n=1083)
Quartile 4
(n=1016)
P-value
Demographics
Age – mean (± SD) 61.8 (19.4) 59.3 (16.5) 48.6 (15.6) 46.9 (14.5) <0.001
Female gender – n (%) 435 (61) 538 (48) 525 (48) 446 (44) <0.001
Comorbid conditions
Diabetes mellitus – n (%) 91 (13) 96 (9) 68 (6) 45 (4) <0.001
Hypertension – n (%) 189 (27) 242 (22) 160 (15) 119 (12) <0.001
Cerebrovascular disease – n (%) 67 (10) 87 (8) 39 (4) 10 (<1) <0.001
Cardiac disease – n (%) 184 (26) 239 (21) 131 (12) 76 (8) <0.001
Malignant disease – n (%) 218 (31) 321 (29) 223 (21) 184 (18) <0.001
Pulmonary disease – n (%) 128 (18) 197 (18) 124 (12) 79 (8) <0.001
surgery risk
Low – n (%) 363 (51) 653 (58) 681 (63) 671 (66) <0.001
Intermediate – n (%) 345 (49) 469 (42) 402 (37) 345 (34) <0.001
Behavioral risk factors
Smoking * – n (%) 236 (46) 431 (51) 428 (52) 284 (39) <0.001
BMI – mean (± SD) 26.1 (4.7) 26.2 (4.4) 26.5 (4.8) 25.7 (4.3) 0.004
Type of anesthesia
General – n (%) 618 (87) 936 (84) 920 (85) 855 (84) 0.135
socioeconomic status
Median income – € (IQR) 16 620.50
(13 914.25 – 
19 280.75)
29 375.50
(25 119.50 – 
34 474.75)
50 971.00
(44 961.00 – 
57 645.00)
83 490.50
(72 924.50 – 
101 192.75)
-
* approximately 25% missing values
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in continuous analysis (Table 4). In multivariable step 1, as well as adjusted for 
behavioral risk factors in step 2, mortality hazards proved to increase as income 
diminished (HR: 1.05 per 10.000 euro decrease in household income, 95% CI: 
1.01 – 1.10,). A similar relation was found in income quartile analysis. In step 2 
multivariable analysis, patients in the first quartile (i.e. the lowest income quar-
tile) had significantly higher mortality risks (HR: 1.58, 95% CI: 1.08 – 2.31). The 
association lost significance in the second and third quartile, although a trend 
remained (HR: 1.41, 95% CI: 0.99 – 2.02, HR: 1.32, 95% CI: 0.90 – 1.93, 
respectively for the second and third quartile).
Cause specific mortality
Of the 570 deaths, 108 (19%) were due to cardiovascular causes. In both step 1 
and step 2 continuous analysis, low SES was significantly associated with increased 
cardiovascular mortality risks (HR: 1.26 per 10.000 euro decrease in household 
income, 95% CI: 1.07 – 1.48, Table 5). In income quartile analysis, a significant 
independent SES-related cardiovascular survival hazard was observed in the first 
quartile (HR: 3.10, 95% CI: 1.04 – 9.22). No relation could be established for the 
higher two quartiles.
Cancer-related death was ascertained in 281 (49%) cases. In continuous 
analysis, a significant relation was found between SES and cancer-related sur-
vival in univariate analysis (HR: 1.19, 95% CI: 1.13 – 1.24). The relation was 
lost after adjusting for conventional risk estimators in multivariable analysis. 
Similarly, lower quartile patients were not burdened by additional cancer-related 
mortality in multivariable income quartile analysis.
sensitivity analyses
Sensitivity analyses with vascular surgery patients included showed that SES 
was associated with worse overall survival in continuous step 2 multivariable 
analysis (HR: 1.05 per 10.000 euro decrease in household income, 95% CI: 1.01 
– 1.09,), as well as cardiovascular survival (HR: 1.21, 95% CI: 1.02 – 1.41), 
while no increased risk was found for cancer-related survival (HR: 1.01, 95% 
CI: 0.96 – 1.07). Income quartile analyses showed similar results for overall and 
cancer-related mortality as well. For cardiovascular mortality, a non-significant 
trend towards increased cardiovascular survival hazards was observed among first 
quartile patients (P=0.055).
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DIsCUssIOn
The principal finding of this study is that SES is a significant predictor of long-
term survival in an overall surgical population. Cause specific mortality analysis 
indicated that the mortality hazards associated with low SES were not caused 
by increased risks of death due to cancer-related causes, but rather a higher 
risk of cardiovascular death. Since the association maintained after adjusting for 
demographics, comorbidities and behavioral risk factors, the mortality risks add to 
conventionally considered risk estimators. Secondly, this study showed that SES 
is not related to short-term postoperative outcome, as demonstrated by the lack 
of association with major 30-day complications.
Differences in outcome after surgery between socioeconomic classes have 
previously been attributed to disparities in quality and provision of care.1, 6, 9, 21, 22 
However, the equality in access to and provision of care provided by this study 
setting suggests that not healthcare inequalities, but rather patient-related 
factors play a causal role in SES-related outcome differences. Hence, even in 
countries where healthcare is not publicly provided, differences in healthcare 
utilization are unlikely to fully account for divergences in outcome.23, 24
Although the relation between SES and outcome has not been described for 
a general surgical population, population-based studies have been conducted. 
In a study among Finnish men, it was shown that known behavioral risk factor 
pathways mediated much of the inverse relation between SES and survival, 
which is in line with our observation that smoking was more common in lower 
income quartiles.25 However, as in the Finnish study, a residual association was 
established which was not fully captured by the wide variety of other risk factors 
also included in the analysis. Moreover, previous studies have reported that less 
than 50% of socioeconomic differences in disease occurrence and prognosis are 
explained by combined common behavioral risk factors, such as smoking.18, 25-27
Several factors may mediate the independent relation between low SES and 
worse surgical outcome. First, socioeconomic disadvantage is a known risk fac-
tor for poor compliance to medication, diet, and lifestyle restrictions.28-32 Second, 
psychosocial risk factors implicated in the etiology of cardiovascular disease, 
such as psychological stress, depression and social isolation, are more often 
observed in low SES populations.33-36 Also, material deprivation in individuals 
from disadvantaged backgrounds is associated with worse dietary quality.37-40 
In addition, SES has been has been established as an important determinant of 
physical activity and exercise,41 which –in turn– is associated with health status 
and life-expectancy.41, 42 Fifth, low SES patients tend to reside in more disadvan-
taged neighborhoods with higher concentrations of harmful air pollutants and 
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worse housing conditions, which are associated with worse health outcomes.43-45 
Physical demand, low decision latitude and high job strain, which are more com-
mon in lower employment grades, may also explain some of the excess risk 
among disadvantaged groups.46
These factors have been linked to especially increased risks of cardiovascular 
disease and mortality.25, 45, 47-49 Moreover, literature based models suggest that 
perhaps even epigenetical factors among lower socioeconomic classes may be 
responsible for the higher prevalence of cardiovascular disease among lower 
socioeconomic classes.50 This provides a valid explanation as to why low SES 
predominantly implied cardiovascular survival hazards in our study.51, 52 Although 
no relation between SES and cancer-related death was found in the full model, 
studies have proven such relation to exist.53, 54 Our results showed an association 
between SES and cancer-related mortality in univariate analysis, but no relation 
could be established when adjusting for conventional risk factors.54 This is in line 
with previous studies showing that that much of the SES-related risk of cancer 
occurrence and mortality are through conventional risk factors, most importantly 
smoking.51, 55-57 Although the association between low SES and worse outcome is 
multifactorial and complex, a better understanding of this relation may help to 
attenuate health disparities. Increased physician awareness and focus on bet-
tering these established SES-related risk factors may help to improve outcome 
of low SES surgical patients.
In regards to the association between SES and major complications follow-
ing surgery, a relation was found in univariate analysis, but point estimates 
decreased to 1 and significance was lost in the multivariable model. The fact 
that the relation did not maintain significance after adjusting for commonly 
considered health hazards suggests that SES is merely a proxy measure in this 
association and that it provides no additional value over conventional risk factors 
for the prediction of the short-term postoperative course.
This study has some limitations that should be considered. First of all, it should 
be noted that only patients who underwent surgery were included. Patients who 
were conservatively treated and those with prohibitive surgical risks due to se-
vere comorbidity were consequently excluded. In addition, smoking status was 
unobtainable for a considerable amount of patients, and resulted in the exclusion 
of approximately 25% of cases in the full model. Finally, American studies that 
have reported on SES-related outcome and healthcare disparities often describe 
divergences between racial groups as well. Due to Dutch legislation, documen-
tation of ethnicity in patient records is only allowed when medically relevant. 
Consequently, racial disparities could unfortunately not be investigated.
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In conclusion, this study demonstrates that low SES is a risk factor for overall 
and cardiovascular mortality following surgery. Considering the equality in access 
to and provision of healthcare provided by this study setting, we can conclude 
that the observed health hazards accompanying low socioeconomic status are 
caused by patient factors, rather than differences in medical care. Although the 
exact mechanism mediating the postoperative SES-related survival risk remains 
unclear, increased physician awareness and improvement of known SES-related 
risk factors and behaviors may help to improve surgical outcome among low SES 
patients.
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supplemental Table 1. Risk classification of included surgical procedures
Low risk surgery Procedure
Hernia surgery (except incisional hernia surgery)
Varicose vein surgery
Perianal surgery
Minor trauma surgery
Minor surgery of soft tissue
Intermediate risk surgery Procedure
Appendectomy
Cholecystectomy
Major abdominal surgery (i.e. liver, gastric, bowel, 
spleen esophagus, incisional hernia surgery)
Head and neck surgery
Thoracic surgery
Major trauma surgery (i.e. multitrauma or trauma 
involving the femur or hip)
12
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
C
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ABsTRACT
Objective
Although it has become clear that aneurysmal and occlusive arterial disease are 
two distinct etiologic entities, it is still unknown whether the two vascular patholo-
gies are prognostically different. We aim to assess the long-term vital prognosis 
of patients with abdominal aortic aneurysmal disease (AAA) or peripheral artery 
disease (PAD), focusing on possible differences in survival, prognostic risk profiles 
and causes of death.
Methods
Patients undergoing elective surgery for isolated AAA or PAD between 2003 and 
2011 were retrospectively included. Differences in postoperative survival were de-
termined using Kaplan-Meier and Cox regression analysis. Prognostic risk profiles 
were also established with Cox regression analysis.
Results
429 and 338 patients were included in the AAA and PAD groups, respectively. 
AAA patients were older (71.7 vs. 63.3 years, p < 0.001), yet overall survival 
following surgery did not differ (HR: 1.16, 95% CI: 0.87–1.54). Neither was type 
of vascular disease associated with postoperative cardiovascular or cancer-related 
death. However, in comparison with age- and gender-matched general popula-
tions, cardiovascular mortality was higher in PAD than AAA patients (48.3% vs. 
17.3%). Survival of AAA and PAD patients was negatively affected by age, history 
of cancer and renal insufficiency. Additional determinants in the PAD group were 
diabetes and ischemic heart disease.
Conclusions
Long-term survival after surgery for PAD and AAA is similar. However, overall life 
expectancy is significantly worse among PAD patients. The contribution of car-
diovascular disease towards mortality in PAD patients warrants more aggressive 
secondary prevention to reduce cardiovascular mortality and improve longevity.
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InTRODUCTIOn
Traditionally, dilatation and occlusion were considered to represent two extremes 
on the same spectrum of arterial disease. As such, it was presumed that both 
entities were the result of extensive atherosclerosis.1 This assumption was largely 
based on the fact that the two vascular diseases share a number of risk factors, 
such as smoking, hypertension, and older age.2-6
However, over the years, disparities in etiologic cardiovascular risk profiles 
were demonstrated, 7-11 as well as differences in the severity of atherosclerotic 
burden between patients suffering from aneurysmal and occlusive disease.7, 12-16 
In addition, differences in cytokine levels, inflammation, and enzyme activity 
were found in the arterial walls affected by aneurysmal or occlusive disease.9, 17, 18 
Also, recent studies show that genetic susceptibility, rather than environmental 
risk factors, plays a particularly important role in the pathogenesis of aneurys-
mal disease.19-21 Although it is becoming clear that aneurysm formation and 
atherosclerosis are two separate clinical entities, it remains unclear whether this 
also translates into long-term prognostic differences between the two patient 
categories. Differences in long-term outcome, particularly of cardiovascular na-
ture, would warrant more aggressive secondary prevention regimens for those 
at the highest risk.
With surgical treatment as a uniform indicator of severe disease, we aim to 
determine the long-term vital prognosis for abdominal aneurysmal and periph-
eral occlusive disease patients, focusing on possible differences in survival, risk 
profiles, and causes of death.
METHODs
Patients undergoing elective surgery for AAA or PAD at the Erasmus University 
Medical Centre in Rotterdam between January 2003 and December 2011 were 
retrospectively identified using operation codes and surgical reports. Long-term 
survival was assessed from the day of surgery onward. In order to improve ho-
mogeneity in terms of operative stress and severity of disease, all percutaneous 
endovascular procedures, i.e. percutaneous endovascular aneurysm repair (EVAR) 
and percutaneous lower limb PTA or stenting procedures, were excluded. AAA 
patients who underwent prior endovascular or open surgical revascularization for 
lower limb ischemia were excluded from this study. PAD patients who underwent 
prior treatment of an abdominal or thoracic aortic aneurysm were also excluded. 
Treatment indications for AAA and PAD were both in accordance with the Euro-
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pean Society for Vascular Surgery guidelines.22, 23 Similarly, all vascular surgery 
patients were treated in accordance with these guidelines regarding secondary 
cardiovascular prevention. As a result, all patients followed a lifelong regimen of 
anti-platelets and statins, as well as anti-hypertensive and anti-diabetes medica-
tion on indication. Baseline characteristics were obtained from hospital charts 
and included age, gender, comorbidity, prior vascular interventions, smoking 
status (current/former or non-smoker), and body mass index (BMI). Institutional 
approval for this study was obtained, and no informed consent was required ac-
cording to local directives for retrospective studies. The study complies with the 
Helsinki declaration on research ethics.
Definitions: Diabetes mellitus was recorded if diabetes was mentioned in the 
medical history or if patients used insulin or oral anti-diabetics. Hypertension was 
defined as blood pressure >140/90 mmHg or use of anti-hypertensive medication. 
A history of cancer was defined as past or current malignant neoplastic disease, 
except for basal cell carcinoma. Renal insufficiency was defined as an estimated 
glomerular filtration rate (eGFR) <60 ml/min as calculated from preoperative 
serum creatinine levels using the MDRD formula. Smoking status and BMI were 
derived from the medical records. Cerebrovascular disease was defined as men-
tioning of symptomatic carotid artery disease (i.e., transient ischemic attack or 
stroke) and/or a carotid endarterectomy or stenting procedure in the medical his-
tory. Ischemic heart disease was considered if one of the following was present: 
reference to previous cardiac ischemic events in cardiology notes, prior coronary 
intervention or evidence of myocardial ischemia in provocative pre-operative tests 
(dobutamine stress echocardiography or myocardial scintigraphy). Prior vascular 
interventions were defined as either surgical or percutaneous vascular treatment 
prior to the index operation, not including coronary revascularization.
Endpoints: The primary endpoint was overall mortality. Secondary endpoints were 
cardiovascular and cancer-related death.
Cause of death: Causes of death were obtained from the Dutch Central Bureau of 
Statistics (CBS). A database consisting of medical data on the study participants 
was anonymized by authorized data managers employed by CBS. This dataset was 
subsequently imported and linked to the Dutch death registry, which is maintained 
by the CBS. According to Dutch privacy legislation, data analysis was only allowed 
to authorized researchers (KU, FBG) from designated institutions inside a secure 
environment after approval from the institutional ethical committee. Furthermore, 
output was checked by the CBS for privacy violations before it was allowed for 
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publication purposes. Autopsy was not routinely performed. The cause of death 
was defined as the initial cause of health deterioration, consequently resulting 
in death. This approach is similar to the strategy used for the overall Dutch 
population. The causes of death were grouped according to the International 
Classification of Diseases, 10th Revision (ICD-10). For cardiovascular death, the 
following codes were used: I10-I79; for cancer-related death: C00-C43, C45-C97, 
D00-D03, and D05–09; for death due to obstructive pulmonary disease: J40-J47; 
and for digestive system-related causes: K00-K93.
For survival estimation in the general population, a comparative age and gen-
der matched control group was derived from civil registries of the Dutch popula-
tion –also maintained by the CBS– for both the AAA and PAD group separately. 
To assess differences in causes of death compared to the general population, 
deaths in the respective study groups were individually matched on demographic 
properties to cause of death distributions in the general population. For example, 
if deaths in the AAA group consisted for 5% of males between the aged between 
80-85 at the time of death, the AAA matched cohort corresponds proportionally 
to the death distribution for males with the same age and gender characteristics 
from the general population.
Statistical methods: Baseline characteristics were described as counts and per-
centages (dichotomous variables), or means and standard deviations (continuous 
variables). Differences at baseline were determined using Pearson’s chi-square 
analysis and student t-test, where appropriate. Survival for the aneurysmal and 
occlusive disease cohorts was initially assessed using Kaplan-Meier and log-rank 
analyses. Differences in the vital prognosis were subsequently investigated using 
adjusted Cox proportional hazards regression. Multivariable analyses adjusted for 
demographics, comorbidities, and other risk factors (age, gender, diabetes mel-
litus, ischemic heart disease [IHD], a history of cancer, renal insufficiency, BMI, 
and current smoking). The AAA group was designated as the reference category in 
these analyses. Prognostic risk profiles for the two study groups were established 
by determining hazard ratios for potential risk factors separately for the AAA and 
PAD group using Cox proportional hazards model. Univariately significant covari-
ates were included in the multivariable model. All tests were two-sided and sig-
nificance was considered when P-value < 0.05. Statistical analysis was performed 
using the SPSS Statistics 20 (IBM Inc., Chicago, IL).
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REsULTs
A total of 470 patients undergoing elective surgery for AAA and 353 patients for 
PAD were identified. In the AAA group, 40 patients were excluded because of prior 
treatment for PAD, while 14 patients were excluded in the PAD group for prior 
aneurysm treatment. Two patients, one in each treatment group, were excluded 
due to unavailable follow-up data as a result of emigration. The remaining 429 
AAA and 338 PAD patients were considered suited for analysis.
Baseline characteristics
Baseline characteristics are detailed in Table 1. Compared to the PAD group, AAA 
patients were older at the time of surgery (71.7 vs. 63.3 years, p < 0.001), and 
more often male (88% vs. 66%, p < 0.001). In addition, patients in de AAA group 
were more commonly affected by cancer (21% vs. 14%, p = 0.025) and renal 
insufficiency (29% vs. 20%, p = 0.006). Conversely, diabetes and current smok-
ing were less common among AAA patients (16% vs. 30%, p < 0.001 and 38% 
vs. 49%, p = 0.003, respectively). AAA patients also less frequently underwent 
vascular interventions prior to the index operation (4% vs. 46%, p < 0.001).
Table 1. Baseline characteristics per study group.
Variable
AAA
(n=429)
PAD
(n=338)
P-value
Demographics
Female gender – n (%) 51 (12) 114 (34) < 0.001
Age – (years, mean ± SD) 71.7 ± 7.5 63.3 ± 11.1 < 0.001
Cardiovascular risk factors
Diabetes– n (%) 67 (16) 102 (30) < 0.001
Hypertension – n (%) 291 (68) 231 (69) 0.782
Current smoking – n (%) 161 (38) 164 (49) 0.003
Body mass index – (mean ± SD) 26.2 ± 4.1 25.8 ± 4.6 0.217
Peripheral artery disease – n (%) 40 (9.3%) 338 (100%) -
Comorbidities
History of cancer – n (%) 88 (21) 48 (14) 0.025
Ischemic heart disease – n (%) 203 (47) 152 (45) 0.512
Coronary revascularization – n (%) 92 (21) 80 (24) 0.613
Cerebrovascular disease – n (%) 73 (17) 52 (15) 0.544
Renal insufficiency – n (%) 125 (29) 69 (20) 0.006
History of vascular interventions – n 
(%)
19 (4) 157 (46) < 0.001
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Overall survival
During a median follow-up of 3.6 years after surgery (IQR: 2.1 – 5.4 years) 154 
patients died in the AAA group. For PAD patients, median follow-up time was 
3.8 years (IQR: 2.0 – 5.9 years), during which 107 patients died. Postoperative 
survival proved to be similar for the two groups, in both unadjusted analysis, 
as determined by log-rank testing (p = 0.105; Figure 1a), as well as adjusted 
Cox-regression analysis (HR: 1.16, 95% CI: 0.87 – 1.54, Table 2). However, since 
AAA patients were substantially older at the time of intervention (71.7 vs. 63.3 
years), postoperative survival did not adequately refl ect life expectancy of the 
respective groups. Figure 1b represents the postoperative life expectancies for the 
two groups with the average age at the time of treatment as the starting point. 
A direct comparison with a Dutch general population with similar age and gen-
der properties shows that in particular survival in the PAD cohort more strongly 
deviates from its matched general population (30.0% vs. 16.9%, respectively), 
indicating more life years lost as compared to the AAA cohort.
Figure 1. Long-term survival analysis for postoperative survival after AAA and PAD. (A) 
Kaplan-Meier analysis comparing survival after surgical intervention for AAA and PAD. (B) 
Postoperative life expectancy for patients treated for AAA and PAD. The starting points of the 
survival curves correspond to the average age at intervention in the study groups (i.e. 63.3 
and 71.7 years, respectively in the PAD and AAA groups). Survival estimates of the general 
population are age- and gender-adjusted in accordance with the respective cohorts.
Figure 1. Long-term survival analysis for postoperative survival after AAA and 
PAD. (A) Kaplan-Meier analysis comparing survival after surgical intervention for AAA 
and PAD. (B) Postoperative life expectancy for patients tr ated for AAA and PAD. The 
starting points f the su vival curves correspond to the average ge at intervention n the 
study groups (i.e. 63.3 and 71.7 years, respectively in the PAD and AAA groups). 
Survival estimates of the gener l population re age- and gender-adjusted in accordance 
with the r spective cohorts. 
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Cause of death
Causes of death could be obtained for 153 out of 154 patients (99.4%) in the AAA 
group and for all 107 deceased patients in the PAD group. Deaths were classified 
in five categories: cardiovascular, cancer-related, chronic obstructive pulmonary 
disease (COPD), intestinal disease, and other causes (Figure 2). Cardiovascular 
mortality was the leading cause of death in both AAA and PAD patients (35.3% 
vs. 39.3%, p = 0.944), followed by cancer-related death (28.8% vs. 24.3%, 
respectively, p = 0.220). However, cardiovascular mortality encompasses a much 
larger proportion in the PAD group as compared to the age- and gender-matched 
general population (39.3% vs. 26.5%) than in the AAA group (35.3% vs. 30.1%). 
Death due to intestinal disease or other causes was similar in the AAA and the PAD 
group (5.9% vs. 1.9%, p = 0.124; 21.6% vs. 31.8%, p = 0.249, respectively). 
Mortality resulting from COPD, however, was significantly more common among 
AAA patients compared to PAD patients (8.5 vs. 2.8%, p = 0.043).
Figure 2. Cause of death distribution in the AAA and PAD groups and an age- and gender-
matched general Dutch population.
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Figure 2. Cause of death distribution in the AAA and PAD groups and an age- and gender-matched 
general Dutch population. 
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Risk adjusted survival analyses was additionally performed to assess whether 
cause-specific mortality risks differed between AAA and PAD patients. These 
analyses showed that no difference exists in risks of cardiovascular and cancer-
related death between treatment groups (HR: 1.47, 95% CI: 0.93 – 2.31; HR: 
1.14, 95% CI: 0.64 – 2.03, respectively, Table 2). For causes of death with 
smaller proportions, adjusted survival analysis was not possible due to limited 
number of events.
Risk profile all-cause mortality
Risk profile analysis was performed for the two study groups separately (Table 
3). In the AAA group, univariately significant risk factors that proved to be inde-
pendently associated with increased mortality were age (HR: 1.70, 95% CI: 1.34 
– 2.15, per 10 year increase), history of cancer (HR: 2.44, 95% CI: 1.72 – 3.46) 
and renal insufficiency (HR: 1.78, 95% CI: 1.27 – 2.51). Higher BMI was protec-
tive against mortality (HR: 0.93, 95% CI: 0.89 – 0.97, per BMI unit increase). 
Ischemic heart disease appeared to negatively affect survival of AAA patients in 
univariable analysis, but this effect was lost in the multivariable model (HR: 1.33, 
95% CI: 0.95 – 1.85).
Similar risk factors found in the PAD cohort were age (HR: 1.30, 95% CI: 1.08 
– 1.57, per 10 year increase), a history of cancer (2.26, 95% CI: 1.45 – 3.54) 
and renal insufficiency (HR: 1.57, 95% CI: 1.02 – 2.42). Additionally, diabetes 
(HR: 1.69, 95% CI: 1.14 – 2.50) and ischemic heart disease (HR: 1.76, 95% CI: 
1.18 – 2.60) worsened survival of PAD patients. Hypertension was a significant 
predictor of mortality in univariable analysis in the PAD group, but could not be 
established as an independent risk factor in the adjusted model (HR: 1.18, 95% 
CI: 0.75 – 1.85).
Table 2. Adjusted survival analysis for overall and cause-specific mortality. The AAA group 
served as the reference category.
Univariate Multivariate
HR 95% CI HR 95% CI
Overall death 0.82 0.64 – 1.04 1.16 0.87 – 1.54
Cardiovascular death 0.91 0.61 – 1.37 1.47 0.93 – 2.31
Cancer-related death 0.70 0.43 – 1.14 1.14 0.64 – 2.03
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DIsCUssIOn
This study demonstrates that postoperative survival is similar for patients under-
going surgery for aneurysmal or atherosclerotic occlusive arterial disease, despite 
the fact that PAD patients were almost 10 years younger at the time of surgery. 
The mortality rate of PAD patients was much higher than that of AAA patients 
as compared to their respective age- and gender-matched general populations. 
These data indicate a relatively greater loss of life years in PAD patients as com-
pared to AAA patients.
What causes this difference in life expectancy between PAD and AAA patients? 
The leading causes of death, i.e. cardiovascular disease and cancer, were similar 
in the two patient groups in unadjusted as well as adjusted analyses. This is 
in agreement with a study from the REACH registry, showing no difference in 
1-year cardiovascular death between the two patient groups.8 Interestingly, 
however, the proportion of cardiovascular mortality in PAD patients was almost 
50% higher than in the age- and gender-matched general population, whereas 
in the AAA group the difference with the general population was rather small. 
This suggests that cardiovascular disease is a relatively more important de-
terminant of life expectancy in PAD when compared to AAA patients in spite 
of their younger age. These findings are in line with previous studies showing 
more severe systemic atherosclerosis – reflected by increased carotid intima-
Table 3. Risk profiles for all-cause mortality for the AAA and PAD group.
Variables
AAA PAD
Univariate Multivariate Univariate Multivariate
HR 95% CI HR 95% CI HR 95% CI HR 95% CI
Age per 10 year 
incr.
1.83 1.47 – 2.30 1.70 1.34 – 2.15 1.47 1.22 – 1.76 1.30 1.08 – 1.57
Gender 1.06 0.64 – 1.76 - - 1.15 0.77 – 1.70 - -
Diabetes 0.91 0.58 – 1.45 - - 2.03 1.38 – 2.99 1.69 1.14 – 2.50
IHD 1.41 1.03 – 1.94 1.33 0.95 – 1.85 2.01 1.36 – 2.96 1.76 1.18 – 2.60
Cancer 2.57 1.84 – 3.59 2.44 1.72 – 3.46 3.14 2.04 – 4.82 2.26 1.45 – 3.54
Renal 
insufficiency
1.96 1.42 – 2.71 1.78 1.27 – 2.51 2.46 1.64 – 3.69 1.57 1.02 – 2.42
Hypertension 1.39 0.98 – 1.97 - - 1.62 1.04 – 2.52 1.18 0.75 – 1.85
BMI per unit 
incr.
0.93 0.89 – 0.97 0.93 0.89 – 0.97 1.03 0.98 – 1.07 - -
Current 
smoking
0.90 0.65 – 1.25 - - 0.93 0.64 – 1.37 - -
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media thickness – in patients with occlusive arterial disease as compared to 
those with AAA.7, 12-16 Interestingly, it has been demonstrated that as little as 
a tenth of a millimeter increase in arterial wall thickness is already associated 
with considerable increases in risk of myocardial infarction, stroke, and even 
death.24-27 In PAD patients, a relatively severe progression of atherosclerotic 
disease is therefore likely to be responsible for the similar survival compared to 
the much older AAA patients, and the poor prognosis compared to the matched 
general population. Of note, COPD-related death was more frequent among AAA 
patients, which may be due to a common -genetically determined- defect in the 
extracellular matrix.28, 29 This further supports the divergence in pathophysiology 
between aneurysmal and occlusive vascular disease.
In order to identify what drives mortality in the respective groups, we com-
pared their mortality risk profiles. These analyses showed that age was more 
than twice as important for AAA patients as compared to PAD patients (HR: 1.70 
vs. 1.30, per 10 year increase). Conversely, a history of ischemic heart disease 
and the presence of diabetes were more important for the prediction of death in 
PAD patients. Besides hazardous risk estimators, we found that higher BMI was 
associated with prolonged survival in the AAA group. This phenomenon, known 
as the obesity paradox, has been described multiple times in many different 
study populations. Although the exact mechanism for this phenomenon remains 
unknown, the association between chronic disease and malnutrition is believed 
to play a role.30, 31 The hazard ratios of 0.9 for current smoking and diabetes in 
univariate analysis appear to represent a protective effect of these factors for 
mortality. However, the wide confidence intervals indicate that rather no associa-
tion existed between these factors and mortality.
Since cardiovascular risk factors, as opposed to age, are potentially modifi-
able, this provides the opportunity to improve life expectancy in PAD patients. 
Regrettably, in spite of widespread guidelines for cardiovascular risk manage-
ment and the undeniable benefits of secondary prevention, studies such as the 
REACH registry show that PAD patients do not achieve adequate risk factor 
control as frequently as individuals with coronary or cerebrovascular disease,32 
despite comparable risks of future cardiovascular events. Pande et al. found 
that only 27% of primary PAD patients were on antiplatelet therapy, and a mere 
19% received statins.33 Thus, there is still a large gap between therapeutic goals 
and current secondary preventive care for PAD patients.34, 35 Furthermore, tight 
control of blood pressure (i.e. ≤ 130-135 mmHg), as opposed to relaxed con-
trol (i.e. ≤140 mmHg), is associated with a further reduction in cardiovascular 
morbidity and mortality.36, 37 The recent SPRINT trial even determined that blood 
pressure control with a target of <120 mmHg resulted in a 43% reduction in 
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cardiovascular mortality.38 Similarly, tight regulation of blood glucose and lipids 
has been reported to improve the overall and cardiovascular prognosis.39-41 In 
light of these benefits, narrowing of the tolerable margins of these classical 
cardiovascular risk factors should be considered, particularly in PAD patients.
This study has limitations that should be addressed. First, this study is of ret-
rospective nature, which has inherent limitations with regard to data collection. 
Also, it should be considered that only patients who underwent surgery were 
identified. Patients treated conservatively, or by less invasive -percutaneous- 
techniques, and those with prohibitive surgical risks were not included in this 
study. Although this approach provided more uniformity in terms of severity of 
disease and operative risks, a selection bias towards patients suited for surgery 
may have resulted. Also, Dutch law prohibits the documentation of ethnicity in 
medical records, which precluded its consideration in this study. For reference, a 
review of the ethnical proportions in the Dutch general population showed that 
77.8% is of Dutch descent, 6.2% African descent, and 7.0% Mediterranean de-
scent. In addition, it is virtually impossible to determine the onset of aneurysmal 
or atherosclerotic disease. As surgical treatment is a uniform indicator of severe 
disease, long-term survival was assessed from the day of surgery onward. PAD 
patients more often underwent some kind of revascularization prior to the index 
operation in this study, which indicates that the age difference demonstrated 
for timing of the index operation between occlusive and aneurysmal disease 
may even underestimate the difference in the age at onset between the two 
respective diseases. This adds support to the argument that AAA and PAD are 
two distinct entities. Finally, the increasing utilization of endovascular treatment 
approaches warrants evaluation and comparative assessment of the postopera-
tive prognosis following minimally invasive AAA and PAD treatment under local 
anesthesia.
In conclusion, this study shows that aneurysmal and occlusive vascular dis-
ease do not only differ in terms of etiology and pathophysiology, but are also 
distinct entities in terms of prognosis. Life expectancy in PAD patients is shorter 
and is predominantly reduced by cardiovascular morbidity, as opposed to age in 
AAA patients. This warrants emphasis on aggressive cardiovascular risk factor 
modification particularly for PAD patients in order to maximize longevity.
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ABsTRACT
Objective
While evidence has shown that ischemic heart disease (IHD) in vascular surgery 
patients has a negative impact on the prognosis after surgery, it is unclear whether 
directed treatment of IHD may influence cause-specific and overall mortality. The 
objective of this study is to determine the prognostic implication of coronary 
revascularization (CR) on overall and cause-specific mortality in vascular surgery 
patients.
Methods
Patients undergoing surgery for abdominal aortic aneurysm (AAA), carotid artery 
stenosis (CAS) or peripheral artery disease (PAD) in a university hospital in the 
Netherlands between January 2003 and December 2011 were retrospectively in-
cluded. Survival estimates were obtained using Kaplan-Meier and Cox regression 
analysis.
Results
A total of 1104 patients were included. Adjusted survival analyses showed that 
IHD significantly increased the risk of overall and cardiovascular death (HR: 1.50, 
95% CI: 1.21 – 1.87 and HR: 1.93, 95% CI: 1.35 – 2.76, respectively). Patients 
previously undergoing CR had similar overall and cardiovascular mortality com-
pared to those without CR (HR: 1.38 vs. 1.62, P = .274; HR: 1.83 vs. 2.02, P = 
.656, respectively). Non-revascularized IHD patients were more likely to die of 
IHD (6.9% vs. 35.7%), whereas revascularized IHD patients more frequently died 
of cardiovascular causes unrelated to IHD (39.1% vs. 64.3%, P = .018).
Conclusion
This study confirms the significance of IHD for postoperative survival of vascular 
surgery patients. Coronary revascularization was associated with lower IHD-
related death rates. However, it failed to provide an overall survival benefit due 
to an increased rate of cardiovascular mortality unrelated to IHD. Intensification 
of secondary prevention regimens may be required to prevent this shift towards 
non-IHD-related death and thereby improving life expectancy.
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InTRODUCTIOn
A number of reports have shown that long-term survival in patients undergoing 
vascular surgery procedures is as low as 25% after 10 years.1 Cardiovascular 
causes account for the majority of early and late mortality following vascular sur-
gery, surpassing 60%.2 It is well known that patients undergoing vascular surgery 
are frequently affected by coronary artery disease, symptomatic or not.3 Since 
the presence of ischemic heart disease (IHD) is associated with postoperative 
morbidity and mortality after non-cardiac vascular surgery, IHD has been the 
subject of numerous studies regarding survival, preoperative evaluation, as well 
as perioperative management. While evidence has shown that IHD in vascular 
surgery patients has a negative impact on the prognosis after surgery, it is unclear 
whether this is solely due to IHD-related death or due to non-IHD-related mortal-
ity risks as well.4, 5
In an attempt to improve postoperative survival, several studies have in-
vestigated the effectiveness of coronary revascularization on the prognosis of 
patients undergoing non-cardiac interventions. 6-14 The interpretation of these 
studies in terms of survival benefits is hampered by either relatively short follow 
up periods, small sample sizes, or heterogeneity within the studied population 
regarding patient and procedural risks. Retrospective data suggested that prior 
coronary bypass surgery was associated with a reduction of 30-day myocardial 
infarction and death rates.6 However, subsequent randomized trials demonstrat-
ed that coronary revascularization prior to vascular surgery does not improve 
survival. 7, 8
In light of these results and the systemic nature of atherosclerotic disease, 
we hypothesize that long-term survival will be similar between IHD patient with 
or without coronary revascularization due to a shift from IHD-related towards 
non-IHD-related mortality. 15-17 The objective of this study is to determine the 
prognostic implication of ischemic heart disease and coronary revascularization 
on long-term overall and cardiovascular mortality in patients undergoing vascu-
lar surgery.
METHODs
Patients undergoing elective open or endovascular surgery under general or 
locoregional anesthesia for abdominal aortic aneurysm (AAA), carotid artery ste-
nosis (CAS) or peripheral artery disease (PAD) in the Erasmus University Medical 
Center between January 2003 and December 2011 were retrospectively included. 
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Identification was done with the use of operation codes and surgical reports. Since 
we were interested in the effect of IHD and prior coronary revascularization (CR) 
on procedures that are accompanied by severe cardiac stress, patients undergo-
ing percutaneous procedures (i.e. percutaneous EVAR, carotid artery stenting and 
lower extremity revascularization) or procedures performed under local anesthe-
sia were not included in this study. When a patient underwent multiple vascular 
procedures within the study period, the first operation in this period was defined 
as the index operation and survival was assessed from that moment onward. 
Baseline characteristics were obtained from hospital records and included age, 
gender, cardiac history, other comorbidities, smoking status (current, former or 
never) and body mass index (BMI). Patients were grouped according to their 
cardiac status prior to the index operation. Ischemic heart disease was considered 
if one of the following was present: reference to previous cardiac ischemic events 
in cardiology notes, prior coronary intervention or evidence of myocardial isch-
emia in provocative pre-operative tests (dobutamine stress echocardiography or 
myocardial scintigraphy). CR was defined as coronary artery bypass graft (CABG) 
surgery or percutaneous coronary intervention (PCI) at any time prior to the index 
vascular operation. Treatment indications for coronary revascularization were in 
accordance with the AHA guidelines (Appropriateness Criteria for Coronary Revas-
cularization). Institutional approval for this study was obtained, and no informed 
consent was required according to local directives for retrospective studies. The 
study complies with the Helsinki declaration on research ethics.
Definitions: Diabetes mellitus was recorded if diabetes was mentioned in the 
medical history or if patients used insulin or oral anti-diabetics. Hypertension was 
defined as blood pressure >140/90 mmHg or use of anti-hypertensive medication. 
A history of cancer was defined as past or current malignant neoplastic disease, 
except for basal cell carcinoma. Renal insufficiency was defined as an estimated 
glomerular filtration rate (eGFR) <60 ml/min as calculated from preoperative 
serum creatinine levels using the MDRD formula. Smoking status and BMI were 
derived from the medical records.
Follow up: Survival status was obtained by inquiry of the civil registry. The latest 
date of follow up was considered December 31st 2012.
Cause of death: Data regarding the causes of death were obtained from the Dutch 
Central Bureau of Statistics (CBS). A database containing all relevant patient 
characteristics from the hospital records was anonymised and imported into the 
CBS and was subsequently linked to the Dutch death registries. Because of CBS 
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regulation, data analysis was only performed by authorized researchers (KU, FBG) 
in a secure environment at the CBS head office. Before data was approved to be 
used for publication purposes, all output was independently checked for privacy 
violations by two separate reviewers. The cause of death was defined as the 
cause for the initial health deterioration, which subsequently resulted in death. 
This approach is similar to the strategy employed for the overall Dutch population 
death registrations and reports. Autopsy was not regularly performed. The causes 
of death were grouped according to the International Classification of Diseases, 
10th Revision (ICD-10). For cardiovascular death, the following codes were used: 
I10-I79; for IHD-related death: I20-I25, I50; and for non-IHD cardiovascular 
death: I10-I19, I26-I49, I51-I79 (Supplemental Table 1). Since ischemic heart 
disease is the principal etiology of heart failure, death due to heart failure-related 
causes was classified as IHD-related death.18, 19
Endpoints: The primary endpoints were long-term overall and cardiovascular mor-
tality. Secondary endpoints were IHD-related and non-IHD-related cardiovascular 
mortality.
Statistical methods: Baseline characteristics were described as counts and per-
centages (dichotomous variables), or means and standard deviations (continuous 
variables). Differences at baseline were determined using Pearson’s chi-square 
analysis and one-way ANOVA-testing, where appropriate. For survival analyses, 
patients were grouped according to their cardiac medical history. Patients overall 
survival was initially assessed using Kaplan-Meier analyses. Cox proportional 
hazards models were constructed to study the impact of IHD and the influence of 
invasive treatment on overall and cardiovascular survival in an adjusted manner. 
Multivariate analyses included demographics (i.e. age and gender), comorbidities 
(i.e. diabetes, hypertension, a history of cancer, renal insufficiency and body mass 
index) and behavioural risk factors (i.e. smoking). To determine the prognostic 
implications of invasive and non-invasive treatment strategies for IHD (i.e. CABG 
or PCI), the overall IHD group was subdivided into a non-coronary revasculariza-
tion group (non-CR) and a coronary revascularization group (CR). The non-IHD 
group was designated the reference category for the Cox regression analyses. 
Differences in cardiovascular death distribution, i.e. different proportions of 
IHD-related and non-IHD-related death, were tested with the use of chi-square 
analyses. All tests were two-sided and significance was considered when P-value 
< .05. Statistical analysis was performed using the IBM SPSS Statistics 20 (IBM 
Inc., Chicago, IL).
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REsULTs
Between January 2003 and December 2011, a total of 1107 patients received sur-
gical treatment for AAA, CS or PAD. Three patients (0.3%) were excluded because 
of unobtainable follow up due to emigration. Among the resulting 1104 patients, 
499 (45.2%) had a history of IHD. Within the IHD group, coronary revasculariza-
tion was performed preoperatively in 245 cases (22.2%).
Baseline characteristics
Baseline characteristics per study group (i.e. non-IHD, non-CR IHD and CR IHD) 
are listed in Table 1. Vascular surgical patients with IHD were older, were more 
frequently of male gender, and had a higher BMI as compared to those without 
IHD. Furthermore, diabetes, renal insufficiency, and hypertension were more 
Table 1. Baseline characteristics.
Variable
non-IHD
(n=605)
non-CR IHD
(n=254)
CR IHD
(n=245)
P-value
Demographics
Female gender – N (%) 174 (29) 47 (19) 36 (15) < .001
Age (years, mean ± SD) 67.4 (± 10.2) 70.0 (± 9.6) 69.4 (±9.3) .001
Prior medical history
Diabetes mellitus – N (%) 112 (19) 65 (26) 67 (27) .006
History of cancer – N (%) 98 (16) 45 (18) 41 (17) .868
Peripheral arterial occlusive disease 
– N (%)
251 (41) 108 (43) 123 (50) .062
Renal insufficiency – N (%) 126 (21) 76 (30) 82 (33) < .001
Cerebrovascular disease – N (%) 238 (39) 100 (39) 94 (38) .962
Hypertension – N (%) 375 (62) 190 (75) 190 (78) < .001
History of vascular interventions – N 
(%)
133 (22) 64 (25) 63 (26) .406
IHD Characteristics
Myocardial infarction – N (%) 0 186 (73) 189 (77) -
Angina – N (%) 0 91 (36) 202 (83) -
CABG/PTCA – N (%) 0 0 245 (100) -
Environmental Risk Factors
Smoking – N (%) 257 (43) 97 (38) 75 (31) .005
Body Mass Index – (kg/length2, 
mean ± SD)
25.7 (±4.1) 26.2 (±4.3) 26.9 (4.1) .001
IHD: Ischemic Heart Disease.
CR: Coronary Revascularization (i.e. CABG or PTCA).
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common among patients with IHD. Finally, current smoking was more frequently 
observed among non-IHD patients.
Overall mortality
During a median follow up of 4.1 years (IQR: 2.3 – 5.9), 164 (27.1%), 108 
(42.5%) and 91 (37.1%) deaths occurred in the non-IHD, non-CR IHD, and CR 
IHD groups, respectively (Table 2). Kaplan-Meier analyses showed a significant 
difference in the postoperative prognosis between non-IHD and IHD patients, with 
an expected survival at 5 years of 74% and 62%, respectively (P < .001; Figure 
1). There was no significant difference in survival between IHD patients without 
or with coronary revascularization (60% and 62% at 5 years for non-CR and CR 
IHD groups, respectively, P = .167). Ischemic heart disease was confirmed as 
an independent risk factor for all cause mortality in Cox-regression analysis as 
compared to vascular surgical patients without a history of IHD (HR: 1.50, 95% 
CI: 1.21 – 1.87, Table 3). Regarding survival for the non-CR IHD and CR IHD 
separately, both groups were burdened by additional survival hazards compared 
with the non-IHD group (HR: 1.62, 95% CI: 1.26 – 2.08, HR: 1.38, 95% CI: 
1.05 – 1.80, respectively, for the non-CR IHD and the CR IHD groups.). However, 
Table 2. Mortality and the causes of death for the study groups separately. Percentages are 
relative to the total obtained deaths per study group.
Cause of Death non-IHD
(n=605)
non-CR IHD
(n=254)
CR IHD
(n=245)
All cause 164a 108 91
Cancer 54 (33.1) 23 (21.3) 20 (22.0)
Cardiovascular 53 (32.5) 46 (42.6) 42 (46.2)
IHD-related 13 (8.0) 28 (25.9) 15 (16.5)
Non-IHD cardiovascular 40 (24.5) 18 (16.7) 27 (29.7)
Cerebrovascular disease 14 (8.6) <5 (<4.6)c <5 (<5.5)
Other arterial disease 17 (10.4) 13 (12.0) 17 (18.7)
Non-ischemic heart 
diseaseb
6 (3.7) <5 (<4.6) 6 (6.6)
Otherd <5 (<3.1) <5 (<4.6) <5 (<5.5)
COPD 10 (6.1) <5 (<4.6) 5 (5.5)
Digestive system 10 (6.1) <5 (<4.6) <5 (<5.5)
Other causes 36 (22.1) 32 (29.6) 22 (24.2)
a 163/164 deaths (99.3%) were obtained.
b e.g. valvular heart disease, cardiomyopathy
c Numbers smaller than 5 were not provided to protect privacy
d i.e. hypertensive and pulmonary circulatory disease
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there was no significant difference in overall survival between the revascularized 
and the non-revascularized IHD groups (P = .274).
Cardiovascular mortality
Causes of death could be obtained for all but one patient (99.7%). Cardiovascular 
disease was reported as the cause of death in 53 (32.5%) cases in the non-IHD 
group, and in 46 (42.6%) and 42 (46.2%) cases in the non-CR and CR IHD 
groups, respectively (Table 2). Adjusted analysis showed that patients with IHD 
were at higher risk of cardiovascular death compared to patients without IHD (HR: 
1.93, 95% CI: 1.35 – 2.76, Table 3). Both the non-revascularized and the revas-
cularized groups had an increased risk of cardiovascular death compared to the 
non-IHD group (HR: 2.02, 95% CI: 1.34 – 3.04, HR: 1.83, 95% CI: 1.19 – 2.81). 
Equivalently to overall survival, cardiovascular survival between the non-CR and 
CR groups was similar (P = .656).
Ischemic heart disease-related and non-ischemic heart disease 
related cardiovascular mortality
IHD-related death occurred 13 times (8.0%) in the non-IHD group during the 
follow-up period. In the non-revascularized and revascularized IHD groups, IHD-
related death was determined in 28 (25.9%) and 15 (16.5%) cases, respectively 
(Table 2, Figure 2). Death due to cardiovascular causes other than IHD was ascer-
Figure 1. Kaplan-Meier analyses for overall survival.
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Figure I. Kaplan-Meier analyses for overall survival. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure II. Proportions of specific cardiovascular death causes among the different study 
groups. Percentages are relative to the total cardiovascular deaths per study group. 
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tained in 40 (24.5%), 18 (16.7%) and 27 (29.7%) cases. The distribution of the 
cardiovascular cause of death subgroups, IHD-related and non-IHD related, was 
significantly different between the non-IHD and the non-CR IHD groups. Patients 
with a history of IHD were more likely to die of IHD-related causes, whereas 
the majority of cardiovascular death among non-IHD patients was unrelated to 
coronary artery disease (P < .001). No significant divergences were found in the 
cardiovascular death distributions between the non-IHD and the CR-IHD groups 
(P = .235). The distribution between non-revascularized and revascularized IHD 
patients, however, differed significantly. Cardiovascular death in the non-CR IHD 
Figure 2. Proportions of specific cardiovascular death causes among the different study 
groups. Percentages are relative to the total cardiovascular deaths per study group.
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 Table 3. Cox regression analyses for overall and cardiovascular mortality. Hazard ratio’s 
for the two IHD groups separately were established in a model with the non-IHD group as 
reference category.
Overall death
Univariate Multivariate
HR 95% CI P-value HR 95%CI P-value
Overall IHD 1.64 1.33 – 2.01 < .001 1.50 1.21 – 1.87 < .001
non-CR 1.80 1.41 – 2.29 < .001 1.62a 1.26 – 2.08 < .001
CR 1.48 1.15 – 1.92 .003 1.38a 1.05 – 1.80 .019
Cardiovascular death HR 95% CI P-value HR 95%CI P-value
Overall IHD 2.24 1.59 – 3.15 < .001 1.93 1.35 – 2.76 < .001
non-CR 2.36 1.59 – 3.50 < .001 2.02b 1.34 – 3.04 .001
CR 2.12 1.41– 3.18 < .001 1.83b 1.19 – 2.81 .006
a Overall survival between the non-CR and the CR IHD did not differ (P = .274).
b Cardiovascular survival between the non-CR and the CR IHD did not differ
 (P = .656).
Chapter 18
340
group was predominantly due to IHD-related causes, whereas the majority of 
cardiovascular death among revascularized patients was due to non-IHD-related 
disease (P = .018).
DIsCUssIOn
The results of the present study confirm that prior ischemic heart disease is a 
significant prognostic factor for long-term overall and cardiovascular survival after 
vascular surgery. Interestingly, patients with previous coronary revascularization 
had similar total cardiovascular mortality but proportionally less ischemic cardiac 
related deaths compared to patients with a history of IHD but no prior revascu-
larization. However, prior coronary revascularization did not provide a survival 
benefit for patients with IHD. This indicates that coronary intervention had an 
impact on the occurrence of subsequent cardiac events, but failed to provide 
protection for cardiovascular death in general.
Our findings are in line with the study by Back et al., who showed that although 
perioperative cardiac factors are the primary determinants of life expectancy, 
patients with a history of coronary revascularization did not have a better survival 
following major arterial reconstruction.12 In addition, the CARP and DECREASE-V 
trials demonstrated that even preoperative coronary revascularization in patients 
with extensive myocardial ischemia on preoperative cardiac testing failed to im-
prove postoperative survival compared to best medical treatment alone in patients 
undergoing elective vascular surgery.7-9, 20 These studies formed the basis for the 
current standpoint that coronary revascularization prior to major non-cardiac 
surgery should not routinely be performed.21
As hypothesized, overall mortality and the death rate distribution among the main 
categories, including cardiovascular and cancer-related death, were similar in 
the non-CR and CR IHD group. Further, we found that cardiovascular death in 
patients with established IHD who had not been treated for coronary stenosis 
by CABG or PCI was most frequently due to ischemic cardiac events. However, 
those who underwent prior coronary treatment more often died of non-cardiac 
ischemic events, the majority of which were related to peripheral arterial rather 
than cerebrovascular disease. Thus, in spite of the impact on cardiac events, 
treatment of IHD induces a shift in the cause, rather than providing protection 
against cardiovascular death. Such a shift in mortality from IHD-related towards 
non-IHD-related death implicates that a history of IHD in vascular surgery pa-
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tients should be regarded as a sign of advanced atherosclerotic disease. This is in 
agreement with several previous studies showing that vascular patients are often 
burdened by advanced atherosclerotic disease, whether or not symptomatic, in 
multiple vascular beds.22, 23 Also, it has been shown that the rates of ischemic 
events in other vascular beds are higher in vascular patients with a history of IHD 
as compared to those without.24-26
In view of the risks conferred by advanced atherosclerotic disease, intensification 
of cardiovascular risk management may be a potential means to reduce non-
cardiac cardiovascular health hazards and improve postoperative outcome in 
these high-risk individuals. Although the effectiveness of secondary prevention 
measures for reducing overall and cardiovascular death is well established, stud-
ies have demonstrated that adherence to the guidelines is less than 60%.27 A lack 
of knowledge and attitude of both patients and physicians have been implicated 
to play a causal role.28, 29 Therefore, improving patient and physician attitude 
regarding the importance of atherothrombotic risk and secondary prevention is 
worthwhile. In addition to stimulating guideline adherence, stricter management 
of the cardiovascular risk factors should be considered. For example, tight control 
of blood pressure (i.e. ≤ 130-135mmHg), as opposed to relaxed control (i.e. 
≤140mmHg), might be associated with a reduction in cardiovascular morbidity 
and mortality.30, 31 Moreover, lowering blood pressure by as little as 10mmHg has 
been reported to reduce the lifetime risk for cardiovascular and stroke-related 
death by 25% to 40%.32 Similar associations have been found for both blood 
glucose and lipid levels.33-35
The limitations of this study are inherent to its retrospective nature. Since all 
symptomatic IHD patients were grouped into a single ischemic heart disease group, 
we could not differentiate between prognostic differences in relation to severity 
of ischemic heart disease. Previous studies have questioned whether survival 
benefits from coronary revascularization are generalizable.36 Evidence suggests 
that survival benefits from coronary revascularization before vascular surgery are 
most significant among severely affected coronary patients.6 Additionally, no dif-
ference was made based on the time between CR and the index operation. Prior 
research has shown that the protective effect of coronary revascularization for 
adverse cardiac events diminishes as time progresses.11, 37 This suggests that the 
demonstrated shift from IHD towards non-IHD-related cardiovascular mortality 
will be more apparent in vascular patients who have undergone recent coronary 
revascularization. Our study could not discriminate between CABG and PCI in 
survival benefit analysis. Finally, stratified analyses for each surgical indication 
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separately was not performed due to the limited event rates in the subgroups and 
the consequent lack of statistical power.
COnCLUsIOn
In conclusion, this study adds new insights in the implications of IHD on long-term 
survival in vascular surgery patients. Our data confirms the significance of IHD for 
postoperative survival of these patients as well as the effectiveness of coronary 
revascularization in the reduction of cardiac ischemic events. However, we also 
show that treatment of IHD alone is insufficient to improve life expectancy in 
these high-risk patients. Patients with prior revascularization for IHD indeed have 
reduced risks of fatal cardiac ischemic events, but this does not translate into 
an overall survival benefit since they have a greater risk to die of cardiovascular 
causes unrelated to ischemic heart disease. Further research is warranted to 
determine whether more aggressive secondary prevention regimens are justified 
to prevent the shift towards non-IHD-related health hazards and thus improve 
postoperative survival in patients with advanced atherosclerotic disease.
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supplemental Table 1. Causes of death definitions in accordance with ICD-10 classifica-
tion
Cancer-related death
ICD-10 Description
C00-C75 Malignant neoplasms, stated or presumed to be primary, of specified 
sites, except of lymphoid, haematopoietic and related tissue
C76-C80 Malignant neoplasms of ill-defined, secondary and unspecified sites
C81-C96 Malignant neoplasms, stated or presumed to be primary, of lymphoid, 
haematopoietic and related tissue
C97-C97 Malignant neoplasms of independent (primary) multiple sites
D00-D09 In situ neoplasms
D10-D36 Benign neoplasms
D37-D48 Neoplasms of uncertain or unknown behavior
Cardiovascular death
Ischemic heart disease-related cardiovascular death
ICD-10 Description
I20-I25 Ischemic heart disease
I50-I50 Heart failure
non-ischemic heart disease-related cardiovascular death
ICD-10 Description
I10-I15 Hypertensive disease
I26-I28 Pulmonary heart disease and diseases of the circulatory system
I30-I49 Other forms of heart disease
I51-I52 Other forms of heart disease
I60-I69 Cerebrovascular disease
I70-I79 Diseases of arteries, arterioles and capillaries
Chronic obstructive pulmonary disease-related death
ICD-10 Description
J40-J47 Chronic lower respiratory diseases
Digestive system-related death
ICD-10 Description
K00-K14 Diseases of oral cavity, salivary glands and jaws
K20-K31 Diseases of oesophagus, stomach and duodenum
K35-K38 Diseases of appendix
K40-K46 Hernia
K50-K52 Noninfective enteritis and colitis
K55-K64 Other disease of intestines
K65-K67 Diseases of peritoneum
K70-K77 Diseases of liver
K80-K87 Disorders of gallbladder, biliary tract and pancreas
K90-K93 Other diseases of the digestive system
summary
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sUMMARY
In Part I, the current position of endovascular repair for the treatment of acute 
thoracic and abdominal aortic pathologies was assessed. Chapter 1 demonstrates 
that thoracic endovascular aortic repair (TEVAR) is now the dominant surgical 
approach for traumatic thoracic aortic injuries, with substantial perioperative 
morbidity and mortality benefits over open repair. Overall mortality following ad-
mission for traumatic aortic injuries has declined, which appears to be the result of 
both the replacement of open repair by TEVAR, as well as the broadened eligibility 
for surgical repair. In line with these findings, Chapter 2 showed that TEVAR is 
now the primary surgical treatment for ruptured thoracic aortic aneurysms as 
well. The introduction of endovascular treatment appears to have broadened the 
proportion of patients undergoing surgical repair, particularly among the elderly. 
Also, overall mortality has declined significantly since the introduction of TEVAR. 
For ruptured abdominal aortic aneurysms, the compiled evidence in Chapter 3 
suggests that endovascular repair (EVAR) is an effective and safe strategy as 
a primary treatment modality for ruptured abdominal aortic aneurysms (AAA). 
Although the survival advantage for EVAR persisted during the first five years after 
repair, no difference in survival was observed thereafter. The institutional series 
in Chapter 4 supports this conclusion, demonstrating that endovascular repair 
is associated with superior perioperative mortality over open repair, which was 
maintained for three years. Additionally, these data suggest that elderly patients, 
and those presenting with haemodynamic instability may particularly benefit from 
minimally invasive treatment. Chapter 5 focuses on early outcomes of symp-
tomatic AAA repair. It was observed that patients with symptomatic AAAs have 
a two-fold increased risk of perioperative mortality, compared to asymptomatic 
aneurysms undergoing repair. Endovascular repair proved to be favorable to open 
repair for this acute indication as well.
Part II was dedicated to clarify, and assess risks associated with technical 
aspects of performing AAA repair. Chapter 6 and Chapter 7 focused on the risks 
of performing concomitant procedures at the time of elective AAA repair. This 
analysis revealed that performing concomitant procedures is not risk free, with 
simultaneous femoral endarterectomy and renal angioplasty or stenting during 
endovascular aneurysm repair (EVAR) established as independent risk factors for 
30-day mortality. For open repair, performing concomitant renal bypass surgery, 
a thrombo-embolectomy, and other abdominal procedures is predictive of early 
mortality. These and other procedures during endovascular and open repair are 
additionally risk factors for the occurrence of various other adverse perioperative 
outcomes. Chapter 8 assessed the relative performance of endovascular repair 
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for abdominal aneurysms with complex proximal anatomy. This study revealed 
that EVAR for anatomically complex AAA is associated with significantly reduced 
perioperative morbidity and mortality compared to complex open repair, but –in 
turn– does carry a higher risk of adverse outcomes than standard infrarenal 
EVAR. In Chapter 9, differences between patients undergoing transperitoneal 
vs. retroperitoneal AAA repair were assessed. The data showed that retroperi-
toneal surgery is more commonly used for proximally located aneurysms, and 
aneurysms during which concomitant renal, visceral, and lower extremity re-
vascularization procedures were performed. Although crude analysis indicated 
a more complicated postoperative period following retroperitoneal surgery, no 
significant differences were established after adjustment for confounding fac-
tors. Chapter 10 shows that vascular surgeons are performing an increasing 
majority of AAA repairs, in large part driven by the increased utilization of EVAR 
for both intact and ruptured AAA repair. However, cardiac surgeons and general 
surgeons still perform AAA repair, in particular ruptured AAAs treated through 
open repair. Chapter 11 was dedicated to assess long-term outcome after AAA 
repair, focusing on the implications of surgical techniques and timing of the 
procedure. While rupture was associated with more than a tenfold increase in 
early mortality, patients with a ruptured AAA surviving the first 30 days proved 
to have a similar vital prognosis as those undergoing elective repair. A trend 
towards improved overall and cardiovascular survival was observed following 
EVAR, with an increasing importance of cancer-related mortality.
In Part III, various complications encountered after AAA repair are analyzed 
in detail to clarify their incidence, significance, and risk factors for occurrence. 
Chapter 12 reveals that the incidence of bowel ischemia following intact AAA 
repair was 1.6%, and 15.2% following ruptured repair. The cause of postopera-
tive bowel ischemia is multifactorial in nature, and can be attributed to patient 
factors, including age, gender, comorbid conditions, and smoking, as well as 
operative characteristics such as operative time, treatment approach, and hypo-
gastric interruption. The most important risk factors, however, are open repair 
and rupture, which were associated with a three-fold and six-fold increase, 
respectively. Chapter 13 demonstrates that early renal complications occur in 
1% of patients undergoing EVAR and 5% of those undergoing open repair. Early 
mortality is significantly greater among patients with renal complications, and 
preoperative creatinine, perioperative transfusion, and open technique are the 
major predictors of its occurrence. Chapter 14 shows that conversion surgery 
to open repair is performed in 1.2 per 100 EVAR cases. Conversion surgery 
is hazardous, with perioperative mortality rates more than twice as high as 
standard open AAA repair. Factors associated with conversion are large diameter 
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of the aneurysm, young age, female gender, and non-white race, while obesity 
is inversely related to conversion surgery.
In Part IV, the authors shed light on underexposed characteristics affect-
ing the long-term performance after surgery. Chapter 15 demonstrated that 
socioeconomic deprivation is a predictor of adverse outcome after vascular 
surgery independent of healthcare disparities and conventional risk factors. For 
AAA patients, the association was of an exponential nature, while for peripheral 
artery disease (PAD) patients the relation followed a linear path. In Chapter 
16, we attempted to extrapolate this association beyond vascular surgery. The 
relation between socioeconomic status and long-term postoperative survival 
was confirmed to exist in a general surgical population. Additionally, this study 
showed that the predictive value of socioeconomic deprivation was particularly 
apparent for cardiovascular mortality, while for cancer-related mortality it was 
not. Chapter 17 confirms the significance of ischemic heart disease (IHD) for 
postoperative survival of vascular surgery patients. More importantly, the data 
show that coronary revascularization is associated with lower IHD-related death 
rates, but fails to provide an overall survival benefit due to an increased rate of 
cardiovascular mortality unrelated to IHD. Chapter 18 demonstrates that aneu-
rysmal and occlusive vascular disease do not only differ in terms of etiology and 
pathophysiology, but are also distinct entities in terms of prognosis. Life expec-
tancy in PAD patients is shorter and is predominantly reduced by cardiovascular 
morbidity, as opposed to age in AAA patients.
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GEnERAL DIsCUssIOn
Endovascular repair for acute aortic pathologies
As an alternative to open repair, endovascular surgery (TEVAR) was first reported 
for acute thoracic aortic surgery in 1997.1-3 Although single institution series 
showed promising results favoring TEVAR, an absolute survival benefit of TEVAR 
over open repair could not be confirmed for traumatic thoracic aortic injuries, nor 
for ruptured descending thoracic aortic injuries on a large scale.17, 18 Chapter 1 
and 2 confirmed that for thoracic traumatic aortic injuries as well as ruptured an-
eurysms, TEVAR has replaced open repair as the primary mode of treatment and 
showed that the use of TEVAR has led to an increase in the proportion of patients 
treated surgically, particularly among patients older than 80. More importantly, 
TEVAR provided favorable perioperative outcome in terms of in-hospital mortal-
ity and adverse perioperative events compared to open repair, despite a worse 
preoperative condition of patients selected for endovascular repair. Although 
consistent with institutional-based studies,4-16 the favorability of TEVAR over open 
repair in the perioperative period was yet to be established on this scale. The 
conflicting results with prior national studies is most likely due to a combination of 
improved outcome of TEVAR in more recent years, as well an increase in TEVAR 
volume in the present study. The present findings support the Society for Vascular 
Surgery Practice Guideline (2011) to preferentially perform TEVAR over open 
surgical repair and nonoperative management.19 In Chapter 3, the controversial 
subject of utilizing endovascular repair (EVAR) for acute abdominal aortic surgery 
is handled. A literature review was conducted to compare open surgery to EVAR in 
the setting of ruptured AAA repair. It was demonstrated that concurrent with the 
widespread adoption of EVAR since the turn of the century, perioperative mortality 
declined from 53% to 39%. Moreover, 30-day mortality was less than half of that 
following open repair. Yet so far, the completed randomized-controlled trials failed 
to establish a benefit of endovascular repair (EVAR) over open repair for ruptured 
abdominal aortic aneurysms.20, 21 This apparent contradiction stresses the need for 
future studies investigating the use of EVAR in the acute setting. It is important 
to realize that endpoints in these trials may not have been the most clinically 
relevant. Furthermore, these trials were analyzed on an intention-to-treat basis, 
which may have precluded clarification of the most important clinical questions. 
As a result, the use of an endovascular-first strategy has remained controversial. 
In the institutional series of ruptured AAA patients described in Chapter 4, crude 
mortality for EVAR was very similar to the mortality rate presented in in the IM-
PROVE trial (approximately 24%),21 and much lower than the reported mortality 
after open repair which did not notably change during the last decades. Consistent 
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with the findings for thoracic aortic surgery in this thesis and the IMPROVE trial, 
older patients and those in worse preoperative condition benefitted most from the 
introduction of endovascular repair.21 Additionally, the present results indicate that 
variability exists in the role of preoperative risk factors for each of the treatment 
strategies, which suggests that different patient factors affect outcome depending 
on the type of repair. Although less life-threatening than ruptured aneurysms, 
symptomatic disease is also considered to require (semi-)acute repair. Prior to the 
introduction of EVAR, many studies have demonstrated symptomatic AAA repair 
to be associated with substantially worse perioperative prognosis compared to 
elective surgery.22-27 In a more recent study, which showed no difference between 
elective and symptomatic patients, it was suggested that increased utilization 
of endovascular repair, as well as improved perioperative care have reduced 
adverse outcomes of symptomatic AAA patients.28 The largest series of symp-
tomatic AAAs to date presented in Chapter 5 demonstrates that symptomatic 
AAA repair remains associated with twice the perioperative mortality compared 
with asymptomatic patients in the endovascular era. Nevertheless, perioperative 
mortality among patients with symptomatic aneurysms was substantially lower in 
comparison with prior reports in which the majority were treated with open repair. 
Therefore, these data support an EVAR-first approach for symptomatic aneurysms 
with suitable anatomy.
Clarifying procedural risk factors for AAA repair
Although numerous technical aspects of both open and endovascular AAA repair 
have been studied over the years, the safety and effectiveness of many other 
facets of AAA surgery remain elusive. AAA repair may be performed in conjunction 
with additional procedures. These concomitant procedures are done for various 
reasons, such as gaining adequate access to aorto-iliac vessels, establishing 
adequate endograft seal, but also to resolve intraoperative pitfalls, or to treat 
unrelated conditions. With 29% of patients undergoing one or more additional 
procedure, Chapter 6 demonstrates that concomitant procedures are commonly 
performed during elective endovascular AAA repair.29 Renal artery angioplasty or 
stenting and femoral endarterectomy were independent risk factors for periop-
erative mortality, with various other interventions, including iliac angioplasty or 
stenting, hypogastric embolization, femoro-femoral bypass, being predictors of 
30-day complications and prolonged length of stay. This is somewhat in contrast 
to the largest report on this subject by Hobo et al., which showed that only open 
surgical interventions for peripheral vascular disease significantly worsened out-
come, while concomitant endovascular procedures were associated with low to 
zero additional risks.29 Although some concomitant procedure are a necessitated 
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by their facilitating role to the endograft delivery, the present findings highlight 
the importance of careful deliberation of the operative risks and the necessity of 
additional procedures during operative planning. The poor outcome of thrombo-
embolectomy stresses the importance of adequate intraoperative anticoagulation. 
Similar conclusions may be drawn for concomitant procedures during open repair, 
as Chapter 7 showed that concomitant renal artery bypass surgery, other ab-
dominal interventions, and performing a thrombo-embolectomy were predictive 
of substantially increased 30-day mortality. Moreover, for concomitant renal 
bypass it has even been demonstrated that normotension is less often achieved 
after combined aortorenal reconstruction as compared to a staged approach.30, 31 
Through advancements in endovascular treatment techniques, including chimney, 
fenestrated and branched stent grafts, EVAR can now be offered to patients with 
complex proximal neck anatomy.32 Chapter 8 demonstrates that endovascular 
repair for juxta- and suprarenal aneurysms has favorable outcome compared to 
open repair, but –in turn– is associated with increased perioperative risks com-
pared to infrarenal EVAR. This is in agreement with a large national series from 
the United Kingdom, which demonstrated that fenestrated endovascular repair can 
be performed with a high degree of technical and clinical success,33 even though 
systematic reviews showed conflicting results.34-36 Nevertheless, this study dem-
onstrates that as a result of advancements in endovascular treatment techniques, 
EVAR has become a good alternative to conventional open repair for treatment of 
anatomically juxta- and suprarenal aneurysms. Further research is warranted to 
determine whether the favorable outcome of EVAR for juxta- and suprarenal AAA is 
maintained during long-term follow-up. In spite of these technical advancements 
and the consequent increasing eligibility for EVAR, open surgical repair remains 
necessary to treat patients anatomically unsuitable for endovascular repair and 
those unable to comply with long-term surveillance.37-40 Some studies compar-
ing perioperative outcomes of transperitoneal and retroperitoneal approach for 
AAA repair suggest that the retroperitoneal approach may result in lower rates of 
ileus, shortened hospital length of stay, and improved respiratory function than 
transperitoneal procedures.41-47 Randomized data, however, indicated that such 
trends were independent of transperitoneal versus retroperitoneal approach.48, 49 
In Chapter 9, we confirmed the findings from the randomized study in a larger 
cohort, as multivariable analysis showed that the associations with worse outcome 
were mostly mediated by concomitant procedures, and that neither of the two 
operative approaches showed clear benefits over the other in adjusted analysis. In 
light of these findings, the operative approach may be motivated by anatomy and 
surgeon preference. Chapter 10 reveals that as the utilization of EVAR increases, 
vascular surgeons are performing an increasing majority of AAA repairs. In addi-
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tion to the widespread adoption of EVAR, regionalization of open AAA repairs to 
high-volume centers since the turn of the century is likely to have contributed.50 
The rise in responsibility of vascular surgeons for AAA care is endorsed by the 
fact that patient outcomes of EVAR were found to be better when procedures 
were performed by surgeons instead of interventionalists.51 Nevertheless, gen-
eral surgeons and cardiac surgeons still participate in the care for AAA patients, 
particularly emergent AAA repair, which is likely due to rural geographic locations 
where the presence of specialized vascular surgeons is lacking.52 Operating these 
patients with ruptured AAA can only be truly beneficial if they have a reason-
able life expectancy afterwards. Previous studies have shown that the long-term 
prognosis of patients surviving the perioperative period after ruptured AAA repair 
is similar to that of electively treated patients.53 Chapter 11 confirms this in a 
more recent cohort, and additionally reveals a shift towards cancer as a dominant 
cause of late mortality. The reason for this substantial contribution is unknown, 
and is in contrast to current mortality trends showing a decrease in the incidence 
of malignant disease in the Western world.54 Nevertheless, the marked impact of 
cancer on the prognosis of AAA patients suggests that the focus of care should not 
only be on secondary cardiovascular prevention, but also on early detection and 
treatment of malignancies.
Complications following AAA repair
Aside from generic complications such as pneumonia and wound infections, the 
postoperative period after AAA repair may be troubled by adverse outcomes specific 
to AAA repair. A better understanding of their etiology may aid in prevention and 
adequate allocation of the necessary care. Chapter 12 confirms that although the 
incidence of bowel ischemia following AAA repair is low, it is associated with very 
poor outcomes. The increase in perioperative mortality ranged from of a factor of 
two among patients undergoing open repair for ruptured AAA, and a factor of 38 
among those undergoing EVAR for intact AAA. The cause of postoperative bowel 
ischemia is multifactorial in nature, and can be attributed to patient factors, as 
well as operative characteristics. In contrast to some previous work, open repair 
proved to be an important predictor.55 In addition to bowel ischemia, open AAA 
surgery is also a well-established risk factor for renal dysfunction. Chapter 13 
revealed that postoperative renal complications occur in 1% of elective infrarenal 
EVARs and 5% of open repairs, and are associated with a detrimental progno-
sis, with perioperative mortality ranging between 30-55%. Elevated baseline 
creatinine, open surgical approach, transfusion, and operative time were most 
predictive of renal complications. Given the dramatic increase in mortality in those 
affected, care should be taken to utilize an endovascular approach when techni-
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cally feasible, to achieve meticulous hemostasis, and to employ renal protective 
strategies, including adequate perioperative volume expansion and minimization 
of exposure to nephrotoxic drugs and contrast agents.
Recently, it has become apparent that endovascular treatment is associated 
with more early and late graft-related complications compared to open repair, 
and that endovascular patients more commonly undergo reinterventions.56-58 As 
an ultimate failure of endovascular treatment, some patients require conver-
sion to open repair. This subject was studied in Chapter 14. Our data showed 
an occurrence rate for conversion of 1.2 per 100 EVARs in a cohort of almost 
25,000 EVAR cases from 2005 onward. This is substantially lower than the first 
conversion series from 1997 showing a rate of nearly 16% (11.5% acute, 4.5% 
late).59 The difference is most likely the result of improved patient selection and 
surgeon experience, as well as technical advances in endovascular repair allow-
ing for patients with more challenging anatomy to be successfully treated using 
endovascular treatment modalities. This is supported by a decline in conversion 
rates in more recent reports.57, 60 In contrast to the largest conversion cohort to 
date, the data presented in Chapter 14 revealed that conversion surgery is as-
sociated with more than double the 30-day mortality compared to standard open 
repair (10.0% vs. 4.2%).61 However, since conversion to open repair is a rare 
occurrence, we believe that open surgery should not regularly be considered as 
a first line treatment with future risks of conversion in mind.
Long-term prognosis after vascular surgery
Many studies have been dedicated to assessing risk factors for long-term survival 
after vascular surgery, among which socioeconomic status (SES). These studies 
were often performed in the United States, where SES-related disparity in access 
to and provision of healthcare exists and is extensively affected by income. As a 
result, the relationship between low SES and poor outcome is often attributed to 
healthcare disparities.62-66 Healthcare in the Netherlands is publicly provided and 
has been credited the most equally accessible healthcare system in the world.67, 68 
Hence, as opposed to the US system, the Dutch healthcare system provides the 
unique opportunity to study the association between SES and outcome irrespec-
tive of healthcare disparities. In Chapter 15 we were able to demonstrate that 
socioeconomic deprivation is a predictor of adverse outcome after vascular sur-
gery independent from conventional risk factors, in particular for peripheral artery 
disease patients. Considering the equality of care provided by the study setting, 
the increased health hazards observed in this study should be attributed to patient 
related factors rather than differences in medical care. The SES-related mortality 
hazard most likely comprises of various established health risks associated with 
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low socioeconomic status, including poor dietary habits, limited physical activ-
ity, psychosocial stress, and perhaps even epigenetical factors.69-88 Chapter 16 
showed that the survival risks associated with low SES not only affect vascular 
patients, whom are considered to be relatively more susceptive to environmental 
risk factors, but rather all surgical patients. Furthermore, it was shown that low 
SES particularly worsens cardiovascular survival, and was not predictive of cancer-
related mortality after adjusting conventional risk factors. Although the associa-
tion between low SES and worse outcome is multifactorial and complex, a better 
understanding of this relation may help to attenuate health disparities. In addition, 
increased physician awareness, perhaps through the consideration of SES in pre-
operative risk scores, and focus on improving these established SES-related risk 
factors may help to improve outcome of low SES surgical patients. In Chapter 17 
we investigated the subject of heterogeneity within vascular disease, and the pos-
sible long-term differences between aneurysmal and occlusive vascular disease. 
The results showed that aneurysmal and occlusive vascular disease not only differ 
in terms of etiology and pathophysiology, but are also distinct entities in terms 
of prognosis. The relative high contribution of cardiovascular disease towards 
mortality in PAD patients suggests that emphasis on aggressive cardiovascular 
risk factor modification in particularly these patients may be beneficial in order to 
maximize longevity. Therefore, increased attention to medication compliance,89 
and implementation of intensified secondary prevention strategies, such as tight-
ened control of blood pressure, lipids, and glucose margins in diabetics, should be 
considered in these patients.90-95 Due to the systemic nature of atherosclerosis, 
vascular surgery patients are frequently affected by ischemic heart disease (IHD), 
symptomatic or not.96 While evidence has shown that IHD in vascular surgery pa-
tients has a negative impact on the postoperative prognosis, it is unclear whether 
this is solely due to IHD-related death or due to non-IHD-related mortality risks 
as well.97, 98 In an attempt to improve postoperative survival, several studies have 
investigated the effectiveness of coronary revascularization on the prognosis of 
patients undergoing non-cardiac interventions.99-107 Chapter 18 revealed that 
coronary revascularization was associated with lower IHD-related death rates 
compared to conservatively treated IHD, but failed to provide an overall survival 
benefit due to an increased rate of cardiovascular mortality unrelated to ischemic 
heart disease. Therefore, these data suggests that vascular surgery patients who 
have undergone a coronary revascularization may also benefit from intensification 
of cardiovascular risk management.
In conclusion, this thesis demonstrates that endovascular repair for aortic surgery 
has become a widely implemented and good alternative to open repair not only 
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in an elective setting, but also for those requiring acute aortic repair. Through 
an assessment of various procedural aspects of aortic repair, as well as a critical 
review of the perioperative and long-term prognosis after aortic and peripheral 
vascular surgery, this thesis has contributed to a better understanding of patient 
performance following vascular surgery. Although continued research remains 
necessary in this ever-evolving field, these new findings may provide clinical guid-
ance and serve as potential leads for improvement of patient care, and thereby 
patient outcome.
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In deel I wordt de huidige positie van endovasculaire behandeling voor acute 
thoracale en abdominale aortapathologie bestudeerd. Hoofdstuk 1 laat zien 
dat endovasculaire behandeling van de thoracale aorta (TEVAR) tegenwoordig 
de dominante chirurgische aanpak is voor traumatische thoracaal aortaletsel. 
Bovendien was TEVAR geassocieerd met aanzienlijke verbeteringen in periope-
ratieve morbiditeit en mortaliteit in vergelijking met open chirurgie. De algehele 
mortaliteit na opname voor traumatisch thoracaal aortaletsel is afgenomen, wat 
het gevolg is van zowel de vervanging van open chirurgie door TEVAR, als een 
toename in het aantal patiënten dat door de introductie van TEVAR in aanmerking 
komt voor chirurgische reparatie. In lijn met deze bevindingen blijkt uit hoofdstuk 
2 dat TEVAR tevens de primaire chirurgische behandeling van geruptureerde 
thoracale aorta-aneurysmata is. Ook hier lijkt de hoeveelheid patiënten die in 
aanmerking komt voor chirurgische behandeling te zijn toegenomen door de 
introductie van TEVAR, met name onder ouderen. De literatuurbespreking in 
hoofdstuk 3 concludeert dat endovasculaire behandeling (EVAR) als primaire 
behandelingsmodaliteit een effectieve en veilige strategie is voor geruptureerde 
aneurysmata van de abdominale aorta (AAA). Alhoewel het perioperatieve over-
levingsvoordeel na EVAR in vergelijking met open chirurgie gedurende de eerste 
vijf jaar blijft bestaan, wordt er op een langere termijn geen verschil in mortaliteit 
geconstateerd. Het institutionele cohort in hoofdstuk 4 ondersteunt deze conclu-
sie gezien de bevinding dat endovasculaire behandeling geassocieerd is met een 
lagere perioperatieve sterfte in vergelijking met open reparatie, welke op middel-
lange termijn gehandhaafd blijft. Daarnaast toont de data dat oudere patiënten 
en patiënten die zich presenteren met hemodynamische instabiliteit met name 
kunnen profiteren van deze minimaal invasieve behandeling. Hoofdstuk 5 richt 
zich op de vroege uitkomsten na de behandeling van het symptomatische AAA. 
Patiënten met een symptomatisch AAA hebben een tweemaal verhoogd risico op 
perioperatieve mortaliteit in vergelijking met patiënten die behandeld worden 
voor een asymptomatische aneurysma. Naast geruptureerde aneurysmata blijkt 
endovasculair herstel eveneens voor deze indicatie gunstigere resultaten op te 
leveren dan open chirurgie.
Deel II is gewijd aan het ophelderen van de risico’s verbonden aan verscheidene 
operatieve aspecten van AAA zorg. Hoofdstuk 6 en hoofdstuk 7 zijn gericht op het 
in kaart brengen van de risico’s die gekoppeld zijn aan het uitvoeren van gelijk-
tijdige procedures tijdens electieve AAA chirurgie. Deze onderzoeken laten zien 
dat het uitvoeren van gelijktijdige procedures niet geheel zonder risico’s is. Ge-
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lijktijdige endarteriëctomie van het femoraaltraject en renale angioplastiek tijdens 
EVAR blijken onafhankelijke risicofactoren voor dertigdagenmortaliteit te zijn. Bij 
open AAA chirurgie zijn het gelijktijdig uitvoeren van een renale bypassoperatie, 
een trombo-embolectomie en andere abdominale procedures risicofactoren voor 
perioperatieve mortaliteit. Deze en andere behandelingen tijdens endovasculaire 
en open AAA chirurgie zijn bovendien geassocieerd met het optreden van ver-
scheidene andere perioperatieve complicaties. In hoofdstuk 8 zijn de prestaties 
van EVAR in vergelijking met open chirurgie voor AAA’s met complexe anatomie 
van de aneurysmahals onderzocht. Deze studie toonde dat EVAR voor anatomisch 
complexe AAA geassocieerd is met significant lagere perioperatieve morbiditeit en 
mortaliteit vergeleken met open chirurgie. Op zijn beurt draagt complexe EVAR 
wel een hoger risico op complicaties met zich mee in vergelijking met standaard 
infrarenale EVAR. In hoofdstuk 9 zijn de verschillen tussen de transperitoneale 
en retroperitoneale benadering van open AAA chirurgie beoordeeld. Een retro-
peritoneale benadering werd vaker toegepast voor relatief proximaal gelegen 
aneurysmata en bij patiënten die gelijktijdig een revascularisatie van de viscerale 
arteriën, nier en onderste extremiteit ondergingen. Alhoewel de retroperitoneale 
benadering bij initiële analyse geassocieerd leek met een meer gecompliceerd 
postoperatief beloop, werden na correctie geen significante verschillen gevonden. 
Uit hoofdstuk 10 blijkt dat vaatchirurgen verantwoordelijk zijn voor een groeiende 
meerderheid van AAA chirurgie. Dit is grotendeels het gevolg van de toename van 
het gebruik van EVAR voor zowel intacte als geruptureerde AAA’s. Echter, hartchi-
rurgen en algemeen chirurgen voeren nog steeds AAA operaties uit, voornamelijk 
de behandeling van geruptureerde AAA’s middels open chirurgie. Hoofdstuk 11 is 
gewijd aan de langetermijnresultaten na AAA reparatie en richt zich op de invloed 
van de verschillende chirurgische technieken en de timing van de procedure. De 
behandeling van een geruptureerd aneurysma was geassocieerd met een meer 
dan tienvoudig risico op perioperatieve mortaliteit in vergelijking met electieve 
chirurgie. Echter, na de eerste dertig dagen was de overleving vrijwel identiek 
voor patiënten met een geruptureerde en intact AAA. Daarnaast werd een trend in 
de richting van een verbeterde algehele en cardiovasculaire overleving gevonden 
in patiënten behandeld middels EVAR, met een toenemend aandeel van kanker-
gerelateerde sterfte.
In deel III zijn verscheidene complicaties na AAA reparatie in detail geanalyseerd 
om hun incidentie, klinische betekenis en risicofactoren op te helderen. Hoofdstuk 
12 laat zien dat de incidentie van darmischemie na intacte AAA chirurgie 1,6% 
is en 15,2% na een operatie voor geruptureerde aneurysmata. De oorzaak van 
postoperatieve darmischemie is multifactorieel en kan worden toegeschreven aan 
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patiëntfactoren zoals leeftijd, geslacht, comorbiditeit en roken, maar ook aan 
operatieve parameters als operatieduur, type chirurgie en onderbreking van de 
arteria hypogastrica. De belangrijkste risicofactoren zijn echter open chirurgie 
en ruptuur van het aneurysma, welke respectievelijk geassocieerd zijn met een 
drie- en zesvoudig verhoogd perioperatief sterfterisico. Uit hoofdstuk 13 blijkt dat 
nierfunctiestoornissen optreden bij één procent van de patiënten na EVAR en bij 
vijf procent na open chirurgie. Perioperatieve mortaliteit was aanzienlijk hoger in 
deze patiëntengroep. Risicofactoren voor het ontstaan van nierfunctiestoornis-
sen zijn preoperatieve creatinine, perioperatieve transfusie en open chirurgie. In 
hoofdstuk 14 werden de incidentie en risico’s van converteren van endovasculaire 
naar open AAA herstel onderzocht. Hieruit is gebleken dat conversiechirurgie 1,2 
keer per honderd EVAR’s voorkomt. Met een relatieve perioperatieve sterftekans 
van meer dan twee in vergelijking met standaard open AAA chirurgie is con-
versiechirurgie zeer risicovol. Factoren geassocieerd met converteren naar open 
chirurgische behandeling zijn grote diameter van het aneurysma, jonge leeftijd, 
vrouwelijk geslacht en niet-blanke afkomst, terwijl obesitas een invers verband 
heeft met conversiechirurgie.
In deel IV wordt aandacht besteed aan de onderbelichte kenmerken die van 
invloed zijn op de lange termijn uitkomsten na (vaat)chirurgie. Hoofdstuk 15 
toont aan dat sociaaleconomische achterstelling een voorspeller is voor een 
slechte prognose na vaatchirurgische interventie onafhankelijk van verschillen in 
de kwaliteit en toegankelijkheid van gezondheidszorg en andere conventionele 
risicofactoren. Voor AAA patiënten liet deze relatie een exponentieel verband 
zien, terwijl voor patiënten met perifeer vaatlijden (PAV) deze relatie van een 
lineaire aard was. In hoofdstuk 16 hebben we geprobeerd om deze associatie 
te extrapoleren naar vakgebieden buiten de vaatchirurgie. De relatie tussen 
sociaaleconomische status en postoperatieve overleving werd bevestigd voor 
een algemeen chirurgische populatie. Bovendien werd aangetoond dat de voor-
spellende waarde van de sociaaleconomische achterstelling voornamelijk van 
toepassing is op cardiovasculaire mortaliteit, terwijl het voor kanker-gerelateerde 
mortaliteit geen predictieve waarde heeft. Hoofdstuk 17 bevestigt het klinische 
belang van ischemische hartziekten (IHZ) voor de postoperatieve overleving van 
vaatchirurgische patiënten. Belangrijker is dat coronaire revascularisatie geas-
socieerd was met lagere IHZ-gerelateerde sterftecijfers, maar er niet in slaagt om 
een totaal overlevingsvoordeel te bewerkstelligen als gevolg van een verhoogde 
cardiovasculaire mortaliteit die niet verwant is aan IHZ. Uit hoofdstuk 18 blijkt 
dat aneurysmatische en occlusieve vaatziekten niet alleen verschillen ten aanzien 
van etiologie en pathofysiologie, maar ook afzonderlijke entiteiten zijn voor wat 
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betreft prognose. De levensverwachting van PAV patiënten is korter en wordt 
hoofdzakelijk beperkt door cardiovasculaire morbiditeit, terwijl een hoge leeftijd 
voor AAA patiënten op de voorgrond staat.
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